

Save As Word Doc

---

## Saturday, June 9, 2018

**ISGIDAR**

**Sapphire LP  
8:00 - 5:00 PM**

**NIDA INTERNATIONAL FORUM**

**Sapphire DH  
8:30 - 5:00 PM**

**(PRE-REGISTRANTS ONLY)  
NIDA GRANT-WRITING**

**Aqua C  
1:00 - 5:00 PM**

**REGISTRATION**

**Sapphire NW Foyer  
1:30 - 5:30 PM**

**OPENING RECEPTION**

**Promenade Plaza  
7:00 - 9:00 PM**

## Sunday, June 10, 2018

**PLENARY PROGRAM**

**Indigo BCFG  
8:30 - 11:00 AM**

- 8:30 *Welcome*
- 8:40 CPDD President Alan Budney
- 8:45 *Celebrating the 80th Annual Scientific Meeting of The Committee/College on Problems of Drug Dependence*
- 9:00 CPDD Executive Officer, Loretta P. Finnegan
- 9:15 *Presentation of the Stephen G. Holtzman Travel Award for Preclinical Investigators to Lais Berro*
- 9:18 Introduction by Alan J. Budney
- 9:21 *Presentation of the CPDD/NIDA Media Award to Maia Szalavitz*
- 9:26 Introduction by Meg Chisolm
- 9:36 *Presentation of the Martin & Toby Adler Distinguished Service Award to Bertha Madras*

- 9:39 Introduction by Loretta Finnegan  
 9:42 *Presentation of the J. Michael Morrison Award to Ivan D. Montoya*  
 9:45 Introduction by Francis Levin  
 9:48 *Presentation of the Joseph Cochin Young Investigator Award to Kelly Dunn*  
 9:51 Introduction by Maxine Stitzer  
 9:54 *Presentation of the Mentorship Award to Leonard Howell*  
 9:57 Introduction by Lais Berro  
 10:00 *Presentation of the Innovator Award to Thomas Prisinzano*  
 10:05 Introduction by Christopher Cunningham  
 10:10 *Presentation of the Nathan B. Eddy Award to Alexandros Makriyannis*  
 10:15 Introduction by Thomas Prisinzano  
 10:20 *Nathan B. Eddy Award Lecture: Cannabinoid Receptors, Their Structures and Functions*  
 10:25 Alexandros Makriyannis, Northeastern University

## POSTER SESSION I A GENETICS

**Sapphire ABC/EFG  
11:00 - 1:00 PM**

- 1 *Greater oxycodone self-administration by male and female A112G mice than wild type A112A mice*  
Yong Zhang, Devon Collins, Mary Jeanne Kreek, The Rockefeller University, New York, NY
- 2 *Oprm1 A112G, a single nucleotide polymorphism, alters expression of stress-responsive genes in multiple brain regions in male and female mice*  
Devon Collins, Yong Zhang, Matthew Randesi, Joel Correa da Rosa, Mary Jeanne Kreek, The Rockefeller University, New York, NY
- 3 *Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence found in genome-wide and subsequent association studies*  
Daisuke Nishizawa<sup>1</sup>, Shinya Kasai<sup>1</sup>, Junko Hasegawa<sup>1</sup>, Naomi Sato<sup>2</sup>, Hidetaka Yamada<sup>2</sup>, Fumihiko Tanioka<sup>3</sup>, Makoto Nagashima<sup>4</sup>, Hiroshi Ujike<sup>5</sup>, Ryota Hashimoto<sup>6</sup>, Tomio Arai<sup>7</sup>, Seiji Mori<sup>7</sup>, Motoji Sawabe<sup>8</sup>, Makiko Naka-Mieno<sup>9</sup>, Yoshiji Yamada<sup>8</sup>, Miki Yamada<sup>8</sup>, Noriko Sato<sup>8</sup>, Masaaki Muramatsu<sup>8</sup>, Masashi Tanaka<sup>10</sup>, Masakazu Hayashida<sup>11</sup>, Haruhiko Sugimura<sup>2</sup>, Kazutaka Ikeda<sup>1</sup>, <sup>1</sup>Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Japan, <sup>2</sup>Hamamatsu University School of Medicine, Hamamatsu, Japan, <sup>3</sup>Iwata City Hospital, Iwata, Japan, <sup>4</sup>Toho University Sakura Medical Center, Sakura, Japan, <sup>5</sup>Ujike Nishiguchi Clinic, Okayama, <sup>6</sup>Osaka University Graduate School of Medicine, Osaka, Japan, <sup>7</sup>Tokyo Metropolitan Geriatric Hospital, Tokyo, <sup>8</sup>Tokyo Medical and Dental University, Tokyo, Japan, <sup>9</sup>Jichi Medical University, Shimotsuke, Japan, <sup>10</sup>Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, <sup>11</sup>Juntendo University School of Medicine, Tokyo, Japan
- 4 *Gender-specific association of functional PDYN 68-base pair repeats with cannabis exposure in an African-American cohort*  
Vadim Yuferov, The Rockefeller University, New York, NY
- 5 *Gene-environment correlation in affiliating with substance using friends from childhood to young adulthood*  
Cristina Bares<sup>1</sup>, Berenice Castillo<sup>1</sup>, Kenneth Kendler<sup>2</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Virginia Commonwealth University, Richmond, VA

## POSTER I B STIMULANTS PRECLINICAL I

**Sapphire ABC/EFG  
11:00 - 1:00 PM**

- 6 *The Cocaine Biobank: A repository of biological samples from genetically characterized outbred rats that exhibit compulsive-like escalation of cocaine self-administration*  
Olivier George<sup>1</sup>, Lisa Maturin<sup>1</sup>, Giordano De Guglielmo<sup>1</sup>, Molly Brennan<sup>1</sup>, Leah Solberg-Woods<sup>2</sup>, Dana Conlisk<sup>1</sup>, Abraham Palmer<sup>1</sup>, <sup>1</sup>The Scripps Research Institute, La Jolla, CA, <sup>2</sup>Wake Forest University School of Medicine, Winston-Salem, NC
- 7 *The effect of a recombinant humanized anti-cocaine monoclonal antibody on the urinary clearance of cocaine and metabolites in rats*  
Jordan Marckel<sup>1</sup>, Hanna Wetzel<sup>2</sup>, Andrew Norman<sup>1</sup>, Hassane Amlal<sup>2</sup>, <sup>1</sup>University of Cincinnati, College of Medicine, Cincinnati, OH, <sup>2</sup>University of Cincinnati, Cincinnati, OH
- 8 *Repeated cocaine and novel environmental exposures have divergent effects on locus coeruleus cFOS expression and forebrain region monoamine concentrations*  
Michael Lisieski, Klevis Karavidha<sup>1</sup>, Ali Gheidi<sup>2</sup>, Rafael Garibyan<sup>1</sup>, Alana Conti<sup>3</sup>, Jonathan Morrow<sup>4</sup>, Shane Perrine<sup>3</sup>, <sup>1</sup>Wayne State University School of Medicine, Detroit, MI, <sup>2</sup>University of Michigan Medical School, Ann Arbor, MI, <sup>3</sup>Wayne State University, Detroit, MI, <sup>4</sup>University of Michigan, Ann Arbor, MI
- 9 *Expression of DeltaFosB in taurine-cocaine treated rat brains*  
Tianna Irving<sup>1</sup>, Ayana Cole<sup>2</sup>, Temitayo Adebawale<sup>3</sup>, Cladimar Vasquez<sup>2</sup>, Ugochukwu Akpara<sup>4</sup>, Rina Liang<sup>3</sup>, Kaliris Salas-Ramirez<sup>5</sup>, Avery Villa-Gonzalez<sup>3</sup>, <sup>1</sup>TRACC Training Grant, Elmont, NY, <sup>2</sup>CUNY School of Medicine, New York, NY, <sup>3</sup>The City College of New York, New York, NY, <sup>4</sup>TRACC Training Grant, Brooklyn, NY, <sup>5</sup>The Sophie Davis School of Biomedical Education, New York, NY
- 10 *Role of ventral tegmental area serum- and glucocorticoid-inducible kinase 1 (SGK1) catalytic activity and phosphorylation in drug-related behaviors*  
Marie Doyle<sup>1</sup>, Vedrana Bali<sup>1</sup>, Sarah Cooper<sup>1</sup>, Sophia Kaska<sup>1</sup>, Michelle Mazei-Robison<sup>1</sup>, Shane Perrine<sup>2</sup>, <sup>1</sup>Michigan State University, East Lansing, MI, <sup>2</sup>Wayne State University, Detroit, MI
- 11 *Hypocretin/orexin innervation within ventral midbrain: Afferent topography and function in psychostimulant use disorders*  
Steven Simmons, Rose Martorana, Taylor Gentile, Helene Philogene, Scott Rawls, John Muschamp, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 12 *Opposing action of dynorphin and orexin in the posterior paraventricular nucleus of the thalamus: Cellular and behavioral evidence.*  
Remi Martin-Fardon, Marsida Kallupi, Olivier George, Paul Schweitzer, Alessandra Matzeu, The Scripps Research Institute, La Jolla, CA
- 13 *Orexin A in the posterior paraventricular nucleus of the thalamus promotes cocaine-seeking behavior: Differential hypothalamic activation during abstinence.*  
Alessandra Matzeu, Remi Martin-Fardon, The Scripps Research Institute, La Jolla, CA
- 14 *Reconsolidation of cocaine reward memory requires NMDA-GSK3 signaling*  
Xiangdang Shi<sup>1</sup>, Eva Von Weltin<sup>2</sup>, Ellen Unterwald<sup>1</sup>, <sup>1</sup>Lewis Katz School of Medicine at Temple University, Philadelphia, PA, <sup>2</sup>Temple University, Philadelphia, PA
- 15 *Remembering addictive behaviours: Effect of cocaine-associated stimuli on memory formation*  
Francesco Leri, Michael Wolter, Boyer Winters, Ethan Huff, University of Guelph, Guelph, ON, Canada
- 16 *SNC80, a delta opioid receptor agonist, reduces cocaine-induced increases in CRF mRNA in female rats*  
Krista Connelly, Ellen Unterwald, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 17 *Comparison of the reinstatement of cocaine-seeking in remission induced by cues, drug or a drug/cue combination – an IVSA study in rats*  
Elaine Keogh<sup>1</sup>, Sharon Smith<sup>2</sup>, David Heal<sup>2</sup>, <sup>1</sup>RenaSci Ltd, Nottingham, United Kingdom, <sup>2</sup>RenaSci Ltd, Nottingham
- 18 *The wrong crowd: Social influences on cue-induced cocaine seeking.*  
Lindsey Hammerslag, Joshua Beckmann, Michael Bardo, University of Kentucky, Lexington, KY

- 19 *A data analysis strategy for rodent self-administration studies*  
Sharon Rowton<sup>1</sup>, Kelly Ashcroft-Hawley<sup>1</sup>, Beatriz Rocha<sup>2</sup>, <sup>1</sup>Covance Laboratories, Harrogate, United Kingdom, <sup>2</sup>Covance, Princeton, NJ

**POSTER I C**  
**PERINATAL**

**Sapphire ABC/EFG**  
**11:00 - 1:00 PM**

- 20 *Perceived stressors reported by mothers with Opioid Use Disorder: Qualitative findings from an inpatient substance use program*  
Angela Moreland, Aimee McRae-Clark, Medical University of South Carolina, Charleston, SC
- 21 *Post-birth treatment outcomes in pregnant, methadone-maintained women*  
Jennifer Ellis<sup>1</sup>, Meagan Carr<sup>2</sup>, Molly Cairncross<sup>3</sup>, Cara Struble<sup>1</sup>, Leslie Lundahl<sup>1</sup>, <sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>Eastern Michigan University, Detroit, MI, <sup>3</sup>University of Windsor, Windsor, ON, Canada
- 22 *A pilot randomized clinical trial of Bupropion Sustained Release as an aid for smoking cessation during pregnancy: Challenges of recruitment and retention of subjects*  
Valentina Fokina<sup>1</sup>, Cheryl Oncken<sup>2</sup>, Richard Feinn<sup>3</sup>, Holly West<sup>1</sup>, Shannon Clark<sup>1</sup>, Gary Hankins<sup>1</sup>, Mahmoud Ahmed<sup>1</sup>, Tatiana Nanovskaya<sup>1</sup>, <sup>1</sup>University of Texas Medical Branch, Galveston, TX, <sup>2</sup>University of Connecticut Health Center, Farmington, CT, <sup>3</sup>Frank H Netter, MD, School of Medicine, Medical Sciences, Quinnipiac University, North Haven, CT
- 23 *Anticipated vs. actual postpartum contraceptive use among pregnant cigarette smokers*  
Sarah Heil<sup>1</sup>, Ivori Zvorsky<sup>2</sup>, Allison Kurti<sup>1</sup>, Ira Bernstein<sup>1</sup>, Stephen Higgins<sup>1</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>Vermont Center on Behavior and Health, Burlington, VT
- 24 *Examining interrelationships between delay discounting and simulated demand for cigarettes among pregnant women*  
Tyler Nighbor<sup>1</sup>, Ivori Zvorsky<sup>2</sup>, Allison Kurti<sup>1</sup>, Warren Bickel<sup>3</sup>, Derek Reed<sup>4</sup>, Stephen Higgins<sup>1</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>Vermont Center on Behavior and Health, Burlington, VT, <sup>3</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>4</sup>University of Kansas, Lawrence, KS
- 25 *A new method with improved sensitivity of the detection of marijuana metabolite in human umbilical cord tissue using 2-D GC/MSMS*  
Jason Hulen, Joseph Jones, Mary Jones, Andre Sukta, United States Drug Testing Laboratories, Des Plaines, IL
- 26 *Trends in self-reported and biochemically tested marijuana use among pregnant adolescents and adults in California from 2009-2016*  
Kelly Young-Wolff, Lue-Yen Tucker, Stacey Alexeeff, Mary Anne Armstrong, Amy Conway, Constance Weisner, Nancy Goler, Kaiser Permanente Northern California, Oakland, CA

**POSTER I D**  
**ADOLESCENT DRUG ABUSE I**

**Sapphire ABC/EFG**  
**11:00 - 1:00 PM**

- 27 *Contributions of sexual violence perpetration and victimization to drug and alcohol abuse risk in adolescence: A four-year longitudinal study*  
Sara Stein<sup>1</sup>, Philip Veliz<sup>1</sup>, Yasamin Kusunoki<sup>2</sup>, Carol Boyd<sup>1</sup>, Quyen Ngo<sup>3</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Michigan, School of Nursing, Ann Arbor, MI, <sup>3</sup>University of Michigan Injury Prevention Center, Ann Arbor, MI
- 28 *Association between youth recall of alcohol marketing across venues and underage drinking*

- Joy Gabrielli<sup>1</sup>, Mike Stoolmiller<sup>2</sup>, Zoe Brennan<sup>3</sup>, Susanne Tanski<sup>4</sup>, Auden McClure<sup>4</sup>, <sup>1</sup>Geisel School of Medicine at Dartmouth, Enfield, NH, <sup>2</sup>Michigan State University, Lansing, MI, <sup>3</sup>Department of Biomedical Data Science at Dartmouth, Hanover, NH, <sup>4</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH
- 29 *Tobacco incidence in school-attending Brazilian adolescents: Contextual factors and comorbid patterns*  
Marcos Ribeiro<sup>1</sup>, Silvia Martins<sup>2</sup>, Thiago Fidalgo<sup>1</sup>, Zila M. Sanchez<sup>1</sup>, Sheila C. Caetano<sup>1</sup>, <sup>1</sup>Universidade Federal de Sao Paulo, São Paulo, <sup>2</sup>Columbia University, New York, NY
- 30 *A videogame intervention for tobacco product use prevention in adolescents*  
Lynn Fiellin, Yale University, New Haven, CT
- 31 *High school adolescents use several types of e-cigarette devices*  
Asti Jackson<sup>1</sup>, Grace Kong<sup>1</sup>, Deepa Camenga<sup>1</sup>, Meghan Morean<sup>2</sup>, Krysten Bold<sup>1</sup>, Dana Cavallo<sup>1</sup>, Patricia Simon<sup>1</sup>, Ran Wu<sup>1</sup>, Suchitra Krishnan-Sarin<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Oberlin College, Oberlin, OH
- 32 *Has alternative tobacco product use influenced future cigarette smoking intention differently in male and female adolescents from 2011 to 2015?*  
Luis Segura<sup>1</sup>, Julian Santaella-Tenorio<sup>1</sup>, Shivani Mantha<sup>2</sup>, Pia Mauro<sup>1</sup>, Daniel Giovenco<sup>1</sup>, Silvia Martins<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY
- 33 *Trends in cannabis and nicotine co-use among adolescent cannabis users*  
Ashley Knapp<sup>1</sup>, Dustin Lee<sup>2</sup>, Joy Gabrielli<sup>3</sup>, Jacob Borodovsky<sup>1</sup>, Samantha Auty<sup>4</sup>, Alan Budney<sup>5</sup>, <sup>1</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Geisel School of Medicine at Dartmouth, Enfield, NH, <sup>4</sup>Geisel School of Medicine at Dartmouth, Lebanon, <sup>5</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH
- 34 *Longitudinal brain metabolites changes in young marijuana users*  
Christine Cloak<sup>1</sup>, Thomas Ernst<sup>2</sup>, Linda Chang<sup>3</sup>, <sup>1</sup>University of Maryland, School of Medicine, Baltimore, MD, <sup>2</sup>Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Baltimore, MD, <sup>3</sup>John A. Burns School of Medicine, Honolulu, HI
- 35 *Adding working memory training to contingency management for adolescent cannabis misuse: A sequential multiple assignment randomized trial*  
Catherine Stanger<sup>1</sup>, Emily Scherer<sup>1</sup>, Ashley Knapp<sup>2</sup>, Hoa Vo<sup>3</sup>, Marc Fishman<sup>3</sup>, Alan Budney<sup>4</sup>, <sup>1</sup>Dartmouth College, Hanover, NH, <sup>2</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, <sup>3</sup>Mountain Manor Treatment Center, Baltimore, MD, <sup>4</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH
- 36 *Is heavy cannabis use associated with reduced motivation among adolescents?*  
Ileana Pacheco-Colon, Raul Gonzalez, Florida International University, Miami, FL
- 37 *Investigating the relationship between perceived availability of marijuana and marijuana use among adolescents in Chile, Argentina, and Uruguay over time*  
Julia Schleimer<sup>1</sup>, Ariadne Rivera-Aguirre<sup>2</sup>, Alvaro Castillo-Carniglia<sup>2</sup>, Hannah Sybil Laqueur<sup>2</sup>, Silvia Martins<sup>1</sup>, Magdalena Cerda<sup>2</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>University of California Davis, Sacramento, CA
- 38 *Medical marijuana laws, dispensary status and design, and past 30-day youth marijuana and heavy marijuana use: A 46 state analysis, 1991-2015*  
Julie Johnson<sup>1</sup>, Renee Johnson<sup>2</sup>, Abenaa Jones<sup>1</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD
- 39 *Perceptions of primary care services among Veterans with opioid use disorder in the Veterans Health Administration*  
Audrey Jones<sup>1</sup>, Ying Suo<sup>2</sup>, Adam Gordon<sup>2</sup>, <sup>1</sup>VA Salt Lake City Health Care System, Salt Lake City, UT,

- <sup>2</sup>University of Utah, Salt Lake City, UT
- 40 *Predictors of nonmedical prescription opioid use in adolescents*  
Junhan Cho<sup>1</sup>, Lorraine Kelley-Quon<sup>2</sup>, Afton Kechter<sup>1</sup>, Adam Leventhal<sup>1</sup>, <sup>1</sup>University of Southern California, Los Angeles, CA, <sup>2</sup>Children's Hospital Los Angeles, Los Angeles, CA
- 41 *Peer norms and access to prescription drugs in the home are associated with nonmedical prescription opioid use among adolescents*  
Kathleen Egan<sup>1</sup>, Eric Gregory<sup>2</sup>, Amy Elliott<sup>1</sup>, Linda Cottler<sup>1</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>Community Survey Solutions, LLC, Bowling Green, KY
- 42 *Association of nonmedical prescription opioid use with subsequent heroin use Initiation in adolescents*  
Lorraine Kelley-Quon<sup>1</sup>, David Stong<sup>2</sup>, Junhan Cho<sup>3</sup>, Afton Kechter<sup>3</sup>, Adam Leventhal<sup>3</sup>, <sup>1</sup>Children's Hospital Los Angeles, Los Angeles, CA, <sup>2</sup>University of California San Diego, La Jolla, CA, <sup>3</sup>University of Southern California, Los Angeles, CA
- 43 *Receipt of medications for opioid use disorder among youth: Data from 8 health systems*  
Sarah Bagley<sup>1</sup>, Laura Chavez<sup>2</sup>, Jordan Braciszewski<sup>3</sup>, Gavin Bart<sup>4</sup>, Bobbi Jo Yarborough<sup>5</sup>, Gwen Lapham<sup>6</sup>, Denise Boudreau<sup>6</sup>, Jeffrey Samet<sup>1</sup>, Andrew Saxon<sup>7</sup>, Cynthia Campbell<sup>8</sup>, Kathy Bradley<sup>6</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Ohio State University, Columbus, OH, <sup>3</sup>Henry Ford Health System, Detroit, MI, <sup>4</sup>University of Minnesota, Minneapolis, MN, <sup>5</sup>Kaiser Permanente Northwest Center for Health Research, Portland, OR, <sup>6</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA, <sup>7</sup>VA Puget Sound Healthcare System, Seattle, WA, <sup>8</sup>Kaiser Permanente North California Division of Research, Oakland, CA
- 44 *Injectors v. non-injectors: Baseline sample differences from a study of vivitrol treatment for youth with opioid use disorder*  
Shannon Mitchell<sup>1</sup>, Laura Monico<sup>1</sup>, Robert Schwartz<sup>1</sup>, Jan Gryczynski<sup>1</sup>, Kevin O'Grady<sup>2</sup>, Marc Fishman<sup>3</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>University of Maryland, College Park, MD, <sup>3</sup>Mountain Manor Treatment Center, Baltimore, MD
- 45 *Substance use and mental health trends in the adolescent population in Ontario, Canada*  
Bruna Brands<sup>1</sup>, Angela Boak<sup>2</sup>, Robert Mann<sup>2</sup>, Hayley Hamilton<sup>2</sup>, <sup>1</sup>Health Canada, Toronto, ON, Canada, <sup>2</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada
- 46 *Association of concern over societal increases in discrimination with substance use and mental health amongst adolescents during 2016-2017*  
Adam Leventhal, Junhan Cho, University of Southern California, Los Angeles, CA
- 47 *Does a major depression precursor state influence adolescent-onset heroin use? Epidemiologic case-control evidence*  
Alyssa Vanderziel<sup>1</sup>, James Anthony<sup>2</sup>, <sup>1</sup>Michigan State University, East Lansing, MI, <sup>2</sup>Michigan State University, Lansing, MI
- 48 *Depression among adolescent newly incident cannabis users from 2012 to 2015*  
Natalie Gukasyan<sup>1</sup>, Eric Strain<sup>2</sup>, <sup>1</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD
- 49 *Effects of modes of nicotine administration on depression*  
Sophia Holmqvist<sup>1</sup>, Sandra Brown<sup>2</sup>, Kevin Cummins<sup>2</sup>, <sup>1</sup>University of California San Diego, San Diego, CA, <sup>2</sup>University of California San Diego, La Jolla, CA

**POSTER I E**  
**CANNABINOIDS/THC**

**Sapphire ABC/EFG**  
**11:00 - 1:00 PM**

- 50 *Synthetic cannabinoid AM2201 induces epileptic seizures by enhancing glutamatergic transmission in the hippocampus*  
Masahiko Funada<sup>1</sup>, Mika Takebayashi-Ohsawa<sup>2</sup>, Tomiyama Kenichi<sup>3</sup>, <sup>1</sup>NIMH, NCNP, Kodaira, <sup>2</sup>NIMH, NCNP, Kodaira, Japan, <sup>3</sup>National Center of Neurology and Psychiatry, Kodaira, Japan
- 51 *Cannabinoid-like effects of five novel MDMB and FUBINACA synthetic cannabinoids*  
Michael Forster, Michael Gatch, University of Texas Health Science Center, Fort Worth, TX
- 52 *Synthetic and natural cannabinoid use in relation to psychosis: Evaluation of childhood trauma*  
Anahita Bassir Nia<sup>1</sup>, Claire Mann<sup>1</sup>, Sharron Spriggs<sup>1</sup>, Charles Perkel<sup>1</sup>, Lingyun Li<sup>2</sup>, Daniel DeFransosco<sup>1</sup>, Samantha Jankowski<sup>1</sup>, Nina-Lucia Rodriguez<sup>1</sup>, Hadi Estakhri<sup>1</sup>, Anna Oprescu<sup>1</sup>, Robert Linhardt<sup>3</sup>, Igor Galynker<sup>1</sup>, Yasmin Hurd<sup>1</sup>, <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2</sup>New York State Department of Health, New York, NY, <sup>3</sup>Rensselaer Polytechnic Institute, Troy, NY
- 53 *Effects of smoked cannabidiol on cardiovascular, subjective and reinforcing effects of smoked THC*  
Leslie Lundahl, Mark Greenwald, Wayne State University, Detroit, MI
- 54 *Pilot testing a novel signal-detection task of cannabis-cue attentional bias*  
Joseph Alcorn, William Stoops<sup>1</sup>, Craig Rush<sup>1</sup>, Joshua Lile<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 55 *Biological correlates of self-reported new and continued abstinence in cannabis cessation treatment clinical trials*  
Nathaniel Baker, Kevin Gray, Brian Sherman, Kristen Morella, Gregory Sahlem, Amanda Wagner, Aimee McRae-Clark, Medical University of South Carolina, Charleston, SC
- 56 *Predictors of craving and substance use among patients with alcohol, tobacco, cannabis or opiates addictions: Commonalities and specificities across substances*  
Fuschia Serre<sup>1</sup>, Melina Fatseas<sup>2</sup>, Cecile Denis<sup>3</sup>, Joel Swendsen<sup>4</sup>, Marc Auriacombe<sup>1</sup>, <sup>1</sup>Université de Bordeaux, Bordeaux, <sup>2</sup>Centre Hospitalier Charles Perrens, Bordeaux, France, <sup>3</sup>University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Université de Bordeaux, Bordeaux, France
- 57 *Real-time assessment of marijuana craving, mood, and anxiety among college student marijuana users*  
Kristina Phillips, Michael Phillips, Kerry Duck, University of Northern Colorado, Greeley, CO
- 58 *Demographic and clinical predictors of treatment retention in a randomized, placebo-controlled trial of quetiapine for Cannabis Use Disorder: A preliminary analysis*  
Mariely Hernandez<sup>1</sup>, John Mariani<sup>2</sup>, C. Jean Choi<sup>3</sup>, Daniel Brooks<sup>2</sup>, Frances Levin<sup>3</sup>, <sup>1</sup>The City University of New York, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY, <sup>3</sup>Columbia University and NYSPI, New York, NY
- 59 *Assessing cannabis use outcomes in a clinical trial for Cannabis Use Disorder: self-report, qualitative urine toxicology and quantitative urine toxicology approaches*  
Nicolas Schlienz<sup>1</sup>, Dustin Lee<sup>1</sup>, Erin Martin<sup>1</sup>, Ryan Vandrey<sup>2</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Behavioral Pharmacology Research Unit, Johns Hopkins Hospital, Baltimore, MD
- 60 *Measuring medicinal cannabis outcomes: Inconsistency between symptom outcome measures and patient perception of benefits*  
Mallory Loflin<sup>1</sup>, Travis Hyke<sup>2</sup>, Marcel Bonn-Miller<sup>3</sup>, <sup>1</sup>Veterans Affairs San Diego Healthcare System, San Diego, CA, <sup>2</sup>Palo Alto University, Los Altos, CA, <sup>3</sup>University of Pennsylvania, Southmont, NC
- 61 *Associations between abstinence and reduction in marijuana use and changes in mental and physical health well-being among primary care patients in Los Angeles*  
Chukwuemeka Okafor<sup>1</sup>, Steve Shoptaw<sup>1</sup>, Melvin Rico<sup>2</sup>, Lillian Gelberg<sup>2</sup>, <sup>1</sup>University of California Los Angeles, Los Angeles, CA, <sup>2</sup>University of California, Department of Family Medicine, Los Angeles, CA
- 62 *Factors related to severe substance use and substance use treatment attendance among hospitalized HIV infected patients: A machine learning approach*  
Daniel Feaster<sup>1</sup>, Yue Pan<sup>1</sup>, Raul Mandler<sup>2</sup>, Petra Jacobs<sup>3</sup>, Carlos del Rio<sup>4</sup>, Lisa Metsch<sup>5</sup>, <sup>1</sup>University of Miami

- Miller School of Medicine, Miami, FL, <sup>2</sup>Center for the Clinical Trails Network NIDA, Bethesda, MD, <sup>3</sup>National Institutes of Health, National Institute on Drug Abuse, Center for the Clinical Trials Network, Bethesda, MD, <sup>4</sup>Emory University, Atlanta, GA, <sup>5</sup>Columbia University, New York, NY
- 63 *Substance use and peer use from adolescence to adulthood in the MTA*  
Traci Kennedy<sup>1</sup>, Andrea Howard<sup>2</sup>, James Swanson<sup>3</sup>, John Mitchell<sup>4</sup>, Annamarie Stehli<sup>3</sup>, Brooke Molina<sup>1</sup>,  
<sup>1</sup>University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Carleton University, Department of Psychology, Ottawa, ON, Canada, <sup>3</sup>University of California Irvine, Irvine, CA, <sup>4</sup>Duke University School of Medicine, Durham, NC
- 64 *Patterns of drug use among gay men and their relationship partners: A latent class analysis*  
Gabriel Robles<sup>1</sup>, Jeffrey Parsons<sup>2</sup>, Mark Pawson<sup>3</sup>, Tyrel Starks<sup>2</sup>, <sup>1</sup>Hunter College Center for HIV Educational Studies & Training, New York, NY, <sup>2</sup>Hunter College, CUNY, New York City, NY, <sup>3</sup>Graduate Center and CHEST, New York, NY
- 65 *Cannabis in end-of-life care: Examining the attitudes and practices of palliative care providers*  
Rachel Luba<sup>1</sup>, Mitch Earleywine<sup>1</sup>, Melissa Slavin<sup>1</sup>, Stacey Farmer<sup>2</sup>, <sup>1</sup>State University of New York at Albany, Albany, NY, <sup>2</sup>McLean Hospital, Brain Imaging Center, Belmont, MA
- 66 *Potential risks of cannabis vaping and edible use*  
Connor Jones, Madeline Meier, Arizona State University, Tempe, AZ
- 67 *Changes in driving under the influence of cannabis in the US from 2001-2002 to 2012-2013*  
Bradley Kerridge<sup>1</sup>, Roger Pickering<sup>2</sup>, June Ruan<sup>2</sup>, Patricia Chou<sup>2</sup>, <sup>1</sup>NIH, NIAAA, Bethesda, MD, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 68 *Driving under the influence of cannabis among medical cannabis patients*  
Erin Bonar<sup>1</sup>, Brooke Arterberry<sup>1</sup>, James Cranford<sup>1</sup>, Maureen Walton<sup>2</sup>, Kipling Bohnert<sup>2</sup>, Mark Ilgen<sup>1</sup>,  
<sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Michigan, Addiction Center, Ann Arbor, MI
- 69 *Evaluating perceived risk of driving under the influence of cannabis and driving behavior*  
Jacob Borodovsky<sup>1</sup>, Lisa Marsch<sup>1</sup>, Emily Scherer<sup>2</sup>, Alan Budney<sup>3</sup>, <sup>1</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, <sup>2</sup>Dartmouth College, Hanover, NH, <sup>3</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH
- 70 *Sex differences in the effects of cannabis on simulated driving performance*  
Andrew Fares<sup>1</sup>, Justin Matheson<sup>1</sup>, Robert Mann<sup>1</sup>, Bernard LeFoll<sup>1</sup>, Christine Wickens<sup>1</sup>, Bruna Brands<sup>2</sup>,  
<sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Health Canada, Toronto, ON, Canada

## POSTER I F HIV

**Sapphire ABC/EFG  
11:00 - 1:00 PM**

- 71 *Art adherence among opiate addicted patients treated with naltrexone: Oral and implantable*  
Tatiana Yaroslavtseva<sup>1</sup>, Elena Blokhina<sup>1</sup>, Evgeny Krupitsky<sup>2</sup>, Elena Vladimirovna Verbitskaya<sup>1</sup>, Edwin Zvartau<sup>1</sup>, Vladimir Palatkin<sup>3</sup>, Natalia Bushara<sup>3</sup>, Robert Gross<sup>4</sup>, George Woody<sup>4</sup>, Sabrina Poole<sup>4</sup>, <sup>1</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, <sup>2</sup>V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russian Federation, <sup>3</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, <sup>4</sup>University of Pennsylvania, Philadelphia, PA
- 72 *Mixed-methods study estimating the impact and feasibility of providing HIV antiretroviral treatment (ART) and opioid agonist therapy (OAT) in prison and upon release on HIV incidence among people who inject drugs (PWID) in Tijuana, Mexico*  
Annick Borquez<sup>1</sup>, Daniela Abramovitz<sup>1</sup>, Leo Beletsky<sup>2</sup>, Steffanie Strathdee<sup>1</sup>, Natasha Martin<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>Northeastern University, Boston, MA
- 73 *HIV clinic-based buprenorphine versus methadone impact on the HIV care continuum in Vietnam: BRAVO*



*study 6-Month outcomes*

Philip Todd Korthuis<sup>1</sup>, Gavin Bart<sup>2</sup>, Lynn Kunkel<sup>1</sup>, Thuan Nguyen<sup>1</sup>, Giang Le<sup>3</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>University of Minnesota, Minneapolis, MN, <sup>3</sup>Hanoi Medical University, Hanoi, Viet Nam

- 74 *Engaging in the HIV care continuum: Do opioid users differ from those who use other substances?*  
Lacey Critchley<sup>1</sup>, Adam Carrico<sup>1</sup>, Raul Mandler<sup>2</sup>, Petra Jacobs<sup>3</sup>, Allan Rodriguez<sup>1</sup>, Carlos del Rio<sup>4</sup>, Lisa Metsch<sup>5</sup>, Daniel Feaster<sup>6</sup>, <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>Center for the Clinical Trails Network NIDA, Bethesda, MD, <sup>3</sup>National Institutes of Health, National Institute on Drug Abuse, Center for the Clinical Trials Network, Bethesda, MD, <sup>4</sup>Emory University, Atlanta, GA, <sup>5</sup>Columbia University, New York, NY, <sup>6</sup>University of Miami Miller School of Medicine, Miami, FL
- 75 *HIV continuum of care disparities among Latinos with a history of injection drug use*  
Diana Sheehan, Florida International University, Miami, FL
- 76 *Structural determinants of community viral load trends in New York City (2009-2013)*  
Amar Mandavia<sup>1</sup>, Raksha Kandlur<sup>1</sup>, Daniel Samost<sup>1</sup>, Videesha Bordoloi<sup>1</sup>, Gurmehar Juneja<sup>1</sup>, Nabila El-Bassel<sup>2</sup>, <sup>1</sup>Columbia University, Teachers College, New York, NY, <sup>2</sup>Columbia University, New York, NY
- 77 *Reported substance use and HIV testing among emergency department patients who complete a tablet-based intervention*  
Ian Aronson<sup>1</sup>, Charles Cleland<sup>2</sup>, Lisa Marsch<sup>3</sup>, Theodore Bania<sup>4</sup>, <sup>1</sup>Digital Health Empowerment / NDRI, Brooklyn, NY, <sup>2</sup>NYU Rory Meyers College of Nursing, New York, NY, <sup>3</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, <sup>4</sup>Mount Sinai School of Medicine, New York, NY
- 78 *Interest in HIV PrEP and medications to treat opioid use disorder at a drug detoxification center*  
Sabrina Assoumou<sup>1</sup>, Samantha Paniagua<sup>1</sup>, Curt Beckwith<sup>2</sup>, Jianing Wang<sup>3</sup>, Jeffrey Samet<sup>1</sup>, Jonathan Hall<sup>3</sup>, Benjamin Linas<sup>1</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Brown University, Providence, RI, <sup>3</sup>Boston Medical Center, Boston, MA
- 79 *Length of time injecting and its association with receptive syringe sharing among persons who inject drugs in Philadelphia, PA*  
Jennifer Shinefeld<sup>1</sup>, Sarah Bass<sup>2</sup>, Robert Whitaker<sup>2</sup>, Kathleen Brady<sup>1</sup>, <sup>1</sup>Philadelphia Department of Public Health, Philadelphia, PA, <sup>2</sup>Temple University, Philadelphia, PA
- 80 *Prediction of viral suppression and HIV treatment adherence among hospitalized HIV infected patients using supervised learning algorithms*  
Yue Pan<sup>1</sup>, Lisa Metsch<sup>2</sup>, Raul Mandler<sup>3</sup>, Petra Jacobs<sup>4</sup>, Carlos del Rio<sup>5</sup>, Daniel Feaster<sup>1</sup>, <sup>1</sup>University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>Center for the Clinical Trails Network NIDA, Bethesda, MD, <sup>4</sup>National Institutes of Health, National Institute on Drug Abuse, Center for the Clinical Trials Network, Bethesda, MD, <sup>5</sup>Emory University, Atlanta, GA
- 81 *Do persons with opioid use disorder and injection-related infections really need prolonged hospitalizations to complete intravenous antibiotic therapy?*  
Laura Fanucchi<sup>1</sup>, Sharon Walsh<sup>2</sup>, Alice Thornton<sup>1</sup>, Paul Nuzzo<sup>2</sup>, Michelle Lofwall<sup>1</sup>, <sup>1</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>2</sup>University of Kentucky, Lexington, KY
- 82 *Effects of reduced drug use on HIV outcomes in primary care patients*  
Efrat Aharonovich<sup>1</sup>, Malka Stohl<sup>2</sup>, Deborah Hasin<sup>3</sup>, <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY, <sup>3</sup>Columbia University, New York, NY
- 83 *Effectiveness of an addiction treatment program integrated in an HIV clinic: Results of a 4-year program in Ho Chi Minh, Vietnam*  
Cecile Denis<sup>1</sup>, Loan Nguyen<sup>2</sup>, Huy Tran<sup>2</sup>, Song Chi Trung Nguyen<sup>3</sup>, Vincent Trias<sup>2</sup>, Augustin Voisin<sup>4</sup>, Lisa Huang<sup>2</sup>, Son Mai Thi Hoai<sup>5</sup>, Giang Le Truong<sup>5</sup>, Marc Auriacombe<sup>6</sup>, Jean-Pierre Daulouede<sup>4</sup>, David Metzger<sup>1</sup>,

- Charles O'Brien , University of Pennsylvania, Philadelphia, PA, Expertise France, France, France,  
<sup>3</sup>Expertise France Vietnam, Ho Chi Minh City, Vietnam, <sup>4</sup>Bizia Addiction Clinic, Bayonne, <sup>5</sup>HCMC AIDS  
 Committee, Ho Chi Minh City, Vietnam, <sup>6</sup>Université de Bordeaux, Bordeaux, <sup>7</sup>University of Pennsylvania,  
 VA Medical Center, Philadelphia, PA
- 84 *The role of nominal group technique in scaling up opioid agonist treatment in Ukraine*  
 Lynn Madden<sup>1</sup>, Anna Meteliuk<sup>2</sup>, Scott Farnum<sup>1</sup>, Tetiana Fomenko<sup>3</sup>, Ruthanne Marcus<sup>4</sup>, Iryna Pykalo<sup>5</sup>,  
 Katherine LaMonaca<sup>4</sup>, Declan Barry<sup>4</sup>, Frederick Alice<sup>4</sup>, <sup>1</sup>APT Foundation, Inc., New Haven, CT, <sup>2</sup>ICF  
 Alliance for Public Health, Kyiv, Ukraine, <sup>3</sup>ICF Alliance for Public Health, Kiev, Ukraine, <sup>4</sup>Yale University  
 School of Medicine, New Haven, CT, <sup>5</sup>Ukrainian Institute on Public Health Policy, Kyiv, Ukraine
- 85 *Mortality rate among people who Inject drugs (PWID) in Haiphong, Vietnam: High burden of probable  
 infectious causes*  
 Nicolas Nagot<sup>1</sup>, Don Des Jarlais<sup>2</sup>, the DRIVE Study team<sup>1</sup>, <sup>1</sup>University of Montpellier, Montpellier, France,  
<sup>2</sup>Icahn School of Medicine at Mount Sinai, New York, NY
- 86 *Double stigma among HIV-positive PWID in Russia and health care outcomes*  
 Karsten Lunze<sup>1</sup>, Debbie Cheng<sup>1</sup>, Maryia Vetrova<sup>2</sup>, Christine Lloyd-Travaglini<sup>1</sup>, Elena Blokhina<sup>3</sup>, Sally  
 Bendiks<sup>4</sup>, Natalia Gnatienco<sup>1</sup>, Jason Luoma<sup>5</sup>, Evgeny Krupitsky<sup>6</sup>, Dmitry Lioznov<sup>3</sup>, Jeffrey Samet<sup>1</sup>, <sup>1</sup>Boston  
 University School of Medicine, Boston, MA, <sup>2</sup>First Pavlov State Medical University of St. Petersburg, St.  
 Petersburg, <sup>3</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation,  
<sup>4</sup>Boston Medical Center, Boston, MA, <sup>5</sup>Portland Psychotherapy Clinic, Research, & Training Center, Portland,  
 OR, <sup>6</sup>V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg,  
 Russian Federation

## POSTER I G PRESCRIPTION OPIOIDS

**Sapphire ABC/EFG  
 11:00 - 1:00 PM**

- 87 *Development of a brief screening tool to assess prescription opioid dependence*  
 Suzanne Nielsen<sup>1</sup>, Briony Larance<sup>2</sup>, Gabrielle Campbell<sup>2</sup>, Louisa Degenhardt<sup>3</sup>, Nicholas Lintzeris<sup>4</sup>, Fiona  
 Blyth<sup>5</sup>, Michael Farrell<sup>3</sup>, Richard Mattick<sup>1</sup>, Raimondo Bruno<sup>6</sup>, <sup>1</sup>University of New South Wales, Sydney,  
 Australia, <sup>2</sup>University of South Wales, Sydney, Australia, <sup>3</sup>National Drug and Alcohol Research Centre,  
 Sydney, Australia, <sup>4</sup>Drug and Alcohol Services, South Eastern Sydney Local Health District, Surry Hills,  
 Australia, <sup>5</sup>University of Sydney, Sydney, Australia, <sup>6</sup>University of Tasmania, Sydney, Australia
- 88 *The utility of the pain medication questionnaire to predict aberrant urine drug tests: Results from a  
 prospective cohort study*  
 Ben Morasco<sup>1</sup>, Travis Lovejoy<sup>1</sup>, Steven Dobscha<sup>1</sup>, Richard Deyo<sup>2</sup>, Megan Iacocca<sup>1</sup>, Stephanie Hyde<sup>2</sup>, Bobbi  
 Jo Yarborough<sup>3</sup>, <sup>1</sup>VA Portland Health Care System, Portland, OR, <sup>2</sup>Oregon Health & Science University,  
 Portland, OR, <sup>3</sup>Kaiser Permanente Northwest Center for Health Research, Portland, OR
- 89 *Comparative effectiveness of non-opioid and long-term opioid therapy for pain and health-related outcomes*  
 Ainhoa Coloma-Carmona<sup>1</sup>, José Carballo<sup>1</sup>, Jesús Rodríguez-Marín<sup>1</sup>, Ana Pérez-Carbonell<sup>2</sup>, Carlos Van-der  
 Hofstadt Román<sup>1</sup>, Roberto Secades Villa<sup>3</sup>, Sergio Fernandez-Artamendi<sup>4</sup>, <sup>1</sup>Miguel Hernández University,  
 Elche, Spain, <sup>2</sup>General University Hospital of Elche, Elche, Spain, <sup>3</sup>University of Oviedo, Oviedo, Spain,  
<sup>4</sup>Universidad Loyola Andalucía, Sevilla, Spain
- 90 *Non-medical use of prescription drugs and health-related quality of life among the general population in  
 Taiwan: Results from the 2014 National Survey of Substance Use*  
 Shang-Chi Wu<sup>1</sup>, Wen-Ing Tsay<sup>2</sup>, Chuan-Yu Chen<sup>3</sup>, Jui Hsu<sup>2</sup>, Wei-J Chen<sup>4</sup>, <sup>1</sup>National Taiwan University,

- Epidemiology and Preventive Medicine, Taipei City, Taiwan Food and Drug Administration, Taipei,  
<sup>3</sup>National Yang-Ming University, Taipei, Taiwan, <sup>4</sup>National Taiwan University, Taipei City
- 91 *European opioid addiction treatment survey – EUROPAD – The France experience*  
 Manon Chevalier<sup>1</sup>, Jean-Pierre Daulouede<sup>2</sup>, Fuschia Serre<sup>3</sup>, Didier Touzeau<sup>4</sup>, Amine Benyamina<sup>5</sup>, Carolina Baran<sup>5</sup>, Pierre Villegier<sup>6</sup>, Melina Fatseas<sup>7</sup>, Marc Auriacombe<sup>3</sup>, <sup>1</sup>Université de Bordeaux, Bordeaux, France, <sup>2</sup>Bizia Addiction Clinic, Bayonne, <sup>3</sup>Université de Bordeaux, Bordeaux, <sup>4</sup>Addiction Clinic, CH Paul Guiraud, Bagneux, France, <sup>5</sup>Addiction Clinic, Paul Brousse Hospital, Villejuif, France, <sup>6</sup>Addiction Clinic, CH Esquirol, Limoges, France, <sup>7</sup>Centre Hospitalier Charles Perrens, Bordeaux, France
- 92 *Opioid prescriptions in the year prior to admission to opioid use disorder treatment*  
 Gillian Leichtling<sup>1</sup>, Daniel Hartung<sup>2</sup>, Kirbee Johnston<sup>2</sup>, Christi Hildebran<sup>1</sup>, Philip Todd Korthuis<sup>3</sup>,  
<sup>1</sup>HealthInsight, Portland, OR, <sup>2</sup>Oregon State University/ Oregon Health & Science University College of Pharmacy, Portland, OR, <sup>3</sup>Oregon Health & Science University, Portland, OR
- 93 *Comparing prescription opioids, methadone, and heroin rates from the treatment episode data set to the RADARS® System Treatment Center Programs*  
 Heather Olsen<sup>1</sup>, Stevan Severtson<sup>1</sup>, John Schwarz<sup>1</sup>, Matthew Ellis<sup>2</sup>, Theodore Cicero<sup>2</sup>, Richard Dart<sup>1</sup>, <sup>1</sup>Rocky Mountain Poison & Drug Center, Denver, CO, <sup>2</sup>Washington University, St. Louis, MO
- 94 *Differences between misusers of buprenorphine and other prescription opioids*  
 Howard Chilcoat<sup>1</sup>, Andrew Joyce<sup>2</sup>, Silvia Martins<sup>3</sup>, <sup>1</sup>Indivior Inc., Richmond, VA, <sup>2</sup>Venebio Group, LLC, North Chesterfield, VA, <sup>3</sup>Columbia University, New York, NY
- 95 *Prescription opioid sources for misuse in older adults*  
 Ty Schepis<sup>1</sup>, Christian Teter<sup>2</sup>, Sean McCabe<sup>3</sup>, <sup>1</sup>Texas State University, San Marcos, TX, <sup>2</sup>Psychopharmacology Consultant, Portland, ME, <sup>3</sup>University of Michigan, Ann Arbor, MI
- 96 *Sources of prescription drug misuse among US emerging adults*  
 Sean McCabe<sup>1</sup>, Carol Boyd<sup>1</sup>, Christian Teter<sup>2</sup>, Brady West<sup>1</sup>, Philip Veliz<sup>1</sup>, Jason Ford<sup>3</sup>, Corey Pomykacz<sup>3</sup>, Ty Schepis<sup>4</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Psychopharmacology Consultant, Portland, ME, <sup>3</sup>University of Central Florida, Orlando, FL, <sup>4</sup>Texas State University, San Marcos, TX
- 97 *How characteristics of nonmedical prescription opioid use in adolescence relates to substance use disorder symptoms in adulthood*  
 Philip Veliz<sup>1</sup>, John Schulenberg<sup>1</sup>, Carol Boyd<sup>1</sup>, Ty Schepis<sup>2</sup>, Sean McCabe<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Texas State University, San Marcos, TX
- 98 *Prevalence and predictors of driving after prescription opioid use in an adult emergency department sample*  
 Aaron Dora-Laskey, Jason Goldstick, Brooke Arterberry, Suni Jo Roberts, Amy Bohnert, Patrick Carter, University of Michigan, Ann Arbor, MI
- 99 *Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: A pilot randomized controlled trial*  
 Emily Behar<sup>1</sup>, Glenn-Milo Santos<sup>2</sup>, Christopher Rowe<sup>1</sup>, Talia Rubin<sup>1</sup>, Janelle Silvis<sup>1</sup>, Eric Vittinghoff<sup>2</sup>, Phillip Coffin<sup>1</sup>, <sup>1</sup>San Francisco Department of Public Health, San Francisco, CA, <sup>2</sup>University of California San Francisco, San Francisco, CA
- 100 *County-level overdose deaths and prescription opioid dispensing patterns in Ohio*  
 Erin Winstanley<sup>1</sup>, Brian Hendricks<sup>1</sup>, Yifan Zhang<sup>1</sup>, Cameron McNamee<sup>2</sup>, Alexandria Castracane<sup>3</sup>, Gordon Smith<sup>1</sup>, <sup>1</sup>West Virginia University, Morgantown, WV, <sup>2</sup>State of Ohio Board of Pharmacy, Columbus, OH, <sup>3</sup>West Virginia University School of Pharmacy, Morgantown, WV
- 101 *Prescription drug monitoring programs and opioid overdoses: Exploring sources of heterogeneity*  
 Alvaro Castillo-Carniglia<sup>1</sup>, William Ponicki<sup>2</sup>, Andrew Gaidus<sup>2</sup>, Paul Gruenewald<sup>2</sup>, Brandon Marshall<sup>3</sup>, David Fink<sup>4</sup>, Silvia Martins<sup>5</sup>, Ariadne Rivera-Aguirre<sup>1</sup>, Garen Wintemute<sup>6</sup>, Magdalena Cerda<sup>1</sup>, <sup>1</sup>University of

California Davis, Sacramento, CA, <sup>2</sup>Prevention Research Center, Pacific Institute for Research and Evaluation, Oakland, CA, <sup>3</sup>Brown School of Public Health, Providence, RI, <sup>4</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>5</sup>Columbia University, New York, NY, <sup>6</sup>Violence Prevention Research Program, Department of Emergency Medicine, UC Davis School of Medicine, Sacramento, CA

102 *The relationship between quantity of cannabis use and prescription opioids misuse in medical cannabis patients*

Mark Ilgen<sup>1</sup>, Kipling Bohnert<sup>2</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Michigan, Addiction Center, Ann Arbor, MI

103 *Stimulant prescription drug misuse types, motives and use disorder symptoms among U.S. young adults*

Christian Teter<sup>1</sup>, Ty Schepis<sup>2</sup>, Cody Black<sup>3</sup>, Sean McCabe<sup>4</sup>, <sup>1</sup>Psychopharmacology Consultant, Portland, ME, <sup>2</sup>Texas State University, San Marcos, TX, <sup>3</sup>University of New England, Portland, ME, <sup>4</sup>University of Michigan, Ann Arbor, MI

104 *Alcohol use disorder and motives for prescription opioid misuse*

Victoria Votaw<sup>1</sup>, R. Kathryn McHugh<sup>2</sup>, Katie Witkiewitz<sup>1</sup>, <sup>1</sup>University of New Mexico, Albuquerque, NM, <sup>2</sup>McLean Hospital, Belmont, MA

## POSTER I H EPIDEMIOLOGY I

**Sapphire ABC/EFG  
11:00 - 1:00 PM**

105 *Opioid misuse among Latino primary care patients in Los Angeles*

Melvin Rico<sup>1</sup>, Lillian Gelberg<sup>1</sup>, Chukwuemeka Okafor<sup>2</sup>, <sup>1</sup>University of California, Department of Family Medicine, Los Angeles, CA, <sup>2</sup>University of California Los Angeles, Los Angeles, CA

106 *Trends in engagement in the cascade of care for opioid use disorders, Vancouver, Canada, 2006-2016*

M. Eugenia Socias<sup>1</sup>, Evan Wood<sup>2</sup>, Thomas Kerr<sup>2</sup>, Seonaid Nolan<sup>1</sup>, Kanna Hayashi<sup>3</sup>, Ekaterina Nosova<sup>3</sup>, julio montaner<sup>2</sup>, MJ Milloy<sup>2</sup>, <sup>1</sup>University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>University of British Columbia, Vancouver, <sup>3</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver

107 *The impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada*

Joseph Eibl, David Marsh, Northern Ontario School of Medicine, Sudbury, ON, Canada

108 *Estimating the proportion of crimes caused by alcohol and other drugs in Canada, 2007- 2014*

Matthew Young, Canadian Centre on Substance Abuse, Ottawa, ON, Canada

109 *Trends in illicit drug use among cigarette smokers in the US, 2002-2014*

Scott Moeller<sup>1</sup>, David Fink<sup>2</sup>, Misato Gbedemah<sup>3</sup>, Deborah Hasin<sup>4</sup>, Sandro Galea<sup>5</sup>, Michael Zvolensky<sup>6</sup>, Renee Goodwin<sup>7</sup>, <sup>1</sup>Stony Brook University, Stony Brook, NY, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>3</sup>CUNY Graduate School of Public Health and Health Policy, New York, NY, <sup>4</sup>Columbia University, New York, NY, <sup>5</sup>Boston University School of Public Health, Boston, MA, <sup>6</sup>University of Houston, Houston, TX, <sup>7</sup>The City University of New York, New York, NY

110 *Zero-inflated Poisson growth curve modeling of substance use among young sexual minority men from ages 18 through 21: The P18 Cohort Study*

Danielle Ompad<sup>1</sup>, Stephanie Cook<sup>2</sup>, Richard Marino<sup>2</sup>, Sophia Halkitis<sup>2</sup>, Farzana Kapadia<sup>2</sup>, Perry Halkitis<sup>3</sup>, <sup>1</sup>New York University, College of Public Health, New York, NY, <sup>2</sup>New York University College of Global Public Health, New York, NY, <sup>3</sup>Rutgers University, Piscataway, NJ

111 *Educational achievement of monthly marijuana, tobacco, and alcohol users*

Charles Whitmore<sup>1</sup>, Susan Mikulich-Gilbertson<sup>2</sup>, Shannon McWilliams<sup>2</sup>, Robin Corley<sup>3</sup>, Michael Stallings<sup>1</sup>, John Hewitt<sup>1</sup>, Christian Hopfer<sup>2</sup>, <sup>1</sup>University of Colorado, Aurora, CO, <sup>2</sup>University of Colorado School of

- Medicine, Aurora, CO, Institute for Behavioral Genetics, Boulder, CO
- 112 *Cannabis use and changes in body weight studied prospectively: New estimates for the US*  
Omayma Alshaarawy, James Anthony, Michigan State University, Lansing, MI
- 113 *Characterizing the preferences and practices of those who use marijuana for medical purposes*  
Andrew Fiore, Dominique Easterling, University of Florida, Gainesville, FL
- 114 *Diverging trends in cannabis and cigarette use among youth with depression in the United States, 2002-2016*  
Andrea Weinberger<sup>1</sup>, Misato Gbedemah<sup>2</sup>, Renee Goodwin<sup>3</sup>, <sup>1</sup>Yeshiva University, New York, NY, <sup>2</sup>CUNY  
Graduate School of Public Health and Health Policy, New York, NY, <sup>3</sup>The City University of New York, New  
York, NY
- 115 *Cannabis use disorder among cannabis users by frequency of use in the USA, 2002–2014*  
Julian Santaella-Tenorio<sup>1</sup>, Shivani Mantha<sup>2</sup>, Emily Boller<sup>1</sup>, Luis Segura<sup>1</sup>, Pia Mauro<sup>1</sup>, Christine Mauro<sup>1</sup>,  
Silvia Martins<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Columbia University Mailman School of Public  
Health, New York, NY
- 116 *Patterns of past 30 day concurrent use of drugs among varying age cohorts: Self-reported data from  
community members*  
Catherine Woodstock Striley<sup>1</sup>, Mirsada Serdarevic<sup>1</sup>, Bertha Madras<sup>2</sup>, Henry Young<sup>1</sup>, Linda Cottler<sup>1</sup>,  
<sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>McLean Hospital, Belmont, MA
- 117 *Analyzing the initiation of marijuana use in adulthood*  
Shawnta Lloyd<sup>1</sup>, Linda Cottler<sup>2</sup>, Catherine Woodstock Striley<sup>2</sup>, <sup>1</sup>University of Florida, College of Public  
Health and Health Professions, Gainesville, FL, <sup>2</sup>University of Florida, Gainesville, FL
- 118 *Neuropsychological impairment in older adult cannabis users*  
Madeline Meier, Arizona State University, Tempe, AZ
- 119 *Medicaid expansion and treatment for opioid use disorders in Oregon*  
Dennis McCarty, Yifan Gu, Stephanie Renfro, Robin Baker, Bonnie Lind, Oregon Health & Science  
University, Portland, OR
- 120 *Preventing injection initiation: The challenge of high frequency initiators among people who inject drugs*  
Ricky Bluthenthal<sup>1</sup>, Lynn Wenger<sup>2</sup>, Kelsey Simpson<sup>1</sup>, Carol Strike<sup>3</sup>, Alex Kral<sup>4</sup>, <sup>1</sup>Keck School of Medicine  
University of Southern California, Los Angeles, CA, <sup>2</sup>RTI International, San Francisco, CA, <sup>3</sup>Dalla Lana  
School of Public Health University of Toronto, Toronto, ON, Canada, <sup>4</sup>RTI International, Research Triangle  
Park, NC
- 121 *Reasons for assisting with injection initiation: Results from a large survey of people who inject drugs in Los  
Angeles and San Francisco, California, 2016/17.*  
Kelsey Simpson<sup>1</sup>, Alex Kral<sup>2</sup>, Lynn Wenger<sup>3</sup>, Carol Strike<sup>4</sup>, Ricky Bluthenthal<sup>1</sup>, <sup>1</sup>Keck School of Medicine  
University of Southern California, Los Angeles, CA, <sup>2</sup>RTI International, Research Triangle Park, NC, <sup>3</sup>RTI  
International, San Francisco, CA, <sup>4</sup>Dalla Lana School of Public Health University of Toronto, Toronto, ON,  
Canada
- 122 *Enrollment in medication-assisted treatment and its association with injection initiation assistance in  
Vancouver, Canada*  
Maria Luisa Mittal<sup>1</sup>, Sonia Jain<sup>2</sup>, Kanna Hayashi<sup>3</sup>, M-J Milloy<sup>4</sup>, Kora DeBeck<sup>3</sup>, Shelly Sun<sup>2</sup>, Dan Werb<sup>2</sup>,  
<sup>1</sup>University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA,  
<sup>2</sup>University of California San Diego, La Jolla, CA, <sup>3</sup>BC Centre for Excellence in HIV/AIDS, Vancouver,  
<sup>4</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver
- 123 *Receipt of medications for opioid use disorder after injection drug associated endocarditis or osteomyelitis*  
Simeon Kimmel<sup>1</sup>, Alexander Walley<sup>1</sup>, Dana Bernson<sup>2</sup>, Thomas Land<sup>2</sup>, Benjamin Linas<sup>1</sup>, Marc Laroche<sup>1</sup>,  
<sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Massachusetts Department of Public Health, Boston,  
MA

- 124 *Trends in receptive syringe sharing and correlates of 'ever' sharing among a cohort of people who inject drugs regularly in Melbourne, Australia*  
Danielle Horyniak, Daniel O'Keefe, Penny Hill, Jessica Howell, Paul Dietze, Burnet Institute, Melbourne, Australia
- 125 *Men who have sex with men and inject drugs in a Canadian setting*  
Ayden Scheim<sup>1</sup>, Rod Knight<sup>2</sup>, Hennady Shulha<sup>2</sup>, Ekaterina Nosova<sup>3</sup>, Kanna Hayashi<sup>3</sup>, M-J Milloy<sup>3</sup>, Thomas Kerr<sup>4</sup>, Kora DeBeck<sup>3</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>British Columbia Centre on Substance Use, Vancouver, BC, Canada, <sup>3</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, <sup>4</sup>University of British Columbia, BC Centre on Substance Use, Vancouver, BC, Canada
- 126 *Shooting gallery networks and risk: Women's injection venue affiliation networks in Tijuana, Mexico*  
Brooke West<sup>1</sup>, Patricia Gonzalez-Zuniga<sup>1</sup>, James Fowler<sup>1</sup>, Kimberly Brouwer<sup>2</sup>, Steffanie Strathdee<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>University of California San Diego, San Diego, CA
- 127 *Heroin resurgence: Evidence from a national study of harm reduction among people who inject drugs (PWID)*  
Usaney Perngpan<sup>1</sup>, Chitlada Areesantichai<sup>1</sup>, Linda Cottler<sup>2</sup>, <sup>1</sup>Chulalongkorn University, Bangkok, Thailand, <sup>2</sup>University of Florida, Gainesville, FL

## POSTER I I POLYDRUG ABUSE I

**Sapphire ABC/EFG**  
**11:00 - 1:00 PM**

- 128 *Factors associated with inability to access health clinics among people who inject drugs in a Canadian setting with universal healthcare*  
Rupinder Brar<sup>1</sup>, Seonaid Nolan<sup>1</sup>, Ekaterina Nosova<sup>2</sup>, M-J Milloy<sup>2</sup>, Kora DeBeck<sup>2</sup>, Evan Wood<sup>3</sup>, Kanna Hayashi<sup>4</sup>, <sup>1</sup>University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, <sup>3</sup>University of British Columbia, Vancouver, <sup>4</sup>Simon Fraser University, Vancouver, BC, Canada
- 129 *Do incentives and alerts have a modifying effect on the impact of clients' travel time on continuity after discharge?*  
Deborah Garnick<sup>1</sup>, Constance Horgan<sup>2</sup>, Margaret Lee<sup>3</sup>, Andrea Acevedo<sup>4</sup>, Lee Panas<sup>3</sup>, Grant Ritter<sup>3</sup>, Kevin Campbell<sup>5</sup>, <sup>1</sup>Brandeis University, Waltham, MA, <sup>2</sup>Brandeis University, Heller School for Social Policy and Management, Waltham, MA, <sup>3</sup>Institute for Behavioral Health, Brandeis University, Waltham, MA, <sup>4</sup>Tufts University, Medford, MA, <sup>5</sup>Behavioral Health Administration, Olympia, WA
- 130 *A shared parameter pattern-mixture model as a 'missing not at random' sensitivity analysis for substance use disorder randomized clinical trials*  
Sterling McPherson<sup>1</sup>, Ekaterina Burduli<sup>2</sup>, David Ihle<sup>2</sup>, Michael Orr<sup>3</sup>, Crystal Smith<sup>4</sup>, John Roll<sup>4</sup>, <sup>1</sup>Washington State University, Elson S. Floyd College of Medicine, Spokane, WA, <sup>2</sup>Washington State University, Spokane, WA, <sup>3</sup>Washington State University College of Nursing, Spokane, WA, <sup>4</sup>Washington State University, Pullman, WA
- 131 *Combining the WLSMV estimator with multiple imputation for categorical outcomes in substance use disorder randomized clinical trials*  
Ekaterina Burduli<sup>1</sup>, David Ihle<sup>1</sup>, Michael Orr<sup>2</sup>, Crystal Smith<sup>3</sup>, John Roll<sup>3</sup>, Sterling McPherson<sup>4</sup>, <sup>1</sup>Washington State University, Spokane, WA, <sup>2</sup>Washington State University College of Nursing, Spokane, WA, <sup>3</sup>Washington State University, Pullman, WA, <sup>4</sup>Washington State University, Elson S. Floyd College of Medicine, Spokane, WA
- 132 *Understanding the impact and sources of site differences in a multisite clinical trial of a technology-delivered psychosocial intervention for substance use disorders*

1

2

2

3

2 1

- Martina Pavlicova , Leila Vaezazizi , Aimee Campbell , Mei-Chen Hu , Edward Nunes , Columbia University Mailman School of Public Health, New York, NY, <sup>2</sup>Columbia University and NYSPI, New York, NY, <sup>3</sup>Columbia University, New York, NY
- 133 *Examining the influence of individualized homophily over neighbor engagement in those with substance use experience using the social interactome*  
Derek Pope, Virginia Tech Carilion Research Institute, Roanoke, VA
- 134 *Opioid and benzodiazepine co-use among women associated with binge drinking*  
Jennifer Lorvick<sup>1</sup>, Barrot Lambdin<sup>2</sup>, Megan Comfort<sup>2</sup>, Alex Kral<sup>2</sup>, <sup>1</sup>RTI International, San Francisco, CA, <sup>2</sup>RTI International, Research Triangle Park, NC
- 135 *Substance use and sleep in pre-deployed US Army soldiers*  
Alexxa Bessey<sup>1</sup>, Alexa Lopez<sup>2</sup>, Maria St. Pierre<sup>3</sup>, Lillian Skeiky<sup>3</sup>, Walter Sowden<sup>3</sup>, <sup>1</sup>Walter Reed Army Institute of Research, Washington, DC, <sup>2</sup>US Army Medical Research Directorate-West, Tacoma, WA, <sup>3</sup>Walter Reed Army Institute of Research, Silver Spring, MD
- 136 *Prevalence of clinical insomnia in a residential substance use disorder population*  
Denis Antoine<sup>1</sup>, Traci Speed<sup>2</sup>, Eric Strain<sup>1</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Johns Hopkins Hospital, Baltimore, MD
- 137 *Leveraging the patient-counselor relationship to reduce sexual risk behavior: Results from a multi-site study in substance use disorder treatment programs*  
Mary Hatch-Maillette<sup>1</sup>, Robin Harwick<sup>1</sup>, Tatiana Masters<sup>1</sup>, John Baer<sup>2</sup>, Lynette Wright<sup>1</sup>, Blair Beadnell<sup>1</sup>, Elizabeth Wells<sup>1</sup>, <sup>1</sup>University of Washington Alcohol & Drug Abuse Institute, Seattle, WA, <sup>2</sup>VA Puget Sound Healthcare System, Seattle, WA
- 138 *Substance use and sexual assault perpetration: The role of mindfulness and empathy*  
Quyen Ngo<sup>1</sup>, Penny Warmanen<sup>2</sup>, Yasamin Kusunoki<sup>3</sup>, Erin Bonar<sup>2</sup>, Meredith Philyaw-Kotov<sup>2</sup>, Maureen Walton<sup>4</sup>, <sup>1</sup>University of Michigan Injury Prevention Center, Ann Arbor, MI, <sup>2</sup>University of Michigan, Ann Arbor, MI, <sup>3</sup>University of Michigan, School of Nursing, Ann Arbor, MI, <sup>4</sup>University of Michigan, Addiction Center, Ann Arbor, MI
- 139 *Non-partner violence perpetration among emerging adults: Relationship between poly-substance use and trait mindfulness*  
Jessica Ramirez, Sara Stein, University of Michigan, Ann Arbor, MI
- 140 *Systematic review and meta-analysis on the dimensions of anger in men using psychoactive substances*  
Helen Laitano<sup>1</sup>, Felix Kessler<sup>2</sup>, Thiago Hartmann<sup>3</sup>, Felix Kessler<sup>2</sup>, Flavio Pechansky<sup>2</sup>, <sup>1</sup>Luiz Englert Fundação, Porto Alegre, Brazil, <sup>2</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, <sup>3</sup>Center for Drug and Alcohol Research, Porto Alegre, Brazil
- 141 *Patterns of adverse childhood experiences, impulsivity and problematic substance use in young adulthood*  
Sunny Shin, Shelby McDonald, David Conley, Virginia Commonwealth University, Richmond, VA
- 142 *Families in crisis: Understanding the needs of homeless families with parental substance use disorders*  
Roya Ijadi-Maghsoodi<sup>1</sup>, Michelle Quan<sup>1</sup>, Kayleen Ports<sup>1</sup>, Sheryl Kataoka<sup>2</sup>, Gery Ryan<sup>3</sup>, Lillian Gelberg<sup>4</sup>, <sup>1</sup>University of California Los Angeles, Los Angeles, CA, <sup>2</sup>Semel Institute for Neuroscience and Human Behavior (UCLA), Los Angeles, CA, <sup>3</sup>RAND Corporation, Arlington, VA, <sup>4</sup>University of California, Department of Family Medicine, Los Angeles, CA
- 143 *Vulnerability to higher stress levels in people who use drugs linked to maladaptive coping mechanisms*  
Divya Seth<sup>1</sup>, Ndeah Terry<sup>2</sup>, Landhing Moran<sup>3</sup>, David Epstein<sup>3</sup>, Kenzie Preston<sup>3</sup>, Karran Phillips<sup>4</sup>, <sup>1</sup>National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, <sup>2</sup>NIAAA Intramural Research Program, Bethesda, MD, <sup>3</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>4</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 144 *The impact of abstinence on distress tolerance trajectories from pre- to 1-year post substance use treatment*

- Elizabeth Reese<sup>1</sup>, Christopher Conway<sup>2</sup>, Deepika Anand<sup>1</sup>, Daniel Bauer<sup>1</sup>, Stacey Daughters<sup>1</sup>, <sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>2</sup>College of William & Mary, Williamsburg, VA
- 145 *Distinct measures of distress tolerance predict success for different health behaviours*  
Daisy Thompson-Lake<sup>1</sup>, Emma O'Byrne<sup>1</sup>, Richard De La Garza, II<sup>2</sup>, Peter Hajek<sup>1</sup>, <sup>1</sup>Queen Mary University of London, London, United Kingdom, <sup>2</sup>Baylor College of Medicine, Houston, TX
- 146 *Food addiction is associated with higher neuroticism, lower conscientiousness, higher impulsivity, but lower extraversion in obese patients candidates for bariatric surgery*  
Paul Brunault<sup>1</sup>, Pierre-Henri Ducluzeau<sup>2</sup>, Robert Courtois<sup>2</sup>, Céline Bourbao-Tournois<sup>2</sup>, Jérôme Bachellier<sup>2</sup>, Servane Barrault<sup>2</sup>, Damien Mauge<sup>2</sup>, Christian Réveillère<sup>3</sup>, Ballon Nicols<sup>2</sup>, <sup>1</sup>University Hospital of Tours, Tours, France, <sup>2</sup>CHRU de Tours, Clinique Psychiatrique Universitaire, Tours, France, <sup>3</sup>Université Francois Rabelais de Tours, Tours, France
- 147 *Association between obesity and co-occurring heroin- and nicotine-dependence*  
Lian Hu, Paul VanVeldhuisen, The Emmes Corporation, Rockville, MD
- 148 *Acceptability and feasibility of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool in US primary care patients*  
Angeline Adam<sup>1</sup>, Robert Schwartz<sup>2</sup>, Li-Tzy Wu<sup>3</sup>, Geetha Subramaniam<sup>4</sup>, Gaurav Sharma<sup>5</sup>, Eugene Laska<sup>1</sup>, Jennifer McNeely<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>Friends Research Institute, Baltimore, MD, <sup>3</sup>Duke University School of Medicine, Durham, NC, <sup>4</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, <sup>5</sup>The Emmes Corporation, Rockville, MD
- 149 *Impact of SBI training on health professional students' knowledge and confidence in addressing unhealthy substance use*  
Katherine Covington, Yunmi Chung, Aaron Johnson, Augusta University, Augusta, GA
- 150 *Impact of a multi-year screening, brief intervention, and referral to treatment (SBIRT) curriculum on medical student attitudes toward patients with substance use disorders*  
Jeremy Kidd<sup>1</sup>, Jennifer Smith<sup>1</sup>, Mei-Chen Hu<sup>1</sup>, Adam Bisaga<sup>2</sup>, Edward Nunes<sup>1</sup>, Frances Levin<sup>1</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>Columbia University College of Physicians and Surgeons, New York, NY
- 151 *Mentorship for addiction problems (MAP)*  
Kathlene Tracy<sup>1</sup>, Leah Wachtel<sup>1</sup>, Emily Goldmann<sup>2</sup>, Samuel Ball<sup>3</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>New York University College of Global Public Health, New York, NY, <sup>3</sup>Yale University School of Medicine, New Haven, CT

**ANIMALS IN RESEARCH FORUM: TRANSLATIONAL AND REVERSE-TRANSLATIONAL RESEARCH IN ADDICTION: HOW HUMAN AND ANIMAL STUDIES MUTUALLY INFORM ONE ANOTHER** **Indigo A** **1:00 - 2:45 PM**

Chairs: Mark Smith and Ziva Cooper

*Bi-directional translation of monkey and human methods to develop functionally equivalent cocaine self-administration choice procedures*

J. Lile, University of Kentucky, College of Medicine, Lexington, KY

*Utility of preclinical drug-vs.-food choice procedures to translate effective treatments for drug addiction*

M. Banks, Virginia Commonwealth University, Richmond, VA

*Development of translational models of drug self-administration in humans and non-human primates: Challenges and tribulations*

S. Evans, Columbia University and NYSPI, New York, NY



**CONFIDENTIALITY FORUM****Indigo D**  
**1:00 - 2:45 PM**

Chairs: Jonathan Stoltman and John Roll

- 1:00 *Ethical implications of social media in clinical trials*  
E. Winstanley, West Virginia University, Morgantown, WV
- 1:21 *EMA and geospatial data in addiction research*  
B. Heckman, Medical University of South Carolina, Charleston, SC
- 1:42 *Navigating research ethics in the digital age*  
C. Nebeker, University of California San Diego, La Jolla, CA
- 2:03 *Ethical issues using social media in health behavior research*  
S. Young,
- 2:24 *Ethics, Addiction Research, and Emerging Technologies*  
T. Cvrkel, University of California Los Angeles, Los Angeles, CA

**ORAL COMMUNICATIONS 2**  
**THERE'S SOMETHING IN MY GENES****Indigo H**  
**2:00 - 4:00 PM**

Chairs: Wendy Lynch and Tabitha Moses

- 2:00 *Heroin delay discounting and impulsivity: Modulation by DRD1 genetic variation*  
Tabitha Moses<sup>1</sup>, Margit Burmeister<sup>2</sup>, Mark Greenwald<sup>1</sup>, <sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>University of Michigan, Ann Arbor, MI
- 2:15 *Validating electronic health record (EHR)-based prescription opioid phenotypes for genetic discovery*  
Christopher Rentsch<sup>1</sup>, E. Jennifer Edelman<sup>2</sup>, Amy Justice<sup>3</sup>, Brandon Marshall<sup>4</sup>, Henry Kranzler<sup>5</sup>, Ke Xu<sup>3</sup>, Stephen Crystal<sup>6</sup>, Julie Gaither<sup>7</sup>, Adam Gordon<sup>8</sup>, David Fiellin<sup>2</sup>, Janet Tate<sup>3</sup>, William Becker<sup>3</sup>, <sup>1</sup>VA Connecticut Healthcare System, West Haven, CT, <sup>2</sup>Yale University School of Medicine, New Haven, CT, <sup>3</sup>Yale University, New Haven, CT, <sup>4</sup>Brown School of Public Health, Providence, RI, <sup>5</sup>University of Pennsylvania, Philadelphia, PA, <sup>6</sup>Rutgers University, New Brunswick, NJ, <sup>7</sup>Yale Center for Medical Informatics, New Haven, CT, <sup>8</sup>University of Utah, Salt Lake City, UT
- 2:30 *Variants in stress-signaling genes NR3C1 and FKBP5 modulate opioid abstinence during buprenorphine (BUP) stabilization and dose tapering*  
Mark Greenwald<sup>1</sup>, Margit Burmeister<sup>2</sup>, <sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>University of Michigan, Ann Arbor, MI
- 2:45 *Moderation of buprenorphine therapy efficacy for cocaine dependence by variation of the preprodynorphin gene*  
David Nielsen<sup>1</sup>, Robrina Walker<sup>2</sup>, Mark Harding<sup>3</sup>, Walter Ling<sup>4</sup>, Thomas Kosten<sup>5</sup>, <sup>1</sup>Baylor College of Medicine, Montgomery, TX, <sup>2</sup>University of Texas Southwestern Medical Center, Dallas, TX, <sup>3</sup>Baylor College of Medicine, Houston, TX, <sup>4</sup>University of California Los Angeles, Los Angeles, CA, <sup>5</sup>Baylor College of Medicine, Bellaire, TX
- 3:00 *The efficacy of exercise as in anti-relapse intervention is associated with BDNF and GRM5 gene expression in the prefrontal cortex*  
Wendy Lynch, Jean Abel, Tanseli Nesil, University of Virginia, Charlottesville, VA
- 3:15 *Prenatal cocaine exposure and cortisol reactivity in early adolescence*  
Rina Eiden<sup>1</sup>, Douglas Granger<sup>2</sup>, Pamela Schuetze<sup>3</sup>, Amanda Nickerson<sup>1</sup>, <sup>1</sup>State University of New York at Buffalo, Buffalo, NY, <sup>2</sup>University of California Irvine, Irvine, CA, <sup>3</sup>Buffalo State College, Buffalo, NY

- 3:30 *Evocative gene-environment correlation underlying aggression and family cohesion in adolescent marijuana use*  
Kit Elam, Danielle Pandika, Laurie Chassin, Ariel Sternberg, Leena Bui, Arizona State University, Tempe, AZ
- 3:45 *The Interplay between conduct disorder polygenic score and community disadvantage in predicting marijuana use disorders*  
Jill Rabinowitz<sup>1</sup>, Rashelle Musci<sup>2</sup>, Adam Milam<sup>1</sup>, Kelly Benke<sup>1</sup>, Danielle Sisto<sup>1</sup>, Nicholas Ialongo<sup>3</sup>, Brion Maher<sup>1</sup>, <sup>1</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, <sup>3</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

**ORAL COMMUNICATIONS 1**  
**YOU'RE ALWAYS ON MY MIND: PRE-FRONTAL**  
**CORTEX IN ADDICTION**

**Indigo E**  
**3:00 - 5:00 PM**

Chairs: Julie McCarthy and Stacey Daughters

- 3:00 *Reduced executive control connectivity in women vs. men with chronic and acute nicotine exposure*  
Julie McCarthy, Kelly Dumais, Maya Zegel, Amy Janes, McLean Hospital, Harvard Medical School, Belmont, MA
- 3:15 *Ventromedial prefrontal cortex TMS attenuates smoking cue reactivity in cigarette smokers*  
Tonisha Kearney-Ramos<sup>1</sup>, Sarah Snider<sup>2</sup>, Warren Bickel<sup>3</sup>, Colleen Hanlon<sup>1</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Addiction Recovery Research Center, Roanoke, VA, <sup>3</sup>Virginia Tech Carilion Research Institute, Roanoke, VA
- 3:30 *Transcranial direct current stimulation in nicotine addiction*  
Ilse Verveer<sup>1</sup>, Danielle Remmerswaal<sup>1</sup>, Freddy van der Veen<sup>1</sup>, Ingmar Franken<sup>2</sup>, <sup>1</sup>Erasmus University Rotterdam, Rotterdam, Netherlands, <sup>2</sup>Erasmus University Rotterdam, Rotterdam
- 3:45 *Emotion dysregulation in young smokers: Link to connectivity of the raphe nuclei with the amygdala*  
Paul Faulkner, Andrew Dean, Dara Ghahremani, Zoe Guttman, Edythe London, University of California Los Angeles, Los Angeles, CA
- 4:00 *Sex differences in corticostriatal local field potentials: Implications for alcohol drinking behavior*  
Angela Henricks, Lucas Dwiell, Emily Sullivan, Alan Green, Wilder Doucette, Dartmouth College, Hanover, NH
- 4:15 *Sex differences in the relationship between basal leptin and alcohol- and food-related reward behaviors: A functional magnetic resonance imaging study.*  
Dongju Seo<sup>1</sup>, Chloe Larkin<sup>1</sup>, Cheryl Lacadie<sup>2</sup>, Marc Potenza<sup>1</sup>, Rajita Sinha<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Department of Radiology, Yale University, New Haven, CT
- 4:30 *Effect of non-invasive transcranial alternating currents stimulation (tACS) on inhibitory control among substance users in intensive outpatient substance use treatment*  
Stacey Daughters, Jennifer Yi, Rachel Wells, Rachel Phillips, Sydney Baker, Regina Carelli, Flavio Frohlich, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 4:45 *Cocaine-related differences in neural loss aversion and the moderating effects of socioeconomic status*  
Andréa Hobkirk<sup>1</sup>, Merideth Addicott<sup>2</sup>, Sheri Towe<sup>3</sup>, Christina Meade<sup>3</sup>, <sup>1</sup>Penn State College of Medicine, Hershey, PA, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AK, <sup>3</sup>Duke University School of Medicine, Durham, NC

**SYMPOSIUM I**  
**WEARABLE/BIOSENSORS IN ADDICTION**

**Indigo A**  
**3:00 - 5:00 PM**

**MEDICINE--FUTURE VISTAS**

Chairs: Scott Lukas and Stephanie Carreiro

- 3:00 *Using biosensors to enhance preclinical models of cannabinoid withdrawal*  
C. Paronis, McLean Hospital, Harvard Medical School, Belmont, MA
- 3:25 *Wearable biosensors: Novel applications across the spectrum of addiction*  
S. Carreiro, University of Massachusetts Memorial Medical Center, Worcester, MA
- 3:50 *Design challenges and implementation of wearable biosensors*  
E. Sazonov, University of Alabama, Birmingham, AL
- 4:15 *Geographically-explicit ecological momentary assessment (GEMA): A unifying framework linking sensors and subjective experience.*  
T. Kirchner, New York University, New York, NY
- 4:40 *Neurons to neighborhoods--How novel biosensors and wearables will impact the future of addiction medicine*  
S. Lukas, McLean Hospital, Harvard Medical School, Belmont, MA

**SYMPOSIUM II****Indigo BF****MARIJUANA: THE CHANGING LEGAL LANDSCAPE AND ITS IMPACT ON OPIOID USE****3:00 - 5:00 PM**

Chairs: Marsha Lopez and Heather Kimmel

- 3:00 *Changes in medical and recreational cannabis policies: How do they relate to opioid use, opioid use disorder and opioid overdoses?*  
S. Martins, Columbia University, New York, NY
- 3:25 *Prescription opioid misuse among young adult cannabis users in Los Angeles: A longitudinal study*  
S. Lankenau, Drexel University Dornsife School of Public Health, Philadelphia, PA
- 3:50 *Do adults with chronic pain use marijuana to reduce use of opioids? Results from Oregon*  
J. Dilley, Oregon Health Authority, Portland, OR
- 4:15 *Marijuana legalization and abuse and overdose of opioid analgesics*  
Y. Shi, University of California San Diego, La Jolla, CA
- 4:40 *Discussant*  
B. Fischer, University of Toronto, Toronto, ON, Canada

**SYMPOSIUM III****Indigo D****NOVEL PSYCHOACTIVE SUBSTANCES- A TRANSLATIONAL SCIENCE APPROACH****3:00 - 5:00 PM**

Chairs: Aviv Weinstein and William Fantegrossi

- 3:00 *Chair- NPs- summary of findings presented, and ideas for future research to address the ongoing NPS phenomenon.*  
W. Fantegrossi, University of Arkansas for Medical Sciences, Little Rock, AK
- 3:25 *Pharmacological effects of synthetic cannabinoids and their pyrolysis products in animal models*  
B. Thomas, RTI International, Research Triangle Park, NC
- 3:50 *Impaired executive function and brain imaging in fMRI in human synthetic cannabinoid users*  
A. Weinstein, Ariel University, Ariel, Israel, Israel
- 4:15 *Preclinical studies on the pharmacology of synthetic cathinones and newer non-cathinone compounds*  
M. Baumann, NIDA Intramural Research Program, Baltimore, MD

- 4:40 *The effects of synthetic cathinones after administration to humans under controlled laboratory conditions*  
M. Farré, Hospital Universitari Germans Trias i Pujol, Badalona, Spain, Spain

### **ORAL COMMUNICATIONS 3**

**Indigo H**

#### **STRESSING HORMONES AND DRUGS: PREGNANCY THROUGH MENOPAUSE 4:15 - 5:15 PM**

Chairs: MacKenzie Peltier and Loretta Finnegan

- 4:15 *The effect of sex hormones on smoking cessation across the menopausal transition in a 10-year longitudinal sample*  
MacKenzie Peltier<sup>1</sup>, Philip Smith<sup>2</sup>, Sherry McKee<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>CUNY School of Medicine, New York, NY
- 4:30 *Prenatal cigarette and cannabis exposure effects on parenting: Role of postnatal adversity*  
Meghan Casey<sup>1</sup>, Shannon Shisler<sup>1</sup>, Rina Eiden<sup>2</sup>, <sup>1</sup>Research Institute on Addictions, Buffalo, NY, <sup>2</sup>State University of New York at Buffalo, Buffalo, NY
- 4:45 *Co-occurring tobacco and cannabis use prenatally increases odds of ADHD in kindergarten*  
Shannon Shisler<sup>1</sup>, Rina Eiden<sup>2</sup>, Pamela Schuetze<sup>3</sup>, <sup>1</sup>Research Institute on Addictions, Buffalo, NY, <sup>2</sup>State University of New York at Buffalo, Buffalo, NY, <sup>3</sup>Buffalo State College, Buffalo, NY
- 5:00 *Effects of co-occurring prenatal tobacco and cannabis exposure on cortisol reactivity at early school age*  
Pamela Schuetze<sup>1</sup>, Shannon Shisler<sup>2</sup>, Rina Eiden<sup>3</sup>, Douglas Granger<sup>4</sup>, <sup>1</sup>Buffalo State College, Buffalo, NY, <sup>2</sup>Research Institute on Addictions, Buffalo, NY, <sup>3</sup>State University of New York at Buffalo, Buffalo, NY, <sup>4</sup>University of California Irvine, Irvine, CA

#### **PRIMM-SINGLETON AWARDEES RECEPTION**

**Aqua 310/Terrace  
5:00 - 6:00 PM**

### **WORKSHOP I**

#### **THERAPEUTIC APPLICATIONS AND ABUSE LIABILITY ASSESSMENT OF CANNABIDIOL**

**Indigo A**

**7:00 - 9:00 PM**

Chairs: Royston Gray and Charles France

*Demystifying the legal status of cannabinoids*

A. Mead, Greenwich Biosciences, Carlsbad, CA

*FDA/CSS view on abuse potential assessment during drug development for cannabinoid therapeutics*

D. Chiapperino, Head Controlled Substance Staff, FDA, Silver Spring, MD

*An evaluation of the discriminative and reinforcing properties of cannabidiol in rats*

D. Heal, RenaSci Ltd, Nottingham, Notts

*Assessment of cannabidiol in nonhuman primates*

C. France, University of Texas Health Science Center, San Antonio, TX

*Cannabidiol: Assessment of human abuse potential*

E. Sellers, DL Global Partners Inc., Toronto, ON, Canada

### **WORKSHOP II**

**Indigo D**

**CHARTING THE FUTURE OF HIV RESEARCH  
AMONG RACIAL/ETHNIC SUBSTANCE USERS: THE  
NEXT GENERATION OF RESEARCHERS SPEAK**

**7:00 - 9:00 PM**

Chairs: A. Kathleen Burlew and Carmen Masson

*Evaluating the psychometric properties of the 15-item condom use self efficacy scale among substance using adults*

D. Lanaway, University of Cincinnati, Cincinnati, OH

*Condom use barriers among African American substance users: Age and gender differences*

C. McCuistian, University of Cincinnati, Cincinnati, OH

*Outcome of combined HIV and HCV testing and opportunities for prevention at an acute detoxification center*

S. Assoumou, Boston University School of Medicine, Boston, MA

**WORKSHOP III  
THE ADOLESCENT BRAIN COGNITIVE  
DEVELOPMENT (ABCD) STUDY: EMERGING  
FINDINGS ON SUBSTANCE USE, RISK AND  
PROTECTIVE FACTORS, AND NEUROIMAGING**

**Indigo E**

**7:00 - 9:00 PM**

Chairs: Mary Heitzeg and Krista Lisdahl

*An Introduction and Overview of the ABCD Study and Description of the ABCD Cohort*

S. Tapert, University of California San Diego, La Jolla, CA

*Early Substance Use Rates and Attitudes: Preliminary Findings from the ABCD Study*

K. Lisdahl, University of Wisconsin-Milwaukee, Milwaukee, WI

*Culture and Environmental Risk and Protective Factors: Preliminary Findings from the ABCD Study*

R. Gonzalez, Florida International University, Miami, FL

*Imaging Reward, Emotion and Cognition in the Developing Brain: Preliminary Findings from the ABCD Study*

H. Garavan, University of Vermont, Burlington, VT

*Discussant*

S. Weiss, National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD

**WORKSHOP IV  
NAVIGATING KEY STAGES OF A CAREER IN  
ADDICTION SCIENCE**

**Indigo H**

**7:00 - 9:00 PM**

Chairs: Denise Vidot and Pia Mauro

*Navigating the pre-doctoral stage*

Q. Brown, Rutgers University School of Social Work and School of Public Health, New Brunswick, NJ

*Navigating the post-doctoral stage*

T. Franklin, University of Pennsylvania, Philadelphia, PA

*Navigating an early career in academia*

C. Bares, University of Michigan, Ann Arbor, MI

*Navigating substance use disorder careers outside of academia*

A. Duncan, The Pew Charitable Trusts, Washington, DC

# Monday, June 11, 2018

## POSTER II A DESIGNER DRUGS

Sapphire ABC/EFG  
8:00 - 10:00 AM

- 1 *An investigation of the reinforcing effects of MDMA in rats trained to self-administer heroin.*  
Sharon Smith, Michelle Hallam, David Heal, RenaSci Ltd, Nottingham
- 2 *MDMA-like effects of synthetic cathinones*  
Michael Gatch, Michael Forster, University of Texas Health Science Center, Fort Worth, TX
- 3 *Reinforcer efficacy of entactogen psychostimulants following extended access self-administration in female rats*  
Michael Taffe, Jacques Nguyen, Mehrak Javadi-Paydar, Sophia A. Vandewater, Kevin Creehan, Yanabel Grant, Eric Harvey, Tobin Dickerson, The Scripps Research Institute, La Jolla, CA
- 4 *Analysis of neurotransmitter and inflammatory biomarkers during synthetic cathinone self-administration*  
Julie Marusich<sup>1</sup>, Delisha Stewart<sup>2</sup>, Bruce Blough<sup>1</sup>, <sup>1</sup>RTI International, Research Triangle Park, NC, <sup>2</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC
- 5 *Evaluation of the interoceptive stimulus effects of the synthetic cathinones, 4-MMC and MDPV, using a three-lever drug discrimination procedure*  
Trent Bullock, Amy Goodwin, Lisa Baker, Western Michigan University, Kalamazoo, MI
- 6 *Interactions between reinforcement history and drug-primed reinstatement: Studies with MDPV and mixtures of MDPV and caffeine*  
Michelle Doyle<sup>1</sup>, Agnieszka Sulima<sup>2</sup>, Kenner Rice<sup>2</sup>, Gregory Collins<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, San Antonio, TX, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 7 *Increased executive dysfunction and disinhibition in marijuana and MDMA users compared to controls*  
Kelah Hatcher, University of Wisconsin-Milwaukee, Milwaukee, WI
- 8 *MDMA use disorder and other substance use among international MDMA users*  
Nancy Haug, James Sottile, Palo Alto University, Los Altos, CA
- 9 *Typical MDMA dose per session differs by lifetime frequency and route of administration*  
James Sottile, Nancy Haug, Palo Alto University, Los Altos, CA
- 10 *Establishment of screening method for selective NMDA receptor antagonist using HEK-293 cell line expressing NR1/NR2B*  
Tomiyama Kenichi<sup>1</sup>, Masahiko Funada<sup>2</sup>, <sup>1</sup>National Center of Neurology and Psychiatry, Kodaira, Japan, <sup>2</sup>NIMH, NCNP, Kodaira
- 11 *A study on factors of better treatment outcome for patients with new psychoactive-substances-related disorders in specialized clinics or wards for drug dependence in Japan*  
Yuko Tanibuchi<sup>1</sup>, Toshihiko Matsumoto<sup>2</sup>, Daisuke Funada<sup>3</sup>, Yasunari Kawasoe<sup>4</sup>, Satoshi Sakakibara<sup>5</sup>, Nobuya Naruse<sup>6</sup>, Shunichiro IKEDA Ikeda<sup>7</sup>, Takashi Sunami<sup>8</sup>, Takeo Muto<sup>9</sup>, Tetsuji Cho<sup>10</sup>, <sup>1</sup>Chiba Hospital, Funabashi, Japan, <sup>2</sup>National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan, <sup>3</sup>Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Japan, <sup>4</sup>Asahi General Hospital, Asahi, Japan, <sup>5</sup>Tokyo Metropolitan Matsuzawa Hospital, Setagaya, Japan, <sup>6</sup>Saitama Psychiatric Medical Center, Kita-adachi-gun, Japan, <sup>7</sup>Kansai Medical University, Hirakata, Japan, <sup>8</sup>Okayama Psychiatric Medical Center, Kita-Ku, Japan, <sup>9</sup>Hizen Psychiatric Center, Kanzaki-gun, Japan, <sup>10</sup>Mie Prefectural Mental Medical Center, Tsu, Japan
- 12 *Being online's cracked: The relationship between personality and illicit drug use among online users*  
Hao-Jan Yang, Chung Shan Medical University, Taichung City, Taiwan

- 13 *Willingness to provide a hair sample for drug testing among electronic dance music party attendees*  
Joseph Palamar<sup>1</sup>, Alberto Salomone<sup>2</sup>, Charles Cleland<sup>3</sup>, Scott Sherman<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>Centro Regionale Antidoping e di Tossicologia, Italy, <sup>3</sup>NYU Rory Meyers College of Nursing, New York, NY

**POSTER II B**  
**EPIDEMIOLOGY II**

**Sapphire ABC/EFG**  
**8:00 - 10:00 AM**

- 14 *Trends in adolescent heroin and injection drug use (IDU) in 13 US cities, 1999 to 2015*  
Sherri-Chanelle Brighthaupt<sup>1</sup>, Julie Johnson<sup>2</sup>, Abenaa Jones<sup>2</sup>, Kristin Schneider<sup>1</sup>, Renee Johnson<sup>1</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 15 *“Reverse Transitions” from injecting to non-injecting drug use during the US opioid epidemic*  
Don Des Jarlais<sup>1</sup>, Kamyar Arasteh<sup>1</sup>, Courtney McKnight<sup>1</sup>, Jonathan Feelemyer<sup>1</sup>, David Barnes<sup>1</sup>, Susan Tross<sup>2</sup>, <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2</sup>Columbia University, New York, NY
- 16 *Transition from prescription opioid misuse to injection drug use in social networks of youth and young adults*  
Alia Al-Tayyib<sup>1</sup>, Stephen Muth<sup>2</sup>, Paula Riggs<sup>3</sup>, <sup>1</sup>Denver Public Health, Denver, CO, <sup>2</sup>Quintus-ential Solutions, Colorado Springs, CO, <sup>3</sup>University of Colorado School of Medicine, Aurora, CO
- 17 *A microscope view of heroin incidence from mid-teens to mid-thirties*  
Prashanti Boinapally, James Anthony, Michigan State University, Lansing, MI
- 18 *Medication-assisted treatment for opioids among veterans being treated for pain*  
Lisham Ashrafioun, Kristin Falbo, Wilfred Pigeon, VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY
- 19 *High-dose opioid prescribing is associated with an increased risk of heroin use among US veterans*  
Geetanjali Banerjee<sup>1</sup>, E. Jennifer Edelman<sup>2</sup>, Declan Barry<sup>2</sup>, Stephen Crystal<sup>3</sup>, Julie Gaither<sup>4</sup>, Kirsha Gordon<sup>5</sup>, Robert Kerns<sup>6</sup>, Ajay Manhapra<sup>7</sup>, Brent Moore<sup>2</sup>, David Fiellin<sup>2</sup>, Brandon Marshall<sup>1</sup>, <sup>1</sup>Brown School of Public Health, Providence, RI, <sup>2</sup>Yale University School of Medicine, New Haven, CT, <sup>3</sup>Rutgers University, New Brunswick, NJ, <sup>4</sup>Yale Center for Medical Informatics, New Haven, CT, <sup>5</sup>VA Connecticut Healthcare System, West Haven, CT, <sup>6</sup>Yale University School of Medicine, West Haven, CT, <sup>7</sup>Yale School of Medicine, Norfolk, VA
- 20 *Negative non-deployment emotions associated with substance use among never-deployed reserve soldiers*  
Rachel Hoopsick, D. Lynn Homish, Bonnie Vest, Jessica Kulak, Gregory Homish, State University of New York at Buffalo, Buffalo, NY
- 21 *The impact of buprenorphine and methadone on mortality: A primary care cohort study in the United Kingdom*  
Miranda Cuming, University of Bristol, Bristol, UK
- 22 *Opioid tapering and discontinuation patterns in a large Colorado health system: 2012-2016*  
Ingrid Binswanger, Komal Narwaney, Jason Glanz, Kaiser Permanente Colorado, Denver, CO
- 23 *A survey study characterizing use of kratom (Mitragyna speciosa)*  
Albert Garcia-Romeu, Kelly Dunn, Roland Griffiths, Johns Hopkins University School of Medicine, Baltimore, MD
- 24 *Characteristics of problematic users of trihexyphenidyl in a French overseas territory*  
Gaetan Tomas-Bouil-Broto<sup>1</sup>, Laurent Blum<sup>1</sup>, Michel Spodenkiewicz<sup>1</sup>, David Mété<sup>2</sup>, Jean-Marc Alexandre<sup>3</sup>, Fuschia Serre<sup>3</sup>, Melina Fatseas<sup>4</sup>, Marc Auriacombe<sup>3</sup>, <sup>1</sup>CHU Sud Reunion, University of Reunion, Saint-Pierre, <sup>2</sup>Addiction Clinic, CHU Félix Guyon, Saint-Denis, France, <sup>3</sup>Université de Bordeaux, Bordeaux, <sup>4</sup>Centre Hospitalier Charles Perrens, Bordeaux, France

- 25 *5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT): Patterns of use, motives for consumption, and acute subjective effects*  
Alan Davis<sup>1</sup>, Joseph Barsuglia<sup>2</sup>, Rafael Lancelotta<sup>3</sup>, Robert Grant<sup>4</sup>, Elise Renn<sup>2</sup>, <sup>1</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Crossroads Treatment Center, Mexico, <sup>3</sup>University of Wyoming, Laramie, WY, <sup>4</sup>University of California San Francisco, San Francisco
- 26 *Assessing differential risks of cocaine dependence problems based on cocaine onset lag-times*  
Madhur Chandra<sup>1</sup>, James Anthony<sup>2</sup>, <sup>1</sup>Michigan State University, East Lansing, MI, <sup>2</sup>Michigan State University, Lansing, MI
- 27 *Cocaine use among emerging adults in the united states: Trends by race, sex, and college enrollment in the national survey on drug use and health (2002-2014)*  
Kristin Schneider<sup>1</sup>, Julie Johnson<sup>2</sup>, Renee Johnson<sup>1</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 28 *Past-month substance use by sexual identity among american adult women*  
Emily Greene, Silvia Martins, Columbia University, New York, NY
- 29 *Suicide attempts and death among heroin-involved women seeking methadone treatment in Taiwan*  
Wan-Ting Chen<sup>1</sup>, I-An Wang<sup>2</sup>, Sheng-Chang Wang<sup>3</sup>, Chuan-Yu Chen<sup>4</sup>, <sup>1</sup>National Health Research Institutes, Zhunan, Taiwan, <sup>2</sup>Center of Neuropsychiatric Research, National Health Research Institutes, Miaoli, <sup>3</sup>National Health Research Institutes, Zhunan, <sup>4</sup>National Yang-Ming University, Taipei, Taiwan
- 30 *Of substance: Stressful life events and substance use in a national sample*  
Carol Boyd, Stephen Strobbe, Brady West, Sean McCabe, University of Michigan, Ann Arbor, MI
- 31 *Beyond percent days abstinent: Quality of life indices as a function of time in recovery in a nationally representative sample of US adults*  
M. Claire Greene<sup>1</sup>, Brandon Bergman<sup>2</sup>, John Kelly<sup>2</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Massachusetts General Hospital, Boston, MA
- 32 *Item Response Theory analyses of DSM-5 substance criteria: Comparison of active substance users seeking treatment and those in harm reduction settings*  
Marc Auriacombe<sup>1</sup>, Charlotte Kervran<sup>1</sup>, Fuschia Serre<sup>1</sup>, Cecile Denis<sup>2</sup>, Perrine Roux<sup>3</sup>, Marie Jauffret-Roustide<sup>3</sup>, Laurence Lalanne<sup>4</sup>, Melina Fatseas<sup>5</sup>, Jean-Pierre Daulouede<sup>6</sup>, <sup>1</sup>Université de Bordeaux, Bordeaux, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>INSERM, Marseille, <sup>4</sup>University Hospital of Strasbourg, Strasbourg, <sup>5</sup>Centre Hospitalier Charles Perrens, Bordeaux, France, <sup>6</sup>Bizia Addiction Clinic, Bayonne
- 33 *From DSM-IV to DSM-V alcohol-use disorders among university students from Lebanon: Epidemiological and clinical implications*  
Lilian Ghandour, Sirine Anouti, American University of Beirut, Beirut
- 34 *The neighborhood retail environment & pedestrian injury risk: The unique role of alcohol outlets*  
Elizabeth Nesoff<sup>1</sup>, Adam Milam<sup>2</sup>, Charles Branas<sup>1</sup>, Silvia Martins<sup>1</sup>, Debra Furr-Holden<sup>3</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>3</sup>Michigan State University, Flint, MI
- 35 *Who gets cleared for opioid detoxification trials: From the window of apathy or trauma*  
Alison Oliveto<sup>1</sup>, Prasad Padala<sup>2</sup>, Jeff Thostenson<sup>1</sup>, Michael Mancino<sup>1</sup>, <sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, AK, <sup>2</sup>Eugene J. Towbin Veterans Healthcare Center, North Little Rock, AK

**POSTER II C**  
**ETHNIC DISPARITIES**

**Sapphire ABC/EFG**  
**8:00 - 10:00 AM**

- 36 *Treatment completion outcomes for opioid users: Are there racial and ethnic disparities across large us metropolitan areas?*



- Jerry Stahler, Jeremy Mennis, Temple University, Philadelphia, PA
- 37 *Differences associated with injection drug use (IDU) vs non-IDU among black heroin users in an urban setting*  
Joi-Sheree' Knighton<sup>1</sup>, Mark Greenwald<sup>2</sup>, <sup>1</sup>Wayne State University School of Medicine, Detroit, MI, <sup>2</sup>Wayne State University, Detroit, MI
- 38 *Heroin and non-medical prescription opioid use trends in young adults by race/ethnicity, education, and psychological distress between 2005-2014*  
Leila Vaezazizi<sup>1</sup>, Meghan Cahill<sup>2</sup>, Pia Mauro<sup>3</sup>, Luis Segura<sup>3</sup>, Julian Santaella-Tenorio<sup>3</sup>, Silvia Martins<sup>3</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>3</sup>Columbia University, New York, NY
- 39 *Trauma, race/ethnicity and risk for su and sud among florida justice-involved children*  
Micah Johnson, Linda Cottler, University of Florida, Gainesville, FL
- 40 *Childhood risk factors to early onset cannabis use among African American and European American adolescents*  
Manik Ahuja<sup>1</sup>, Kathleen Bucholz<sup>2</sup>, <sup>1</sup>Postdoctoral Research Scholar, St. Louis, MO, <sup>2</sup>Washington University School of Medicine, St. Louis, MO
- 41 *Social capital predicts cigarette smoking in majority white counties, but not counties that are majority African American, Latina/o, or American Indian/Alaska native*  
Nathan Smith, Kathleen Egan, Micah Johnson, Linda Cottler, University of Florida, Gainesville, FL
- 42 *Examining the relationship of disordered eating and substance use among adolescent females*  
Alia Rowe, Tamika Zapolski, Indiana University Purdue University Indianapolis, Indianapolis, IN
- 43 *Why now? Examining antecedents for substance use initiation among African American adolescents*  
Tamika Zapolski<sup>1</sup>, Tianyi Yu<sup>2</sup>, Gene Brody<sup>2</sup>, Devin Banks<sup>1</sup>, Allen Barton<sup>2</sup>, <sup>1</sup>Indiana University Purdue University Indianapolis, Indianapolis, IN, <sup>2</sup>University of Georgia, Athens, GA

**POSTER II D**  
**PROGRAM DESCRIPTION**

**Sapphire ABC/EFG**  
**8:00 - 10:00 AM**

- 44 *A model to integrate tobacco-free workplace programs into substance use treatment centers*  
Virmarie Correa-Fernandez<sup>1</sup>, Daniel Connor<sup>1</sup>, Bryce Kyburz<sup>2</sup>, Isabel Martinez Leal<sup>1</sup>, Teresa Williams<sup>2</sup>, Kathleen Casey<sup>2</sup>, William Wilson<sup>2</sup>, Shaili Bhavsar<sup>1</sup>, Hiroe Okamoto<sup>1</sup>, Ezemenari Obasi<sup>1</sup>, Lorraine Reitzel<sup>1</sup>, <sup>1</sup>University of Houston, Houston, TX, <sup>2</sup>Integral Care, Austin, TX
- 45 *Smartphone-based financial incentives to promote smoking cessation among pregnant women*  
Allison Kurti<sup>1</sup>, Alex Cohen<sup>2</sup>, Stephen Higgins<sup>1</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>University of Vermont, Burlington
- 46 *Implementation of a substance use-focused ambulatory "ICU" for primary care: the The streamlined unified meaningfully managed interdisciplinary team (SUMMIT)*  
Brian Chan<sup>1</sup>, Matthew Mitchell<sup>2</sup>, Philip Todd Korthuis<sup>1</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>Central City Concern, Portland, OR
- 47 *North Campus: Integrating primary and behavioral healthcare for individuals with substance use disorders*  
Jim May, Dawn Farrell-Moore, Neal Masri, Sara Hilleary, Richmond Behavioral Health Authority, Richmond, VA
- 48 *Public Health Assessment via Structural Evaluation (PHASE): A structure-based approach for assessing the abuse potential of designer drugs*  
Christopher Ellis<sup>1</sup>, Naomi Kruhlak<sup>2</sup>, Greg Hawkins<sup>2</sup>, Lidiya Stavitskaya<sup>2</sup>, <sup>1</sup>U.S. Food and Drug Administration, Columbia, MD, <sup>2</sup>U.S. Food and Drug Administration, Silver Spring, MD

- 49 *Adapting an addiction technology transfer model to address HIV and injection drug use in Ukraine*  
Anna Blyum<sup>1</sup>, Igor Koutsenok<sup>1</sup>, David Grelotti<sup>2</sup>, Sherry Larkins<sup>3</sup>, Irina Pinchuk<sup>4</sup>, Yulia Yachnik<sup>4</sup>, <sup>1</sup>University of California San Diego, San Diego, CA, <sup>2</sup>University of California San Diego, San Diego, Zimbabwe, <sup>3</sup>University of California Los Angeles, Los Angeles, CA, <sup>4</sup>International Addiction Technology Transfer Center in Ukraine, San Diego, CA
- 50 *The rise of overdose deaths involving fentanyl and the value of early warning*  
Zachary Patterson, Bridget Hall, Matthew Young, Canadian Centre on Substance Abuse, Ottawa, ON, Canada
- 51 *Development of a qualitative coding methodology to assess motivations for use of suboxone film*  
Natasha Oyedele, Taryn Dailey-Govoni, Michael Behling, Inflexxion, Inc., Waltham, MA
- 52 *Successful retention strategies for participants in opioid-dependence research in NYC*  
Peter Greco<sup>1</sup>, Sarah Meyers-Ohki<sup>1</sup>, Amber Regis<sup>1</sup>, Rosemary Lopez<sup>1</sup>, Jan Garcia<sup>1</sup>, Ryan McCormack<sup>1</sup>, Michael Bogenschutz<sup>2</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>New York University, New York
- 53 *Academic detailing intervention in primary care: Addressing opioid prescribing*  
Sarah Ball<sup>1</sup>, Megan Pruitt<sup>1</sup>, Jenna McCauley<sup>1</sup>, Jingwen Zhang<sup>1</sup>, William Moran<sup>1</sup>, Kit Simpson<sup>1</sup>, Khosrow Heidari<sup>2</sup>, Kathleen Brady<sup>1</sup>, Patrick Mauldin<sup>1</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>South Carolina Department of Health and Environmental Control, Columbia, SC
- 54 *Hub and spoke model to improve pharmacotherapy use for opioid addiction – early implementation*  
Sharon Reif<sup>1</sup>, Mary Brolin<sup>1</sup>, Maureen Stewart<sup>2</sup>, <sup>1</sup>Brandeis University, Heller School for Social Policy and Management, Waltham, MA, <sup>2</sup>Brandeis University, Waltham, MA
- 55 *Rationale for combination of XR-naltrexone and bupropion for the treatment of methamphetamine use disorder in the NIDA CTN--0068 ADAPT-2 Trial*  
Adriane dela Cruz<sup>1</sup>, Larissa Mooney<sup>2</sup>, Robrina Walker<sup>1</sup>, Maureen Hillhouse<sup>3</sup>, Madhukar Trivedi<sup>1</sup>, Walter Ling<sup>4</sup>, <sup>1</sup>University of Texas Southwestern Medical Center, Dallas, TX, <sup>2</sup>UCLA Integrated Substance Abuse Programs, Los Angeles, CA, <sup>3</sup>New York University, New York, NY, <sup>4</sup>University of California Los Angeles, Los Angeles, CA
- 56 *NIDA CTN Protocol 0068: Design of the accelerated development of additive pharmacotherapy treatment (ADAPT-2) for methamphetamine use disorder trial*  
Robrina Walker<sup>1</sup>, Mora Kim<sup>1</sup>, Gaurav Sharma<sup>2</sup>, Thomas Carmody<sup>1</sup>, Steven Sparenborg<sup>3</sup>, Adriane dela Cruz<sup>1</sup>, Walter Ling<sup>4</sup>, Madhukar Trivedi<sup>1</sup>, <sup>1</sup>University of Texas Southwestern Medical Center, Dallas, TX, <sup>2</sup>The Emmes Corporation, Rockville, MD, <sup>3</sup>Arete Addiction Services and Arete Products, Dallas, TX, <sup>4</sup>University of California Los Angeles, Los Angeles, CA
- 57 *Initiation of STAMPOUT: Study of antibody for methamphetamine outpatient therapy in recreational methamphetamine abusers*  
Ryan Turncliff<sup>1</sup>, Lynn Webster<sup>1</sup>, Misty Stevens<sup>2</sup>, W. Gentry<sup>3</sup>, <sup>1</sup>PRA Health Sciences, Salt Lake City, UT, <sup>2</sup>InterveXion Therapeutics, Little Rock, AR, <sup>3</sup>University of Arkansas for Medical Sciences, Little Rock, AR
- 58 *Towards detecting cocaine use using smartwatches in the NIDA Clinical Trials Network: Rationale, design, and methodology*  
Bethany McLeman<sup>1</sup>, August Holtyn<sup>2</sup>, Lisa Marsch<sup>3</sup>, Santosh Kumar<sup>4</sup>, Emre Ertin<sup>5</sup>, Kenzie Preston<sup>6</sup>, Shahin Samiei<sup>4</sup>, Andrea Meier<sup>7</sup>, Elizabeth Saunders<sup>8</sup>, Julia Collins<sup>9</sup>, Dikla Blumberg<sup>9</sup>, Jennifer McCormack<sup>9</sup>, Udi Ghitza<sup>10</sup>, Olivia Walsh<sup>11</sup>, <sup>1</sup>Northeast Node of the CTN/Dartmouth College, Lebanon, NH, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, <sup>4</sup>University of Memphis, Memphis, TN, <sup>5</sup>Ohio State University, Columbus, OH, <sup>6</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>7</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>8</sup>The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, <sup>9</sup>The Emmes Corporation, Rockville, MD, <sup>10</sup>National Institutes of Health, National Institute on Drug Abuse, Center for the Clinical Trials Network, Bethesda, MD,

- <sup>11</sup>Dartmouth College, Hanover, NH
- 59 *Australian centre for cannabinoid clinical and research excellence (ACRE): A novel multidisciplinary approach to evidence development and translation*  
Jan Copeland<sup>1</sup>, Nadia Solowij<sup>2</sup>, Jennifer Martin<sup>3</sup>, <sup>1</sup>University of South Wales, Sydney, <sup>2</sup>University of Wollongong, Wollongong, Australia, <sup>3</sup>University of Newcastle, Callaghan, Australia
- 60 *Twitter-based intervention for young adult African American blunt smokers*  
LaTrice Montgomery, University of Cincinnati, College of Medicine, Cincinnati, OH
- 61 *Preparing post-graduate trainees to deliver team-based primary care to homeless veterans*  
Lillian Gelberg<sup>1</sup>, Michael Soh<sup>2</sup>, Kristin Kopelson<sup>2</sup>, Kerri Schutz<sup>2</sup>, Brianna Cowan<sup>2</sup>, Margaret Stuber<sup>2</sup>, Shinobu Seragaki<sup>2</sup>, Andrew Shaner<sup>2</sup>, Carole Warde<sup>2</sup>, <sup>1</sup>University of California, Department of Family Medicine, Los Angeles, CA, <sup>2</sup>Greater Los Angeles VA, Los Angeles, CA
- 62 *Building health homes for clients in treatment for substance use disorders*  
Elizabeth Waddell<sup>1</sup>, Tracy Anastas<sup>2</sup>, Gretchen Horton-Dunbar<sup>1</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>School of Science, IUPUI, Indianapolis, IN
- 63 *Counteracting reflexive, dehumanizing responses*  
Michael Soh<sup>1</sup>, Andrew Shaner<sup>1</sup>, Lillian Gelberg<sup>2</sup>, Kristin Kopelson<sup>1</sup>, Margaret Stuber<sup>1</sup>, Carole Warde<sup>1</sup>, <sup>1</sup>Greater Los Angeles VA, Los Angeles, CA, <sup>2</sup>University of California, Department of Family Medicine, Los Angeles, CA
- 64 *The impact of substance use disorders on diabetes quality of care measures*  
Blanca Noriega Esquivas<sup>1</sup>, Rui Duan<sup>1</sup>, Daniel Feaster<sup>2</sup>, Viviana Horigian<sup>1</sup>, <sup>1</sup>University of Miami, Miami, FL, <sup>2</sup>University of Miami Miller School of Medicine, Miami, FL
- 65 *Sex-specific neurobiological differences in substance addiction: An educational pilot program for next generation STEM workforce*  
Philip Vieira, CSU Dominguez Hills, Carson, CA
- 66 *Introducing the NIDA core center of excellence in omics, systems genetics, and the addictome*  
Laura Saba<sup>1</sup>, Saunak Sen<sup>2</sup>, Robert Williams<sup>3</sup>, <sup>1</sup>University of Colorado Anschutz Medical Campus, Aurora, CO, <sup>2</sup>Departments of Preventive Medicine, and Genetics Genomics and Informatics, University of Tennessee, Memphis, TN, <sup>3</sup>University of Tennessee Health Science Center, Memphis, TN

**POSTER II E**  
**STIMULANTS: PRECLINICAL II**

**Sapphire ABC/EFG**  
**8:00 - 10:00 AM**

- 67 *Tat-GluR23Y peptide disrupts the methamphetamine-associated memory and reduces long-term relapse*  
Xiaojie Zhang, Central South University, Changsha, China, China
- 68 *Profile of dasotraline in rats trained to discriminate d-amphetamine from saline compared with various drugs used to treat ADHD*  
Jane Gosden<sup>1</sup>, Nigel Slater<sup>1</sup>, David Heal<sup>2</sup>, Tracy Deats<sup>3</sup>, Seth C. Hopkins<sup>3</sup>, Kenneth Koblan<sup>3</sup>, <sup>1</sup>RenaSci Ltd, Nottingham, United Kingdom, <sup>2</sup>RenaSci Ltd, Nottingham, <sup>3</sup>Sunovion Pharmaceuticals Inc, Marlborough, MA
- 69 *Dasotraline is a monoamine reuptake inhibitor not a releasing agent as revealed by tetrodotoxin (TTX) sensitivity in microdialysis in the nucleus accumbens of freely-moving rats*  
David Heal<sup>1</sup>, Rajiv Kulkarni<sup>2</sup>, Lucy Pinder<sup>2</sup>, Helen Rowley<sup>2</sup>, Tracy Deats<sup>3</sup>, Seth C. Hopkins<sup>3</sup>, Kenneth Koblan<sup>3</sup>, <sup>1</sup>RenaSci Ltd, Nottingham, <sup>2</sup>RenaSci Ltd, Nottingham, United Kingdom, <sup>3</sup>Sunovion Pharmaceuticals Inc, Marlborough, MA
- 70 *Enhanced acquisition of cocaine self-administration in male and female rats following amphetamine exposure during adolescence*

- Ryan Lacy, Hannah Schorsch, Bridget Austin, Franklin and Marshall College, Lancaster, PA
- 71 *Identification of neural circuits recruited during withdrawal from methamphetamines using whole brain imaging*  
Adam Kimbrough<sup>1</sup>, Andres Collazo<sup>2</sup>, Marsida Kallupi<sup>1</sup>, Olivier George<sup>1</sup>, <sup>1</sup>The Scripps Research Institute, La Jolla, CA, <sup>2</sup>Caltech Bioimaging Facility, Pasadena, CA
- 72 *Associations between perceived stress and poor everyday functioning in methamphetamine (METH) dependence and/or HIV infection*  
Mariam Hussain<sup>1</sup>, Jennifer Iudicello<sup>1</sup>, Erin Morgan<sup>1</sup>, Igor Grant<sup>2</sup>, Robert Heaton<sup>1</sup>, <sup>1</sup>University of California San Diego, San Diego, CA, <sup>2</sup>University of California San Diego, La Jolla, CA
- 73 *Unraveling individual differences in the HIV-1 transgenic rat: Therapeutic efficacy of methylphenidate*  
Steven Harrod, Kristen McLaurin, Hailong Li, Rosemarie Booze, Amanda Fairchild, Charles Mactutus, University of South Carolina, Charleston, SC
- 74 *The impact of sex and exercise on methamphetamine preference in a rat animal model*  
Mari Purpura, University of California Santa Barbara, San Francisco, CA
- 75 *The role of E3 ligase parkin deficit in vulnerability to abuse methamphetamine*  
Anna Moszczynska, Wayne State University, Detroit, MI
- 76 *The effect of Hrrnph1 deletion upon reinforcement varies as a function of the reinforcer*  
Elissa Fultz<sup>1</sup>, Qui Ruan<sup>2</sup>, Neema Yazdani<sup>2</sup>, Nicholas Stailey<sup>1</sup>, Sami Ferdousian<sup>1</sup>, Elijah Lustig<sup>1</sup>, Aidan Healy<sup>1</sup>, Camron Bryant<sup>2</sup>, Karen Szumlinski<sup>1</sup>, <sup>1</sup>University of California Santa Barbara, Santa Barbara, CA, <sup>2</sup>Boston University School of Medicine, Boston, MA
- 77 *Cardiovascular safety of dopamine D3 receptor antagonists and cocaine*  
Nathan Appel, Jane Acri, National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 78 *Neurochemical and cardiovascular effects of beta-methyl phenethylamine analogs found in dietary supplements*  
Charles Schindler<sup>1</sup>, Eric Thorndike<sup>1</sup>, Kenner Rice<sup>2</sup>, Michael Baumann<sup>1</sup>, <sup>1</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 79 *Caffeine dose-dependently increases sign tracking and decreases goal tracking in a Pavlovian conditioned approach paradigm*  
Curtis Bradley, Caleb Bailey, Dustin Harryman, Gerald Deehan, Jr., Matthew Palmatier, East Tennessee State University, Johnson City, TN

## POSTER II F IMAGING

**Sapphire ABC/EFG  
8:00 - 10:00 AM**

- 80 *“The amygdala gets what the amygdala wants”: Amygdalar activation by 6 second cocaine videos predicts relapse, and fully mediates outcome prediction by the positive affective bias to implicit cocaine cues.*  
Anna Rose Childress<sup>1</sup>, Kanchana Jagannathan<sup>1</sup>, Paul Regier<sup>1</sup>, Jesse Suh<sup>1</sup>, Ron Ehrman<sup>1</sup>, Stefanie Darnley<sup>1</sup>, Elliott Berkowitz-Sturgis<sup>1</sup>, Zach Monge<sup>1</sup>, Teresa Franklin<sup>1</sup>, Reagan Wetherill<sup>1</sup>, Daniel Langleben<sup>2</sup>, Kimberly Young<sup>1</sup>, Michael Gawrysiak<sup>3</sup>, Regina Szucs-Reed<sup>1</sup>, Kyle Kampman<sup>1</sup>, Charles O'Brien<sup>4</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Veterans Administration, Philadelphia, PA, <sup>3</sup>West Chester University of Pennsylvania, West Grove, PA, <sup>4</sup>University of Pennsylvania, VA Medical Center, Philadelphia, PA
- 81 *Examining the relationship between dopamine 2 (D2) receptor availability, early life stress (ELS), and vulnerability to the reinforcing effects of cocaine in male and female rhesus macaques.*  
Alison Wakeford<sup>1</sup>, Jonathon Nye<sup>2</sup>, Mar Sanchez<sup>3</sup>, Leonard Howell<sup>2</sup>, <sup>1</sup>Yerkes National Primate Research Center, Atlanta, GA, <sup>2</sup>Emory University, Atlanta, GA, <sup>3</sup>Yerkes National Primate Research Center & Emory University, Atlanta, GA

- 82 *White matter abnormalities in cocaine use disorder: are there differences between snorted cocaine and crack cocaine users?*  
Mauricio Serpa<sup>1</sup>, Fabio Duran<sup>1</sup>, Hercílio Pereira de Oliveira Junior<sup>2</sup>, Priscila Goncalves<sup>1</sup>, Caio Vinícius de Melo<sup>3</sup>, Mariella Ometto<sup>2</sup>, Bernardo dos Santos<sup>1</sup>, André Malbergier<sup>2</sup>, Ricardo Amaral<sup>2</sup>, Sergio Nicastrí<sup>4</sup>, Arthur Andrade<sup>2</sup>, Geraldo Busatto Filho<sup>5</sup>, Paulo Jannuzzi Cunha<sup>5</sup>, <sup>1</sup>University of São Paulo, São Paulo, Brazil, <sup>2</sup>University of Sao Paulo Medical School, São Paulo, <sup>3</sup>Student, São Paulo, Brazil, <sup>4</sup>Hospital Israelita Albert Einstein, Sao Paulo, Brazil, <sup>5</sup>University of Sao Paulo Medical School, São Paulo, Brazil
- 83 *Distinct patterns of resting state functional connectivity among inpatients reporting crack use versus snorted cocaine use*  
Priscila Dib Gonçalves<sup>1</sup>, Luciano de Menezes Sanchez<sup>2</sup>, Pedro Rosa<sup>1</sup>, Hercílio Pereira de Oliveira Junior<sup>3</sup>, Danielle Lima<sup>2</sup>, Maya Foigel<sup>2</sup>, Mariella Ometto<sup>3</sup>, Caio Vinícius de Melo<sup>4</sup>, Ricardo Amaral<sup>3</sup>, André Malbergier<sup>3</sup>, Sergio Nicastrí<sup>5</sup>, Arthur Andrade<sup>3</sup>, Geraldo Busatto Filho<sup>2</sup>, Paulo Jannuzzi Cunha<sup>2</sup>, <sup>1</sup>University of São Paulo, São Paulo, Brazil, <sup>2</sup>University of Sao Paulo Medical School, São Paulo, Brazil, <sup>3</sup>University of Sao Paulo Medical School, São Paulo, <sup>4</sup>Student, São Paulo, Brazil, <sup>5</sup>Hospital Israelita Albert Einstein, Sao Paulo, Brazil
- 84 *Naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder*  
Milky Kohno, Laura Dennis, William Hoffman, Holly McCready, Philip Todd Korthuis, Oregon Health & Science University, Portland, OR
- 85 *Using dynamic contrast enhanced MRI to measure methamphetamine's effects on blood brain barrier permeability*  
Mudassir Mumtaz<sup>1</sup>, Jermaine Jones<sup>2</sup>, Alayar Kangarlu<sup>3</sup>, Verena Metz<sup>4</sup>, Jeanne Manubay<sup>5</sup>, Shanthi Mogali<sup>4</sup>, Diana Martinez<sup>3</sup>, Henrik Larsson<sup>6</sup>, Feng Liu<sup>3</sup>, Sandra Comer<sup>4</sup>, <sup>1</sup>CUNY School of Medicine, New York, NY, <sup>2</sup>Columbia University College of Physicians and Surgeons, New York, NY, <sup>3</sup>New York State Psychiatric Institute, New York, NY, <sup>4</sup>Columbia University and NYSPI, New York, NY, <sup>5</sup>Columbia University, New York, NY, <sup>6</sup>Danish Research Center of Magnetic Resonance, Hvidovre, Denmark
- 86 *An effective connectivity study of emotion processing in cannabis use disorder*  
Liangsuo Ma<sup>1</sup>, Joel Steinberg<sup>1</sup>, James Bjork<sup>1</sup>, Lori Keyser-Marcus<sup>1</sup>, Jasmin Vassileva<sup>1</sup>, Sergi Ferré<sup>2</sup>, Antonio Abbate<sup>1</sup>, F. Gerard Moeller<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>NIDA Intramural Research Program, Baltimore, MD
- 87 *Neuromodulation of functional connectivity in emerging adults with cannabis use disorder*  
Michael Wesley<sup>1</sup>, Qiang (Shawn) Cheng<sup>2</sup>, Anil C<sup>2</sup>, Joshua Lile<sup>1</sup>, <sup>1</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>2</sup>University of Kentucky, Lexington, KY
- 88 *The effects of synthetic cannabinoids (SCs) on the brain's structure and function*  
Aviv Weinstein<sup>1</sup>, Abigail Livny<sup>2</sup>, Koby Cohen<sup>1</sup>, Niv Tik<sup>3</sup>, Paola Roska<sup>4</sup>, <sup>1</sup>Ariel University, Ariel, Israel, <sup>2</sup>Sheba Medical Center, Tel Hashomer, Israel, <sup>3</sup>Tel Hashomer Hospital, Tel Hashomer, Israel, <sup>4</sup>Ministry of Health, Jerusalem, Israel
- 89 *Relationship between fMRI response during a nonverbal memory task and marijuana use in college students*  
Alecia Dager<sup>1</sup>, Madelynn Tice<sup>2</sup>, Gregory Book<sup>3</sup>, Sarah Raskin<sup>4</sup>, Howard Tennen<sup>5</sup>, Carol Austad<sup>6</sup>, Rebecca Wood<sup>7</sup>, Carolyn Fallahi<sup>7</sup>, Keith Hawkins<sup>8</sup>, Godfrey Pearlson<sup>8</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Yale University School of Public Health, Hartford, CT, <sup>3</sup>Olin Neuropsychiatry Research Center, Hartford Hospital, Hartford, CT, <sup>4</sup>Trinity College, Hartford, CT, <sup>5</sup>University of Connecticut Health Center, Farmington, CT, <sup>6</sup>Center Connecticut State University, New Britain, CT, <sup>7</sup>Central Connecticut State University, New Britain, CT, <sup>8</sup>Yale University Department of Psychiatry, Hartford, CT
- 90 *Increased mean diffusivity is associated with greater past month cannabis use in emerging adults, but not alcohol or same-day alcohol and cannabis use*  
Natasha Wade<sup>1</sup>, Alicia Thomas<sup>1</sup>, Staci Gruber<sup>2</sup>, Susan Tapert<sup>3</sup>, Francesca Filbey, Krista Lisdahl<sup>1</sup>, <sup>1</sup>University

of Wisconsin-Milwaukee, Milwaukee, WI, <sup>2</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>3</sup>University of California San Diego, La Jolla, CA

- 91 *Slow-wave sleep disruption is associated with increased insula activity during inhibitory control in adolescents*  
Lora Cope<sup>1</sup>, Meghan Martz<sup>1</sup>, Deirdre Conroy<sup>1</sup>, Philip Cheng<sup>2</sup>, Robert Hoffman<sup>1</sup>, J. Todd Arnedt<sup>1</sup>, Mary Heitzeg<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Henry Ford Health System, Detroit, MI
- 92 *Nicotine effects on white matter microstructure in male and female young adults*  
Megan Kangiser, Alicia Thomas, Christine Kaiver, Krista Lisdahl, University of Wisconsin-Milwaukee, Milwaukee, WI
- 93 *Decreased regional gray matter volume in male adolescents with substance use disorder and limited prosocial emotions*  
Janet Kim<sup>1</sup>, Susan Mikulich-Gilbertson<sup>2</sup>, Manish Dalwani<sup>2</sup>, Kristen Raymond<sup>1</sup>, Shannon McWilliams<sup>2</sup>, Joseph Sakai<sup>2</sup>, <sup>1</sup>University of Colorado, Aurora, CO, <sup>2</sup>University of Colorado School of Medicine, Aurora, CO
- 94 *Larger volume in reward-related temporal lobe regions is associated with impulsivity and craving in cigarette smokers*  
Yasmin Mashhoon, Jennifer Betts, Scott Lukas, McLean Hospital, Harvard Medical School, Belmont, MA
- 95 *Lower cortical dopamine D2 receptor availability in smokers compared to nonsmokers and the relationship to cognitive function*  
Yasmin Zakiniaez<sup>1</sup>, Ansel Hillmer<sup>1</sup>, Evan Morris<sup>1</sup>, David Matuskey<sup>1</sup>, Nabeel Nabulsi<sup>1</sup>, Yiyun Henry Huang<sup>1</sup>, Sherry McKee<sup>2</sup>, Kelly Cosgrove<sup>1</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Yale University School of Medicine, New Haven, CT
- 96 *Lighting up: Neural responses to cigarette smoking*  
Ariel Ketcherside<sup>1</sup>, Kanchana Jagannathan<sup>1</sup>, Nathan Hager<sup>2</sup>, Danielle Pelosi<sup>3</sup>, Stefanie Darnley<sup>1</sup>, Fan Nils Yang<sup>1</sup>, H Rao<sup>1</sup>, John Detre<sup>1</sup>, Sudipto Dolui<sup>4</sup>, Teresa Franklin<sup>1</sup>, Reagan Wetherill<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Old Dominion University, Norfolk, VA, <sup>3</sup>Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Department of Radiology, The University of Pennsylvania, Philadelphia, PA
- 97 *Additive effects of HIV-infection and chronic tobacco smoking on brain microstructure*  
Huajun Liang<sup>1</sup>, Thomas Ernst<sup>2</sup>, David Greenstein<sup>3</sup>, Linda Chang<sup>3</sup>, <sup>1</sup>University of Hawaii, Baltimore, MD, <sup>2</sup>Department of Medicine, John A. Burns School of Medicine, University of Hawaii and Queen's Medical Center, Baltimore, MD, <sup>3</sup>Queen's Medical Center, Department of Medicine, John A. Burns School of Medicine, Baltimore, MD
- 98 *Behind the mask: Elevated BOLD, but not behavioral responses to pain in individuals using prescription opiates*  
Logan Dowdle, Jeffrey Borckardt, Sudie Back, Colleen Hanlon, Medical University of South Carolina, Charleston, SC

## POSTER II G HIV/HCV

**Sapphire ABC/EFG  
8:00 - 10:00 AM**

- 99 *Factors related to prescription opioid misuse among HIV positive substance users: Understanding the role of substance use, mental health and ARV adherence*  
Maria Levi-Minzi<sup>1</sup>, Hilary Surratt<sup>2</sup>, <sup>1</sup>Nova Southeastern University, Miami, FL, <sup>2</sup>University of Kentucky, Lexington, KY
- 100 *Impact of syndemic conditions on perceived barriers to pre-exposure prophylaxis use among female sex workers along Mexico's northern border*

- Jennifer Jain<sup>1</sup>, Steffanie Strathdee<sup>2</sup>, Thomas Patterson<sup>2</sup>, Shirley Semple<sup>2</sup>, Alicia Vera<sup>2</sup>, Carlos Magis-Rodriguez<sup>3</sup>, Gustavo Martinez<sup>4</sup>, Heather Pines<sup>2</sup>, <sup>1</sup>University of California, Department of Medicine, San Diego, CA, <sup>2</sup>University of California San Diego, La Jolla, CA, <sup>3</sup>Center for HIV/AIDS Prevention and Control, Mexico City, <sup>4</sup>Federacion Mexicana de Asociaciones Privadas, Ciudad Juarez, Chihuahua, Mexico
- 101 *Associations between unprotected sex, psychiatric comorbidity, and substance use frequency in a cohort of HIV-infected and at-risk women with a history of housing instability*  
Meredith Meacham, Amber Bahorik, Elise Riley, University of California San Francisco, San Francisco, CA
- 102 *The mediating effect of illicit drug use on the relationship between risky sexual behaviors and HIV infection: Results from the 2013 Taiwan Internet MSM Sex Survey*  
Lian-Yu Chen<sup>1</sup>, Shang-Chi Wu<sup>2</sup>, Nai-Ying Ko<sup>3</sup>, <sup>1</sup>Taipei City Hospital, Taipei, Taiwan, <sup>2</sup>National Taiwan University, Epidemiology and Preventive Medicine, Taipei City, <sup>3</sup>National Cheng Kung University, Department of Nursing, Tainan
- 103 *Clusters of substance use and HIV risk behaviors among people who inject drugs in Kazakhstan*  
Phillip Marotta<sup>1</sup>, Daniel Feaster<sup>2</sup>, Assel Terlikbayeva<sup>1</sup>, Louisa Gilbert<sup>1</sup>, Tim Hund<sup>1</sup>, Elwin Wu<sup>1</sup>, Nabila El-Bassel<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>University of Miami Miller School of Medicine, Miami, FL
- 104 *Preliminary efficacy of adjunct components for couples HIV testing and counseling: Reducing drug use and depression in gay couples*  
Tyrel Starks<sup>1</sup>, Trey Dellucci<sup>2</sup>, Mark Pawson<sup>3</sup>, Jeffrey Parsons<sup>1</sup>, <sup>1</sup>Hunter College, CUNY, New York City, NY, <sup>2</sup>Health Psychology and Clinical Science Training Program, Graduate Center, CUNY, New York, NY, <sup>3</sup>Graduate Center and CHEST, New York, NY
- 105 *HIV health care behaviors in substance users during patient navigation with and without contingent financial incentives*  
Maxine Stitzer<sup>1</sup>, James Sorensen<sup>2</sup>, Lisa Metsch<sup>3</sup>, Carlos del Rio<sup>4</sup>, Daniel Feaster<sup>5</sup>, Alexis Hammond<sup>6</sup>, Rui Duan<sup>7</sup>, Tim Matheson<sup>8</sup>, Lauren Gooden<sup>3</sup>, <sup>1</sup>Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>2</sup>University of California San Francisco, San Francisco, CA, <sup>3</sup>Columbia University, New York, NY, <sup>4</sup>Emory University, Atlanta, GA, <sup>5</sup>University of Miami Miller School of Medicine, Miami, FL, <sup>6</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>7</sup>University of Miami, Miami, FL, <sup>8</sup>San Francisco Department of Public Health, San Francisco, CA
- 106 *Recent cannabis use and advanced liver fibrosis among HIV-infected heavy drinkers.*  
Daniel Fuster<sup>1</sup>, Kaku So-Armah<sup>2</sup>, Debbie Cheng<sup>2</sup>, Sharon Coleman<sup>3</sup>, Natalia Gnatienco<sup>2</sup>, Dmitry Lioznov<sup>4</sup>, Evgeny Krupitsky<sup>5</sup>, Matthew Freiberg<sup>6</sup>, Jeffrey Samet<sup>2</sup>, <sup>1</sup>Hospital Universitari Germans, Badalona, Spain, <sup>2</sup>Boston University School of Medicine, Boston, MA, <sup>3</sup>Boston University School of Public Health, Boston, MA, <sup>4</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, <sup>5</sup>V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russian Federation, <sup>6</sup>Vanderbilt University Medical Center, Nashville, TN
- 107 *Prevalence of hazardous drinking differs between HIV+ adults reporting using marijuana for recreational versus medicinal reasons*  
Zachary Mannes<sup>1</sup>, Robert Cook<sup>2</sup>, Erin Ferguson<sup>3</sup>, Nicole Ennis Whitehead<sup>1</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>University of Florida SHARC Center, Gainesville, FL, <sup>3</sup>Graduate Student, Gainesville, FL
- 108 *Hepatitis screening through the analysis of liver enzymes in drug users*  
Octavio Campollo, Arturo Panduro, Sonia Roman, GABRIEL HERNANDEZ, Universidad de Guadalajara, Guadalajara
- 109 *Is HCV elimination among HIV-infected people who inject drugs possible through HCV treatment targeting HIV/HCV coinfection? A modeling analysis for Andalusia, Spain*  
Britt Skaathun<sup>1</sup>, Annick Borquez<sup>1</sup>, Sanjay Mehta<sup>1</sup>, Antonio Rivero-Juarez<sup>2</sup>, Francisco Tellez<sup>3</sup>, Manuel Castaño<sup>4</sup>, Dolores Merino<sup>5</sup>, Jesus Santos<sup>4</sup>, Juan Macias<sup>6</sup>, Antonio Rivero-Juarez<sup>2</sup>, Natasha Martin<sup>1</sup>,

<sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>Instituto Maimonides de Investigaciones Biomedicas de Cordoba, Córdoba, <sup>3</sup>Universidad de Cádiz, Cádiz, <sup>4</sup>Hospital Regional Universitario de Málaga, Málaga, <sup>5</sup>Hospitales Juan Ramón Jiménez e Infanta Elena de Huelva, Huelva, <sup>6</sup>Hospital Universitario de Valme, Instituto de Biomedicina de Sevilla, Sevilla

- 110 *Randomized trial of hepatitis c treatment for people who inject drugs at high risk for secondary transmission*  
Phillip Coffin<sup>1</sup>, Glenn-Milo Santos<sup>2</sup>, Jaclyn Hern<sup>1</sup>, Emily Behar<sup>1</sup>, Kimberly Page<sup>3</sup>, Rena Fox<sup>2</sup>, Eric Vittinghoff<sup>2</sup>, <sup>1</sup>San Francisco Department of Public Health, San Francisco, CA, <sup>2</sup>University of California San Francisco, San Francisco, CA, <sup>3</sup>University of New Mexico, Albuquerque
- 111 *Prescription opioid injection among young adults who use drugs: Associations with HCV infection and drug overdose*  
Pedro Mateu-Gelabert, Honoria Guarino, Jennifer Teubl, Jon Zibbell, Samuel Friedman, National Development and Research Institute, Inc., New York, NY

## POSTER II H CRIMINAL JUSTICE

**Sapphire ABC/EFG  
8:00 - 10:00 AM**

- 112 *HCV status and psychiatric burden of opioid dependent-adults and young offenders in Austrian prisons*  
Laura Brandt<sup>1</sup>, Marisa Silbernagl<sup>2</sup>, Rudolf Slamanig<sup>2</sup>, Gabriele Fischer<sup>3</sup>, <sup>1</sup>University of Vienna, Austria, <sup>2</sup>Medical University of Vienna, Center for Public Health, Vienna, Austria, <sup>3</sup>Medizinische Universität Wien, Wien
- 113 *HIV prevention in rural jails: Implications for re-entry risk reduction*  
Michele Staton<sup>1</sup>, Justin Strickland<sup>2</sup>, Matt Webster<sup>2</sup>, Carl Leukefeld<sup>2</sup>, Carrie Oser<sup>2</sup>, Erika Pike<sup>2</sup>, <sup>1</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>2</sup>University of Kentucky, Lexington, KY
- 114 *A randomized controlled trial of prison-initiated buprenorphine: Longitudinal analysis of HIV-risk behaviors*  
Thomas Blue<sup>1</sup>, Michael Gordon<sup>1</sup>, Robert Schwartz<sup>1</sup>, Frank Vocci, Jr.<sup>1</sup>, Kevin O'Grady<sup>2</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>University of Maryland, College Park, MD
- 115 *A randomized controlled trial of buprenorphine for prisoners: Official rearrest outcomes*  
Michael Gordon<sup>1</sup>, Thomas Blue<sup>1</sup>, Robert Schwartz<sup>1</sup>, Terrence Fitzgerald<sup>2</sup>, Frank Vocci, Jr.<sup>1</sup>, Kevin O'Grady<sup>3</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Glenwood Life Counseling Center, Baltimore, MD, <sup>3</sup>University of Maryland, College Park, MD
- 116 *Polysubstance opioid use profiles in an incarcerated population*  
Amanda Bunting<sup>1</sup>, Carrie Oser<sup>1</sup>, Michele Staton<sup>2</sup>, Erin Winston<sup>1</sup>, Kevin Pangburn<sup>3</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>3</sup>Kentucky Department of Corrections, Frankfort, KY
- 117 *Typology of offenders: Violence and substance use outcomes*  
Cassandra Berbary, Cory Crane, Caroline Easton, Rochester Institute of Technology, Rochester, NY
- 118 *Appalachian clinician's views on medication-assisted treatment for re-entering offenders*  
Carrie Oser<sup>1</sup>, Amanda Bunting<sup>1</sup>, Michele Staton<sup>2</sup>, Erin Winston<sup>1</sup>, Kate Eddens<sup>1</sup>, Hannah Knudsen<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 119 *Correlates of re-entry employment among rural female drug-involved offenders*  
Matt Webster<sup>1</sup>, Megan Dickson<sup>1</sup>, Michele Staton<sup>2</sup>, Carrie Oser<sup>1</sup>, Carl Leukefeld<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 120 *Health needs and health service utilization among reincarcerated drug-using women in rural Appalachia*  
Megan Dickson<sup>1</sup>, Michele Staton<sup>2</sup>, Matt Webster<sup>1</sup>, Carrie Oser<sup>1</sup>, Carl Leukefeld<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY



- 121 *Predictors of recidivism among rural, incarcerated, substance-using women*  
Brittany Miller-Roenigk<sup>1</sup>, Bridgette Peteet<sup>1</sup>, Michele Staton<sup>2</sup>, <sup>1</sup>University of Cincinnati, Cincinnati, OH, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 122 *Age differences in substance use and treatment among African American men incarcerated in North Carolina*  
Joy Scheidell<sup>1</sup>, Samuel Friedman<sup>2</sup>, Maria Khan<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>National Development and Research Institute, Inc., New York, NY
- 123 *Substance Use and Mental Health Profiles of Judicially-Involved Commercially Sexually Exploited Youth*  
Kayleen Ports<sup>1</sup>, Elizabeth Barnert<sup>2</sup>, Sangeeta Mondal<sup>1</sup>, Lindsey Thompson<sup>2</sup>, Mikaela Kelly<sup>3</sup>, Sarah Godoy<sup>3</sup>, Mekeila Cook<sup>1</sup>, Eraka Bath<sup>1</sup>, <sup>1</sup>University of California Los Angeles, Los Angeles, CA, <sup>2</sup>University of California, Pediatrics, Los Angeles, CA, <sup>3</sup>University of California, Psychiatry, Los Angeles, CA
- 124 *Differential associations of marijuana typologies with psychological problems and substance abuse among juvenile detainees*  
Devin Banks, Tamika Zapolski, Indiana University Purdue University Indianapolis, Indianapolis, IN
- 125 *Substance use and other risks associated with offence types among justice involved youth*  
Hayley Hamilton<sup>1</sup>, Evelyn Vingilis<sup>2</sup>, Shannon Stewart<sup>2</sup>, Jane Seeley<sup>2</sup>, Kathleen Einarson<sup>3</sup>, Patricia Erickson<sup>3</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Western University, London, UK, Canada, <sup>3</sup>University of Toronto, Toronto, ON, Canada
- 126 *Examining changes in youth community treatment agency linkages*  
Carl Leukefeld<sup>1</sup>, Rob Seaver<sup>1</sup>, Erin Winston<sup>1</sup>, Martha Tillson<sup>1</sup>, Megan Dickson<sup>1</sup>, Hannah Knudsen<sup>1</sup>, Michele Staton<sup>2</sup>, Matt Webster<sup>1</sup>, Carrie Oser<sup>1</sup>, Jennifer Havens<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 127 *Dynamic model of first-time offenders of illicit drug use trajectory in Taiwan*  
Wei-J Chen<sup>1</sup>, Shang-Chi Wu<sup>2</sup>, Chi-Ya Chen<sup>3</sup>, Hsien-Ho Lin<sup>3</sup>, Kevin Chien-Chang Wu<sup>2</sup>, Tzu-Pin Lu<sup>2</sup>, Susyan Jou<sup>4</sup>, Wen-Ing Tsay<sup>5</sup>, Jui Hsu<sup>5</sup>, <sup>1</sup>National Taiwan University, Taipei City, <sup>2</sup>National Taiwan University, Epidemiology and Preventive Medicine, Taipei City, <sup>3</sup>National Taiwan University, Epidemiology and Preventive Medicine, Taipei City, Taiwan, <sup>4</sup>National Taipei University, New Taipei City, Taiwan, <sup>5</sup>Taiwan Food and Drug Administration, Taipei

## POSTER II I OVERDOSE

**Sapphire ABC/EFG  
8:00 - 10:00 AM**

- 128 *Opioid involvement in intentional and unintentional poisonings: The moderating effect of poisoning severity*  
Sarah Cercone Heavey, Kenneth Conner, Timothy Wiegand, University of Rochester Medical Center, Rochester, NY
- 129 *Non-fatal overdose prevalence among people who inject drugs – A multi-stage systematic review and meta-analysis of recent evidence*  
Samantha Colledge<sup>1</sup>, Amy Peacock<sup>1</sup>, Janni Leung<sup>2</sup>, Miranda Cuming<sup>3</sup>, Michael Farrell<sup>1</sup>, Sarah Larney<sup>1</sup>, Louisa Degenhardt<sup>1</sup>, Jason Grebely<sup>4</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, Sydney, Australia, <sup>2</sup>NDARC, UNSW, Australia, Brisbane, Australia, <sup>3</sup>University of Bristol, Bristol, <sup>4</sup>The Kirby Institute, Sydney, Australia
- 130 *Association between drug use history and non-fatal overdose: A cross-sectional study of community members who use prescription opioids non-medically in West Virginia*  
Kelly Gurka<sup>1</sup>, Kathleen Egan<sup>1</sup>, Alexandria Macmadu<sup>2</sup>, Herbert Linn<sup>3</sup>, Linda Cottler<sup>1</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>The Center for Prisoner Health and Human Rights, The Miriam Hospital, Providence, RI, <sup>3</sup>West Virginia University, Morgantown, WV

- 131 *Implementation and feasibility of a public health led non-fatal overdose response system in New York City*  
Hillary Kunins, Alice Welch, Angela Jeffers, Dominique Chambless, Denise Paone, NYC Department of Health and Mental Hygiene, Queens, NY
- 132 *Life after overdose: Survivor narratives and their implications for emergency department interventions*  
Luther Elliott<sup>1</sup>, Brett Wolfson-Stofko<sup>2</sup>, Alexander Bennett<sup>1</sup>, <sup>1</sup>National Development and Research Institute, Inc., New York, NY, <sup>2</sup>New York University, New York, NY
- 133 *Factors associated with overdose response self-efficacy among adults who report lifetime opioid use*  
Kayla Tormohlen, Karin Tobin, Melissa Davey-Rothwell, Carl Latkin, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 134 *Young adults' opioid use trajectories: Opioid type and route transitions, overdose and treatment*  
Honorio Guarino, Pedro Mateu-Gelabert, Jennifer Teubl, Elizabeth Goodbody, National Development and Research Institute, Inc., New York, NY
- 135 *Risk factors associated with overdose during follow-up in treatment-seeking youth with substance use disorders*  
Amy Yule<sup>1</sup>, Nicholas Carrellas<sup>2</sup>, Maura Fitzgerald<sup>2</sup>, Brandon Bergman<sup>2</sup>, John Kelly<sup>2</sup>, Jessica Nargiso<sup>2</sup>, James McKowen<sup>2</sup>, Timothy Wilens<sup>3</sup>, <sup>1</sup>MGH, Boston, MA, <sup>2</sup>Massachusetts General Hospital, Boston, MA, <sup>3</sup>Harvard Medical School, Boston, MA
- 136 *Examining gaps in the naloxone (Narcan) cascade of care*  
Karin Tobin, Melissa Davey-Rothwell, Carl Latkin, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 137 *Military veterans' overdose risk: Demographic and biopsychosocial influences*  
Alexander Bennett<sup>1</sup>, Luther Elliott<sup>1</sup>, J. Watford<sup>2</sup>, Andrew Golub<sup>1</sup>, Peter Britton<sup>3</sup>, Andrew Rosenblum<sup>4</sup>, Honorio Guarino<sup>1</sup>, <sup>1</sup>National Development and Research Institute, Inc., New York, NY, <sup>2</sup>New York University, New York, NY, <sup>3</sup>VA VISN 2 Center of Excellence for Suicide Prevention, Canandaigua, NY, <sup>4</sup>NDRI, Metuchen, NJ
- 138 *Fentanyl checking interest and overdose risk among opioid users: A multisite study*  
Ju Nyeong Park<sup>1</sup>, Kenneth Morales<sup>2</sup>, Michelle McKenzie<sup>3</sup>, Traci Green<sup>4</sup>, Susan Sherman<sup>1</sup>, <sup>1</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>Lifespan, Providence, RI, <sup>4</sup>Boston University School of Medicine, Boston, MA
- 139 *Precursors to drug use escalation in a New Hampshire convenience sample of current and recent opioid users*  
Sarah Moore<sup>1</sup>, Andrea Meier<sup>1</sup>, Elizabeth Saunders<sup>2</sup>, Stephen Metcalf<sup>3</sup>, Bethany McLeman<sup>4</sup>, Olivia Walsh<sup>5</sup>, Lisa Marsch<sup>3</sup>, <sup>1</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>2</sup>The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, <sup>3</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, <sup>4</sup>Northeast Node of the CTN/Dartmouth College, Lebanon, NH, <sup>5</sup>Dartmouth College, Hanover, NH
- 140 *Trends in Opioid-related overdose deaths in Virginia from 2011-2016*  
Lori Keyser-Marcus, Mary Bowman, Edward Boone, Tamas Gal, F. Gerard Moeller, Virginia Commonwealth University, Richmond, VA
- 141 *A urinalysis-based study of the prevalence of fentanyl use among opioid users in New York City*  
Suky Martinez<sup>1</sup>, Jermaine Jones<sup>2</sup>, Nicholas Allwood<sup>1</sup>, Sandra Comer<sup>1</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>Columbia University College of Physicians and Surgeons, New York, NY
- 142 *Hepatitis C virus as a moderator of opioid treatment and past opioid overdose*  
Samantha Schiavon, Karen Cropsey, University of Alabama, Birmingham, AL
- 143 *Regional heterogeneity in the association between medical marijuana laws and opioid overdose: findings from the National Health Interview Survey, 1986-2011*  
June Kim<sup>1</sup>, Julian Santaella-Tenorio<sup>2</sup>, Christine Mauro<sup>2</sup>, Deborah Hasin<sup>2</sup>, Guohua Li<sup>2</sup>, Silvia Martins<sup>2</sup>, <sup>1</sup>New York University, New York, NY, <sup>2</sup>Columbia University, New York, NY
- 144 *Use of automated data to study trends in heroin and pharmaceutical opioid overdoses in a large health*

system: 2006-2015

Jason Glanz, Komal Narwaney, Kris Wain, Andrew Sterrett, Shane Mueller, LeeAnn Quintana, Ingrid Binswanger, Kaiser Permanente Colorado, Denver, CO

## POSTER II J TECHNOLOGY

**Sapphire ABC/EFG**  
**8:00 - 10:00 AM**

- 145 *A digital therapy to support recovery from opioid use disorder*  
Patricia Cavazos<sup>1</sup>, Melissa Krauss<sup>1</sup>, Shaina Sowles<sup>2</sup>, Elizabeth Cahn<sup>2</sup>, Laura Bierut<sup>2</sup>, <sup>1</sup>Washington University St. Louis, St. Louis, MI, <sup>2</sup>Washington University School of Medicine, St. Louis, MO
- 146 *Perceptions of technology and health resource access among patients in opioid treatment*  
Ida Chen, J. Fokuo, Carmen Masson, University of California San Francisco, San Francisco, CA
- 147 *Usability testing of a mHealth prototype to enhance HIV, HCV, and buprenorphine treatment in primary care*  
Babak Tofighi<sup>1</sup>, Chemi Chemi<sup>1</sup>, Selena Sindhu<sup>1</sup>, Michelle Acosta<sup>2</sup>, Edward Nunes<sup>3</sup>, Joshua Lee<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>National Development and Research Institute, Inc., New York, NY, <sup>3</sup>Columbia University and NYSPI, New York, NY
- 148 *Formative evaluation of a mobile application to assist with methadone stabilization*  
Emily Loscalzo, Robert Sterling, Stephen Weinstein, Thomas Jefferson University, Philadelphia, PA
- 149 *Leveraging technology to address unhealthy drug use in primary care: Development of a clinical decision support tool for primary care providers*  
Jennifer McNeely<sup>1</sup>, Donna Shelley<sup>1</sup>, Antonia Polyn<sup>1</sup>, Christine Chollak<sup>1</sup>, Angeline Adam<sup>1</sup>, Andre Kushniruk<sup>2</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>University of Victoria, Victoria, BC, Canada
- 150 *Implementing substance use screening in rural federally qualified health centers: Results from focus groups*  
Bethany McLeman<sup>1</sup>, Jennifer McNeely<sup>2</sup>, Elizabeth Saunders<sup>3</sup>, SARAH FARKAS<sup>2</sup>, Olivia Walsh<sup>4</sup>, Andrea Meier<sup>5</sup>, Trip Gardner<sup>6</sup>, Noah Nesen<sup>6</sup>, Seamus Higgins<sup>6</sup>, Lisa Marsch<sup>7</sup>, <sup>1</sup>Northeast Node of the CTN/Dartmouth College, Lebanon, NH, <sup>2</sup>New York University School of Medicine, New York, NY, <sup>3</sup>The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, <sup>4</sup>Dartmouth College, Hanover, NH, <sup>5</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>6</sup>Penobscot Community Health Care, Bangor, ME, <sup>7</sup>Geisel School of Medicine at Dartmouth, Hanover, NH
- 151 *Clinical research applications of a statewide health information exchange (HIE)*  
Jan Gryczynski<sup>1</sup>, courtney Nordeck<sup>1</sup>, Robert Schwartz<sup>1</sup>, Shannon Mitchell<sup>1</sup>, Christopher Welsh<sup>2</sup>, Ross Martin<sup>3</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>University of Maryland, School of Medicine, Baltimore, MD, <sup>3</sup>CRISP, Columbia, MD
- 152 *User experience of four point-of-collection oral fluid devices by Brazilian traffic agents – preliminary findings*  
Flavio Pechansky<sup>1</sup>, Juliana Scherer<sup>1</sup>, Vinicius S. Roglio<sup>1</sup>, Yeger Telles<sup>2</sup>, Jaqueline B. Schuch<sup>1</sup>, Roberta B. Silvestrin<sup>1</sup>, Tanara Sousa<sup>1</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, <sup>2</sup>Center for Drug and Alcohol Research, Porto Alegre, Brazil
- 153 *Computer-facilitated 5A's for tobacco use disorders: Using technology to improve screening and brief interventions*  
Jason Satterfield, Steve Gregorich, Maya Vijayaraghavan, University of California San Francisco, San Francisco, CA
- 154 *Feasibility and validity of collecting intensive longitudinal alcohol use data with mechanical turk*  
Justin Strickland, William Stoops, University of Kentucky, Lexington, KY

## ORAL COMMUNICATIONS 4

**Indigo E**

**TWEETMENT 8.0****10:00 - 11:00 AM**

Chairs: Suzette Glasner and Michael Mason

- 10:00 *Exploring trends in breathalyzer test results among participants of the Ria Treatment Program using dynamic structural equation modeling*  
Mary Mitchell<sup>1</sup>, John Mendelson<sup>2</sup>, Jan Gryczynski<sup>1</sup>, Steve Carswell<sup>1</sup>, Robert Schwartz<sup>1</sup>, <sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>Friends Research Institute, San Francisco, CA
- 10:15 *Development of a Facebook intervention for depressed cannabis users*  
Suzette Glasner<sup>1</sup>, Danielle Ramo<sup>2</sup>, Frances Kay-Lambkin<sup>3</sup>, Alan Budney<sup>4</sup>, Helene Chokron Garneau<sup>5</sup>, Alexandra Venegas<sup>5</sup>, <sup>1</sup>Integrated Substance Abuse Programs (UCLA), Los Angeles, CA, <sup>2</sup>University of California San Francisco, San Francisco, CA, <sup>3</sup>University of Newcastle, Callaghan, <sup>4</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>5</sup>University of California Los Angeles, Los Angeles, CA
- 10:30 *Treating cannabis use disorder among young adults: A pilot randomized clinical trial of text vs. in-person delivered peer network counseling*  
Michael Mason<sup>1</sup>, Nikola Zaharakis<sup>2</sup>, <sup>1</sup>University of Tennessee, Knoxville, TN, <sup>2</sup>Arizona State University, Tempe, AZ
- 10:45 *What teens want: A mixed methods study on the use of mobile phones and its technology for substance use treatment*  
Stacy Ryan, Baylor University, Waco, TX

**SYMPOSIUM VI****Indigo D****WHAT'S IN YOUR WEED? ASSESSING THE IMPACT OF CANNABIS PRODUCT SELECTION****10:00 - 11:00 AM**

Chairs: Staci Gruber and Ryan Vandrey

- 10:00 *Variety of cannabis product type, dose, and route of administration in a patient registry of medicinal cannabis users*  
R. Vandrey, Behavioral Pharmacology Research Unit, Johns Hopkins Hospital, Baltimore, MD
- 10:20 *Cannabinoid preferences among veterans when barriers to medicinal cannabis are reduced*  
M. Loflin, Veterans Affairs San Diego Healthcare System, San Diego, CA
- 10:40 *Recipes for success? Exploring the cognitive and clinical impact of cannabinoid constituents and product selection*  
S. Gruber, McLean Hospital, Harvard Medical School, Belmont, MA

**ORAL COMMUNICATIONS 6****Indigo H****TAKING SELFIES: PRECLINICAL SELF-ADMINISTRATION****10:00 - 12:00 PM**

Chairs: Dustin Stairs and Lais Berro

- 10:00 *Cocaine self-administration under an IRT>t schedule of reinforcement in Sprague Dawley rats*  
Dustin Stairs, Rachel Busselman, Creighton University, Omaha, NE
- 10:15 *Sex differences in midazolam self-administration in rats*  
James Cook, Sally Huskinson, James Rowlett, University of Mississippi Medical Center, Jackson, MS
- 10:30 *Vaporized Δ9-tetrahydrocannabinol (THC) modulates intravenous oxycodone self-administration and natural food reward intake*

- 10:45 Jacques Nguyen, Yanabel Grant, Kevin Creehan, Michael Taffe, The Scripps Research Institute, La Jolla, CA  
*Sustained decreases in heroin self-administration in rhesus monkeys after a single administration of SH-1*  
 David Maguire<sup>1</sup>, Lisa Gerak<sup>1</sup>, James Woods<sup>1</sup>, Stephen Husbands<sup>2</sup>, Alex Disney<sup>2</sup>, Charles France<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, San Antonio, TX, <sup>2</sup>University of Bath, Bath, United Kingdom
- 11:00 *Evaluation of mifepristone effects on alcohol seeking and self-administration*  
 Elise Weerts, August Holtyn, Johns Hopkins University School of Medicine, Baltimore, MD
- 11:15 *Observable behavior predicts anxiolytic-like effects but not self-administration of benzodiazepine-type drugs in rhesus monkeys*  
 Lais Berro<sup>1</sup>, Angela Duke<sup>2</sup>, Donna Platt<sup>3</sup>, John Atack<sup>4</sup>, Veera Tiruveedhula<sup>5</sup>, Guanguan Li<sup>5</sup>, Michael Stephen<sup>5</sup>, James Cook<sup>5</sup>, James Rowlett<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Winston-Salem State University, Winston-Salem, NC, <sup>3</sup>Division of Neurobiology and Behavior Research, Jackson, MS, <sup>4</sup>Cardiff University, Cardiff, United Kingdom, <sup>5</sup>University of Wisconsin-Milwaukee, Milwaukee, WI
- 11:30 *Selective biphasic antagonism of intravenous d-methamphetamine self-administration by disulfiram in rhesus monkeys*  
 Fernando de Moura<sup>1</sup>, Nathaniel Gillis<sup>2</sup>, Jessica Nardolillo<sup>2</sup>, Stephen Kohut<sup>1</sup>, Jack Bergman<sup>1</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>McLean Hospital, Belmont, MA
- 11:45 *Effect of abstinence and cue re-exposure on DNA methylation and mRNA expression after cocaine self-administration*  
 Kyle Ploense<sup>1</sup>, Tod Kippin<sup>2</sup>, Timothy Bredy<sup>3</sup>, Karen Szumlinski<sup>2</sup>, <sup>1</sup>University of California Santa Barbara, Goleta, CA, <sup>2</sup>University of California Santa Barbara, Santa Barbara, CA, <sup>3</sup>Queensland Brain Institute, St. Lucia, Australia

**SYMPOSIUM IV**  
**DRUG ADDICTION TREATMENT WITH CLASSIC**  
**PSYCHEDELICS**

**Indigo A**  
**10:00 - 12:00 PM**

Chairs: Roland Griffiths and Matthew Johnson

- 10:00 *Enduring behavior change after psilocybin*  
 R. Griffiths, Johns Hopkins University School of Medicine, Baltimore, MD
- 10:25 *Psilocybin treatment of cocaine use disorder*  
 P. Hendricks, University of Alabama, Birmingham, AL
- 10:50 *Psilocybin treatment of tobacco use disorder*  
 M. Johnson, Johns Hopkins University School of Medicine, Baltimore, MD
- 11:15 *Psilocybin treatment of alcohol use disorder*  
 M. Bogenschutz, New York University, New York, NY
- 11:40 *Psychedelic treatment and neurochemical reductionism: A way forward*  
 B. Adinoff, University of Texas Southwestern Medical Center, Dallas, TX

**SYMPOSIUM V**  
**THE HUMAN MOLECULAR GENETICS OF**  
**NICOTINE AND OPIATE ADDICTION**

**Indigo BF**  
**10:00 - 12:00 PM**

Chairs: Mary Jeanne Kreek and Laura Bierut

- 10:00 *Genetic lessons learned from the big studies and small studies of nicotine addiction*  
 L. Bierut, Washington University School of Medicine, St. Louis, MO

- 10:25 *Heroin addiction: what have we learned from hypothesis-driven association studies in different populations*  
O. Levran, The Rockefeller University, New York, NY
- 10:50 *Reconsidering case and control phenotypes for genetic studies of opioid use disorder*  
E. Nelson, Washington University School of Medicine, St. Louis, MO
- 11:15 *The pharmacogenetics of opioid use disorder treatment*  
R. Crist, University of Pennsylvania, Philadelphia, PA
- 11:40 *Discussant*  
M. Kreek, The Rockefeller University, New York, NY

## ORAL COMMUNICATIONS 5

### ADDICTION PREDICTION: MACHINE LEARNING AND MODELING

**Indigo E**

**11:15 - 12:15 PM**

Chairs: Georgiy Bobashev and Sarah Yip

- 11:15 *Anhedonic symptoms of depression are related to cocaine use severity: A machine learning approach*  
Margaret Wardle<sup>1</sup>, Robert Suchting<sup>1</sup>, Jessica Vincent<sup>1</sup>, Scott Lane<sup>2</sup>, Joy Schmitz<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, Houston, TX, <sup>2</sup>University of Texas, Houston, TX
- 11:30 *Application of machine learning to predict cocaine-use*  
Sarah Yip<sup>1</sup>, Dustin Scheinost<sup>1</sup>, Marc Potenza<sup>2</sup>, Kathleen Carroll<sup>2</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Yale University School of Medicine, New Haven, CT
- 11:45 *Using support vector machine (SVM) to predict heroin addiction*  
Shaw-Ji Chen, Mackay Memorial Hospital, Taitung Branch, Taitung Taiwan, NP, Taiwan
- 12:00 *Heroin type, injecting behavior and HIV transmission: Evidence-based simulation model provides insights from the past into the future*  
Georgiy Bobashev<sup>1</sup>, Daniel Ciccarone, Sarah Mars<sup>2</sup>, William Zule<sup>1</sup>, Clinton Dreisbach<sup>3</sup>, Nicholas Murphy<sup>2</sup>, <sup>1</sup>RTI International, Research Triangle Park, NC, <sup>2</sup>University of California San Francisco, San Francisco, CA, <sup>3</sup>RTI International, Durham, NC

## SYMPOSIUM VII

### LET'S SAVE THE BABY AND THE BATHWATER: IMPROVING NAS CARE FOR BABIES AND THEIR MOTHERS UTILIZING NOVEL METHODS

**Indigo D**

**11:15 - 12:15 PM**

Chairs: Dennis Hand and Yukiko Washio

- 11:15 *TRAC-ON preliminary results: Mobile application to educate nurses and assist in NAS scoring with an aggregated presentation system*  
Y. Washio, Christiana Care Health Services, University of Delaware, Media, PA
- 11:35 *Development of a primer and reference tool to assess and manage neonatal abstinence syndrome in the NICU*  
S. McPherson, Washington State University, Elson S. Floyd College of Medicine, Spokane, WA
- 11:55 *Fetally derived CNS extracellular vesicles: A novel non-invasive method for interrogating fetal brain response to perinatal opioid exposure*  
L. Goetzl, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

## (BY INVITATION ONLY)

### CPDD EARLY CAREER INVESTIGATOR TRAVEL AWARDS LUNCHEON

**Elevation**

**12:00 - 2:00 PM**

**MEMBERS IN TRAINING MEETING****Aqua C**  
**1:00 - 2:00 PM****ORAL COMMUNICATIONS 7**  
**SEEING IS BELIEVING: IMAGING****Indigo E**  
**2:00 - 3:00 PM**

Chairs: Stephen Kohut and Anna Rose Childress

- 2:00 *Altered resting-state functional connectivity in adolescent female nonhuman primates during acute and chronic exposure to the long-acting cannabinoid CB1 receptor agonist, AM2389*  
Stephen Kohut<sup>1</sup>, Brian Kangas<sup>2</sup>, Jessica Nardolillo<sup>3</sup>, David Jacobs<sup>3</sup>, Scott Lukas<sup>1</sup>, Jack Bergman<sup>1</sup>, Blaise Frederick<sup>1</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>ADARC - McLean Hospital, Belmont, MA, <sup>3</sup>McLean Hospital, Belmont, MA
- 2:15 *Preliminary multimodal, multitask investigation of functional brain networks and D2/D3 receptor availability in cocaine use disorder*  
Patrick Worhunsky<sup>1</sup>, Gustavo Angarita<sup>1</sup>, David Matuskey<sup>2</sup>, Robert Malison<sup>1</sup>, Richard Carson<sup>2</sup>, Marc Potenza<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Yale University, New Haven, CT
- 2:30 *Citalopram for controlling impulsivity in cocaine use disorder: Evidence from BOLD and DCM imaging*  
Andrew Snyder, F. Gerard Moeller, Joel Steinberg, Virginia Commonwealth University, Richmond, VA
- 2:45 *Aberrant functional connectivity in large-scale brain networks distinguishes cocaine patients from controls and is linked to drug-use outcomes*  
Paul Regier, Jieqiong Wang, H Rao, Yong Fan, Anna Rose Childress, University of Pennsylvania, Philadelphia, PA

**ORAL COMMUNICATIONS 8**  
**W-EIGHTY ISSUES IN CRIMINAL JUSTICE****Indigo H**  
**2:00 - 4:00 PM**

Chairs: Hilary Surratt and Leo Beletsky

- 2:00 *Pretreatment social networks and source of referral as predictors of retention in residential SUD treatment*  
Erin Kerrison<sup>1</sup>, Hortensia Amaro<sup>2</sup>, <sup>1</sup>University of California at Berkeley, Berkeley, CA, <sup>2</sup>ISC School of Social Work, Los Angeles, CA
- 2:15 *Reducing heavy drinking and alcohol-involved crime with behavioral economics: Insights from 24/7 sobriety*  
Beau Kilmer, Greg Midgette, RAND Drug Policy Research Center, Santa Monica, CA
- 2:30 *How do marijuana decriminalization and legalization affect disparities in adolescent marijuana arrests? Evidence from Massachusetts, Washington and Maryland*  
Andrew Plunk<sup>1</sup>, Stephanie Peglow<sup>1</sup>, Paul Harrell<sup>1</sup>, Richard Grucza<sup>2</sup>, <sup>1</sup>Eastern Virginia Medical School, Norfolk, VA, <sup>2</sup>Washington University School of Medicine, St. Louis, MO
- 2:45 *Evaluating the epidemiological impact of a police education program among people who inject drugs in Tijuana, Mexico*  
Javier Cepeda<sup>1</sup>, Leo Beletsky<sup>2</sup>, Daniela Abramovitz<sup>1</sup>, Annick Borquez<sup>1</sup>, Steffanie Strathdee<sup>1</sup>, Natasha Martin<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>Northeastern University, Boston, MA
- 3:00 *Factors predicting arrest in a jail-based vs. a community-based methadone treatment study*

Sharon Kelly<sup>1</sup>, Robert Schwartz<sup>1</sup>, Kevin O'Grady<sup>2</sup>, Shannon Mitchell<sup>1</sup>, Jan Gryczynski<sup>1</sup>, Jerome Jaffe<sup>1</sup>,  
<sup>1</sup>Friends Research Institute, Baltimore, MD, <sup>2</sup>University of Maryland, College Park, MD

- 3:15 *Criminal justice referral to medication-assisted treatment among opioid treatment admissions, 2014*  
 Shivani Mantha<sup>1</sup>, Pia Mauro<sup>2</sup>, Sara Abiola<sup>1</sup>, Silvia Martins<sup>2</sup>, <sup>1</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>2</sup>Columbia University, New York, NY
- 3:30 *Patterns of buprenorphine use and risk for rapid re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia*  
 Hilary Surratt<sup>1</sup>, Michele Staton<sup>2</sup>, Carl Leukefeld<sup>1</sup>, Carrie Oser<sup>1</sup>, Matt Webster<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 3:45 *The economic impact of jail-based medication-assisted treatment: A cost-effectiveness analysis of a large jail-based methadone maintenance treatment program in New Mexico*  
 Brady Horn<sup>1</sup>, Xiaoxue Li<sup>1</sup>, Barbara Mccrady<sup>1</sup>, Saleh Mamun<sup>1</sup>, Paul Guerrin<sup>1</sup>, Michael French<sup>2</sup>, <sup>1</sup>University of New Mexico, Albuquerque, NM, <sup>2</sup>University of Miami School of Law, Coral Gables, FL

## **SYMPOSIUM IX INNOVATOR SYMPOSIUM**

**Indigo A  
 2:00 - 4:00 PM**

Chairs: Thomas Prisinzano

*Two is Better than One: Discovery of Bifunctional Ligands as Treatments for Substance Abuse Disorders*  
 C. Cunningham, Montefiore Medical Center, Bronx, NY

*Evaluation of Salvinorin A-analogues activating mu and kappa opioid receptors as novel drug abuse and pain therapeutics*

B. Kivell, Victoria University of Wellington, Wellington, New Zealand, New Zealand

*Salvinorin analogs and KOP-r ligands as potential approaches in the treatment of substance use disorders*  
 E. Butelman, The Rockefeller University, New York, NY

*Chemical Approaches for the Development of Drug Abuse Therapies*  
 T. Prisinzano, University of Kansas, Lawrence, KS

## **SYMPOSIUM VIII CANNABIS AND TOBACCO CO-USE: CURRENT FINDINGS ACROSS PRECLINICAL, GENETIC, EXPERIMENTAL AND EPIDEMIOLOGICAL SCIENCE**

**Indigo BF  
 2:00 - 4:00 PM**

Chairs: Erica Peters and Arpana Agrawal

2:00 *Reciprocal relationships between cannabis and tobacco: A Mendelian randomization approach*  
 A. Agrawal, Washington University School of Medicine, St. Louis, MO

2:25 *Cannabis use and stress psychophysiological response: Impact of early life adversity and tobacco co-use*  
 M. al'Absi, University of Minnesota Duluth, Duluth, MN

2:50 *Secondhand smoke from cannabis: The return of a familiar problem*  
 G. St.Helen, University of California San Francisco, San Francisco, CA

3:15 *Co-use of cannabis and tobacco during pregnancy*  
 V. Coleman-Cowger, Battelle Memorial Institute, Baltimore, MD

3:40 *The current state of tobacco and cannabis co-use*  
 E. Peters, Battelle Memorial Institute, Baltimore, MD



**SYMPOSIUM X**

**Indigo D**

**NEONATAL ABSTINENCE SYNDROME: EFFECTS OF OPIOIDS ON THE DEVELOPING BRAIN** **2:00 - 4:00 PM**

Chairs: Henrietta Bada and Gary Peltz

- 2:00 *Fetal neurobehavioral development in buprenorphine exposed pregnancies*  
L. Jansson, Johns Hopkins University School of Medicine, Baltimore, MD
- 2:25 *Opioid versus non-opioid treatment for neonatal abstinence syndrome*  
H. Bada, University of Kentucky, College of Medicine, Lexington, KY
- 2:50 *Clinical and genomic risk factors of neonatal abstinence syndrome*  
J. Davis, Tufts Medical Center, Boston, MA
- 3:15 *Cellular and molecular basis of opiate drug-induced disruption of neuronal and glial maturation in the central nervous system*  
K. Hauser, Virginia Commonwealth University, Richmond, VA
- 3:40 *Current state and future opportunities and challenges in clinical and basic neurobiology of neonatal abstinence syndrome*  
G. Peltz, Stanford University, Stanford, CA

**PRESIDENT'S LECTURE**

**Indigo BCFG**  
**4:15 - 5:15 PM**

*Eyes wide shut: Social and structural process contributing to addiction and its health consequences*

President: Alan Budney, Geisel School of Medicine at Dartmouth

Jamila K. Stockman, University of California San Diego School of Medicine

Steffanie A. Strathdee, University of California San Diego School of Medicine

**PRE/POST-DOCS NETWORKING**

**Indigo Terrace**  
**5:30 - 7:00 PM**

**NIDA INTERNATIONAL FORUM INTERNATIONAL RESEARCH POSTER SESSION**

**Sapphire D/H/L/P**  
**7:00 - 9:00 PM**

*CPDD International Committee: Best research poster competition*

C. McCoy, Comprehensive Drug Research Center, Miami, FL

**WORKSHOP V**

**Indigo D**

**NOT JUST ONE BUT TWO: IMPACT OF OPIOID EPIDEMIC ON ALCOHOL USE AMONG PREGNANT MOTHERS**

**7:30 - 9:00 PM**

Chairs: Victoria Coleman-Cowger and Stacey Klamann

*Clinician's understanding in state of art: prenatal opioid and alcohol use and their pediatric consequences*

D. Coffa, University of California, San Francisco School of Medicine, San Francisco, CA  
*Potential interactive effects of the opioid and alcohol co-use on maternal, neonatal, and child outcomes*  
S. Klamon, University of North Carolina at Chapel Hill, Chapel Hill, NC  
*Treating alcohol use disorder in the presence of opioid use disorder: clinical care of the mother-child dyad*  
N. Poole, Centre of Excellence for Women's Health, Vancouver, BC, Canada  
*The prevalence and behavioral characteristics of prenatal exposure to alcohol and other drugs: results from the San Diego CoFASP study*  
N. Akshoomoff, University of California San Diego, La Jolla, CA  
*Global prevalence of maternal drinking, FAS/FASD, and its economic cost*  
S. Ondersma, Wayne State University School of Medicine, Detroit, MI

## **WORKSHOP VI**

## **Indigo A**

### **SUMI: A FREE INTERACTIVE WEB-BASED TOOL TO SELECT VALID SUBSTANCE USE MEASURES FOR HIV RESEARCH**

**7:30 - 9:00 PM**

Chairs: Steffanie Strathdee and Steve Shoptaw

*Psychometric properties of substance use measures among key populations at risk for HIV*  
G. Santos, University of California San Francisco, San Francisco, CA  
*SUMI Demonstration*  
S. Chen, HIV Prevention and Trial Network, Rockville, MD  
*SUMI Applications*  
S. Shoptaw, University of California Los Angeles, Los Angeles, CA

## **WORKSHOP VII**

## **Indigo E**

### **ANNUAL CPDDD DESIGN AND ANALYSIS WORKSHOP**

**7:30 - 9:00 PM**

Chairs: Sterling McPherson and Susan Mikulich-Gilbertson

*Systems biology (trans-omics) approaches to understanding substance use*  
L. Saba, University of Colorado Anschutz Medical Campus, Aurora, CO  
*Indirect and direct pattern-mixture modeling for the handling of missing values in randomized clinical trials*  
E. Burduli, Washington State University, Spokane, WA  
*Building predictive models for opioid treatment response using multi-center clinical trial datasets from the National Treatment Clinical Trials Network*  
S. Luo, Columbia University, New York, NY  
*How to work collaboratively and effectively with your biostatistician*  
S. Mikulich-Gilbertson<sup>1</sup>, S. McPherson<sup>2</sup>, <sup>1</sup>University of Colorado School of Medicine, Aurora, CO,  
<sup>2</sup>Washington State University, Elson S. Floyd College of Medicine, Spokane, WA

**Tuesday, June 12, 2018**

**CPDD OUTREACH EVENT - FATHER JOE'S VILLAGES**

**Offsite Venue  
6:00 - 9:00 AM**

Meet in Lobby

## **POLICY FORUM**

**Indigo BCFG**  
**8:00 - 9:45 AM**

Chairs: M. Y. Iguchi and Sandra Comer

*Update on activities and accomplishments of Friends of NIDA*

W. Dewey<sup>1</sup>, C. O'Keeffe<sup>2</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Virginia Commonwealth University, School of Medicine, Midlothian, VA

*Report from Capitol Hill – Implications for NIDA's research portfolio*

E. Long, Van Scoyoc Associates, Washington, DC

*Where is MAT available in the US and is it available where needed? A geographic review*

M. Iguchi, RAND Corporation, Santa Monica, CA

*Vermont's care alliance for opioid addiction -- Developing a public health approach to the opioid crisis*

B. Cimaglio, Retired, Burlington, VT

*State-level innovations in response to the opiate overdose crisis*

P. Korthuis, Oregon Health & Science University, Portland, OR

## **SYMPOSIUM XII** **CLINICAL STUDIES OF BIOLOGICS TO TREAT** **SUBSTANCE USE DISORDERS**

**Indigo D**  
**10:00 - 11:00 AM**

Chairs: Ivan Montoya and S. Michael Owens

10:00 *Phase 1 to 2a clinical studies of a monoclonal antibody for treating methamphetamine use disorders*

W. Gentry, University of Arkansas for Medical Sciences, Little Rock, AK

10:20 *Clinical studies of an adenovirus-based anti-cocaine vaccine*

R. Crystal, Weill Cornell Medical College, New York, NY

10:40 *Clinical evaluation of a nanoparticle-based nicotine vaccine*

L. Johnston, Selecta Biosciences, Inc., Watertown, MA

## **ORAL COMMUNICATIONS 10** **CANNABLISS? CANNABINOIDS**

**Indigo E**  
**10:00 - 12:00 PM**

Chairs: Dustin Lee and Rachel Tomko

10:00 *In-vitro to in-vivo translation for the cannabinoid-1 receptor: Value for derisking off-target cannabinoid receptor agonism liabilities in drug discovery*

Susan Goody<sup>1</sup>, Andy Mead<sup>2</sup>, <sup>1</sup>Pfizer, Inc., Groton, CT, <sup>2</sup>AstraZeneca, Cambridge

10:15 *Evaluation of purified cannabidiol (CBD) in rhesus monkeys that self-administer midazolam*

Royston Gray<sup>1</sup>, David Maguire<sup>2</sup>, Lisa Gerak<sup>2</sup>, Martin Javors<sup>2</sup>, Charles France<sup>2</sup>, <sup>1</sup>GW Pharmaceuticals PLC, Cambridge, <sup>2</sup>University of Texas Health Science Center, San Antonio, TX

10:30 *Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder*

Dustin Lee<sup>1</sup>, Nicolas Schlienz<sup>1</sup>, Erin Martin<sup>1</sup>, Jeannie-Marie Leoutsakos<sup>1</sup>, Alan Budney<sup>2</sup>, Michael Smith<sup>1</sup>, D. Andrew Tompkins<sup>3</sup>, Aidan Hampson<sup>4</sup>, Ryan Vandrey<sup>5</sup>, <sup>1</sup>Johns Hopkins University School of Medicine,

- Baltimore, MD, Geisel School of Medicine at Dartmouth, Lebanon, NH, University of California San Francisco School of Medicine, San Francisco, CA, <sup>4</sup>National Institute of Drug Abuse, National Institutes of Health, Rockville, MD, <sup>5</sup>Behavioral Pharmacology Research Unit, Johns Hopkins Hospital, Baltimore, MD
- 10:45 *The effects of celecoxib on a human laboratory model of cannabis withdrawal and relapse*  
Caroline Arout<sup>1</sup>, Sachin Patel<sup>2</sup>, Ziva Cooper<sup>3</sup>, Gillinder Bedi<sup>4</sup>, Evan Herrmann<sup>5</sup>, Stephanie Reed<sup>4</sup>, Richard Foltin<sup>1</sup>, Margaret Haney<sup>1</sup>, <sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>Vanderbilt University Medical Center, Nashville, TN, <sup>3</sup>Columbia University and NYSPI, New York, NY, <sup>4</sup>Columbia University, New York, NY, <sup>5</sup>Battelle Memorial Institute, Baltimore, MD
- 11:00 *N-acetylcysteine for adolescent cannabis use disorder: Do depressive symptoms moderate abstinence outcomes?*  
Rachel Tomko, Amanda Gilmore, Kevin Gray, Medical University of South Carolina, Charleston, SC
- 11:15 *A case series exploring the effect of twenty sessions of repetitive transcranial magnetic stimulation (rTMS) on cannabis use and craving*  
Gregory Sahlem<sup>1</sup>, Margaret Caruso<sup>2</sup>, Robert Malcolm<sup>1</sup>, Mark George<sup>1</sup>, Aimee McRae-Clark<sup>1</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC
- 11:30 *Impact of three weeks of sustained abstinence on cognition in young adult cannabis users*  
Alexander Wallace, Kyle Jennette, Krista Lisdahl, University of Wisconsin-Milwaukee, Milwaukee, WI
- 11:45 *An examination of gender differences in adolescent marijuana use trends post-implementation of liberalized recreational cannabis policies in Washington State*  
Andrea Stone, University of Washington, Bothell, WA

## ORAL COMMUNICATIONS 11 BASICALLY OPIOIDS

**Indigo H**  
**10:00 - 12:00 PM**

Chairs: M. Foster Olive and Lisa Brents

- 10:00 *Quantifying G-protein and arrestin bias for structurally diverse KOR ligands*  
Jose Erazo, Amelia Dunn, Alexandra Dunn, Brian Reed, Mary Jeanne Kreek, The Rockefeller University, New York, NY
- 10:15 *Neuropharmacodynamic profile of NKTR-181: Correlation to low abuse potential*  
Laurie VanderVeen, Takahiro Miyazaki, Irene Choi, Michael Eldon, Hema Gursahani, Faye Hsieh, Aleksandrs Odinecs, Jonathan Zalevsky, Stephen Doberstein, Nektar Therapeutics, San Francisco, CA
- 10:30 *Chemogenetic approaches to restoring prosocial functioning in rats following opiate use*  
M. Foster Olive<sup>1</sup>, Seven Tomek<sup>2</sup>, Gabriela Stegmann<sup>1</sup>, <sup>1</sup>Arizona State University, Tempe, AZ, <sup>2</sup>Arizona State University, Phoenix, AZ
- 10:45 *Norbuprenorphine, an active metabolite of buprenorphine, induces opioid dependence in a rat model of neonatal abstinence syndrome*  
Lisa Brents<sup>1</sup>, Bryce Griffin<sup>1</sup>, Caitlin Caperton<sup>1</sup>, Lauren Russell<sup>1</sup>, Christian Cabalong<sup>1</sup>, Catheryn Wilson<sup>1</sup>, Kyle Urquhart<sup>1</sup>, Bradford Martins<sup>1</sup>, Amy Patton<sup>2</sup>, Alex Alund<sup>2</sup>, S. Michael Owens<sup>1</sup>, William Fantegrossi<sup>1</sup>, Jeffery Moran<sup>2</sup>, <sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, AK, <sup>2</sup>PinPoint Testing, LLC, Little Rock, AR
- 11:00 *Pharmacological characterization of six synthetic opioids: Radioligand binding and analgesia activities*  
Takato Hiranita<sup>1</sup>, Aaron Janowsky<sup>2</sup>, Amy Eshleman<sup>3</sup>, Saki Fukuda<sup>4</sup>, Cassandra Prioleau<sup>5</sup>, Li Fang<sup>6</sup>, Srihari Tella<sup>7</sup>, Merle Paule<sup>8</sup>, William Fantegrossi<sup>4</sup>, <sup>1</sup>NCTR/FDA, Jefferson, AR, <sup>2</sup>University and VA Portland Health Care System, Portland, OR, <sup>3</sup>Oregon Health & Science University, Portland, OR, <sup>4</sup>University of Arkansas for Medical Sciences, Little Rock, AK, <sup>5</sup>Department of Justice, Springfield, VA, <sup>6</sup>Drug Enforcement

Administration, Washington, DC, <sup>7</sup>Drug and Chemical Evaluation Section, Arlington, VA, <sup>8</sup>U.S. Food and Drug Administration, Silver Spring, MD

- 11:15 *Rapid assessment of choice between fentanyl and liquid food in male and female rats*  
Drew Townsend<sup>1</sup>, S. Stevens Negus<sup>1</sup>, Barak Caine<sup>2</sup>, Morgane Thomsen<sup>3</sup>, Matthew Banks<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>McLean Hospital, Belmont, MA, <sup>3</sup>University Hospital of Copenhagen, Copenhagen
- 11:30 *Oxycodone self-administration on a progressive-ratio schedule is reduced by contingent administration of the atypical kappa-opioid agonist, nalfurafine, in rhesus monkeys*  
Carlos Zamarripa<sup>1</sup>, Sally Huskinson<sup>1</sup>, Thomas Prisinzano<sup>2</sup>, Christopher McCurdy<sup>3</sup>, Kevin Freeman<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>University of Kansas, Lawrence, KS, <sup>3</sup>University of Florida, Gainesville, FL
- 11:45 *Assessment of the priming strength of opioids before and during chronic naltrexone treatment in squirrel monkeys*  
Sarah Withey<sup>1</sup>, Carol Paronis<sup>1</sup>, Jack Bergman<sup>2</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>Preclinical Pharmacology - McLean Hospital, Belmont, MA

**SYMPOSIUM XI**  
**UNMET NEED FOR TREATMENT OF OPIOID USE**  
**DISORDER: AN INTERNATIONAL PERSPECTIVE**

**Indigo A**  
**10:00 - 12:00 PM**

Chairs: Howard Chilcoat and Michelle Lofwall

- 10:00 *Unmet need for treatment for opioid use disorder in the United States*  
M. Lofwall, University of Kentucky, College of Medicine, Lexington, KY
- 10:25 *Unmet need for opioid use disorder treatment: a European perspective*  
M. Auriacombe, Université de Bordeaux, Bordeaux, France
- 10:50 *Universal unmet need in opioid use disorders: Spring training for getting a life*  
W. Ling, University of California Los Angeles, Los Angeles, CA
- 11:15 *Unmet treatment need for OUD treatment in Australia*  
R. Ali, University of Adelaide, Adelaide, SA, Australia
- 11:40 *Discussant: Addressing the global need for OUD treatment*  
G. Woody, University of Pennsylvania, Philadelphia, PA

**ORAL COMMUNICATIONS 9**  
**GREATEST AMERICAN HEROES: VETERANS AND**  
**MILITARY**

**Indigo D**  
**11:15 - 12:15 PM**

Chairs: Erin Anderson Goodell and Stephen Baldassarri

- 11:15 *Brief counseling for veterans with musculoskeletal disorders, risky substance use and service-connection claims*  
Marc Rosen<sup>1</sup>, Anne Black<sup>2</sup>, William Becker<sup>2</sup>, Steve Martino<sup>3</sup>, Ellen Edens<sup>1</sup>, Robert Kerns<sup>4</sup>, <sup>1</sup>VA Connecticut Healthcare System, West Haven, CT, <sup>2</sup>Yale University, New Haven, CT, <sup>3</sup>Yale University Department of Psychiatry, New Haven, CT, <sup>4</sup>Yale University School of Medicine, West Haven, CT
- 11:30 *Incidence of newly diagnosed opioid use disorder in veterans with chronic pain prescribed opioids*  
Tessa Rife, David Pennington, Katelyn Brady, Stephanie Cardoos, Payal Mapara, Tauheed Zaman, Steven Batki, San Francisco Veterans Affairs Health Care System, San Francisco, CA

- 11:45 *Nicotine dependence in us military veterans: Results from the national health and resilience in veterans study*  
Stephen Baldassarri<sup>1</sup>, Lorig Kachadourian<sup>2</sup>, Irina Esterlis<sup>1</sup>, Robert Pietrzak<sup>2</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>VA Connecticut Healthcare System, West Haven, CT
- 12:00 *Deployment, traumatic brain injury, and social influence on recent illicit drug use among U.S. Army Reserve and National Guard couples*  
Erin Anderson Goodell<sup>1</sup>, D. Lynn Homish<sup>2</sup>, Gregory Homish<sup>2</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>State University of New York at Buffalo, Buffalo, NY

## **MEDIA FORUM**

### **MEDIA FORUM 2018: WHAT'S HOT?**

**Indigo A**

**12:15 - 1:45 PM**

Chairs: Margaret Chisolm and Bertha Madras

*Media Forum 2018: What's Hot*

M. Chisolm, Johns Hopkins University School of Medicine, Baltimore, MD

## **TOWN HALL**

### **ARE ABUSE-DETERRENT OPIOID FORMULATIONS THE ANSWER TO THE UNITED STATES OPIOID EPIDEMIC? A PERSPECTIVE FROM INDUSTRY, GOVERNMENT, AND ACADEMIA**

**Indigo D**

**12:15 - 1:45 PM**

Chairs: Marco Pravetoni and Sidney Schnoll

*How epidemiologic data can inform the real world effects of abuse-deterrent opioid formulations*

R. Dart, Rocky Mountain Poison & Drug Center, Denver, CO

*The reformulated OxyContin® and its effect on abuse epidemiology*

P. Coplan, Purdue Pharma, University of Pennsylvania, Fort Washington, PA

*Food and Drug Administration post-marketing surveillance: What's needed for Category 4 labeling*

J. McAninch, U.S. Food and Drug Administration, Bozeman, MT

*How does a new product with low market penetration meet Category 4 labeling*

S. Passik, Collegium Pharmaceutical Inc., Canton, MA

*Discussant. Bringing together industry, academia, and government to evaluate and use abuse-deterrent opioid formulations*

S. Schnoll, Pinney Associates, Inc., Stamford, CT

## **MARIAN W. FISCHMAN MEMORIAL AWARD LECTURE**

**Indigo BCFG**

**2:00 - 3:00 PM**

*Presentation of the Marian W. Fischman Award to Kenzie L. Preston*

Introduction by George Bigelow

*In the Footsteps of Fischman*

Kenzie L. Preston

## **ORAL COMMUNICATIONS 12 CLUB DRUGS: PARTY LIKE IT'S 1929**

**Indigo E**

**3:15 - 5:15 PM**

Chairs: Gregory Collins and Katharine Nelson

- 3:15 *Neuropharmacology of n-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2c counterparts in male rats*  
Michael Baumann<sup>1</sup>, Kenner Rice<sup>2</sup>, Agnes Sulima<sup>2</sup>, Ann Decker<sup>3</sup>, Bruce Blough<sup>3</sup>, John Partilla<sup>1</sup>, Joshua Elmore<sup>1</sup>, <sup>1</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, <sup>3</sup>RTI International, Research Triangle Park, NC
- 3:30 *In vitro and in vivo pharmacology of "bath salts" constituent 4-chloro-N-ethylcathinone: radioligand binding and locomotor stimulant effects*  
William Fantegrossi<sup>1</sup>, Aaron Janowski<sup>2</sup>, Amy Eshleman<sup>2</sup>, Saki Fukuda<sup>1</sup>, Jyoti Gogoi<sup>1</sup>, Lauren Russell<sup>1</sup>, Cassandra Prioleau<sup>3</sup>, Li Fang<sup>4</sup>, Srihari Tella<sup>5</sup>, Merle Paule<sup>6</sup>, Takato Hiranita<sup>7</sup>, <sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, AK, <sup>2</sup>Oregon Health & Science University, Portland, OR, <sup>3</sup>Department of Justice, Springfield, VA, <sup>4</sup>Drug Enforcement Administration, Washington, DC, <sup>5</sup>Drug and Chemical Evaluation Section, Arlington, VA, <sup>6</sup>U.S. Food and Drug Administration, Silver Spring, MD, <sup>7</sup>NCTR/FDA, Jefferson, AR
- 3:45 *Stereoselective effects of the second generation 'bath salt'  $\alpha$ -pyrrolidinopentiophenone ( $\alpha$ -PVP): Assessments of aversion, locomotor activity and thermoregulation*  
Katharine Nelson<sup>1</sup>, Briana Hempel<sup>1</sup>, Madeline Crissman<sup>1</sup>, Claudia Woloshchuk<sup>1</sup>, Matthew Clasen<sup>1</sup>, Kenner Rice<sup>2</sup>, Anthony Riley<sup>1</sup>, <sup>1</sup>The American University, Washington, DC, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 4:00  *$\alpha$ -PVP alters the reinforcing value of activity wheel access in male wistar rats*  
Eric Harvey, Kevin Creehan, Mehrak Javadi-Paydar, Jacques Nguyen, Sophia A. Vandewater, Yanabel Grant, Tobin Dickerson, Michael Taffe, The Scripps Research Institute, La Jolla, CA
- 4:15 *Relative reinforcing effects of the synthetic cathinones MDPV and  $\alpha$ -PVP in rhesus monkeys*  
Gregory Collins<sup>1</sup>, Agnieszka Sulima<sup>2</sup>, Kenner Rice<sup>2</sup>, Charles France<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, San Antonio, TX, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 4:30 *Relative reinforcing effectiveness of the synthetic cathinones MDPV and methylone, administered alone and in combination with caffeine in rats*  
Brenda Gannon<sup>1</sup>, Agnieszka Sulima<sup>2</sup>, Kenner Rice<sup>2</sup>, Gregory Collins<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, San Antonio, TX, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 4:45 *Monoamine re-uptake inhibitors potentiate the discriminative stimulus effects of 3,4-methylenedioxypyrovalerone (MDPV) in male Sprague-Dawley rats*  
Lisa Baker, Harmony Risca, Western Michigan University, Kalamazoo, MI
- 5:00 *GHB in adolescent rat attenuates hippocampus-associated learning*  
Ratna Sircar, The City University of New York, New York, NY

**ORAL COMMUNICATIONS 13**  
**THIS IS YOUR BRAIN ON CYTOKINES:**  
**NEUROINFLAMMATION AND IMMUNE**

**Indigo D**  
**3:15 - 5:15 PM**

Chairs: Judith Tsui and Lee Anne Cannella

- 3:15 *Pathological changes in the corticostriatal pathway induced by experimental traumatic brain injury and subsequent rewarding effects of cocaine in rodents*  
Lee Anne Cannella<sup>1</sup>, Fionya Tran<sup>1</sup>, Allison Andrews<sup>2</sup>, Roshanak Razmpour<sup>1</sup>, Scott Rawls<sup>1</sup>, Servio Ramirez<sup>1</sup>, <sup>1</sup>Lewis Katz School of Medicine at Temple University, Philadelphia, PA, <sup>2</sup>Temple University, Philadelphia, PA

- 3:30 *N-acetylcysteine-mediated restoration of GLT-1 and inhibition of neuroinflammation in the nucleus accumbens core attenuates cue-induced nicotine seeking*  
Mark Namba, Gregory Powell, Julianna Goenaga, Cassandra Gipson-Reichardt, Arizona State University, Tempe, AZ
- 3:45 *Granulocyte-colony stimulating factor mediates neuronal and behavioral responses to cocaine*  
Drew Kiraly, Arthur Godino, Emily Peck, Erin Calipari, Icahn School of Medicine at Mount Sinai, New York, NY
- 4:00 *HIV-1 Tat protein expression elevates dopamine levels and increases morphine consumption and conditioned place preference*  
Thomas Cirino<sup>1</sup>, Shainnel Eans<sup>1</sup>, Heather Stacy<sup>1</sup>, Marc Kaufman<sup>2</sup>, Jun Zhu<sup>3</sup>, Jay McLaughlin<sup>1</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>McLean Hospital, Brain Imaging Center, Belmont, MA, <sup>3</sup>University of South Carolina, Charleston, SC
- 4:15 *Brain inflammation and cognitive bias in methamphetamine dependence*  
Ziwei Zhang<sup>1</sup>, Kyoji Okita<sup>1</sup>, Mark Mandelkern<sup>2</sup>, Andrew Dean<sup>1</sup>, Maritza Johnson<sup>1</sup>, Arthur Brody<sup>3</sup>, Judah Farahi<sup>4</sup>, Erika Nurmi<sup>1</sup>, Lauren Seaman<sup>1</sup>, Edythe London<sup>1</sup>, <sup>1</sup>University of California Los Angeles, Los Angeles, CA, <sup>2</sup>University of California Irvine, Irvine, CA, <sup>3</sup>University of California San Diego, La Jolla, <sup>4</sup>VA of Greater Los Angeles Health System, Los Angeles, CA
- 4:30 *Immune dysregulation among HIV-infected individuals with opioid-use disorders*  
Michelle Underwood, Lynn Kunkel, Thuan Nguyen, Erin Merrifield, Philip Todd Korthuis, Christina Lancioni, Oregon Health & Science University, Portland, OR
- 4:45 *Double dissociation of HIV and SUD effects on tasks dependent on striatal integrity*  
Eileen Martin<sup>1</sup>, Raul Gonzalez<sup>2</sup>, Jasmin Vassileva<sup>3</sup>, Jessica Fogel, Antoine Bechara<sup>4</sup>, <sup>1</sup>Rush University Medical Center, Chicago, IL, <sup>2</sup>Florida International University, Miami, FL, <sup>3</sup>Virginia Commonwealth University, Richmond, VA, <sup>4</sup>University of Southern California, Los Angeles, CA
- 5:00 *Opioid use disorder among persons with hepatitis C and HIV: Data from 8 health systems*  
Judith Tsui<sup>1</sup>, Gwen Lapham<sup>2</sup>, Denise Boudreau<sup>2</sup>, Eric Johnson<sup>2</sup>, Ingrid Binswanger<sup>3</sup>, Chinazo Cunningham<sup>4</sup>, Manu Thakral<sup>2</sup>, Julia Arnsten<sup>4</sup>, Andrew Saxon<sup>5</sup>, Joseph Merrill<sup>1</sup>, Jeffrey Samet<sup>6</sup>, Gavin Bart<sup>7</sup>, Cynthia Campbell<sup>8</sup>, Kathy Bradley<sup>2</sup>, <sup>1</sup>University of Washington, Seattle, WA, <sup>2</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA, <sup>3</sup>Kaiser Permanente Colorado, Denver, CO, <sup>4</sup>Montefiore Medical Center, Bronx, NY, <sup>5</sup>VA Puget Sound Healthcare System, Seattle, WA, <sup>6</sup>Boston University School of Medicine, Boston, MA, <sup>7</sup>University of Minnesota, Minneapolis, MN, <sup>8</sup>Kaiser Permanente North California Division of Research, Oakland, CA

**ORAL COMMUNICATIONS 14**  
**SERVING THE UNDERSERVED: HEALTH**  
**DISPARITIES**

**Indigo H**  
**3:15 - 5:15 PM**

Chairs: Scott Hadland and Hannah Carliner

- 3:15 *The opioid epidemic: Media attention to a white-death crisis*  
Stephanie Peglow<sup>1</sup>, Paul Harrell<sup>1</sup>, Richard Grucza<sup>2</sup>, Andrew Plunk<sup>1</sup>, Anna Davids<sup>1</sup>, <sup>1</sup>Eastern Virginia Medical School, Norfolk, VA, <sup>2</sup>Washington University School of Medicine, St. Louis, MO
- 3:30 *Racial/ethnic disparities in referral to substance use disorder screening among justice-involved children*  
Amy Elliott, Micah Johnson, Linda Cottler, University of Florida, Gainesville, FL
- 3:45 *Race/ethnicity and sex differences in heroin use among adolescents in 3 US cities: Baltimore, MD, Washington, DC, & Jacksonville, FL (2015)*  
Abenaa Jones<sup>1</sup>, Kristin Schneider<sup>2</sup>, Sherri-Chanelle Brighthaupt<sup>2</sup>, Julie Johnson<sup>1</sup>, Sabriya Linton<sup>1</sup>, Renee



Johnson<sup>2</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD

- 4:00 *Access to substance abuse treatments: Whites and Hispanics*  
Darlene Santiago, Chengli Shen, Darlene Santiago, University of Pittsburgh, Pittsburgh, PA
- 4:15 *Poly-product drug use disparities in adolescents of lower socioeconomic status: Emerging trends in nicotine products, marijuana products, and prescription drugs*  
Mariel Bello<sup>1</sup>, Rubin Khoddam<sup>1</sup>, Yoewon Yoon<sup>2</sup>, Matthew Stone<sup>3</sup>, Junhan Cho<sup>1</sup>, Jungeun Lee<sup>2</sup>, Adam Leventhal<sup>1</sup>, <sup>1</sup>University of Southern California, Los Angeles, CA, <sup>2</sup>University of Southern California Suzanne Dworak-Peck School of Social Work, Los Angeles, CA, <sup>3</sup>University of California San Diego, La Jolla, CA
- 4:30 *Evidence-based medication treatment among Medicaid-enrolled youth with opioid use disorder, 2014-2015*  
Scott Hadland<sup>1</sup>, Sarah Bagley<sup>1</sup>, Jonathan Rodean<sup>2</sup>, Sharon Levy<sup>3</sup>, Michael Silverstein<sup>1</sup>, Marc Laroche<sup>1</sup>, Bonnie Zima<sup>4</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Children's Hospital Association, Lenexa, KS, <sup>3</sup>Boston Children's Hospital, Boston, MA, <sup>4</sup>University of California Los Angeles, Los Angeles, CA
- 4:45 *Neighborhood socioeconomic disadvantage, crime, and availability associated with binge drinking from adolescence into emerging adulthood*  
Brian Fairman<sup>1</sup>, Bruce Simons-Morton<sup>1</sup>, Denise Haynie<sup>1</sup>, Liu Danping<sup>1</sup>, Rise Goldstein<sup>2</sup>, Ralph Hingson<sup>3</sup>, Stephen Gilman<sup>1</sup>, <sup>1</sup>National Institute of Child Health and Human Development, Bethesda, MD, <sup>2</sup>Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, <sup>3</sup>National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD
- 5:00 *Non-medical prescription opioid use and disorder in midlife by race, gender, and poverty level in the united states*  
Hannah Carliner<sup>1</sup>, Luis Segura<sup>2</sup>, Julian Santaella-Tenorio<sup>2</sup>, Pia Mauro<sup>2</sup>, Shivani Mantha<sup>3</sup>, Deborah Hasin<sup>2</sup>, Silvia Martins<sup>2</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>Columbia University Mailman School of Public Health, New York, NY

## **SYMPOSIUM XIII**

### **NEXT GENERATION ANALGESICS**

**Indigo A**  
**3:15 - 5:15 PM**

Chairs: David McCann and Jane Acri

- 3:15 *PPL-103: A kappa partial agonist with potent antinociceptive activity, low abuse potential, and reduced risk of overdose*  
L. Toll, Florida Atlantic University, Boca Raton, FL
- 3:40 *Preclinical evaluation of AT-121, a novel bifunctional NOP/MOP receptor agonist, suggests dual analgesic and anti-opioid therapeutic action without risk of respiratory depression or abuse liability*  
N. Zaveri, Astraera Therapeutics, Mountain View, CA
- 4:05 *The combination of PF614 (an oxycodone prodrug) and MPAR technology to address risks from overdose*  
L. Kirkpatrick, Ensycce Biosciences Inc., San Diego, CA
- 4:30 *Biased ligands as a path to safer analgesics (oliceridine, TRV734 and TRV250)*  
J. Violin, Trevena, Chesterbrook, PA
- 4:55 *Discussant: New mechanisms to address pain and the future of NIH/NIDA support for pain research*  
N. Volkow, National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD

## **SYMPOSIUM XIV**

### **POLYSUBSTANCE USE IS THE NORM: TIME FOR RESEARCH AND PRACTICE TO RECOGNIZE AND**

**Indigo BF**  
**3:15 - 5:15 PM**

## ADDRESS IT

Chairs: Richard Saitz and Carlos Blanco

- 3:15 *Use of multiple substances in general health settings: challenges for clinical research*  
R. Saitz, Boston University School of Public Health, Boston, MA
- 3:40 *Smoking and toking: Translationally relevant animal models*  
J. Marusich, RTI International, Research Triangle Park, NC
- 4:05 *Shared versus specific effects of treatment on multiple outcomes in clinical trials using latent variable modeling*  
M. Wall, Columbia University and NYSPI, New York, NY
- 4:30 *Public health policy and practice to reduce health consequences of polysubstance use*  
H. Kunins, NYC Department of Health and Mental Hygiene, Queens, NY
- 4:55 *Polysubstance use and addiction: Integrating treatment and research needs*  
C. Blanco, Columbia University, New York, NY

## WORKSHOP IX SUBSTANCE USE AMONG JUVENILE JUSTICE- INVOLVED ADOLESCENTS: IDENTIFYING AND ADDRESSING THE NEED FOR TREATMENT SERVICES/SASATE BUSINESS MEETING

**Indigo A**  
**5:30 - 7:30 PM**

Chairs: Danica Knight and Michael Dennis

*JJ-TRIALS: A multi-site, collaborative initiative to improve substance use interventions for adolescents in the legal system*

D. Knight, Texas Christian University, Fort Worth, TX

*Understanding the substance use treatment needs of justice-involved youth*

S. Belenko, Temple University, Philadelphia, PA

*Demonstrating the need for and feasibility of applying a behavioral health services cascade framework in juvenile justice*

M. Dennis, Chestnut Health Systems, Normal, IL

*Need identification and substance use service receipt among opioid-using justice-involved youth*

T. Wiley, National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD

## WORKSHOP VIII EPIDEMIOLOGY AND PUBLIC HEALTH RESEARCH METHODS

**Indigo BF**  
**5:30 - 7:30 PM**

Chairs: Howard Chilcoat and Georgiy Bobashev

*Integrating contagion and chronic disease models to study drug use epidemics*

G. Bobashev, RTI International, Research Triangle Park, NC

*Epidemiological analysis of user-generated digital media*

M. Gilbert, Booz Allen Hamilton, Portland, OR

*Using survey data to understand drug use epidemics*

C. Mauro, Columbia University, New York, NY

*Uniformity of personalized treatment and individualized prediction of success. Example of naltrexone trials in Russia.*

B. Carper, RTI International, Research Triangle Park, NC

**WORKSHOP X**  
**WOMEN IN ADDICTIONS TEN YEARS ON:**  
**REVIEWING PROGRESS AND DEVELOPING A**  
**RESEARCH AND IMPLEMENTATION ROADMAP**

**Indigo D**  
**5:30 - 7:30 PM**

Chairs: Wendee Wechsberg and Loretta Finnegan

*Management of pregnant women with comorbid substance use disorders and other psychiatric illness*

A. Hammond, Johns Hopkins University School of Medicine, Baltimore, MD

*Sex trafficking, HIV and substance use: Current agenda and future needs*

F. Browne, RTI International, Research Triangle Park, NC

*LGBT: A global perspective on substance use, treatment, and gaps in research*

C. Powell, University of Arizona Southwest Institute for Research on Women, Tucson, AZ

*Policy and structural barriers to women's engagement in substance use disorder treatment: A global scoping review*

M. Lawental, University of South Florida, Tampa, FL

*Discussant: What we know and future directions*

J. Meyer, Yale University School of Medicine, New Haven, CT

**WORKSHOP XI**  
**24TH ANNUAL CONTINGENCY MANAGEMENT**  
**WORKING GROUP**

**Indigo E**  
**5:30 - 7:30 PM**

Chairs: Diann Gaalema and August Holtyn

**WORKSHOP XII**  
**THE NIH CLINICAL TRIALS STEWARDSHIP**  
**INITIATIVE: NEW POLICIES AND PROCEDURES**  
**AND HOW TO IMPLEMENT THEM.**

**Indigo H**  
**5:30 - 7:30 PM**

Chairs: Katia Howlett and David White

*Doing human subject research? Changing NIH policies may impact you--overview, timeline, impact*

K. Howlett, National Institute of Drug Abuse, National Institutes of Health, Rockville, MD

*NIH clinical trials and transparency reforms & initiatives: Impact on applications and review*

I. Montoya, National Institutes of Health, Bethesda, MD

*Stewardship responsibilities for the investigator: Good clinical practice, registration and reporting, single IRB*

D. White, Medications Discovery and Toxicology Branch, Bethesda, MD

**Wednesday, June 13, 2018**

**CPDD/INRC PLENARY**

**Indigo BCFG**  
**8:00 - 9:00 AM**

*Welcome to INRC*

Alan Budney, CPDD President

Fred Nyberg, INRC President

*Report from the National Institute on Drug Abuse*

*Drug abuse & addiction research: Progress, priorities, & challenges*

Nora Volkow, Director, National Institute on Drug Abuse

## **ORAL COMMUNICATIONS 15** **IS THERE A DOWNSIDE? HARM REDUCTION**

**Indigo D**  
**9:15 - 11:15 AM**

Chairs: Howard Chilcoat and Kirsten Smith

- 9:15 *“A lethal dose in every batch”: New Hampshire opioid consumers’ behavior in seeking fentanyl and drugs known to cause overdose*  
Andrea Meier<sup>1</sup>, Sarah Moore<sup>2</sup>, Elizabeth Saunders<sup>3</sup>, Stephen Metcalf<sup>2</sup>, Bethany McLeman<sup>4</sup>, Olivia Walsh<sup>5</sup>, Lisa Marsch<sup>2</sup>, <sup>1</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>2</sup>Geisel School of Medicine at Dartmouth, Hanover, NH, <sup>3</sup>The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, <sup>4</sup>Northeast Node of the CTN/Dartmouth College, Lebanon, NH, <sup>5</sup>Dartmouth College, Hanover, NH
- 9:30 *Rapid scale-up of low-threshold supervised consumption sites in response to a fentanyl-driven overdose crisis: A rapid ethnographic study in Vancouver, Canada*  
Ryan McNeil<sup>1</sup>, Samara Mayer<sup>2</sup>, Alexandra Collins<sup>2</sup>, Mary Clare Kennedy<sup>3</sup>, Jade Boyd<sup>3</sup>, <sup>1</sup>University of British Columbia, BC Centre on Substance Use, Vancouver, BC, Canada, <sup>2</sup>BC Centre on Substance Use, Vancouver, BC, Canada, <sup>3</sup>British Columbia Centre on Substance Use, Vancouver, BC, Canada
- 9:45 *Kratom use patterns among opioid users in United States: A novel form of harm-reduction?*  
Kirsten Smith<sup>1</sup>, Amanda Bunting<sup>2</sup>, Robert Walker<sup>3</sup>, Martin Hall<sup>4</sup>, Olivia Castillo<sup>5</sup>, <sup>1</sup>University of Louisville, Versailles, KY, <sup>2</sup>University of Kentucky, Lexington, KY, <sup>3</sup>University of Kentucky, Center on Drug and Alcohol Research, Lexington, KY, <sup>4</sup>University of Louisville, Louisville, KY, <sup>5</sup>University of Miami School of Law, Coral Gables, FL
- 10:00 *Improved frequency of ART initiation and use of harm reduction services among HIV-positive PWID in Ukraine.*  
Oleksandr Zeziulin<sup>1</sup>, Yuliia Sereda<sup>2</sup>, Pavlo Smyrnov<sup>3</sup>, Olga Denisiuk<sup>3</sup>, Tetiana Kiriazova<sup>2</sup>, Sergii Dvoriak<sup>2</sup>, Charles Vitek<sup>4</sup>, Trista Bingham<sup>5</sup>, Roksolana Kulchynska<sup>4</sup>, Kostyantyn Dumchev<sup>1</sup>, <sup>1</sup>Ukrainian Institute on Public Health Policy, Kyiv, Ukraine, <sup>2</sup>Ukrainian Institute on Public Health Policy, Kiev, Ukraine, <sup>3</sup>Alliance for Public Health, Kyiv, Ukraine, <sup>4</sup>The Centers for Disease Control and Prevention, Kyiv, Ukraine, <sup>5</sup>The Centers for Disease Control and Prevention, Atlanta, GA
- 10:15 *Who doesn’t swab, and why? An analysis of correlates and reasons for not swabbing injection sites among Australians who regularly inject drugs*  
Sarah Larney<sup>1</sup>, Amy Peacock<sup>1</sup>, Daniel O’Keefe<sup>2</sup>, Kerryn Butler<sup>3</sup>, Raimondo Bruno<sup>4</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, Sydney, Australia, <sup>2</sup>Burnet Institute, Melbourne, Australia, <sup>3</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia, <sup>4</sup>University of Tasmania, Sydney, Australia
- 10:30 *Global review of drug checking services 2017*  
Larissa Maier<sup>1</sup>, Alison Ritter<sup>2</sup>, Michala Kowalski<sup>3</sup>, Leigh Coney<sup>3</sup>, Danielle Ramo<sup>1</sup>, Monica Barratt<sup>2</sup>, <sup>1</sup>University of California San Francisco, San Francisco, CA, <sup>2</sup>National Drug and Alcohol Research Centre,

Sydney, Australia, <sup>3</sup>NDARC Drug Policy Modelling Program, Randwick, Australia

10:45 *A retrospective case series of a hospital-based managed alcohol program in Vancouver, Canada*

Christopher Fairgrieve<sup>1</sup>, Seonaid Nolan<sup>2</sup>, Jeffrey Samet<sup>3</sup>, <sup>1</sup>St. Paul's Hospital, Vancouver, BC, Canada, <sup>2</sup>University of British Columbia, Vancouver, BC, Canada, <sup>3</sup>Boston University School of Medicine, Boston, MA

11:00 *Stakeholder perspectives on delivering pre-exposure prophylaxis (PrEP) to people who inject drugs*

Katie Biello<sup>1</sup>, Angela Bazzi<sup>2</sup>, Dea Biancarelli<sup>2</sup>, Alberto Edeza<sup>1</sup>, Peter Salhaney<sup>1</sup>, Matthew Mimiaga<sup>1</sup>, Marilyn Drainoni<sup>2</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Boston University School of Public Health, Boston, MA

## ORAL COMMUNICATIONS 16 STIMULATING DISCOVERIES: COCAINE AND AMPHETAMINE MEDICATIONS DEVELOPMENT

**Indigo E**  
**9:15 - 11:15 AM**

Chairs: William Stoops and Jessica Higginbotham

9:15 *Protein kinase C $\beta$  inhibitors alter responding for amphetamine in rats under different schedules of reinforcement*

Rachel Altshuler, Margaret Gnegy, Emily Jutkiewicz, University of Michigan, Ann Arbor, MI

9:30 *GZ-11608-induced blockade of methamphetamine's reinforcing effect is not surmounted by increasing the dose of methamphetamine in male rats*

Linda Dwoskin<sup>1</sup>, Na-Ra Lee<sup>1</sup>, Emily Denehy<sup>1</sup>, Gaungrong Zheng<sup>2</sup>, Peter Crooks<sup>2</sup>, Michael Bardo<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Arkansas for Medical Sciences, Little Rock, AK

9:45 *The semi-synthetic kappa-agonist 16-Br-salvinorin A decreases the locomotor stimulant effects of cocaine in mice, without causing overt locomotor effects on its own*

Eduardo Butelman<sup>1</sup>, Bryan McElroy<sup>1</sup>, Samuel Williamson<sup>2</sup>, Thomas Prinszano<sup>2</sup>, Mary Jeanne Kreek<sup>1</sup>, <sup>1</sup>The Rockefeller University, New York, NY, <sup>2</sup>University of Kansas, Lawrence, KS

10:00 *Bidirectional, CBI receptor-mediated mechanisms of cocaine-memory reconsolidation and subsequent context-induced cocaine-seeking behavior*

Jessica Higginbotham<sup>1</sup>, Nicole Jones<sup>1</sup>, Shi Min Tan<sup>1</sup>, Rong Wang<sup>1</sup>, Mark Presker<sup>1</sup>, Rita Fuchs<sup>2</sup>, <sup>1</sup>Washington State University, Pullman, WA, <sup>2</sup>Washington State University, Chapel Hill, NC

10:15 *Effects of chronic cocaine self-administration and N-acetyl cysteine treatment on cognitive behavior and cocaine reinstatement in nonhuman primates*

Brian Kangas<sup>1</sup>, Rachel Doyle<sup>2</sup>, Stephen Kohut<sup>3</sup>, Timothy Gillis<sup>1</sup>, Jack Bergman<sup>3</sup>, Marc Kaufman<sup>4</sup>, <sup>1</sup>ADARC - McLean Hospital, Belmont, MA, <sup>2</sup>McLean Hospital, Belmont, MA, <sup>3</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>4</sup>McLean Hospital, Brain Imaging Center, Belmont, MA

10:30 *Influence of phendimetrazine maintenance on the reinforcing, subjective and physiological effects of intranasal cocaine*

William Stoops<sup>1</sup>, Joseph Alcorn, Justin Strickland<sup>1</sup>, Hays Lon<sup>1</sup>, Abner Rayapati<sup>1</sup>, Joshua Lile<sup>2</sup>, Craig Rush<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY

10:45 *Topiramate-phentermine combinations as a pharmacotherapy for cocaine dependence*

Craig Rush<sup>1</sup>, Anna Reynolds<sup>1</sup>, B. Levi Bolin<sup>1</sup>, William Stoops<sup>1</sup>, Joshua Lile<sup>2</sup>, Abner Rayapati<sup>1</sup>, Hays Lon<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY

11:00 *Extended release mixed amphetamine salts and topiramate for cocaine dependence: A replication trial with frequent users*

Frances Levin<sup>1</sup>, John Mariani<sup>2</sup>, Martina Pavlicova<sup>3</sup>, C. Jean Choi<sup>1</sup>, Amy Mahony<sup>2</sup>, Daniel Brooks<sup>2</sup>, Adam Bisaga<sup>4</sup>, Elias Dakwar<sup>5</sup>, Kenneth Carpenter<sup>5</sup>, Nasir Naqvi<sup>5</sup>, Kyle Kampman<sup>6</sup>, <sup>1</sup>Columbia University and

NYSPI, New York, NY, <sup>2</sup>New York State Psychiatric Institute, New York, NY, <sup>3</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>4</sup>Columbia University College of Physicians and Surgeons, New York, NY, <sup>5</sup>Columbia University, New York, NY, <sup>6</sup>University of Pennsylvania, Philadelphia, PA

## ORAL COMMUNICATIONS 17 TRAUMA

**Indigo H**  
**9:15 - 11:15 AM**

Chairs: Elizabeth Evans and Jeremy Kane

- 9:15 *Gender differences in associations between childhood adversity and mental health comorbidity among adults with opioid use disorders: Results from the 2012-2013 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III)*  
Elizabeth Evans<sup>1</sup>, Christine Grella<sup>2</sup>, <sup>1</sup>University of Massachusetts, Amherst, MA, <sup>2</sup>University of California, Chestnut Health Systems, Los Angeles, CA
- 9:30 *Measurement of the role of parental closeness in emerging adulthood in altering the association between childhood trauma and adulthood drug use*  
Kailyn Pearce<sup>1</sup>, Joy Scheidell<sup>1</sup>, MacRegga Severe<sup>1</sup>, Kelly Quinn<sup>2</sup>, Christopher Frueh<sup>3</sup>, Daniel Schatz<sup>4</sup>, Maria Khan<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>NYU Rory Meyers College of Nursing, New York, NY, <sup>3</sup>University of Hawaii at Hilo, Hilo, <sup>4</sup>New York University, New York, NY
- 9:45 *The effectiveness of trauma-focused cognitive behavioral therapy in reducing substance use among orphans and vulnerable children in Zambia*  
Jeremy Kane<sup>1</sup>, Paul Bolton<sup>1</sup>, Stephanie Skavenski van Wyk<sup>1</sup>, Christopher Akiba<sup>1</sup>, Saphira Munthali<sup>2</sup>, Ravi Paul<sup>3</sup>, Laura Murray<sup>1</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Serenity Harm Reduction Programme Zambia, Lusaka, Zambia, <sup>3</sup>University of Zambia Teaching Hospital, Lusaka, Zambia
- 10:00 *Polyvictimization and women's risk of drug overdose*  
Janna Ataiants, Stephen Lankenau, Drexel University Dornsife School of Public Health, Philadelphia, PA
- 10:15 *Susceptibility to traumatic stress accelerates the development of cocaine-associated dopamine transients and drives cocaine use vulnerability*  
Zachary Brodник, Rodrigo Espana, Drexel University College of Medicine, Philadelphia, PA
- 10:30 *Early trauma exposure, neural response inhibition, and risk for substance use disorders in adolescence and young adults: Trajectories of frontal oscillations during a Go/NoGo task*  
Jacquelyn Meyers<sup>1</sup>, Vivia McCutcheon<sup>2</sup>, Ashwini Pandey<sup>1</sup>, Chella Kamarajan<sup>1</sup>, Stacey Subbie<sup>1</sup>, David Chorlian<sup>1</sup>, Jessica Salvatore<sup>3</sup>, Victor Hesselbrock<sup>4</sup>, John Kramer<sup>5</sup>, Samuel Kuperman<sup>5</sup>, Arpana Agrawal<sup>2</sup>, Kathleen Bucholz<sup>2</sup>, Bernice Porjesz<sup>1</sup>, <sup>1</sup>State University of New York Downstate Medical Center, Brooklyn, NY, <sup>2</sup>Washington University School of Medicine, St. Louis, MO, <sup>3</sup>Virginia Commonwealth University, Richmond, VA, <sup>4</sup>University of Connecticut School of Medicine, Farmington, CT, <sup>5</sup>University of Iowa, Iowa City, IA
- 10:45 *Trauma-focused treatment for veterans in buprenorphine maintenance treatment for opioid use disorder*  
Sarah Meshberg-Cohen<sup>1</sup>, Anne Black<sup>2</sup>, Marc Rosen<sup>1</sup>, Ismene Petrakis<sup>1</sup>, <sup>1</sup>VA Connecticut Healthcare System, West Haven, CT, <sup>2</sup>Yale University, New Haven, CT
- 11:00 *Experiences in emergency department settings among people who use drugs in Vancouver, Canada*  
Samara Mayer<sup>1</sup>, Verena Langheimer<sup>2</sup>, Will Small<sup>3</sup>, Ryan McNeil<sup>3</sup>, <sup>1</sup>BC Centre on Substance Use, Vancouver, BC, Canada, <sup>2</sup>Goldcorp Addiction Medicine Fellowship, Vancouver, BC, Canada, <sup>3</sup>University of British Columbia, BC Centre on Substance Use, Vancouver, BC, Canada

## SYMPOSIUM XV

**Indigo BCFG**

## **FENTANYL ABUSE: FROM MEDICINAL CHEMISTRY 9:15 - 11:15 AM TO CLINICAL MANAGEMENT**

Chairs: Sandra Comer and Catherine Cahill

- 9:15 *Synthesis of fentanyl: A little goes a long way*  
F. Carroll, RTI International, Research Triangle Park, NC
- 9:40 *Behavioral pharmacology of fentanyl: Preclinical models*  
J. Woods, University of Texas Health Science Center, San Antonio, TX
- 10:05 *Illicitly made fentanyl overdose: Prevention and management in real-world settings*  
A. Walley, Boston University School of Medicine, Boston, MA
- 10:30 *Opioid use disorders: Vaccination as a therapeutic strategy*  
K. Janda, The Scripps Research Institute, La Jolla, CA
- 10:55 *Fentanyl: How did we get here and what do we do about it?*  
S. Comer, Columbia University and NYSPI, New York, NY

## **SYMPOSIUM XVI GUT-BRAIN AXIS IN ADDICTIONS: PEPTIDES, LANCETS AND BUGS**

**Indigo A  
9:15 - 11:15 AM**

Chairs: Lorenzo Leggio and Rajita Sinha

- 9:15 *Gut hormones, stress and craving: Do they underlie the overlapping biology of addiction and obesity?*  
R. Sinha, Yale University School of Medicine, New Haven, CT
- 9:40 *Mesolimbic encoding of affective stimuli: Tuning by physiological state and its proxies*  
M. Roitman, University of Illinois, Chicago, IL
- 10:05 *A plausible role for gut-brain signaling in increased susceptibility to alcohol and opiate misuse following bariatric surgery*  
E. Orellana, Penn State University of Medicine, Hershey, PA
- 10:30 *The role of the microbiota-gut-brain axis in alcohol use disorder*  
D. Kiraly, Icahn School of Medicine at Mount Sinai, New York, NY
- 10:55 *Discussant*  
A. Hajnal, Penn State College of Medicine, Hershey, PA

## **POSTER III A NICOTINE ANIMAL BEHAVIOR**

**Sapphire ABC/EFG  
11:30 - 1:30 PM**

- 11:30 *N-Acetylcysteine exacerbates cue-induced reinstatement of nicotine seeking in an estrous cycle phase-dependent manner*  
Julianna Goenaga<sup>1</sup>, Jose Pina<sup>1</sup>, Sandy Phan<sup>1</sup>, Laura Vesala<sup>1</sup>, Amanda Ariola<sup>1</sup>, Jacqueline Moreno<sup>1</sup>, Jason Nguyen<sup>1</sup>, Gregory Powell<sup>1</sup>, Mark Namba<sup>1</sup>, Stephanie Koebele<sup>1</sup>, Alesia Prakapenka<sup>1</sup>, Erin McClure<sup>2</sup>, Heather Bimonte-Nelson<sup>1</sup>, Cassandra Gipson-Reichardt<sup>1</sup>, <sup>1</sup>Arizona State University, Tempe, AZ, <sup>2</sup>Medical University of South Carolina, Charleston, SC
- 11:30 *Stress- and drug priming-induced reinstatement of drug-seeking in rats: comparison of nicotine and cigarette smoke condensate*  
Seong Shoon Yoon<sup>1</sup>, In Soo Ryu<sup>2</sup>, Young-Eun Lee<sup>2</sup>, Zhan-Hui Li<sup>2</sup>, Eun Sang Choe<sup>3</sup>, Joung-Wook Seo<sup>2</sup>,  
<sup>1</sup>Korea Institute of Toxicology, Daejeon, Republic of Korea, <sup>2</sup>Korea Institute of Toxicology, Daejeon, Korea,

- Republic of, <sup>3</sup>Pusan National University, Busan, Korea, Republic of
- 11:30 *Comparison of rewarding and reinforcing properties of nicotine and cigarette smoke condensate in rodents*  
In Soo Ryu<sup>1</sup>, Seong Shoon Yoon<sup>2</sup>, Young-Eun Lee<sup>1</sup>, Zhan-Hui Li<sup>1</sup>, Eun Sang Choe<sup>3</sup>, Joung-Wook Seo<sup>1</sup>,  
<sup>1</sup>Korea Institute of Toxicology, Daejeon, Korea, Republic of, <sup>2</sup>Korea Institute of Toxicology, Daejeon,  
Republic of Korea, <sup>3</sup>Pusan National University, Busan, Korea, Republic of
- 11:30 *Effects of dextromethorphan on nicotine-induced reward, behavioral sensitization, withdrawal signs, and drug seeking-related behavior in rats*  
Eagle Yi-Kung Huang<sup>1</sup>, Lok-Hi Chow<sup>2</sup>, Yuan-Hao Chen<sup>3</sup>, Ai-Lun Tsai<sup>1</sup>, <sup>1</sup>National Defense Medical Center, Taipei, Taiwan, <sup>2</sup>Taipei Veterans General Hospital, New Taipei City, Taiwan, <sup>3</sup>Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
- 11:30 *E-cigarette based inhalation of nicotine increases locomotion in rats*  
Mehrak Javadi-Paydar, Sophia A. Vandewater, Michael Taffe, The Scripps Research Institute, La Jolla, CA

**POSTER III B**  
**SEX/GENDER I**

**Sapphire ABC/EFG**  
**11:30 - 1:30 PM**

- 6 *Juvenile fluoxetine exposure induces an enduring anxiogenic-like behavioral profile in female c57bl/6 mice*  
Sergio Iñiguez<sup>1</sup>, Francisco Flores-Ramirez<sup>1</sup>, Arturo Zavala<sup>2</sup>, Anapaula Themann<sup>1</sup>, Minerva Rodriguez<sup>1</sup>,  
<sup>1</sup>University of Texas at El Paso, El Paso, TX, <sup>2</sup>California State University Long Beach, Long Beach, CA
- 7 *Sex differences in oxycodone preference choice task*  
Julian Gerson, University of California Santa Barbara, Goleta, CA
- 8 *Birth control knowledge and interest in reproductive health services in patients receiving treatment for opioid use disorder*  
Laura Lander<sup>1</sup>, Jonathan Stoltman<sup>1</sup>, Julie Hicks Patrick<sup>1</sup>, Mishka Terplan<sup>2</sup>, <sup>1</sup>West Virginia University, Morgantown, WV, <sup>2</sup>Virginia Commonwealth University, Richmond, VA
- 9 *Birth control use and talking with health professionals about birth control in female patients receiving treatment for opioid use disorder in rural Appalachia*  
Jonathan Stoltman<sup>1</sup>, Laura Lander<sup>1</sup>, Hendree Jones<sup>2</sup>, Julie Hicks Patrick<sup>1</sup>, Mishka Terplan<sup>3</sup>, <sup>1</sup>West Virginia University, Morgantown, WV, <sup>2</sup>University of North Carolina at Chapel Hill, Carrboro, NC, <sup>3</sup>Virginia Commonwealth University, Richmond, VA
- 10 *Sex differences among treatment-seeking men and women who use opioids*  
Tanya Saraiya<sup>1</sup>, Martina Pavlicova<sup>2</sup>, Mei-Chen Hu<sup>3</sup>, Denise Hien<sup>4</sup>, Edward Nunes<sup>5</sup>, Aimee Campbell<sup>5</sup>,  
<sup>1</sup>Adelphi University & The TRACC Program, New York, NY, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>3</sup>Columbia University, New York, NY, <sup>4</sup>Adelphi University, Garden City, NY, <sup>5</sup>Columbia University and NYSPI, New York, NY
- 11 *Sex differences among patients with opioid use disorder undergoing medically supervised withdrawal*  
Aimee Campbell<sup>1</sup>, Celestina Barbosa-Leiker<sup>2</sup>, Sarah Mennenga<sup>3</sup>, Martina Pavlicova<sup>4</sup>, Jennifer Scodes<sup>1</sup>, Shannon Mitchell<sup>5</sup>, Patricia Novo<sup>3</sup>, Tanya Saraiya<sup>6</sup>, Edward Nunes<sup>1</sup>, Shelly Greenfield<sup>7</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>Washington State University College of Nursing, Spokane, WA, <sup>3</sup>New York University School of Medicine, New York, NY, <sup>4</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>5</sup>Friends Research Institute, Baltimore, MD, <sup>6</sup>Adelphi University & The TRACC Program, New York, NY, <sup>7</sup>McLean Hospital, Harvard Medical School, Belmont, MA
- 12 *Gender differences in opioid agonist treatment and outcomes among persons with opioid use disorder in the United States*  
Jennifer Manuel<sup>1</sup>, Dace Svikis<sup>2</sup>, Cristina Bares<sup>3</sup>, <sup>1</sup>New York University, New York, NY, <sup>2</sup>Virginia



- Commonwealth University, Richmond, VA, <sup>3</sup>University of Michigan, Ann Arbor, MI
- 13 *Gender differences in nonmedical prescription drug use trends among adolescents in three South American countries from 2007-2015*  
Alexander Perlmutter<sup>1</sup>, Ariadne Rivera-Aguirre<sup>2</sup>, Alvaro Castillo-Carniglia<sup>2</sup>, Pia Mauro<sup>1</sup>, Magdalena Cerda<sup>2</sup>, Silvia Martins<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>University of California Davis, Sacramento, CA
- 14 *Alcohol use among individuals with prescription opiate use disorder: The role of distress tolerance and gender*  
Amanda Gilmore, Jennifer Jones, Angela Moreland, Christine Hahn, Kathleen Brady, Sudie Back, Medical University of South Carolina, Charleston, SC
- 15 *Sex differences in sources and routes of non-medical prescription opioid use in youth*  
Vicki Osborne, Catherine Woodstock Striley, Linda Cottler, University of Florida, Gainesville, FL
- 16 *Male-female differences in heroin incidence*  
Samantha Bauer<sup>1</sup>, James Anthony<sup>2</sup>, <sup>1</sup>Michigan State University, East Lansing, MI, <sup>2</sup>Michigan State University, Lansing, MI
- 17 *Sex differences in risk factors for opioid overdose*  
Munachimso Amadife<sup>1</sup>, Jermaine Jones<sup>2</sup>, Sandra Comer<sup>1</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>Columbia University College of Physicians and Surgeons, New York, NY
- 18 *A gender paradox in overdose among young opioid users*  
Kelly Quinn<sup>1</sup>, Honoria Guarino<sup>2</sup>, Pedro Mateu-Gelabert<sup>2</sup>, <sup>1</sup>NYU Rory Meyers College of Nursing, New York, NY, <sup>2</sup>National Development and Research Institute, Inc., New York, NY

## POSTER III C STIMULANTS HUMAN STUDIES

**Sapphire ABC/EFG  
11:30 - 1:30 PM**

- 19 *Differential effects of crack-cocaine and crack-cocaine + cannabis on neurocognitive functioning*  
Hercilio Oliveira<sup>1</sup>, Priscila Dib Gonçalves<sup>2</sup>, Mariella Ometto<sup>3</sup>, Bernardo Santos<sup>3</sup>, André Malbergier<sup>3</sup>, Ricardo Amaral<sup>3</sup>, Sergio Nicastrì<sup>4</sup>, Arthur Andrade<sup>3</sup>, Paulo Jannuzzi Cunha<sup>5</sup>, <sup>1</sup>Universidade de Sao Paulo, Sao Paulo, Brazil, <sup>2</sup>University of São Paulo, São Paulo, Brazil, <sup>3</sup>University of Sao Paulo Medical School, São Paulo, Brazil, <sup>4</sup>Hospital Israelita Albert Einstein, Sao Paulo, Brazil, <sup>5</sup>University of Sao Paulo Medical School, São Paulo, Brazil
- 20 *Cognitive function in aging cocaine smokers*  
Thomas Chao<sup>1</sup>, Margaret Haney<sup>2</sup>, Ziva Cooper<sup>3</sup>, Gillinder Bedi<sup>4</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Columbia University Medical Center, New York, NY, <sup>3</sup>Columbia University and NYSPI, New York, NY, <sup>4</sup>Columbia University, New York, NY
- 21 *Personality and neurocognitive dimensions of impulsivity as candidate endophenotypes specific to heroin and amphetamine dependence*  
Elizabeth Long<sup>1</sup>, Georgi Vasilev<sup>2</sup>, Radka Kaneva<sup>3</sup>, F. Gerard Moeller<sup>1</sup>, Jasmin Vassileva<sup>1</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Bulgarian Addictions Institute, Sofia, <sup>3</sup>Medical University - Sofia, Sofia, Bulgaria
- 22 *The serotonin-2C agonist lorcaserin potentiates the subjective effects of cocaine, but not its self-administration*  
Ken Grasing<sup>1</sup>, Thomas Newton<sup>2</sup>, <sup>1</sup>Kansas City VA Medical Center, Kansas City, MO, <sup>2</sup>Baylor College of Medicine, Houston, TX
- 23 *Exploring the actions of intranasal naloxone (INN) on limbic activation triggered by cocaine cues: a case series.*

1

1

1

1

1

1

- Kyle Kampman , Kanchana Jagannathan , Kimberly Young , Paul Regier , Stefanie Darnley , Jesse Suh , Elliott Berkowitz-Sturgis<sup>1</sup>, Michael Gawrysiak<sup>2</sup>, Regina Szucs-Reed<sup>1</sup>, Charles O'Brien<sup>3</sup>, Arvind Agrawal<sup>4</sup>, Roger Crystal, Tanya Ramey<sup>5</sup>, Anna Rose Childress<sup>1</sup>, <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>West Chester University of Pennsylvania, West Grove, PA, <sup>3</sup>University of Pennsylvania, VA Medical Center, Philadelphia, PA, <sup>4</sup>Opiant, Harrow, United Kingdom, <sup>5</sup>National Institutes of Health, Bethesda, MD
- 24 *The effects of stress and impulsivity on treatment retention and outcomes among Black and White cocaine users*  
Angela Haeny<sup>1</sup>, Brian Kiluk<sup>2</sup>, Charla Nich<sup>1</sup>, Donna LaPaglia<sup>1</sup>, Kathleen Carroll<sup>2</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Yale University School of Medicine, New Haven, CT
- 25 *Considerations when assessing delay discounting among individuals with SUD: comparison of AUC, log k, and AUClog*  
Jin-Ho Yoon<sup>1</sup>, Matthew Weaver<sup>2</sup>, Richard De La Garza, II<sup>3</sup>, Thomas Newton<sup>3</sup>, Robert Suchting<sup>1</sup>, Gregory Brown<sup>4</sup>, Yasmine Omar<sup>5</sup>, Ilana Haliwa<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, Houston, TX, <sup>2</sup>Mercyhurst University, Erie, PA, <sup>3</sup>Baylor College of Medicine, Houston, TX, <sup>4</sup>University of Texas at Austin, Austin, TX, <sup>5</sup>Rutgers University, New Brunswick, NJ
- 26 *Neuroactive steroid and pregnenolone levels in men and women with cocaine use disorder*  
Verica Milivojevic<sup>1</sup>, Gustavo Angarita<sup>1</sup>, Jonathan Covault<sup>2</sup>, Rajita Sinha<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>University of Connecticut, Farmington, CT
- 27 *A study of occupational therapy-based cognitive rehabilitation to improve cognition in veterans with cocaine use disorder: Feasibility & tolerability*  
Rajkumar Kalapatapu<sup>1</sup>, Gordon Giles<sup>2</sup>, Steven Batki<sup>3</sup>, <sup>1</sup>University of California San Francisco, San Francisco, CA, <sup>2</sup>Samuel Merritt University, Oakland, CA, <sup>3</sup>San Francisco Veterans Affairs Health Care System, San Francisco, CA
- 28 *Methamphetamine-paired contexts acquire incentive salience: A human CPP study*  
Emma Childs, Joseph Lutz, Nia Sotto, University of Illinois, Chicago, IL
- 29 *Ecological momentary assessments optimize sexual risk reduction among gay and bisexual men enrolled in a methamphetamine abuse treatment program*  
Cathy Reback<sup>1</sup>, Dennie Rünger<sup>1</sup>, Jesse Fletcher<sup>1</sup>, Dallas Swendeman<sup>2</sup>, <sup>1</sup>Friends Research Institute, Los Angeles, CA, <sup>2</sup>University of California Los Angeles, Los Angeles, CA
- 30 *Sexual risk associated with having sex with men among men who use methamphetamine in a Mexico-US border city*  
Oralia Loza<sup>1</sup>, João Ferreira-Pinto<sup>1</sup>, Maria Elena Ramos Rodriguez<sup>2</sup>, Rebeca Ramos<sup>3</sup>, <sup>1</sup>University of Texas at El Paso, El Paso, TX, <sup>2</sup>Programa Compañeros, A.C., Ciudad Juárez, Mexico, <sup>3</sup>Alliance of Border Collaboratives, El Paso, TX
- 31 *Law enforcement reports of increasing methamphetamine use and associations with the opioid epidemic*  
Mance Buttram, Steven Kurtz, Nova Southeastern University, Miami, FL

## POSTER III D POLICY

**Sapphire ABC/EFG  
11:30 - 1:30 PM**

- 32 *Linking DSM-V alcohol-use disorders with policy-relevant correlates in young adults: Implications for an evidence-informed national alcohol harm reduction policy*  
Sirine Anouti<sup>1</sup>, Lilian Ghandour<sup>2</sup>, <sup>1</sup>American University of Beirut, Beirut, Lebanon, <sup>2</sup>American University of Beirut, Beirut
- 33 *The impact of minimum legal drinking age (MLDA) laws on self-reported violent victimization among young people in Canada, 1988-2009: A regression-discontinuity approach.*

- Russell Callaghan<sup>1</sup>, Marcos Sanches<sup>2</sup>, Jodi Gatley<sup>3</sup>, Claire Benny<sup>4</sup>, <sup>1</sup>Northern Medical Program, Prince George, BC, Canada, <sup>2</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>3</sup>University of Northern British Columbia, Prince George, <sup>4</sup>University of British Columbia, Vancouver, BC, Canada
- 34 *Health reform and health insurance among persons who use drugs in eastern Kentucky: A prospective cohort analysis*  
Hannah Knudsen<sup>1</sup>, Michelle Lofwall<sup>2</sup>, Sharon Walsh<sup>1</sup>, April Young<sup>3</sup>, Jennifer Havens<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>3</sup>University of Kentucky, College of Public Health, Lexington, KY
- 35 *Cost-effectiveness of expanding opioid agonist therapy in Ukraine: dynamic modeling analysis*  
Olga Morozova<sup>1</sup>, Forrest Crawford<sup>1</sup>, Sergii Dvoriak<sup>2</sup>, Frederick Alice<sup>3</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>Ukrainian Institute on Public Health Policy, Kiev, Ukraine, <sup>3</sup>Yale University School of Medicine, New Haven, CT
- 36 *Naloxone training and distribution among users does not increase risky opioid use*  
Karen Cropsey, Samantha Schiavon, Richard Shelton, University of Alabama, Birmingham, AL
- 37 *State naloxone access laws and opioid overdose death rates*  
Laura Monico, Jan Gryczynski, Robert Schwartz, Shannon Mitchell, Friends Research Institute, Baltimore, MD
- 38 *Pharmaceutical industry marketing of opioid products to physicians and opioid prescribing: A national study*  
Brandon Marshall<sup>1</sup>, Magdalena Cerda<sup>2</sup>, Yu Li<sup>3</sup>, Scott Hadland<sup>4</sup>, <sup>1</sup>Brown School of Public Health, Providence, RI, <sup>2</sup>University of California Davis, Sacramento, CA, <sup>3</sup>Brown University School of Public Health, Providence, RI, <sup>4</sup>Boston University School of Medicine, Boston, MA
- 39 *Trends in opioid prescribing volume and risk indicators in the context of PDMP policy changes: 2010-2016*  
Jenna McCauley<sup>1</sup>, Sarah Ball<sup>1</sup>, Jingwen Zhang<sup>1</sup>, William Moran<sup>1</sup>, Kit Simpson<sup>1</sup>, Khosrow Heidari<sup>2</sup>, Kathleen Brady<sup>1</sup>, Patrick Mauldin<sup>1</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>South Carolina Department of Health and Environmental Control, Columbia, SC
- 40 *The associations of neighborhood availability of marijuana dispensaries and buprenorphine treatment practitioners with hospital stays related to opioid analgesics*  
Di Liang, Yuyan Shi, University of California San Diego, La Jolla, CA
- 41 *Illicit drug use among young adult marijuana users in Los Angeles: a qualitative analysis of contextual factors, life events, and marijuana use*  
Ekaterina Fedorova<sup>1</sup>, Stephen Lankenau<sup>2</sup>, <sup>1</sup>Drexel University, Philadelphia, PA, <sup>2</sup>Drexel University Dornsife School of Public Health, Philadelphia, PA
- 42 *Do recreational marijuana laws impact state-level alcohol and tobacco use?*  
Christine Mauro<sup>1</sup>, Thomas Corbeil<sup>1</sup>, Daniel Giovenco<sup>1</sup>, Pia Mauro<sup>1</sup>, Magdalena Cerda<sup>2</sup>, Silvia Martins<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>University of California Davis, Sacramento, CA
- 43 *Marijuana and other drug use after becoming a medical marijuana patient: A mixed-method approach*  
Avat Kioumarsis<sup>1</sup>, Carolyn Wong<sup>2</sup>, Ellen Iverson<sup>2</sup>, Stephen Lankenau<sup>3</sup>, <sup>1</sup>Drexel University, Columbia, MD, <sup>2</sup>Children's Hospital Los Angeles, Los Angeles, CA, <sup>3</sup>Drexel University Dornsife School of Public Health, Philadelphia, PA
- 44 *A survey assessing drug legalization beliefs*  
Alexis Hammond, Kelly Dunn, Eric Strain, Johns Hopkins University School of Medicine, Baltimore, MD
- 45 *Professional students' knowledge attitudes and perceptions of the medical use of cannabis*  
Lynnece Bowen, Aimee McRae-Clark, Jeffrey Korte, Medical University of South Carolina, Charleston, SC
- 46 *Marijuana use and attitudes in the context of recreational cannabis legalization in California: Comparison of 2016 and 2017 in the California Adult Tobacco Survey*  
Danielle Ramo, Manpreet Kaur, Corie Apollonio, Laurie Jacobs, Joanne Spetz, Mandy Chan, Laura Schmidt, University of California San Francisco, San Francisco, CA

- 47 *Associations between state-level policy liberalism, cannabis use, and cannabis use disorder from 2004 to 2012: Looking beyond medical cannabis law status*  
Morgan Philbin<sup>1</sup>, Pia Mauro<sup>2</sup>, Julian Santaella-Tenorio<sup>2</sup>, Christine Mauro<sup>2</sup>, Elizabeth Kinnard<sup>1</sup>, Magdalena Cerda<sup>3</sup>, Silvia Martins<sup>2</sup>, <sup>1</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>University of California Davis, Sacramento, CA

## POSTER III E PREVENTION

**Sapphire ABC/EFG**  
**11:30 - 1:30 PM**

- 48 *How do we measure craving? Intensive longitudinal assessment of craving and cannabis use among young adults with problematic use.*  
Matthew Enkema<sup>1</sup>, Adam Kuczynski<sup>1</sup>, Sarah Bowen<sup>2</sup>, Kristen Lindgren<sup>1</sup>, Kevin Hallgren<sup>1</sup>, Mary Larimer<sup>1</sup>, Christine Lee<sup>1</sup>, <sup>1</sup>University of Washington, Seattle, WA, <sup>2</sup>Pacific University, Forest Grove, OR
- 49 *Characteristics of patients using cannabis in a surgical cohort*  
Jenna Goesling, Stephanie Moser, Chad Brummett, Kevin Boehnke, Erin Bonar, University of Michigan, Ann Arbor, MI
- 50 *An unsanctioned supervised consumption service in the United States: Data from the first three years of operation*  
Peter Davidson<sup>1</sup>, Alex Kral<sup>2</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>RTI International, Research Triangle Park, NC
- 51 *Looking ahead: Syringe distribution at a rural syringe services program*  
Sean Allen<sup>1</sup>, Allison O'Rourke<sup>2</sup>, Sherri-Chanelle Brighthaupt<sup>3</sup>, Michael Brumage<sup>4</sup>, Susan Sherman<sup>1</sup>, <sup>1</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>George Washington University, Washington, DC, <sup>3</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, <sup>4</sup>Kanawha-Charleston Health Department, Charleston, WV
- 52 *Community members are Interested in Deterra® drug deactivation pouches to dispose of unused medications*  
Linda Cottler<sup>1</sup>, Ayodeji Otufowora<sup>2</sup>, Dottie Baker<sup>3</sup>, Kathleen Egan<sup>1</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>University of Florida, College of Public Health and Health Professions, Gainesville, FL, <sup>3</sup>Alachua County Health Promotion and Wellness Coalition, Gainesville, FL
- 53 *Perceived HIV risk mediates the relationship between HIV risk behavior and willingness to use pre-exposure prophylaxis (PrEP) among drug users*  
Roman Shrestha<sup>1</sup>, Michael Copenhaver<sup>2</sup>, <sup>1</sup>University of Connecticut, Branford, CT, <sup>2</sup>University of Connecticut, Storrs, CT
- 54 *Effect of a behavioral activation treatment on reductions in HIV sexual transmission risk behavior from pretreatment to a 1-year follow up*  
Catherine Paquette<sup>1</sup>, Jessica Magidson<sup>2</sup>, CJ Seitz-Brown<sup>3</sup>, Stacey Daughters<sup>1</sup>, <sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>2</sup>Massachusetts General Hospital, Harvard Medical School, Boston, MA, <sup>3</sup>University of Maryland, College Park, MD
- 55 *Evaluating the administration of naloxone in hospital settings*  
Kelly Barth, Genevieve Hayes, Keri Holmes-Maybank, Medical University of South Carolina, Charleston, SC
- 56 *Opioid education and naloxone distribution programs for residents and staff of abstinence only recovery homes may decrease risk of opioid overdose*  
Karen Ablondi<sup>1</sup>, Benjamin Howell<sup>1</sup>, Frank Buono<sup>1</sup>, Tamara Malm<sup>2</sup>, Ashton Gores<sup>3</sup>, Anthony Eller<sup>3</sup>, Declan Barry<sup>1</sup>, Curtis Bone<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>St. Joseph School of Pharmacy, Hartford, CT, <sup>3</sup>Yale School of Public Health, New Haven, CT
- 57 *Opportunities and challenges from a tenant-led overdose response intervention in single room occupancy*

*hotels in Vancouver, Canada*

Geoff Bardwell<sup>1</sup>, Taylor Fleming<sup>2</sup>, Alexandra Collins<sup>2</sup>, Jade Boyd<sup>3</sup>, Ryan McNeil<sup>1</sup>, <sup>1</sup>University of British Columbia, BC Centre on Substance Use, Vancouver, BC, Canada, <sup>2</sup>BC Centre on Substance Use, Vancouver, BC, Canada, <sup>3</sup>British Columbia Centre on Substance Use, Vancouver, BC, Canada

58 *Understanding the social geography of overdose prevention site utilization in Vancouver, Canada: Facilitators and barriers to engagement*

Alexandra Collins<sup>1</sup>, Jade Boyd<sup>2</sup>, Samara Mayer<sup>1</sup>, Mary Clare Kennedy<sup>2</sup>, Ryan McNeil<sup>3</sup>, <sup>1</sup>BC Centre on Substance Use, Vancouver, BC, Canada, <sup>2</sup>British Columbia Centre on Substance Use, Vancouver, BC, Canada, <sup>3</sup>University of British Columbia, BC Centre on Substance Use, Vancouver, BC, Canada

59 *Hardiness protects against future substance use in US Army Reserve/National Guard soldiers*

D. Lynn Homish<sup>1</sup>, Paul Bartone<sup>2</sup>, Rachel Hoopsick<sup>1</sup>, Bonnie Vest<sup>1</sup>, Gregory Homish<sup>1</sup>, <sup>1</sup>State University of New York at Buffalo, Buffalo, NY, <sup>2</sup>National Defense University, Washington, DC

60 *Acceptability of mindfulness-based relapse prevention for ethnically diverse women*

Tara Bautista<sup>1</sup>, Hortensia Amaro<sup>2</sup>, David Black<sup>3</sup>, <sup>1</sup>Arizona State University, Phoenix, AZ, <sup>2</sup>ISC School of Social Work, Los Angeles, CA, <sup>3</sup>University of Southern California, Los Angeles, CA

61 *A culturally adapted parenting intervention for Latino/a immigrant families: Integrating culture and evidence-based knowledge*

Jose Parra-Cardona<sup>1</sup>, Hsueh-Han Yeh<sup>2</sup>, James Anthony<sup>3</sup>, <sup>1</sup>University of Texas at Austin, Austin, TX, <sup>2</sup>Henry Ford Health System, Detroit, MI, <sup>3</sup>Michigan State University, Lansing, MI

62 *Substance use and high-risk firearm behaviors (HRFBs) among youth treated in an urban Emergency Department: Preliminary findings from Project IntERact*

Patrick Carter<sup>1</sup>, Maureen Walton<sup>2</sup>, James Cranford<sup>1</sup>, Marc Zimmerman<sup>1</sup>, Ken Resnicow<sup>3</sup>, Bethany Buschmann<sup>4</sup>, Rebecca Cunningham<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Michigan, Addiction Center, Ann Arbor, MI, <sup>3</sup>University of Michigan School of Public Health, Ann Arbor, MI, <sup>4</sup>University of Michigan Injury Prevention Center, Ann Arbor, MI

63 *Pediatrician-initiated screening and referral to treatment (prevention) for 10- to 13-year-olds at high risk for substance use initiation before high school*

Ty Ridenour<sup>1</sup>, Maureen Reynolds<sup>2</sup>, Daniel Shaw<sup>2</sup>, <sup>1</sup>RTI International, Research Triangle Park, NC, <sup>2</sup>University of Pittsburgh, Pittsburgh, PA

64 *The main barriers and facilitators to implement Adolescent Screening and Brief Intervention in primary care unit: a follow up from 17 years.*

Denise De Micheli<sup>1</sup>, Bruno Pinheiro<sup>2</sup>, <sup>1</sup>Federal University of São Paulo, Guarulhos, Brazil, <sup>2</sup>Universidade Federal de Sao Paulo, São Paulo, Brazil

65 *A missing voice: the consent practice in school-based drug prevention programs in Taiwan*

Chuan-Yu Chen<sup>1</sup>, Yu Lo<sup>1</sup>, Wenmay Rei<sup>1</sup>, Shao-You Fang<sup>2</sup>, Su-Hui Chang<sup>2</sup>, Joyce Yen Fen<sup>3</sup>, <sup>1</sup>National Yang-Ming University, Taipei, Taiwan, <sup>2</sup>National Taiwan University, Children and Family Research Center, Taipei, <sup>3</sup>Children and Family Research Center, Taipei, Taiwan

66 *Evaluating the translational potential of NIDA-sponsored behavioral clinical trials*

Stephen Magura, Brad Watts, Western Michigan University, Kalamazoo, MI

## **POSTER III F LITERATURE REVIEW**

**Sapphire ABC/EFG  
11:30 - 1:30 PM**

67 *Clinical and toxicological profile of NBOMESs: A systematic review*

Nino Marchi<sup>1</sup>, Juliana Scherer<sup>2</sup>, Leticia Fara<sup>1</sup>, Lysa Remy<sup>3</sup>, Rafaela Ornell<sup>2</sup>, Monique Reis<sup>4</sup>, Amanda

- Zamboni<sup>4</sup>, Mariana Paim<sup>1</sup>, Tais Fiorentin<sup>3</sup>, Carlos Alberto Wayhs<sup>4</sup>, Lisia von Diemen<sup>2</sup>, Flavio Pechansky<sup>2</sup>, Felix Kessler<sup>2</sup>, Renata Limberger<sup>3</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Porto Alegre, Brazil, <sup>2</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre, <sup>3</sup>Federal University of Rio Grande do Sul, Porto Alegre, <sup>4</sup>Labtoxico, Federal University, Porto Alegre, Brazil
- 68 *Efficacy of ketamine in the treatment of substance use disorders: A review of the literature*  
Jennifer Jones, Camilo Mateus, Robert Malcolm, Sudie Back, Medical University of South Carolina, Charleston, SC
- 69 *Examining the sensitivity of purchase tasks to individual differences in risk among substance users: A literature review*  
Ivori Zvorsky<sup>1</sup>, Tyler Nighbor<sup>2</sup>, Allison Kurti<sup>2</sup>, Stephen Higgins<sup>2</sup>, <sup>1</sup>Vermont Center on Behavior and Health, Burlington, VT, <sup>2</sup>University of Vermont, Burlington, VT
- 70 *Sensation-seeking personality trait and its association to drug seeking behavior in adolescents: A systematic review of the literature*  
Thiago Fidalgo<sup>1</sup>, Nitasha Sharma<sup>2</sup>, Sheila C. Caetano<sup>1</sup>, Zila M. Sanchez<sup>1</sup>, Silvia Martins<sup>3</sup>, <sup>1</sup>Universidade Federal de Sao Paulo, São Paulo, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>3</sup>Columbia University, New York, NY
- 71 *Limited inclusion of women in functional neuroimaging studies of opioid-use disorder: A systematic review*  
Hestia Moningka<sup>1</sup>, Dustin Scheinost<sup>2</sup>, Sarah Yip<sup>2</sup>, <sup>1</sup>Yale Child Study Center and University College London, New Haven, CT, <sup>2</sup>Yale University, New Haven, CT
- 72 *Pharmacogenetics of methadone adverse events*  
Francina Fonseca, Claudio Castillo, Gloria Marin, Claudio Tamarit, Lina Oviedo, Marta Torrens, Institut de Neuropsiquiatria i Addiccions, Barcelona, Spain
- 73 *The case for providing opioid agonist therapy in the hospital setting*  
Kelsey Priest, Oregon Health & Science University, Portland, OR
- 74 *Knowledge synthesis of the effectiveness of prescription monitoring programs*  
Beth Sproule, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 75 *Effect of prescription drug monitoring programs on nonfatal and fatal drug overdoses: A systematic review*  
David Fink<sup>1</sup>, Julia Schleimer<sup>2</sup>, Aaron Sarvet<sup>3</sup>, Kiran Grover<sup>2</sup>, C Delcher<sup>4</sup>, June Kim<sup>5</sup>, Alvaro Castillo-Carniglia<sup>6</sup>, Ariadne Rivera-Aguirre<sup>6</sup>, Stephen Henry<sup>6</sup>, Silvia Martins<sup>2</sup>, Magdalena Cerda<sup>6</sup>, <sup>1</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>Harvard Medical School, Boston, MA, <sup>4</sup>University of Florida, Gainesville, FL, <sup>5</sup>New York University, New York, NY, <sup>6</sup>University of California Davis, Sacramento, CA
- 76 *Transitional trends in women's prescription drug misuse: A systematic review*  
Bridgette Peteet, Cami Mosley, Brittany Miller-Roenigk, Caravella McCuistian, Shapree Dixon, University of Cincinnati, Cincinnati, OH
- 77 *Extremely low HIV incidence among PWID: Terminology, high/middle income settings, methodology, and addressing new outbreaks*  
Don Des Jarlais<sup>1</sup>, Risk Factors, DRIVE & Recent HIV Outbreaks Study Team<sup>2</sup>, <sup>1</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>2</sup>Mount Sinai School of Medicine, New York, NY
- 78 *Use of opioids and stimulants by people who inject drugs: A multi-stage systematic review and meta-analysis of global evidence*  
Amy Peacock<sup>1</sup>, Adam Trickey<sup>2</sup>, Sarah Larney<sup>1</sup>, Samantha Colledge<sup>1</sup>, Janni Leung<sup>3</sup>, Jason Grebely<sup>4</sup>, Evan Cunningham<sup>5</sup>, Miranda Cuming<sup>6</sup>, Jack Stone<sup>2</sup>, Peter Vickerman<sup>2</sup>, Louisa Degenhardt<sup>1</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, Sydney, Australia, <sup>2</sup>Bristol University, Clifton, United Kingdom, <sup>3</sup>NDARC, UNSW, Australia, Brisbane, Australia, <sup>4</sup>The Kirby Institute, Sydney, Australia, <sup>5</sup>University of New South Wales, Sydney, Australia, <sup>6</sup>University of Bristol, Bristol

- 79 *Pre-exposure prophylaxis (PrEP) for people who inject drugs? A scoping review of HIV treatment adherence research*  
Angela Bazzi<sup>1</sup>, Mari-Lynn Drainoni<sup>1</sup>, Dea Biancarelli<sup>1</sup>, Josh Hartman<sup>1</sup>, Matthew Mimiaga<sup>2</sup>, Katie Biello<sup>2</sup>,  
<sup>1</sup>Boston University School of Public Health, Boston, MA, <sup>2</sup>Brown University, Providence, RI
- 80 *Factors associated with uptake or willingness to use pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID): A systematic review*  
Yohansa Fernández, New York University, New York, NY
- 81 *Addiction-related characteristics of substances users in harm reduction settings: A systematic review*  
Charlotte Kervran<sup>1</sup>, Fuschia Serre<sup>1</sup>, Cecile Denis<sup>2</sup>, Perrine Roux<sup>3</sup>, Marie Jauffret-Roustide<sup>3</sup>, Laurence Lalanne<sup>4</sup>, Melina Fatseas<sup>5</sup>, Jean-Pierre Daulouede<sup>6</sup>, Marc Auriacombe<sup>1</sup>, <sup>1</sup>Université de Bordeaux, Bordeaux, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>INSERM, Marseille, <sup>4</sup>University Hospital of Strasbourg, Strasbourg, <sup>5</sup>Centre Hospitalier Charles Perrens, Bordeaux, France, <sup>6</sup>Bizia Addiction Clinic, Bayonne
- 82 *Variability in the definition of “daily use” of cannabis across three large U.S. epidemiological surveys*  
Chloe Lee, Silvia Martins, Pia Mauro, Columbia University, New York, NY
- 83 *Cannabis and cannabinoids for the treatment of people with chronic non-cancer pain conditions: A systematic review and meta-analysis*  
Emily Stockings<sup>1</sup>, Gabrielle Campbell<sup>2</sup>, Wayne Hall<sup>3</sup>, Suzanne Nielsen<sup>4</sup>, Dino Zagic<sup>5</sup>, Rakin Rahman<sup>5</sup>, Bridin Murnion<sup>6</sup>, Megan Weier<sup>4</sup>, Michael Farrell<sup>7</sup>, Louisa Degenhardt<sup>7</sup>, <sup>1</sup>National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia, <sup>2</sup>University of South Wales, Sydney, Australia, <sup>3</sup>University of Queensland, Brisbane, Australia, <sup>4</sup>University of New South Wales, Sydney, Australia, <sup>5</sup>University of New South Wales, Randwick, Australia, <sup>6</sup>University of Sydney, Sydney, Australia, <sup>7</sup>National Drug and Alcohol Research Centre, Sydney, Australia
- 84 *Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis*  
Aaron Sarvet<sup>1</sup>, Melanie Wall<sup>2</sup>, David Fink<sup>3</sup>, Emily Greene<sup>4</sup>, Katherine Keyes<sup>5</sup>, Magdalena Cerda<sup>6</sup>, Deborah Hasin<sup>4</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Columbia University and NYSPI, New York, NY, <sup>3</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>4</sup>Columbia University, New York, NY, <sup>5</sup>Columbia University Mailman School of Public Health, Newark, NJ, <sup>6</sup>University of California Davis, Sacramento, CA
- 85 *Does liberalization of cannabis policy influence adolescents’ levels of use? A systematic review*  
Maria Melchior, Camille Bolze, Félix Hausfater, Murielle Mary-Krause, Marine Azevedo Da Silva, Pierre Louis Institute for Epidemiology and Public Health, Department of Social Epidemiology, Paris, France
- 86 *Analysis of existing problematic mobile phone and smartphone use scales*  
Bethany Harris, Sherece Fields, Timothy Regan, Texas A&M University, College Station, TX
- 87 *Policing behaviors and HIV/drug-related risk behaviors among people who inject drugs – a literature review*  
Leo Beletsky<sup>1</sup>, Liliana Avalos<sup>2</sup>, Christopher Venegas<sup>2</sup>, Javier Cepeda<sup>2</sup>, Pieter Baker<sup>2</sup>, <sup>1</sup>Northeastern University, Boston, MA, <sup>2</sup>University of California San Diego, La Jolla, CA
- 88 *Heroin reigns as top treatment for opioid addiction, but are we ready for it?*  
Brittany Dennis<sup>1</sup>, Pavel Roshanov<sup>2</sup>, Ashley Bonner<sup>2</sup>, Leen Naji<sup>2</sup>, Monica Bawor<sup>2</sup>, James Paul<sup>2</sup>, Michael Varenbut<sup>3</sup>, Jeff Daiter<sup>3</sup>, Carolyn Plater<sup>3</sup>, Andrew Worster<sup>2</sup>, Guillaume Pare<sup>2</sup>, David Marsh<sup>4</sup>, Dipika Desai<sup>5</sup>, Lehana Thabane<sup>2</sup>, Zainab Samaan<sup>2</sup>, <sup>1</sup>Peter Boris Centre for Addictions Research, Hamilton, ON, Canada, <sup>2</sup>McMaster University, Hamilton, ON, Canada, <sup>3</sup>Canadian Addiction Treatment Centres, Markham, ON, Canada, <sup>4</sup>Northern Ontario School of Medicine, Sudbury, ON, Canada, <sup>5</sup>Population Health Research Institute, Hamilton, ON, Canada

## ADOLESCENT DRUG ABUSE II

11:30 - 1:30 PM

- 89 *How do demographics, psychosocial factors, and access to care, lead to receiving treatment among adolescents and young adults at risk for a substance use disorder?*  
Jose Martinez, Emily Garcia, William Kazanis, Megan Curtis, Claudina Tami, Suyen Schneegans, Jennifer Sharpe Potter, University of Texas Health Science Center, San Antonio, TX
- 90 *Screening and brief intervention of drug use in adolescence from the professional perspective*  
Maria Angélica Alves da Silva<sup>1</sup>, Andre Luiz Monezi Andrade<sup>2</sup>, Bruno Pinheiro<sup>3</sup>, Denise De Micheli<sup>4</sup>,  
<sup>1</sup>Federal University of São Paulo, São Paulo, Brazil, <sup>2</sup>Universidade Federal de Sao Paulo, São Paulo,  
<sup>3</sup>Universidade Federal de Sao Paulo, São Paulo, Brazil, <sup>4</sup>Federal University of São Paulo, Guarulhos, Brazil
- 91 *Factors associated with injection initiation during adolescence*  
Sara Warfield<sup>1</sup>, Robin Pollini<sup>1</sup>, Jennifer Syverston<sup>2</sup>, Catherine Paquette<sup>3</sup>, <sup>1</sup>West Virginia University,  
Morgantown, WV, <sup>2</sup>University of California Riverside, Riverside, CA, <sup>3</sup>University of North Carolina at  
Chapel Hill, Chapel Hill, NC
- 92 *Latent classes of internal assets and behavior problems in at-risk adolescents*  
Meeyoung Min<sup>1</sup>, Dalhee Yoon<sup>1</sup>, Sonia Minnes<sup>2</sup>, Lynn Singer<sup>1</sup>, <sup>1</sup>Case Western Reserve University, Cleveland,  
OH, <sup>2</sup>Case Western Reserve University, Jack, Joseph and Morton Mandel School of Applied Social Sciences,  
Cleveland, OH
- 93 *Body self-image, physical activity level and drug use in adolescence*  
Bruno Pinheiro<sup>1</sup>, Maria Angélica Alves da Silva<sup>2</sup>, Andre Luiz Monezi Andrade<sup>3</sup>, Denise De Micheli<sup>4</sup>,  
<sup>1</sup>Universidade Federal de Sao Paulo, São Paulo, Brazil, <sup>2</sup>Federal University of São Paulo, São Paulo, Brazil,  
<sup>3</sup>Universidade Federal de Sao Paulo, São Paulo, <sup>4</sup>Federal University of São Paulo, Guarulhos, Brazil
- 94 *What influences safe medication practices: Investigating the relationship between parents' intentions, self-efficacy, and knowledge*  
Emily Garcia, Jose Martinez, Megan Curtis, Claudina Tami, William Kazanis, Suyen Schneegans, Jennifer Sharpe Potter, University of Texas Health Science Center, San Antonio, TX
- 95 *Exploring cannabis-specific parenting as a mechanism of the intergenerational transmission of cannabis use and cannabis use disorder on offspring adolescent cannabis use*  
Ariel Sternberg, Melanie Hill, Hye Won Suk, Madeline Meier, Laurie Chassin, Arizona State University,  
Tempe, AZ
- 96 *Long-term effects of childhood's family and school capitals on subsequent alcohol drinking behaviors*  
Yu Lo<sup>1</sup>, Nadia Wang<sup>1</sup>, I-An Wang<sup>2</sup>, Wei-J Chen<sup>3</sup>, Chuan-Yu Chen<sup>1</sup>, <sup>1</sup>National Yang-Ming University, Taipei,  
Taiwan, <sup>2</sup>Center of Neuropsychiatric Research, National Health Research Institutes, Miaoli, <sup>3</sup>National Taiwan  
University, Taipei City
- 97 *U.S. national data on prevalence and correlates of 8th and 10th grade runaway youth, 2005-2016*  
Berenice Castillo, John Schulenberg, Cristina Bares, University of Michigan, Ann Arbor, MI
- 98 *Tolerance of deviance in early adolescents with prenatal cocaine exposure: Latent classes, irritability and risk behaviors*  
June-Yung Kim<sup>1</sup>, Sonia Minnes<sup>1</sup>, Ty Ridenour<sup>2</sup>, Lynn Singer<sup>3</sup>, <sup>1</sup>Case Western Reserve University, Jack,  
Joseph and Morton Mandel School of Applied Social Sciences, Cleveland, OH, <sup>2</sup>RTI International, Research  
Triangle Park, NC, <sup>3</sup>Case Western Reserve University, Cleveland, OH
- 99 *Altered reward feedback processing in prenatally cocaine exposed adolescents: Evidence from theta and alpha oscillations*  
Kristen Morie<sup>1</sup>, Jia Wu<sup>1</sup>, Nicole Landi<sup>2</sup>, Marc Potenza<sup>3</sup>, Linda Mayes<sup>1</sup>, Michael Crowley<sup>1</sup>, <sup>1</sup>Yale University,  
New Haven, CT, <sup>2</sup>Haskins Laboratories, New Haven, CT, <sup>3</sup>Yale University School of Medicine, New Haven,  
CT



- 100 *Cortical gyrification as a potential predisposition biomarker of adolescent substance abuse*  
Arkadiy Maksimovskiy<sup>1</sup>, Anna Seraikas<sup>1</sup>, Emily Oot<sup>2</sup>, Maya Rieselbach<sup>1</sup>, Carolyn Caine<sup>1</sup>, Julia Cohen-Gilbert<sup>3</sup>, Jennifer Sneider<sup>3</sup>, Sion Harris<sup>4</sup>, Lisa Nickerson<sup>3</sup>, Marisa Silveri<sup>3</sup>, <sup>1</sup>McLean Hospital, Belmont, MA, <sup>2</sup>McLean Hospital, Boston University School of Medicine, Belmont, MA, <sup>3</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>4</sup>Harvard Medical School, Boston, MA
- 101 *Associations between anhedonia and substance use initiation among adolescent never users*  
Matthew Stone<sup>1</sup>, David Stong<sup>1</sup>, Adam Leventhal<sup>2</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>University of Southern California, Los Angeles, CA
- 102 *Adolescent risk and protective factors for substance use disorders in emerging adulthood*  
Angela Heads, University of Texas Health Science Center, McGovern Medical School, Houston, TX
- 103 *Does cannabis onset now trigger onset of drinking alcohol? An epidemiologic case-crossover approach*  
Villisha Gregoire<sup>1</sup>, Karl Alcover<sup>2</sup>, Hui Cheng<sup>2</sup>, James Anthony<sup>2</sup>, <sup>1</sup>Michigan State University, East Lansing, MI, <sup>2</sup>Michigan State University, Lansing, MI
- 104 *The interactive effects of perceived peer drinking and personality on adolescent drinking trajectories*  
Nina Pocuca<sup>1</sup>, Leanne Hides<sup>2</sup>, Catherine Quinn<sup>3</sup>, Melanie White<sup>2</sup>, Louise Mewton<sup>4</sup>, Nicola Newton<sup>5</sup>, Tim Slade<sup>6</sup>, Catherine Chapman<sup>6</sup>, Gavin Andrews<sup>6</sup>, Steve Allsop<sup>7</sup>, Nyanda McBride<sup>7</sup>, Louise Birrell<sup>6</sup>, Brad Shaw<sup>6</sup>, Nina Te Pas<sup>7</sup>, Maree Teesson<sup>5</sup>, <sup>1</sup>Queensland University of Technology, Brisbane, Australia, <sup>2</sup>University of Queensland, Brisbane, <sup>3</sup>University of Queensland, Brisbane, Australia, <sup>4</sup>Centre for Youth Substance Abuse Research, Herston, Australia, <sup>5</sup>University of New South Wales, Sydney, <sup>6</sup>University of New South Wales, Sydney, Australia, <sup>7</sup>Curtin University, Perth, Australia

**POSTER III H**  
**POLY DRUG ABUSE II**

**Sapphire ABC/EFG**  
**11:30 - 1:30 PM**

- 105 *Comparison of alcohol, opioid, and polysubstance-user performance on behavioral measures of impulsivity and risk taking*  
Randi Brown<sup>1</sup>, Thomas Schmidt<sup>2</sup>, David Pennington<sup>2</sup>, Timothy C Durazzo<sup>3</sup>, Dieter Meyerhoff<sup>2</sup>, <sup>1</sup>NCIRE, San Francisco, CA, <sup>2</sup>San Francisco Veterans Affairs Health Care System, San Francisco, CA, <sup>3</sup>Stanford University, Stanford, CA
- 106 *Comparing the acute cognitive effects of cannabis and alcohol: An exploratory analysis*  
Justin Matheson<sup>1</sup>, Robert Mann<sup>1</sup>, Bernard LeFoll<sup>1</sup>, Christine Wickens<sup>1</sup>, Bruna Brands<sup>2</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Health Canada, Toronto, ON, Canada
- 107 *Which factors are associated with first opioid and first benzodiazepine prescription in the military health system?*  
Megan Curtis<sup>1</sup>, William Kazanis<sup>1</sup>, Christina Song<sup>2</sup>, Claudina Tami<sup>1</sup>, Donald McGeary<sup>1</sup>, Erin Finley<sup>2</sup>, Maj Joseph K. Maddry<sup>3</sup>, Vikhyat Bebart<sup>3</sup>, Col David H. Carnahan<sup>4</sup>, Jennifer Sharpe Potter<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, San Antonio, TX, <sup>2</sup>South Texas Veterans Health Care System, San Antonio, TX, <sup>3</sup>San Antonio Military Medical Center, University of Colorado, Fort Sam, <sup>4</sup>Defense Health Agency, University of Colorado, Boulder, CO
- 108 *Frequency of psychiatric disorders and impulsivity among drug-using drivers*  
Leticia Fara<sup>1</sup>, Juliana Scherer<sup>2</sup>, Daiane Silvello<sup>1</sup>, Vanessa Volpatto<sup>1</sup>, Vinicius S. Roglio<sup>2</sup>, Felipe Ornell<sup>2</sup>, Lisia von Diemen<sup>2</sup>, Felix Kessler<sup>2</sup>, Flavio Pechansky<sup>2</sup>, <sup>1</sup>Center for Drug and Alcohol Research, Porto Alegre, Brazil, <sup>2</sup>Center for Drug and Alcohol Research, Federal University of Rio Grande do Sul, Porto Alegre
- 109 *The effects of opioids and alcohol, alone and in combination, on simulated driving performance*  
1 1 1 2 1 2

- Shanna Babalonis , Marion Coe , Paul Nuzzo , Michelle Lofwall , Paul Sloan , Laura Fanucchi , Sharon Walsh<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 110 *Patterns of prescription opioid use and at-risk drinking among older women in north central Florida*  
Mirsada Serdarevic, Kelly Gurka, Catherine Woodstock Striley, Krishna Vaddiparti, Linda Cottler, University of Florida, Gainesville, FL
- 111 *Factors associated with discontinuation of methadone maintenance therapy (MMT) among persons who also use alcohol in Vancouver, Canada*  
Jan Klimas<sup>1</sup>, Ekaterina Nosova<sup>2</sup>, M. Eugenia Socias<sup>3</sup>, Seonaid Nolan<sup>3</sup>, Rupinder Brar<sup>3</sup>, Kanna Hayashi<sup>2</sup>, MJ Milloy<sup>4</sup>, Thomas Kerr<sup>4</sup>, Evan Wood<sup>4</sup>, <sup>1</sup>BC Centre on Substance Use, Vancouver, BC, Canada, <sup>2</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, <sup>3</sup>University of British Columbia, Vancouver, BC, Canada, <sup>4</sup>University of British Columbia, Vancouver
- 112 *Effectiveness of combination pharmaco-behavioral therapy for smoking cessation in people who heavily drink and smoke*  
Daniel Schatz<sup>1</sup>, Babak Tofighi<sup>2</sup>, Joshua Lee<sup>2</sup>, <sup>1</sup>New York University, New York, NY, <sup>2</sup>New York University School of Medicine, New York, NY
- 113 *Crossover associations of alcohol and smoking craving and withdrawal with biochemically-verified alcohol and nicotine use in heavy drinking smokers*  
Crystal Smith<sup>1</sup>, Ekaterina Burduli<sup>2</sup>, Michael Orr<sup>3</sup>, Samantha Martin<sup>4</sup>, Myles Finlay<sup>3</sup>, Oladunni Oluwoye<sup>4</sup>, Michael McDonell<sup>4</sup>, John Roll<sup>1</sup>, Sterling McPherson<sup>5</sup>, <sup>1</sup>Washington State University, Pullman, WA, <sup>2</sup>Washington State University, Spokane, WA, <sup>3</sup>Washington State University College of Nursing, Spokane, WA, <sup>4</sup>Washington State University, Program of Excellence in Addictions Research, Spokane, WA, <sup>5</sup>Washington State University, Elson S. Floyd College of Medicine, Spokane, WA
- 114 *Daily patterns of marijuana and alcohol co-use among individuals with alcohol and cannabis use disorders*  
Jane Metrik<sup>1</sup>, Rachel Gunn<sup>2</sup>, Kristina Jackson<sup>3</sup>, Alexander Sokolovsky<sup>3</sup>, Brian Borsari<sup>4</sup>, <sup>1</sup>Brown University School of Public Health, Providence, RI, <sup>2</sup>Brown University, Providence, RI, <sup>3</sup>Center for Alcohol and Addiction Studies, Providence, RI, <sup>4</sup>San Francisco Veterans Affairs Health Care System, San Francisco, CA
- 115 *Polydrug cannabis use and cannabis dependence: Toward a "latent class with distal outcome" approach*  
Karl Alcover, James Anthony, Michigan State University, Lansing, MI
- 116 *Co-use of marijuana and tobacco in blunts or spliffs among a sample of residential addiction treatment clients*  
Deborah Yip, Thao Le, Denise Williams, Noah Gubner, Joseph Guydish, University of California San Francisco, San Francisco, CA
- 117 *Varenicline for smoking cessation in patients with cocaine-use disorder: A proof-of-concept pilot trial*  
Anna Reynolds<sup>1</sup>, Justin Strickland<sup>1</sup>, William Stoops<sup>1</sup>, Joshua Lile<sup>2</sup>, Craig Rush<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 118 *Predicting opioid and cocaine-use trajectory with objective and subjective neighborhood measures*  
Samuel Stull<sup>1</sup>, Landhing Moran<sup>1</sup>, David Epstein<sup>1</sup>, Jennifer Schroeder<sup>2</sup>, Kenzie Preston<sup>1</sup>, Karran Phillips<sup>3</sup>, <sup>1</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>2</sup>Schroeder Statistical Consulting, LLC, Ellicott City, MD, <sup>3</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 119 *Cannabis use increases cocaine dependence in female cocaine users but does not increase its progression speed*  
Yiyang Liu<sup>1</sup>, Micah Johnson<sup>1</sup>, Barry Setlow<sup>2</sup>, Linda Cottler<sup>1</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>University of Florida College of Medicine, Gainesville, FL
- 120 *Lifetime alcohol consumption conditionally relates to neurocognitive performance based on methamphetamine dependence*  
Rowan Saloner<sup>1</sup>, Emily Paolillo<sup>2</sup>, David Moore<sup>2</sup>, Robert Heaton<sup>2</sup>, Igor Grant<sup>3</sup>, Mariana Cherner<sup>2</sup>, <sup>1</sup>SDSU/UC

- San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, <sup>2</sup>University of California San Diego, San Diego, CA, <sup>3</sup>University of California San Diego, La Jolla, CA
- 121 *Lifetime use of non-nicotine drugs in electronic cigarette devices among a sample of individuals in substance use treatment*  
Noah Gubner, Denise Williams, Joseph Gurdish, University of California San Francisco, San Francisco, CA
- 122 *Venue-based sampling to assess risky behavior and risk factors for drug use among non-school based youths in Thailand.*  
kanittha thaikla, Chiang Mai University, Chiang Mai, Thailand, Thailand
- 123 *Are prior drug use behaviors associated with subsequent initiation of injection drug use?*  
Daniel Chu<sup>1</sup>, Alex Kral<sup>2</sup>, Lynn Wenger<sup>3</sup>, Ricky Bluthenthal<sup>1</sup>, <sup>1</sup>Keck School of Medicine University of Southern California, Los Angeles, CA, <sup>2</sup>RTI International, Research Triangle Park, NC, <sup>3</sup>RTI International, San Francisco, CA
- 124 *Drug treatment seeking behavior subsequent to involuntary treatment among people who inject drugs in Tijuana, Mexico*  
Claudia Rafful<sup>1</sup>, MariaLuisa Zúñiga<sup>2</sup>, Ricardo Orozco<sup>3</sup>, Peter Davidson<sup>1</sup>, David Engstrom<sup>4</sup>, Gudelia Rangel<sup>5</sup>, Steffanie Strathdee<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>San Diego State University School of Social Work, San Diego, CA, <sup>3</sup>National Institute of Psychiatry, Mexico, Mexico City, Mexico, <sup>4</sup>San Diego State University, San Diego, CA, <sup>5</sup>Comision Binacional Fronteriza, Mexico
- 125 *Beyond alcohol: Client change talk about opioids, cannabis, and cocaine*  
Jon Houck, Brigitte Stevens, University of New Mexico, Albuquerque, NM
- 126 *Prevalence and correlates of multiple substance use disorders among adults in primary care: Results from a multisite study*  
William John<sup>1</sup>, He Zhu<sup>1</sup>, Paolo Mannelli<sup>1</sup>, Robert Schwartz<sup>2</sup>, Geetha Subramaniam<sup>3</sup>, Li-Tzy Wu<sup>1</sup>, <sup>1</sup>Duke University School of Medicine, Durham, NC, <sup>2</sup>Friends Research Institute, Baltimore, MD, <sup>3</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 127 *Are discussions about substance use in health care settings associated with substance use disorder treatment use and perception of treatment need?*  
Pia Mauro<sup>1</sup>, Hillary Samples<sup>2</sup>, Kathryn Klein<sup>1</sup>, Silvia Martins<sup>1</sup>, <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY
- 128 *Empirically-derived alcohol and drug use patterns of sexual minority groups presenting to an urban emergency department*  
Brooke Arterberry<sup>1</sup>, Alan Davis<sup>2</sup>, Erin Bonar<sup>1</sup>, Maureen Walton<sup>3</sup>, Frederic Blow<sup>3</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>Johns Hopkins Hospital, Baltimore, MD, <sup>3</sup>University of Michigan, Addiction Center, Ann Arbor, MI
- 129 *Quality of life and the state of health: Ambulatory treatment for substance use disorders in Argentina*  
Nicolás Poliansky<sup>1</sup>, Carolina Gorlero<sup>1</sup>, Damián Gemini<sup>1</sup>, Hendree Jones<sup>2</sup>, <sup>1</sup>Fundación Convivir, Buenos Aires, Argentina, <sup>2</sup>University of North Carolina at Chapel Hill, Carrboro, NC
- 130 *Women's and men's experiences in group therapy for substance use disorders: A mixed-methods analysis*  
Shelly Greenfield<sup>1</sup>, Dawn Sugarman<sup>2</sup>, Meghan Reilly<sup>2</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>McLean Hospital, Belmont, MA

**POSTER III I**  
**OPIOIDS: HUMAN STUDIES I**

**Sapphire ABC/EFG**  
**11:30 - 1:30 PM**

- 131 *Phase 3 trial comparing depot buprenorphine (CAM2038) to sublingual buprenorphine/naloxone for OUD treatment: Subanalysis among persons with heroin as the primary opioid of abuse*

- michael frost<sup>1</sup>, Michelle Lofwall<sup>2</sup>, Genie Bailey<sup>3</sup>, Sharon Walsh<sup>4</sup>, Mark Beacker<sup>5</sup>, Natalie Budilovsky-Kelley<sup>5</sup>, Fredrik Tiberg<sup>6</sup>, Erin Barone<sup>7</sup>, <sup>1</sup>The Frost Medical Group, Conshohocken, PA, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>3</sup>SSTAR: Stanley Street Treatment & Resources, Inc, Fall River, MA, <sup>4</sup>University of Kentucky, Lexington, KY, <sup>5</sup>Braeburn Pharmaceuticals, Princeton, NJ, <sup>6</sup>Camurus, Lund, Sweden, <sup>7</sup>Braeburn, Plymouth Meeting, PA
- 132 *A real-world efficacy and safety comparison of CAM2038 vs SL BPN/NX for the treatment of patients with OUD who inject opioids*  
Genie Bailey<sup>1</sup>, michael frost<sup>2</sup>, Michelle Lofwall<sup>3</sup>, Sharon Walsh<sup>4</sup>, Mark Beacker<sup>5</sup>, Natalie Budilovsky-Kelley<sup>5</sup>, Fredrik Tiberg<sup>6</sup>, Erin Barone<sup>7</sup>, <sup>1</sup>SSTAR: Stanley Street Treatment & Resources, Inc, Fall River, MA, <sup>2</sup>The Frost Medical Group, Conshohocken, PA, <sup>3</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>4</sup>University of Kentucky, Lexington, KY, <sup>5</sup>Braeburn Pharmaceuticals, Princeton, NJ, <sup>6</sup>Camurus, Lund, Sweden, <sup>7</sup>Braeburn, Plymouth Meeting, PA
- 133 *Buprenorphine/naloxone treatment: Dose-finding for prescription opioid dependence*  
Gabriela Garcia Vassallo<sup>1</sup>, Margaret Altemus<sup>2</sup>, Elizabeth Ralevski<sup>2</sup>, Jane Weiner<sup>2</sup>, Ismene Petrakis<sup>2</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>VA Connecticut Healthcare System, West Haven, CT
- 134 *Patient characteristics as moderators in the extended-release naltrexone versus buprenorphine-naloxone to prevent opioid relapse (XBOT, CTN-0051) trial: Who responds to which treatment?*  
Edward Nunes<sup>1</sup>, Joshua Lee<sup>2</sup>, Patricia Novo<sup>2</sup>, Genie Bailey<sup>3</sup>, John Rotrosen<sup>2</sup>, Marc Fishman<sup>4</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>New York University School of Medicine, New York, NY, <sup>3</sup>SSTAR: Stanley Street Treatment & Resources, Inc, Fall River, MA, <sup>4</sup>Mountain Manor Treatment Center, Baltimore, MD
- 135 *Research design and participant experience in clinical addictions randomized controlled trials: A nested qualitative exploration of the CTN-0055 CHOICES study*  
Lindsey Richardson<sup>1</sup>, Kaitlyn Jaffe<sup>1</sup>, Evan Wood<sup>2</sup>, Philip Todd Korthuis<sup>3</sup>, <sup>1</sup>University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>University of British Columbia, Vancouver, <sup>3</sup>Oregon Health & Science University, Portland, OR
- 136 *Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicenter, open-label, randomized controlled trial*  
Patricia Novo<sup>1</sup>, Joshua Lee<sup>1</sup>, Edward Nunes<sup>2</sup>, Ken Bachrach<sup>3</sup>, Genie Bailey<sup>4</sup>, Snehal Bhatt<sup>5</sup>, SARAH FARKAS<sup>1</sup>, Marc Fishman<sup>6</sup>, Phoebe Gauthier<sup>7</sup>, Candace Hodgkins<sup>8</sup>, Jacqueline King<sup>9</sup>, Robert Lindblad<sup>9</sup>, David Liu<sup>10</sup>, Abigail Matthews<sup>9</sup>, Jeanine May<sup>9</sup>, K. Michelle Peavy<sup>11</sup>, Stephen Ross<sup>1</sup>, Dagmar Salazar<sup>9</sup>, Paul Schkolnik<sup>12</sup>, Dikla Blumberg<sup>9</sup>, Geetha Subramaniam<sup>10</sup>, John Rotrosen<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>Columbia University and NYSPI, New York, NY, <sup>3</sup>Tarzana Treatment Centers, Tarzana, CA, <sup>4</sup>SSTAR: Stanley Street Treatment & Resources, Inc, Fall River, MA, <sup>5</sup>University of New Mexico, Albuquerque, NM, <sup>6</sup>Mountain Manor Treatment Center, Baltimore, MD, <sup>7</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>8</sup>Gateway Community Services, Inc., Jacksonville, FL, <sup>9</sup>The Emmes Corporation, Rockville, MD, <sup>10</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, <sup>11</sup>Evergreen Treatment Services, Seattle, WA, <sup>12</sup>Maryhaven Addiction Research Institute, Columbus, OH
- 137 *Cost-effectiveness of extended-release naltrexone versus buprenorphine-naloxone to prevent opioid relapse among individuals initiating treatment in an inpatient detoxification setting*  
Sean Murphy<sup>1</sup>, Kathryn McCollister<sup>2</sup>, Jared Leff<sup>1</sup>, X. April Yang<sup>2</sup>, Philip Jeng<sup>1</sup>, Joshua Lee<sup>3</sup>, Edward Nunes<sup>4</sup>, Patricia Novo<sup>3</sup>, John Rotrosen<sup>3</sup>, Bruce Schackman<sup>1</sup>, <sup>1</sup>Weill Cornell Medical College, New York, NY, <sup>2</sup>University of Miami Miller School of Medicine, Miami, FL, <sup>3</sup>New York University School of Medicine, New York, NY, <sup>4</sup>Columbia University and NYSPI, New York, NY
- 138 *Resources and associated costs of implementing pharmacotherapy for opioid dependence initiated in inpatient*

- detoxification settings: Results from a multisite randomized clinical trial*  
 Kathryn McCollister<sup>1</sup>, X. April Yang<sup>1</sup>, Sean Murphy<sup>2</sup>, Jared Leff<sup>2</sup>, Joshua Lee<sup>3</sup>, Edward Nunes<sup>4</sup>, Patricia Novo<sup>3</sup>, John Rotrosen<sup>3</sup>, Bruce Schackman<sup>2</sup>, <sup>1</sup>University of Miami Miller School of Medicine, Miami, FL, <sup>2</sup>Weill Cornell Medical College, New York, NY, <sup>3</sup>New York University School of Medicine, New York, NY, <sup>4</sup>Columbia University and NYSPI, New York, NY
- 139 *Medication for opioid use disorder and mortality after inpatient opioid detoxification treatment*  
 Alexander Walley<sup>1</sup>, Dana Bernson<sup>2</sup>, Thomas Land<sup>2</sup>, Marc Laroche<sup>1</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Massachusetts Department of Public Health, Boston, MA
- 140 *Impact of change in buprenorphine- naloxone formulation on prescription pattern, treatment adherence and patient satisfaction among patients on buprenorphine maintenance treatment: A cross-sectional study*  
 Shalini Singh<sup>1</sup>, Yatan Pal Singh Balhara<sup>2</sup>, Siddharth Sarkar<sup>2</sup>, <sup>1</sup>All India Institute of Medical Sciences, New Delhi, <sup>2</sup>National Drug Dependence Treatment Centre, New Delhi, India
- 141 *Participants' preferences for BUP-NX or XR-NTX and associations with induction successes and relapse rates in the CTN-0051 opioid treatment trial*  
 Jacqueline King<sup>1</sup>, Jeanine May<sup>1</sup>, Dagmar Salazar<sup>1</sup>, Anne Hoehn<sup>1</sup>, Dikla Blumberg<sup>1</sup>, Patricia Novo<sup>2</sup>, Yunhee Choi-Kuaea<sup>3</sup>, K. Michelle Peavy<sup>3</sup>, Rosson Wiebe<sup>4</sup>, John Rotrosen<sup>2</sup>, Joshua Lee<sup>2</sup>, <sup>1</sup>The Emmes Corporation, Rockville, MD, <sup>2</sup>New York University School of Medicine, New York, NY, <sup>3</sup>Evergreen Treatment Services, Seattle, WA, <sup>4</sup>Cowlitz Tribal Health, Tukwila, WA
- 142 *Baseline characteristics predictive of successful outpatient transition onto extended-release naltrexone*  
 D. Andrew Tompkins<sup>1</sup>, Edward Nunes<sup>2</sup>, Antoine Douaihy<sup>3</sup>, Paolo Mannelli<sup>4</sup>, Miao Yu<sup>5</sup>, Narinder Nangia<sup>5</sup>, Maria Sullivan<sup>5</sup>, Abigail Zavod<sup>5</sup>, Sarah Akerman<sup>6</sup>, <sup>1</sup>University of California San Francisco School of Medicine, San Francisco, CA, <sup>2</sup>Columbia University and NYSPI, New York, NY, <sup>3</sup>University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Duke University School of Medicine, Durham, NC, <sup>5</sup>Alkermes, Inc., Waltham, MA, <sup>6</sup>Alkermes, Inc, Waltham, MA
- 143 *A five-day outpatient induction onto XR-naltrexone in patients with opioid use disorder*  
 Mohammad Sibai<sup>1</sup>, Kaitlyn Mishlen<sup>1</sup>, Edward Nunes<sup>2</sup>, Adam Bisaga<sup>3</sup>, <sup>1</sup>New York State Psychiatric Institute, New York, NY, <sup>2</sup>Columbia University and NYSPI, New York, NY, <sup>3</sup>Columbia University College of Physicians and Surgeons, New York, NY
- 144 *The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults: A randomized trial*  
 Brantley Jarvis<sup>1</sup>, August Holtyn<sup>2</sup>, Anthony DeFulio<sup>3</sup>, Mikhail Koffarnus<sup>4</sup>, Jeannie-Marie Leoutsakos<sup>2</sup>, Annie Umbricht<sup>2</sup>, Michael Fingerhood<sup>5</sup>, George Bigelow<sup>2</sup>, Kenneth Silverman<sup>6</sup>, <sup>1</sup>NorthTide, LLC, Dulles, VA, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Western Michigan University, Kalamazoo, MI, <sup>4</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>5</sup>Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>6</sup>Johns Hopkins Hospital, Baltimore, MD
- 145 *Symptoms of depression, anxiety and insomnia in opioid dependent individuals receiving either long-acting naltrexone injections or oral buprenorphine-naloxone. A randomized clinical trial.*  
 Zill-E-Huma Latif, Akershus Universitetssykehus, Lørenskog , Akershus, Norway
- 146 *Circadian typology in patients in opioid agonist therapy: Associations with social jetlag and cocaine abstinence*  
 Jeremiah Bertz<sup>1</sup>, Samuel Stull<sup>1</sup>, bill Kowalczyk<sup>2</sup>, David Epstein<sup>1</sup>, Kenzie Preston<sup>1</sup>, <sup>1</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>2</sup>Hartwick College, Oneonta, NY
- 147 *Motives for illicit buprenorphine/naloxone use among opioid consumers in New Hampshire*  
 Elizabeth Saunders<sup>1</sup>, Sarah Moore<sup>2</sup>, Andrea Meier<sup>3</sup>, Bethany McLeman<sup>4</sup>, Stephen Metcalf<sup>2</sup>, Olivia Walsh<sup>5</sup>, Lisa Marsch<sup>2</sup>, <sup>1</sup>The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, <sup>2</sup>Geisel School

- of Medicine at Dartmouth, Hanover, NH, Geisel School of Medicine at Dartmouth, Lebanon, NH, Northeast Node of the CTN/Dartmouth College, Lebanon, NH, <sup>5</sup>Dartmouth College, Hanover, NH
- 148 *Perceptions and practices addressing diversion among US buprenorphine prescribers*  
Lewei (Allison) Lin<sup>1</sup>, Michelle Lofwall<sup>2</sup>, Sharon Walsh<sup>3</sup>, Adam Gordon<sup>4</sup>, Hannah Knudsen<sup>3</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY, <sup>3</sup>University of Kentucky, Lexington, KY, <sup>4</sup>University of Utah, Salt Lake City, UT
- 149 *Effects of interim buprenorphine treatment for opioid use disorder for emerging adults*  
Kelly Peck<sup>1</sup>, Taylor Ochalek<sup>2</sup>, Gary Badger<sup>1</sup>, Stacey Sigmon<sup>1</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>Vermont Center on Behavior and Health, Burlington, VT
- 150 *Within-subject evaluation of interim buprenorphine treatment during waitlist delays*  
Taylor Ochalek<sup>1</sup>, Kelly Peck<sup>2</sup>, Maria Parker<sup>2</sup>, Gary Badger<sup>2</sup>, Stephen Higgins<sup>2</sup>, Stacey Sigmon<sup>2</sup>, <sup>1</sup>Vermont Center on Behavior and Health, Burlington, VT, <sup>2</sup>University of Vermont, Burlington, VT
- 151 *Integrating buprenorphine into peer-support: a qualitative study exploring motivators for engagement and retention in a community-based opioid treatment program in Baltimore City*  
Noa Krawczyk<sup>1</sup>, Masoumeh Dejman<sup>2</sup>, Christine Truong<sup>2</sup>, Simon Marshall-Shah<sup>2</sup>, Kayla Tormohlen<sup>2</sup>, Deborah Agus<sup>3</sup>, Judith Bass<sup>2</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>Behavioral Health Leadership Institute, Baltimore, MD
- 152 *Risk factors for premature discontinuation of buprenorphine treatment for opioid use disorder among Medicaid enrollees*  
Hillary Samples<sup>1</sup>, Arthur Robin Williams<sup>2</sup>, Sheree Neese-Todd<sup>3</sup>, Mark Olfson<sup>4</sup>, Stephen Crystal<sup>3</sup>, <sup>1</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>2</sup>Columbia University Division on Substance Use Disorders, New York, NY, <sup>3</sup>Rutgers University, New Brunswick, NJ, <sup>4</sup>Columbia University and NYSPI, New York, NY
- 153 *Association of insurance coverage with specialty treatment, buprenorphine treatment, and stable primary care in a cohort of adults who have injected drugs.*  
Kenneth Feder<sup>1</sup>, Noa Krawczyk<sup>2</sup>, <sup>1</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD
- 154 *Methadone maintenance for opioid dependent patients using pharmaceutical opioids (POs) versus heroin: Is there a difference?*  
Mohit Varshney<sup>1</sup>, Atul Ambekar<sup>2</sup>, Ravindra Rao<sup>1</sup>, Ashwani Mishra<sup>1</sup>, <sup>1</sup>National Drug Dependence Treatment Centre, New Delhi, India, <sup>2</sup>Professor, National Drug Dependence Treatment Centre, AIIMS, New Delhi, New Delhi, India
- 155 *Stigma associated with receiving methadone treatment: Reliability and validity of a theory-based stigma scale for opioid-using populations*  
Laramie Smith<sup>1</sup>, Maria Luisa Mittal<sup>2</sup>, Valerie Earnshaw<sup>3</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>University of California San Diego, Division of Infectious Diseases and Global Public Health, La Jolla, CA, <sup>3</sup>University of Delaware, Newark, DE

**ORAL COMMUNICATIONS 19**  
**OOPS, I DID IT AGAIN: IMPULSIVITY, DECISION**  
**MAKING AND CRAVING**

**Indigo E**  
**1:30 - 3:30 PM**

Chairs: R. Kathryn McHugh and Stephanie Wemm

1:30 *Self-perceived impaired control in alcohol use: An ecological momentary assessment study*

1 1 2 1

- Danielle Remmerswaal<sup>1</sup>, Joran Jongerling<sup>1</sup>, Ingmar Franken<sup>1</sup>, Erasmus University Rotterdam, Rotterdam, Netherlands, <sup>2</sup>Erasmus University Rotterdam, Rotterdam
- 1:45 *Sex differences in the associations between stress reactivity, impulsivity, and problematic use in smokers and gamblers*  
Stephanie Wemm<sup>1</sup>, Edelgard Wulfert<sup>2</sup>, Rajita Sinha<sup>3</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>State University of New York at Albany, Albany, NY, <sup>3</sup>Yale University School of Medicine, New Haven, CT
- 2:00 *The effects of cocaine-dependence and aging on decision making performance and impulsivity*  
Sade Johns, F. Gerard Moeller, Virginia Commonwealth University, Richmond, VA
- 2:15 *The sterile injection equipment discounting task: A novel measure of infectious disease risk among injecting heroin users*  
Evan Herrmann<sup>1</sup>, Youssr Shaltout<sup>2</sup>, Sandra Comer<sup>3</sup>, <sup>1</sup>Battelle Memorial Institute, Baltimore, MD, <sup>2</sup>Columbia University Medical Center, New York, NY, <sup>3</sup>Columbia University and NYSPI, New York, NY
- 2:30 *Craving, non-opioid drugs and alcohol use by HIV-positive patients with opioid use disorder stabilized on naltrexone*  
Elena Blokhina<sup>1</sup>, Evgeny Krupitsky<sup>2</sup>, Edwin Zvartau<sup>1</sup>, Elena Vladimirovna Verbitskaya<sup>1</sup>, Dmitry Lioznov<sup>1</sup>, Tatiana Yaroslavtseva<sup>1</sup>, Natalia Bushara<sup>3</sup>, Vladimir Palatkin<sup>3</sup>, Sabrina Poole<sup>4</sup>, Robert Gross<sup>4</sup>, George Woody<sup>4</sup>, <sup>1</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, Russian Federation, <sup>2</sup>V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russian Federation, <sup>3</sup>First Pavlov State Medical University of St. Petersburg, St. Petersburg, <sup>4</sup>University of Pennsylvania, Philadelphia, PA
- 2:45 *Lofexidine in combination with naltrexone improves control over opioid cravings: A pilot randomized, double-blind, placebo-controlled clinical trial*  
Gretchen Hermes<sup>1</sup>, Scott Hyman<sup>2</sup>, Thomas Kosten<sup>3</sup>, Rajita Sinha<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Carlos Albizu University, Miami, FL, <sup>3</sup>Baylor College of Medicine, Bellaire, TX
- 3:00 *Craving mediates behavioral economic risk for opioid use during prescription opioid addiction treatment*  
Matthew Worley<sup>1</sup>, Bryan Messina<sup>2</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>VA San Diego Healthcare System, San Diego, CA
- 3:15 *The role of sleep disruption in pain-related craving in adults with chronic pain and opioid misuse*  
R. Kathryn McHugh, Rachel Geyer, Monika Kolodziej, Roger Weiss, McLean Hospital, Belmont, MA

**SYMPOSIUM XVII** **Indigo BCFG**  
**COMORBIDITY OF OPIOID ADDICTION AND OTHER 1:30 - 3:30 PM**  
**PSYCHIATRIC DISORDERS**

Chairs: Rita Valentino and Christopher Evans

- 1:30 *Buprenorphine: Opioid dependence and depression*  
T. Kosten, Baylor College of Medicine, Bellaire, TX
- 1:55 *Opioid receptors and diverse contributions to mood regulation*  
B. Kieffer, McGill University, Montreal, QC, Canada
- 2:20 *Kappa/dynorphin systems and anxiety states*  
C. Chavkin, University of Washington, Seattle, WA
- 2:45 *Co-occurrence of mental health and opioid use disorders*  
L. Degenhardt, National Drug and Alcohol Research Centre, Sydney, Australia, Australia
- 3:10 *Discussant: Comorbidity of opioid addiction and other psychiatric disorders*  
R. Valentino, National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD

**SYMPOSIUM XVIII**  
**LONG-ACTING MEDICATION REFORMULATIONS:**  
**A STRATEGY TO ADDRESS THE OPIOID EPIDEMIC**

**Indigo A**  
**1:30 - 3:30 PM**

Chairs: Brantley Jarvis and Philip Todd Korthuis

- 1:30 *Extended-release naltrexone versus buprenorphine for opioid treatment: Results from two comparative effectiveness trials*  
 J. Lee, New York University School of Medicine, New York, NY
- 1:55 *Naltrexone implants for opioid use disorder: Relapse prevention, craving, anhedonia, and HIV prevention*  
 E. Krupitsky, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, St. Petersburg, Russia, Russian Federation
- 2:20 *Once-weekly and once-monthly injectable buprenorphine for opioid use disorder: Human laboratory findings*  
 S. Walsh, University of Kentucky, Lexington, KY
- 2:45 *Recent clinical studies on a once-weekly and once-monthly injectable form of buprenorphine to treat opioid use disorder*  
 E. Nunes, Columbia University and NYSPI, New York, NY
- 3:10 *Curbing the opioid epidemic with long-acting medications: Opportunities and ongoing research in treatment implementation*  
 P. Korthuis, Oregon Health & Science University, Portland, OR

**ORAL COMMUNICATIONS 18**  
**THE PAIN AND STRAIN COMES MAINLY FROM THE BRAIN**

**Indigo D**  
**1:30 - 4:30 PM**

Chairs: Karsten Bartels and Declan Barry

- 1:30 *Assessment of drug abuse-related events with MADDERS in SUMMIT-07: A phase-3 study of NKTR-181 in patients with moderate to severe chronic low-back pain*  
 Ryan Lanier<sup>1</sup>, John Markman<sup>2</sup>, Nathaniel Katz<sup>1</sup>, Jeffrey Gudin<sup>3</sup>, Richard Rauck<sup>4</sup>, Maitreyee Mohanty<sup>1</sup>, Harrison Elder<sup>1</sup>, Dolapo Lawal<sup>1</sup>, Joseph Gimbel<sup>5</sup>, Mary Tagliaferri<sup>6</sup>, Lin Lu<sup>6</sup>, Suresh Siddhanti<sup>6</sup>, Sidney Schnoll<sup>7</sup>, Jack Henningfield<sup>8</sup>, <sup>1</sup>Analgesic Solutions, Natick, MA, <sup>2</sup>University of Rochester School of Medicine and Dentistry, Rochester, NY, <sup>3</sup>Englewood Hospital and Medical Center, Englewood, NJ, <sup>4</sup>Carolinas Pain Institute and The Center for Clinical Research, Winston-Salem, NC, <sup>5</sup>Arizona Research Center, Phoenix, AZ, <sup>6</sup>Nektar Therapeutics, San Francisco, CA, <sup>7</sup>Pinney Associates, Inc., Stamford, CT, <sup>8</sup>Pinney Associates, Inc., Bethesda, MD
- 1:40 *Improvement in pain and retention in a large prospective open label randomized trial of buprenorphine versus methadone for opiate use disorder*  
 Matisyau Shulman<sup>1</sup>, Aimee Campbell<sup>1</sup>, Martina Pavlicova<sup>2</sup>, Jennifer Scodes<sup>1</sup>, Sean Luo<sup>3</sup>, Andrew Saxon<sup>4</sup>, Edward Nunes<sup>1</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>Columbia University Mailman School of Public Health, New York, NY, <sup>3</sup>Columbia University, New York, NY, <sup>4</sup>VA Puget Sound Healthcare System, Seattle, WA
- 1:50 *Opioid and non-opioid analgesic therapy after surgery*  
 Karsten Bartels<sup>1</sup>, Katharine Mahoney<sup>1</sup>, Kristen Raymond<sup>1</sup>, Shannon McWilliams<sup>2</sup>, Lena Mayes<sup>1</sup>, Ana Fernandez-Bustamante<sup>1</sup>, Christian Hopfer<sup>2</sup>, Susan Mikulich-Gilbertson<sup>2</sup>, <sup>1</sup>University of Colorado, Aurora, CO, <sup>2</sup>University of Colorado School of Medicine, Aurora, CO
- 2:00 *Incisional injury and its recovery modulates morphine's rewarding properties*

1

2

3 1



- Chinwe Nwaneshiudu , David Clark , Xiao-Yu Shi , Stanford University School of Medicine, Redwood City, CA, <sup>2</sup>Stanford University School of Medicine, Palo Alto, CA, <sup>3</sup>Veterans Affairs Health System, Palo Alto, CA
- 2:10 *Analgesic effects of the g-protein biased mu-opioid receptor agonist, kurkinol*  
Amy Alder<sup>1</sup>, Rachel Crowley<sup>2</sup>, Thomas Prisinzano<sup>2</sup>, Bronwyn Kivell<sup>1</sup>, <sup>1</sup>Victoria University of Wellington, Wellington, New Zealand, <sup>2</sup>University of Kansas, Lawrence, KS
- 2:20 *The association of marijuana use and mental health symptoms with pain severity among persons living with HIV infection: Results from a community-recruited sample*  
Verlin Joseph<sup>1</sup>, Zachary Mannes<sup>1</sup>, Abenaa Jones<sup>2</sup>, Huiyin Lu<sup>1</sup>, Dominique Easterling<sup>1</sup>, Gladys Ibanez<sup>3</sup>, Christa Cook<sup>4</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, <sup>3</sup>Department of Epidemiology, Robert Stempel College of Public Health & Social Work, Miami, FL, <sup>4</sup>University of Florida, College of Nursing, Gainesville, FL
- 2:30 *The impact of psychological distress on pain volatility in adults with chronic pain and prescription opioid addiction*  
Bryan Messina<sup>1</sup>, Matthew Worley<sup>2</sup>, <sup>1</sup>VA San Diego Healthcare System, San Diego, CA, <sup>2</sup>University of California San Diego, La Jolla, CA
- 2:40 *Sex differences in co-occurring substance use, mental health and pain disorders, in primary care patients diagnosed with opioid use disorders*  
Celestina Barbosa-Leiker<sup>1</sup>, Aimee Campbell<sup>2</sup>, Mary Hatch-Maillette<sup>3</sup>, Gwen Lapham<sup>4</sup>, Denise Boudreau<sup>4</sup>, Manu Thakral<sup>4</sup>, Judith Tsui<sup>5</sup>, Bobbi Jo Yarborough<sup>6</sup>, Julia Arnsten<sup>7</sup>, Ingrid Binswanger<sup>8</sup>, Angela Stotts<sup>9</sup>, Amy Loree<sup>10</sup>, Jordan Braciszewski<sup>10</sup>, Joe Glass<sup>4</sup>, Viviana Horigian<sup>11</sup>, Rebecca Hutcheson<sup>5</sup>, Cynthia Campbell<sup>12</sup>, Gavin Bart<sup>13</sup>, Kathy Bradley<sup>4</sup>, <sup>1</sup>Washington State University College of Nursing, Spokane, WA, <sup>2</sup>Columbia University and NYSPI, New York, NY, <sup>3</sup>University of Washington Alcohol & Drug Abuse Institute, Seattle, WA, <sup>4</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA, <sup>5</sup>University of Washington, Seattle, WA, <sup>6</sup>Kaiser Permanente Northwest Center for Health Research, Portland, OR, <sup>7</sup>Montefiore Medical Center, Bronx, NY, <sup>8</sup>Kaiser Permanente Colorado, Denver, CO, <sup>9</sup>University of Texas Medical Branch, Houston, TX, <sup>10</sup>Henry Ford Health System, Detroit, MI, <sup>11</sup>University of Miami, Miami, FL, <sup>12</sup>Kaiser Permanente North California Division of Research, Oakland, CA, <sup>13</sup>University of Minnesota, Minneapolis, MN
- 2:50 *Effectiveness of self-management for the treatment of chronic pain and aberrant drug-related behavior: Patients' experiences with a web-based, cognitive behavior therapy intervention*  
Andrew Rosenblum<sup>1</sup>, Honoria Guarino<sup>2</sup>, Sarah Moore<sup>3</sup>, Lisa Marsch<sup>4</sup>, <sup>1</sup>NDRI, Metuchen, NJ, <sup>2</sup>National Development and Research Institute, Inc., New York, NY, <sup>3</sup>Geisel School of Medicine at Dartmouth, Lebanon, NH, <sup>4</sup>Geisel School of Medicine at Dartmouth, Hanover, NH
- 3:00 *A pilot randomized clinical trial of cognitive behavioral therapy for opioid use disorder and chronic pain*  
Declan Barry<sup>1</sup>, Mark Beitel<sup>2</sup>, Christopher Cutter<sup>3</sup>, David Fiellin<sup>1</sup>, Robert Kerns<sup>4</sup>, Brent Moore<sup>1</sup>, Lynn Madden<sup>5</sup>, Richard Schottenfeld<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Yale University, APT Foundation, New Haven, CT, <sup>3</sup>Yale University, New Haven, CT, <sup>4</sup>Yale University School of Medicine, West Haven, CT, <sup>5</sup>APT Foundation, Inc., New Haven, CT
- 3:10 *Training addiction counselors to deliver a brief psychosocial intervention for chronic pain among patients in opioid agonist treatment: A pilot investigation*  
Jenna Butner<sup>1</sup>, Curtis Bone<sup>1</sup>, Mark Beitel<sup>2</sup>, Lynn Madden<sup>3</sup>, Madeline Bono<sup>4</sup>, Anthony Eller<sup>5</sup>, Declan Barry<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Yale University, APT Foundation, New Haven, CT, <sup>3</sup>APT Foundation, Inc., New Haven, CT, <sup>4</sup>New York University, New York, NY, <sup>5</sup>Yale School of Public Health, New Haven, CT
- 3:20 *Prevalence of pain conditions among persons with an opioid use disorder diagnosis in a primary care*

*population*

Manu Thakral<sup>1</sup>, Gwen Lapham<sup>1</sup>, Jennifer Bobb<sup>1</sup>, Judith Tsui<sup>2</sup>, Denise Boudreau<sup>1</sup>, Cynthia Campbell<sup>3</sup>, Julia Arnsten<sup>4</sup>, Jane Liebschutz<sup>5</sup>, Angela Stotts<sup>6</sup>, Jordan Braciszewski<sup>7</sup>, Andrew Saxon<sup>8</sup>, Kathy Bradley<sup>1</sup>, <sup>1</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA, <sup>2</sup>University of Washington, Seattle, WA, <sup>3</sup>Kaiser Permanente North California Division of Research, Oakland, CA, <sup>4</sup>Montefiore Medical Center, Bronx, NY, <sup>5</sup>University of Pittsburgh, Pittsburgh, PA, <sup>6</sup>University of Texas Medical Branch, Houston, TX, <sup>7</sup>Henry Ford Health System, Detroit, MI, <sup>8</sup>VA Puget Sound Healthcare System, Seattle, WA

**LATE-BREAKING RESEARCH NEWS****Indigo H****3:45 - 4:45 PM**

Chairs: William Stoops

- 3:45 *Driver alcohol detection system for safety (DADSS) – preliminary human testing results of two passive methods for detecting alcohol in tissue and breath compared to venous blood alcohol concentration*  
S. Lukas<sup>1</sup>, E. Ryan<sup>1</sup>, J. McNeil<sup>2</sup>, J. Shepherd<sup>1</sup>, K. Davis<sup>3</sup>, L. Bingham<sup>2</sup>, K. Ozdemir<sup>4</sup>, N. Dalal<sup>4</sup>, K. Pirooz<sup>4</sup>, M. Willis<sup>4</sup>, A. Zaouk<sup>4</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>McLean Hospital, Belmont, MA, <sup>3</sup>Clean Hospital, Belmont, MA, <sup>4</sup>KEA Technologies, Inc, Marlborough, MA
- 3:50 *Opioid overdose detection using smartphones*  
J. Sunshine<sup>1</sup>, R. Nandakumar<sup>1</sup>, C. Banta-Green<sup>1</sup>, J. Buxton<sup>2</sup>, S. Gollakota<sup>1</sup>, <sup>1</sup>University of Washington, Seattle, WA, <sup>2</sup>University of British Columbia, Vancouver, BC, Canada
- 3:55 *Efficacy of oral naltrexone with buprenorphine for transitioning from buprenorphine to XR-NTX: A hybrid residential-outpatient randomized control trial*  
S. Comer<sup>1</sup>, P. Mannelli<sup>2</sup>, D. Alam<sup>3</sup>, A. Douaihy<sup>4</sup>, N. Nangia<sup>5</sup>, A. Zavod<sup>5</sup>, B. Silverman<sup>5</sup>, S. Akerman<sup>6</sup>, <sup>1</sup>Columbia University and NYSPI, New York, NY, <sup>2</sup>Duke University School of Medicine, Durham, NC, <sup>3</sup>Neuroscience Research Institute, Winfield, IL, <sup>4</sup>University of Pittsburgh, Pittsburgh, PA, <sup>5</sup>Alkermes, Inc., Waltham, MA, <sup>6</sup>Alkermes, Inc, Waltham, MA
- 4:00 *Pre-clinical efficacy of vaccines for treatment of prescription opioid abuse using novel carrier proteins*  
A. Huseby Kelcher<sup>1</sup>, F. Baruffaldi<sup>1</sup>, C. Hassler<sup>2</sup>, A. Lees<sup>3</sup>, S. Runyon<sup>2</sup>, M. Pravetoni<sup>1</sup>, <sup>1</sup>Minneapolis Medical Research Foundation, Minneapolis, MN, <sup>2</sup>RTI International, Research Triangle Park, NC, <sup>3</sup>Fina BioSolutions, Rockville, MD
- 4:05 *Modulation of M5 muscarinic acetylcholine receptors decreases stimulant and opioid self-administration and cue-induced reactivity without affecting oxycodone-induced analgesia in rats*  
R. Gould<sup>1</sup>, B. Gunter<sup>2</sup>, M. Bubser<sup>1</sup>, R. Matthews<sup>1</sup>, D. Winder<sup>1</sup>, C. Lindsley<sup>1</sup>, C. Jones<sup>1</sup>, <sup>1</sup>Vanderbilt University, Nashville, TN, <sup>2</sup>Vanderbilt University Medical Center, Nashville, TN
- 4:10 *Galantamine effects on opioid use from a placebo-controlled trial among cocaine-dependent methadone maintained individuals*  
K. Carroll<sup>1</sup>, M. Sofuoglu<sup>2</sup>, S. Yip<sup>2</sup>, E. DeVito<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>Yale University, New Haven, CT
- 4:15 *Substantial increases in methamphetamine use among a national sample of treatment-seeking opioid users*  
M. Ellis, Z. Kasper, T. Cicero, Washington University, St. Louis, MO
- 4:20 *Immune functioning markers relate to cognitive abilities in individuals with cocaine use disorder*  
S. Stamatovich<sup>1</sup>, L. Stertz<sup>1</sup>, C. Walss-Bass<sup>1</sup>, S. Lane<sup>2</sup>, C. Green<sup>3</sup>, J. Schmitz<sup>1</sup>, M. Wardle<sup>1</sup>, <sup>1</sup>University of Texas Health Science Center, Houston, TX, <sup>2</sup>University of Texas, Houston, TX, <sup>3</sup>University of Texas Health Science Center, McGovern Medical School, Houston, TX
- 4:25 *Gene expression in the prefrontal cortex associated with impulsivity*

- E. Vallender<sup>1</sup>, R. Gilmore<sup>1</sup>, S. Hutchins<sup>1</sup>, X. Zhang<sup>1</sup>, G. Mahajan<sup>1</sup>, A. Athey<sup>2</sup>, J. Overholser<sup>2</sup>, L. Dieter<sup>2</sup>, G. Jurjus<sup>3</sup>, G. Rajkowska<sup>1</sup>, C. Stockmeier<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Case Western Reserve University, Cleveland, OH, <sup>3</sup>Louis Stokes Cleveland VA Medical Center, Cleveland, OH
- 4:30 *Weight gain and insulin resistance in mice lacking cannabinoid-2 receptor*  
O. Alshaarawy<sup>1</sup>, E. Kurjan<sup>2</sup>, N. Truong<sup>2</sup>, L. Olson<sup>2</sup>, <sup>1</sup>Michigan State University, Lansing, MI, <sup>2</sup>Michigan State University, East Lansing, MI
- 4:35 *Key findings from an RCT of nabiximols for the treatment of cannabis dependence*  
N. Lintzeris<sup>1</sup>, A. Dunlop<sup>2</sup>, J. Copeland<sup>3</sup>, D. Allsop<sup>4</sup>, A. Bhardwaj<sup>5</sup>, I. McGregor<sup>5</sup>, R. Bruno<sup>6</sup>, L. Mills<sup>5</sup>, <sup>1</sup>Drug and Alcohol Services, South Eastern Sydney Local Health District, Surry Hills, Australia, <sup>2</sup>Hunter New England Local Health District, Newcastle, Australia, <sup>3</sup>University of South Wales, Sydney, <sup>4</sup>University of New South Wales, Sydney, Australia, <sup>5</sup>University of Sydney, Sydney, Australia, <sup>6</sup>University of Tasmania, Sydney, Australia
- 4:40 *Prolonged exposure to reduced-nicotine cigarettes reduces behavioral economic demand for full- and reduced-nicotine cigarettes*  
S. Dolan, M. Berry, M. Johnson, Johns Hopkins University School of Medicine, Baltimore, MD

**(MEMBERS ONLY)  
BUSINESS MEETING**

**Aqua C  
5:00 - 6:00 PM**

**DINNER/DANCING**

**Indigo Ballroom  
7:30 - 10:30 PM**

**Thursday, June 14, 2018**

**(PRE-REGISTRANTS ONLY)  
BREAKFAST WITH CHAMPIONS**

**Aqua 310/Terrace  
8:00 - 9:00 AM**

**CPDD/INRC PLENARY**

**Indigo BCFG  
9:00 - 10:00 AM**

*Deaths of Despair: Alcohol Misuse, Pain and Negative Reinforcement*

George Koob, Director, National Institute on Alcohol Abuse and Alcoholism

**ORAL COMMUNICATIONS 20  
NOVEL TREATMENTS STRATEGIES: OUT WITH  
THE OLD**

**Indigo D  
10:00 - 12:00 PM**

Chairs: Michael Mancino and Jae Kim

10:00 *New theranostic clathrin-nanoparticles efficiently deliver D3R-antibodies noninvasively to targeted dopamine*

*brain regions*

Gordana Vitaliano<sup>1</sup>, Franco Vitaliano<sup>2</sup>, Martin Teicher<sup>3</sup>, Scott Lukas<sup>1</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>EXQOR, Boston, MA, <sup>3</sup>McLean Hospital, Belmont, MA

- 10:15 *Targeted noninvasive delivery of novel clathrin-based superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of dopamine transporters in mouse brain*

Jae Kim<sup>1</sup>, Dionyssios Mintzopoulos<sup>2</sup>, Adam Christopher<sup>3</sup>, Scott Lukas<sup>1</sup>, Marc Kaufman<sup>2</sup>, Franco Vitaliano<sup>4</sup>, Gordana Vitaliano<sup>1</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>McLean Hospital, Brain Imaging Center, Belmont, MA, <sup>3</sup>McLean Hospital, Belmont, MA, <sup>4</sup>EXQOR, Boston, MA

- 10:30 *Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial*

M Trigo<sup>1</sup>, Alexandra Soliman<sup>1</sup>, Quilty Lena<sup>2</sup>, Benedikt Fischer<sup>3</sup>, Jürgen Rehm<sup>4</sup>, Peter Selby<sup>1</sup>, Allan Barnes<sup>5</sup>, Marilyn Huestis<sup>6</sup>, Tony George<sup>3</sup>, David Streiner<sup>7</sup>, Gregory Staios<sup>1</sup>, Bernard LeFoll<sup>1</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>Campbell Family Mental Health Research Institute, CAMH, Toronto, ON, Canada, <sup>3</sup>University of Toronto, Toronto, ON, Canada, <sup>4</sup>Institute for Mental Health Policy Research, CAMH, Toronto, ON, Canada, <sup>5</sup>National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, <sup>6</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, <sup>7</sup>Department of Psychiatry & Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada

- 10:45 *Impact of buprenorphine taper and oral naltrexone induction schedules on successful outpatient transition to injectable naltrexone*

Michael Mancino<sup>1</sup>, Edward Nunes<sup>2</sup>, Jeff Thostenson<sup>1</sup>, Joseph Guise<sup>1</sup>, Janette McGaugh<sup>1</sup>, Alison Oliveto<sup>1</sup>, <sup>1</sup>University of Arkansas for Medical Sciences, Little Rock, AK, <sup>2</sup>Columbia University and NYSPI, New York, NY

- 11:00 *Is risk-targeted, coping skills enhanced motivational interviewing (MI) more efficacious than MI alone in young people with alcohol related-injuries accessing emergency department and crisis support care?*

Leanne Hides<sup>1</sup>, David Kavanagh<sup>2</sup>, Susan Cotton<sup>3</sup>, Jason Connor<sup>4</sup>, Mark Daghlish<sup>5</sup>, Catherine Quinn<sup>6</sup>, Nina Pocuca<sup>2</sup>, Ross Young<sup>4</sup>, <sup>1</sup>University of Queensland, Centre for Youth Substance Abuse Research, Brisbane, Australia, <sup>2</sup>Queensland University of Technology, Brisbane, Australia, <sup>3</sup>Orygen The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, Australia, <sup>4</sup>University of Queensland, Brisbane, <sup>5</sup>Royal Brisbane and Women's Hospital, Brisbane, Australia, <sup>6</sup>University of Queensland, Brisbane, Australia

- 11:15 *Stimulating future value: Episodic future thinking decreases delay discounting in recreational and chronic cocaine users*

Sarah Snider<sup>1</sup>, Jamie K.<sup>2</sup>, Warren Bickel<sup>3</sup>, <sup>1</sup>Addiction Recovery Research Center, Roanoke, VA, <sup>2</sup>Virginia Tech Carilion Research Institute, Roanoke, <sup>3</sup>Virginia Tech Carilion Research Institute, Roanoke, VA

- 11:30 *Epigenetic detection of alcohol use disorder in a clinically ascertained sample*

Allan Andersen, Robert Philibert, University of Iowa, Iowa City, IA

- 11:45 *The efficacy of lidocaine in disrupting cocaine cue-induced memory reconsolidation*

Josh Becker<sup>1</sup>, Julianne Price<sup>2</sup>, David Leonard<sup>3</sup>, Alina Suris<sup>4</sup>, Enas Kandil<sup>1</sup>, Meredith Shaw<sup>4</sup>, Sven Kroener<sup>5</sup>, E Sherwood Brown<sup>1</sup>, Bryon Adinoff<sup>1</sup>, <sup>1</sup>University of Texas Southwestern Medical Center, Dallas, TX, <sup>2</sup>University of Florida, Gainesville, FL, <sup>3</sup>David Leonard Statistical Consulting, Wichita Falls, TX, <sup>4</sup>VA North Texas Health Care System, Dallas, TX, <sup>5</sup>University of Texas, Dallas, TX

**ORAL COMMUNICATIONS 21****IT'S OKAY TO BE A QUITTER: NICOTINE AND E-CIGS****Indigo E****10:00 - 12:00 PM**

Chairs: Maria Parker

- 10:00 *Flavor additives increase motivation for nicotine and nicotine-evoked dopamine release in rats*  
Amanda Smith, Matthew Palmatier, Curtis Bradley, Samantha Malone, Gerald Deehan, Jr., East Tennessee State University, Johnson City, TN
- 10:15 *Effects of sweet-flavored e-cigarettes on smoking reinstatement and tobacco withdrawal symptoms in nicotine-deprived smokers*  
Nicholas Goldenson, Matthew Kirkpatrick, Jessica Barrington-Trimis, Adam Leventhal, University of Southern California, Los Angeles, CA
- 10:30 *Associations between delay discounting, e-cigarette use, and cigarette smoking*  
Jeffrey Stein<sup>1</sup>, Elan Perry<sup>1</sup>, Bryan Heckman<sup>2</sup>, Derek Pope<sup>1</sup>, Warren Bickel<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Medical University of South Carolina, Charleston, SC
- 10:45 *Reinforcing efficacy of cigarettes vs. little cigars in smokers differing in socioeconomic status*  
Jennifer Tidey<sup>1</sup>, Mollie Miller<sup>2</sup>, Rachel Cassidy<sup>1</sup>, Rachel Denlinger-Apte<sup>3</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Brown University Center for Alcohol and Addiction Studies, Providence, RI, <sup>3</sup>Brown University School of Public Health, Providence, RI
- 11:00 *Patterns and frequency of current e-cigarette use in U.S. adults, 2012-2013*  
Maria Parker, Stacey Sigmon, Andrea Villanti, University of Vermont, Burlington, VT
- 11:15 *Patterns of cigarette, e-cigarette, and cannabis use among adult smokers in primary care*  
Johannes Thrul, Maya Vijayaraghavan, Jason Satterfield, University of California San Francisco, San Francisco, CA
- 11:30 *Prevalence and correlates of adolescents' e-cigarette use frequency and dependence*  
Erin Vogel, Danielle Ramo, Mark Rubinstein, University of California San Francisco, San Francisco, CA
- 11:45 *Gender differences in use, attitudes, and intention to use tobacco products*  
Irene Pericot-Valverde, Diann Gaalema, University of Vermont, Burlington, VT

**SYMPOSIUM XIX**  
**INTERNATIONAL OPIOID GUIDELINES**

**Indigo BCFG**  
**10:00 - 12:00 PM**

Chairs: Fred Nyberg and Gabriele Fischer

*Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence within EU*  
G. Fischer, Medizinische Universität Wien, Wien, Austria

*The Nordic approach to opioid addiction; service provision and organization*  
T. Clausen, The Norwegian Institute of Public Health, Oslo, Norway, Norway

*Opioid use disorder clinical guidelines: A Canadian model*  
P. Voon, BC Centre on Substance Use, Vancouver, BC, Canada

*Methadone treatment guidelines development for states in Southeast Asia*  
G. Bart, University of Minnesota, Minneapolis, MN

*Opioid treatment programs – Aspects to deal with in the future perspective*  
F. Nyberg, Uppsala University, Faculty of Medicine & Pharmacy, Uppsala, Sweden, Sweden

**SYMPOSIUM XX**  
**KRATOM: BITTER NARCOTIC OR SWEET**  
**MEDICINE FOR PAIN AND OPIOID ADDICTION?**

**Indigo A**  
**10:00 - 12:00 PM**

Chairs: Jay McLaughlin and Christopher McCurdy

- 10:00 *History, chemistry and pharmacology of Kratom*  
C. McCurdy, University of Florida, Gainesville, FL
- 10:25 *Pharmacokinetics and analytical analysis of Kratom products and components*  
B. Avery, University of Florida, Gainesville, FL
- 10:50 *Evaluating the opioid-like discriminative stimulus effects of Kratom alkaloids*  
L. McMahan, University of Florida, Gainesville, FL
- 11:15 *Assessment of abuse liability of Kratom constituents, mitragynine and 7-hydroxymitragynine*  
S. Hemby, High Point University, Fred Wilson School of Pharmacy, High Point, NC
- 11:40 *Human clinical effects of Kratom*  
E. Boyer, Brigham and Women's Hospital, Boston, MA

**POSTER IV A**  
**OPIOID: HUMAN STUDIES II**

**Sapphire ABC/EFG**  
**12:00 - 2:00 PM**

- 1 *Opioid use disorder rates and treatment retention after implementation of a primary care tiered-based approach*  
Steffani Bailey<sup>1</sup>, Rebecca Cantone<sup>1</sup>, Brian Garvey<sup>1</sup>, John Muench<sup>1</sup>, Joan Fleishman<sup>1</sup>, Bruin Ruge<sup>1</sup>, Allison O'Neill<sup>2</sup>, Deborah Cohen<sup>1</sup>, Dennis McCarty<sup>1</sup>, <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>OCHIN, Inc., Portland, OR
- 2 *The use of ketamine in opioid withdrawal: Case studies*  
Jérôme Bachellier<sup>1</sup>, Servane Barrault<sup>1</sup>, Paul Brunault<sup>2</sup>, Damien Mauge<sup>1</sup>, Ballon Nicols<sup>1</sup>, <sup>1</sup>CHRU de Tours, Clinique Psychiatrique Universitaire, Tours, France, <sup>2</sup>University Hospital of Tours, Tours, France
- 3 *Empirical evidence of different clinically meaningful opioid withdrawal phenotypes*  
Kelly Dunn<sup>1</sup>, Elise Weerts<sup>1</sup>, Andrew Huhn<sup>1</sup>, Jennifer Schroeder<sup>2</sup>, D. Andrew Tompkins<sup>3</sup>, George Bigelow<sup>1</sup>, Eric Strain<sup>1</sup>, <sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Schroeder Statistical Consulting, LLC, Ellicott City, MD, <sup>3</sup>University of California San Francisco School of Medicine, San Francisco, CA
- 4 *Effect of lofexidine on cardiac repolarization (QTcF) during treatment of opioid withdrawal*  
Borje Darpo<sup>1</sup>, Mark Pirner<sup>2</sup>, James Longstreth<sup>3</sup>, Georg Ferber<sup>4</sup>, Charles Gorodetzky<sup>5</sup>, <sup>1</sup>Danderyd's Hospital, Stockholm, Sweden, <sup>2</sup>US WorldMeds, LLC, Louisville, KY, <sup>3</sup>Longstreth & Associates, Inc., Mundelein, IL, <sup>4</sup>Statistik Georg Ferber GmbH, Riehen, Switzerland, <sup>5</sup>Consultant, Kansas City, MO
- 5 *"Some hang themselves because the arosta is one thing that is unbearable": Experience of withdrawal among South Africans who use whoonga and its implications for intervention development*  
Griffin Tyree<sup>1</sup>, Nzwakie Mosery<sup>2</sup>, Elizabeth Closson<sup>3</sup>, Zonke Mabude<sup>2</sup>, Mxolisi Mathenjwa<sup>2</sup>, Sibusiso Sibiyi<sup>2</sup>, Tshana Watkins<sup>2</sup>, Carol du Toit<sup>4</sup>, David Bangsberg<sup>5</sup>, Steven Safren<sup>6</sup>, Kenneth Mayer<sup>7</sup>, Jennifer Smit<sup>2</sup>, Matthew Mimiaga<sup>8</sup>, David Grelotti<sup>9</sup>, <sup>1</sup>University of California San Diego, San Diego, CA, <sup>2</sup>MatCH Research, University of the Witwatersrand, Durban South Africa, Durban, South Africa, <sup>3</sup>The Fenway Institute, Boston, Boston, MA, <sup>4</sup>SANCA Durban Alcohol & Drug Centres, Durban, Berea, South Africa, <sup>5</sup>Oregon Health & Science University, Portland, OR, <sup>6</sup>University of Miami School of Law, Coral Gables, FL, <sup>7</sup>Harvard Medical School, Boston, MA, <sup>8</sup>Brown University, Providence, RI, <sup>9</sup>University of California San Diego, San Diego, Zimbabwe
- 6 *Developing and testing a novel prospective memory training program in opioid and polysubstance users across 15 and 30 sessions of training*  
Meredith Berry, Mary Sweeney, Lisa Mitchell, Matthew Johnson, Johns Hopkins University School of Medicine, Baltimore, MD
- 7 *Behavioral activation and right thalamic activation during monetary and environmental reward anticipation*

- among opiate users in detoxification*  
Jennifer Yi, Ryan Bell, Anna Bartuska, Katlyn McKay, Jennifer Stein, Stacey Daughters, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 8 *Benefits of long-term opioid agonist treatment participation for patients with opioid use disorder*  
Kathryn Hawk<sup>1</sup>, Marek Chawarski<sup>2</sup>, Patrick O'Connor<sup>3</sup>, Patricia Owens<sup>1</sup>, Micheal Pantalon<sup>1</sup>, Steven Bernstein<sup>4</sup>, David Fiellin<sup>3</sup>, Gail D'Onofrio<sup>3</sup>, <sup>1</sup>Yale University Department of Emergency Medicine, New Haven, CT, <sup>2</sup>Yale University Department of Psychiatry, New Haven, CT, <sup>3</sup>Yale University School of Medicine, New Haven, CT, <sup>4</sup>Yale Department of Emergency Medicine, New Haven, CT
- 9 *12-month outcomes of methadone and buprenorphine maintained patients: A study in naturalistic conditions*  
Melina Fatseas<sup>1</sup>, Fuschia Serre<sup>2</sup>, Cecile Denis<sup>3</sup>, Jean-Pierre Daulouede<sup>4</sup>, Marc Auriacombe<sup>2</sup>, <sup>1</sup>Centre Hospitalier Charles Perrens, Bordeaux, France, <sup>2</sup>Université de Bordeaux, Bordeaux, <sup>3</sup>University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Bizia Addiction Clinic, Bayonne
- 10 *A care management approach to facilitate entry and retention in medically assisted treatment among women with opioid use disorder*  
Dennis Hand, Alice Fischer, Kimberly McLaughlin, Diane Abatemarco, Thomas Jefferson University, Philadelphia, PA
- 11 *Methadone treatment programs may be a key venue to engage women with opioid use disorder in family planning*  
Curtis Bone<sup>1</sup>, Lynn Madden<sup>2</sup>, Jeanette Tetrault<sup>3</sup>, Mishka Terplan<sup>4</sup>, Declan Barry<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>APT Foundation, Inc., New Haven, CT, <sup>3</sup>Yale University, New Haven, CT, <sup>4</sup>Virginia Commonwealth University, Richmond, VA
- 12 *Familiarity, knowledge and barriers to long-acting reversible contraceptives among opioid-maintained women*  
Catalina Rey, Heidi Melbostad, Stacey Sigmon, Lauren Macafee, Anne Dougherty, Sarah Heil, University of Vermont, Burlington, VT
- 13 *Contraceptive knowledge of men and women receiving medication-assisted treatment for opioid use disorder*  
Heidi Melbostad, Catalina Rey, Stacey Sigmon, Lauren Macafee, Anne Dougherty, Sarah Heil, University of Vermont, Burlington, VT
- 14 *Factors associated with medication-assisted treatment adherence for offenders: The role of drug cravings and socialization*  
Yang Yang<sup>1</sup>, Jennifer Pankow<sup>2</sup>, Pat Flynn<sup>2</sup>, Kevin Knight<sup>2</sup>, <sup>1</sup>University of Louisville, Lafayette, LA, <sup>2</sup>Texas Christian University, Fort Worth, TX
- 15 *Mobilizing community support for people who inject drugs: A network intervention*  
Michael Kidorf<sup>1</sup>, Nicolas Schlienz<sup>2</sup>, Jessica Peirce<sup>2</sup>, Carl Latkin<sup>3</sup>, Robert Brooner<sup>2</sup>, <sup>1</sup>Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>3</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
- 16 *Documented prevalence of opioid use disorder and its treatment across 8 diverse health care systems in the U.S.*  
Denise Boudreau<sup>1</sup>, Gwen Lapham<sup>1</sup>, Eric Johnson<sup>1</sup>, Jennifer Bobb<sup>1</sup>, Abigail Matthews<sup>2</sup>, Jennifer McCormack<sup>2</sup>, David Liu<sup>3</sup>, Cynthia Campbell<sup>4</sup>, Rebecca Rossom<sup>5</sup>, Ingrid Binswanger<sup>6</sup>, Bobbi Jo Yarborough<sup>7</sup>, Julia Arnsten<sup>8</sup>, Chinazo Cunningham<sup>8</sup>, Joe Glass<sup>1</sup>, Mark Murphy<sup>9</sup>, Paul Amoroso<sup>10</sup>, Mohammad Zare<sup>11</sup>, Rulin Hechter<sup>12</sup>, Brian Ahmedani<sup>13</sup>, Jordan Braciszewski<sup>13</sup>, Viviana Horigian<sup>14</sup>, Jose Szapocznik<sup>14</sup>, Jeffrey Samet<sup>15</sup>, Andrew Saxon, Kathy Bradley<sup>1</sup>, <sup>1</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA, <sup>2</sup>The Emmes Corporation, Rockville, MD, <sup>3</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, <sup>4</sup>Kaiser Permanente North California Division of Research, Oakland, CA, <sup>5</sup>Health Partners, Minneapolis, MN, <sup>6</sup>Kaiser Permanente Colorado, Denver, CO, <sup>7</sup>Kaiser Permanente Northwest Center for Health Research, Portland, OR, <sup>8</sup>Montefiore Medical Center, Bronx, NY, <sup>9</sup>MultiCare Tacoma Central,

- Tacoma, WA, <sup>10</sup>MultiCare Institute for Research & Innovation, Tacoma, WA, <sup>11</sup>University of Texas Health Science Center, Houston, TX, <sup>12</sup>Kaiser Permanente Southern California, Pasadena, CA, <sup>13</sup>Henry Ford Health System, Detroit, MI, <sup>14</sup>University of Miami, Miami, FL, <sup>15</sup>Boston University School of Medicine, Boston, MA, <sup>16</sup>Puget Sound Healthcare System, Seattle, WA
- 17 *Opioid-related hospitalizations in an integrated health system*  
Pooja Lagisetty<sup>1</sup>, Lewei (Allison) Lin<sup>1</sup>, Dara Ganoczy<sup>2</sup>, Rebecca Haffajee<sup>1</sup>, Amy Bohnert<sup>1</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>VA Government, Ann Arbor, MI
- 18 *Misperceptions towards opioid agonist therapies among residents and staff in community recovery homes may serve as barriers to uptake of evidence based treatment for opioid use disorder*  
Benjamin Howell<sup>1</sup>, Karen Ablondi<sup>1</sup>, Frank Buono<sup>1</sup>, Tamara Malm<sup>2</sup>, Ashton Gores<sup>3</sup>, Anthony Eller<sup>3</sup>, Declan Barry<sup>1</sup>, Curtis Bone<sup>1</sup>, <sup>1</sup>Yale University School of Medicine, New Haven, CT, <sup>2</sup>St. Joseph School of Pharmacy, Hartford, CT, <sup>3</sup>Yale School of Public Health, New Haven, CT
- 19 *Experiences of burnout among drug counselors in a large opioid treatment program: A qualitative investigation*  
Mark Beitel<sup>1</sup>, Lindsay Oberleitner<sup>2</sup>, Dharushana Muthulingam<sup>3</sup>, David Oberleitner<sup>4</sup>, Lynn Madden<sup>5</sup>, Ruthanne Marcus<sup>3</sup>, Anthony Eller<sup>6</sup>, Madeline Bono<sup>7</sup>, Declan Barry<sup>3</sup>, <sup>1</sup>Yale University, APT Foundation, New Haven, CT, <sup>2</sup>Yale University, New Haven, CT, <sup>3</sup>Yale University School of Medicine, New Haven, CT, <sup>4</sup>University of Bridgeport, Bridgeport, CT, <sup>5</sup>APT Foundation, Inc., New Haven, CT, <sup>6</sup>Yale School of Public Health, New Haven, CT, <sup>7</sup>New York University, New York, NY
- 20 *Opioid recovery initiation: Pilot test of a peer outreach and modified recovery management checkup intervention for out-of-treatment opioid users*  
Christy Scott, Christine Grella<sup>1</sup>, Lisa Nicholson<sup>2</sup>, Michael Dennis<sup>3</sup>, <sup>1</sup>University of California, Chestnut Health Systems, Los Angeles, CA, <sup>2</sup>Chestnut Health Systems, Chicago, IL, <sup>3</sup>Chestnut Health Systems, Normal, IL
- 21 *A more dangerous 'heroin': Lessons learned from anthropological research in four US heroin and fentanyl hotspots*  
Daniel Ciccarone, Sarah Mars, Jeff Ondocsin, University of California San Francisco, San Francisco, CA

## POSTER IV B OPIOIDS - PRECLINICAL

**Sapphire ABC/EFG  
12:00 - 2:00 PM**

- 22 *Modeling opioid maintenance therapy in rats: Effect of chronic buprenorphine on responding for drug-paired discrete cues in a non-drug context, context-induced reinstatement of drug seeking, and reacquisition of oxycodone self-administration*  
Jennifer Hoots<sup>1</sup>, S. Stevens Negus<sup>2</sup>, Bruce Blough<sup>3</sup>, Gerta Cami-Kobeci<sup>4</sup>, Stephen Husbands<sup>4</sup>, Yavin Shaham<sup>1</sup>, Jennifer Bossert<sup>1</sup>, <sup>1</sup>National Institute of Drug Abuse, National Institutes of Health, Baltimore, MD, <sup>2</sup>Virginia Commonwealth University, Richmond, VA, <sup>3</sup>RTI International, Research Triangle Park, NC, <sup>4</sup>University of Bath, Bath, United Kingdom
- 23 *Samidorphan attenuates the effects of buprenorphine in rat models evaluating abuse potential*  
Jacobi Cunningham<sup>1</sup>, Nikita Burke<sup>2</sup>, Mark Todtenkopf<sup>1</sup>, David Finn<sup>3</sup>, Michelle Roche<sup>3</sup>, John Kelly<sup>3</sup>, Connie Sanchez<sup>1</sup>, <sup>1</sup>Alkermes, Inc., Waltham, MA, <sup>2</sup>National University of Ireland, Galway, Ireland, <sup>3</sup>National University of Ireland, Galway, Galway, Ireland
- 24 *Oxycodone self-administration is altered by microbiome modulation in Copenhagen rats*  
Sierra Simpson, Giordano De Guglielmo, Marsida Kallupi, Olivier George, The Scripps Research Institute, La Jolla, CA
- 25 *Differences in cognitive, motivational and/or sensorimotor processing preclude detection of substrain*



- differences in oxycodone reward between 129P3/J and 129S1/SvlmJ mice*  
Michal Coelho, Sami Ferdousian, Karen Szumlinski, University of California Santa Barbara, Santa Barbara, CA
- 26 *CXCR4 & CCR5 chemokine receptor antagonists significantly enhanced morphine-induced antinociception in female, but not male, mice in the formalin test*  
Xiaohong Chen<sup>1</sup>, Toby Eisenstein<sup>1</sup>, S. Inan<sup>1</sup>, Christopher Tallarida<sup>1</sup>, A. Cowan<sup>1</sup>, Ellen Geller<sup>2</sup>, J.J. Meissler<sup>1</sup>, Scott Rawls<sup>2</sup>, M.N. Watson<sup>1</sup>, Menahem Doura<sup>1</sup>, Martin Adler<sup>2</sup>, <sup>1</sup>Center for Substance Abuse Research, Lewis Katz School of Medicine of Temple University, Philadelphia, PA, <sup>2</sup>Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- 27 *A stable heroin analog that can serve as a vaccine hapten to induce antibodies that block the effects of heroin and its metabolites in rodents and that cross-react immunologically with related drugs of abuse*  
Gary Matyas<sup>1</sup>, Agnieszka Sulima<sup>2</sup>, Arthur Jacobson<sup>3</sup>, Oscar Torres<sup>4</sup>, Zoltan Beck<sup>4</sup>, Carl R Alving<sup>5</sup>, Kenner Rice<sup>2</sup>, <sup>1</sup>Walter Reed Army Institute of Research, Silver Spring, MD, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, <sup>3</sup>National Institutes of Health, Bethesda, MD, <sup>4</sup>Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, <sup>5</sup>Walter Reed Army Institute of Research, Sandy Spring, MD
- 28 *The effects of estradiol and progesterone on proestrus-induced decreases in heroin intake*  
Andrea Robinson, Sarah Ethridge, Huailin Zhang, Mark Smith, Davidson College, Davidson, NC
- 29 *Social influences on remifentanyl self-administration in male rats*  
Rebecca Hofford<sup>1</sup>, Paige Bond<sup>1</sup>, Shoshana Eitan<sup>2</sup>, Michael Bardo<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>Texas A&M University, College Station, TX
- 30 *Role of delta opioid receptors in modulating reward-related behaviors*  
Emily Jutkiewicz<sup>1</sup>, Ashleigh Matthews<sup>1</sup>, Kenner Rice<sup>2</sup>, <sup>1</sup>University of Michigan, Ann Arbor, MI, <sup>2</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 31 *Anti-cocaine and analgesic properties of MP1104, a mixed kappa & delta opioid receptor agonist in rats*  
Diana Atigari<sup>1</sup>, Rajendra Uprety<sup>2</sup>, Susruta Majumdar<sup>2</sup>, Bronwyn Kivell<sup>1</sup>, <sup>1</sup>Victoria University of Wellington, Wellington, New Zealand, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, NY
- 32 *Quantification of unconditioned behaviors induced by kappa agonists in rhesus monkeys: Effects of signaling bias*  
Sally Huskinson<sup>1</sup>, Donna Platt<sup>2</sup>, Thomas Prisinzano<sup>3</sup>, Bruce Blough<sup>4</sup>, Kevin Freeman<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Division of Neurobiology and Behavior Research, Jackson, MS, <sup>3</sup>University of Kansas, Lawrence, KS, <sup>4</sup>RTI International, Research Triangle Park, NC

**POSTER IV C**  
**ABUSE LIABILITY**

**Sapphire ABC/EFG**  
**12:00 - 2:00 PM**

- 33 *Total synthesis of salvinorin A-inspired opioids*  
Samuel Williamson, Alexander Sherwood, Rachel Crowley, Thomas Prisinzano, University of Kansas, Lawrence, KS
- 34 *Characterization of mitragynine and an analog for analgesia, tolerance, physical dependence and reinforcing liabilities in mouse models*  
Jay McLaughlin<sup>1</sup>, Shainnel Eans<sup>1</sup>, Heather Stacy<sup>1</sup>, Rajendra Uprety<sup>2</sup>, Gavril Pasternak<sup>2</sup>, Susruta Majumdar<sup>2</sup>, <sup>1</sup>University of Florida, Gainesville, FL, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, NY
- 35 *Tradipitant, an NK-1 antagonist, does not substantively modify opioid abuse liability or self-administration in opioid-experienced individuals*  
Sharon Walsh<sup>1</sup>, Marion Coe<sup>1</sup>, Paul Nuzzo<sup>1</sup>, Michelle Lofwall<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY,

- <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 36 *NKTR-181 demonstrates low abuse potential in recreational opioid users in two double-blind, randomized crossover human abuse potential studies*  
Jack Henningfield<sup>1</sup>, Lynn Webster<sup>2</sup>, Debra Kelsh<sup>3</sup>, Brad Vince, Lin Lu<sup>4</sup>, Janet Jobs<sup>4</sup>, August Buchhalter<sup>1</sup>, Suresh Siddhanti<sup>4</sup>, Margaret Ziola<sup>4</sup>, John Silowsky<sup>4</sup>, Aleksandrs Odinecs<sup>4</sup>, Sunny Xie<sup>4</sup>, Carlo Di Fonzo<sup>4</sup>, Michael Eldon<sup>4</sup>, Xue Snow Ge<sup>4</sup>, <sup>1</sup>Pinney Associates, Inc., Bethesda, MD, <sup>2</sup>Lifetree Clinical Research, Salt Lake City, UT, <sup>3</sup>Vince and Associates, Malvern, PA, <sup>4</sup>Nektar Therapeutics, San Francisco, CA
- 37 *Considering “take drug again” as the primary endpoint in clinical studies of abuse deterrent formulations*  
Erik Hansen, Joya He, Lynn Webster, Ryan Turncliff, PRA Health Sciences, Salt Lake City, UT
- 38 *Abuse liability assessment of ENDS: What is the right level to support a public health benefit?*  
Sarah Baxter<sup>1</sup>, Leanne Campbell<sup>1</sup>, Tao Jin<sup>1</sup>, Jack Henningfield<sup>2</sup>, Reginald Fant<sup>2</sup>, Stiles Mitchell<sup>1</sup>, <sup>1</sup>RAI Services Company, Winston-Salem, NC, <sup>2</sup>Pinney Associates, Inc., Bethesda, MD
- 39 *Assessing correspondence between subjective effects measures and concurrent choice data in a laboratory study evaluating the effects of cigarettes with varying levels of nicotine*  
Cecilia Bergeria<sup>1</sup>, Sarah Heil<sup>1</sup>, Stacey Sigmon<sup>1</sup>, Jennifer Tidey<sup>2</sup>, Diann Gaalema<sup>1</sup>, John Hughes<sup>1</sup>, Maxine Stitzer<sup>3</sup>, Christopher Arger<sup>1</sup>, Mollie Miller<sup>4</sup>, Hanna Durand<sup>1</sup>, Janice Bunn<sup>1</sup>, Jeff Priest<sup>1</sup>, Danielle Davis<sup>1</sup>, Joanna Streck<sup>5</sup>, Joan Skelly<sup>1</sup>, Morgan Tromblee<sup>5</sup>, Stephen Higgins<sup>1</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>Brown University, Providence, RI, <sup>3</sup>Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>4</sup>Brown University Center for Alcohol and Addiction Studies, Providence, RI, <sup>5</sup>Vermont Center on Behavior and Health, Burlington, VT
- 40 *Role of propylene glycol and vegetable glycerin concentration on the behavioral effects of electronic cigarette aerosol*  
Arit Harvanko<sup>1</sup>, Catherine Martin<sup>1</sup>, Thomas Kelly<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 41 *Vaporization of marijuana among recreational users: A qualitative study*  
Elizabeth Aston<sup>1</sup>, Samantha Farris<sup>2</sup>, Jane Metrik<sup>3</sup>, Rochelle Rosen<sup>4</sup>, <sup>1</sup>Center for Alcohol and Addiction Studies, Providence, RI, <sup>2</sup>Warren Alpert Medical School, Providence, RI, <sup>3</sup>Brown University School of Public Health, Providence, RI, <sup>4</sup>The Miriam Hospital, Centers for Behavioral & Preventive Medicine, Providence, RI

## POSTER IV D SEDATIVE HYPNOTICS

**Sapphire ABC/EFG  
12:00 - 2:00 PM**

- 42 *Combination with pregnanolone increases the sedative effects of triazolam and zolpidem in rhesus macaques*  
Daniela Rüedi-Bettschen<sup>1</sup>, James Cook<sup>1</sup>, Lais Berro<sup>1</sup>, Donna Platt<sup>2</sup>, Barak Gunter<sup>3</sup>, James Rowlett<sup>1</sup>, <sup>1</sup>University of Mississippi Medical Center, Jackson, MS, <sup>2</sup>Division of Neurobiology and Behavior Research, Jackson, MS, <sup>3</sup>Vanderbilt University Medical Center, Nashville, TN
- 43 *Residual next-day effects of alprazolam on psychomotor performance and simulated driving in healthy normal volunteers*  
Marion Coe<sup>1</sup>, Lindy Howe<sup>1</sup>, Paul Nuzzo<sup>1</sup>, Michelle Lofwall<sup>2</sup>, Laura Fanucchi<sup>2</sup>, Shanna Babalonis<sup>1</sup>, Sharon Walsh<sup>1</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 44 *Benzodiazepines use “to get high” in patients admitted for addiction treatment in Spain*  
Marta Torrens<sup>1</sup>, Francina Fonseca<sup>1</sup>, Magí Farré<sup>2</sup>, Karin McBride<sup>3</sup>, Icro Maremmanni<sup>4</sup>, Marilena Guareschi<sup>4</sup>, Richard Dart<sup>5</sup>, <sup>1</sup>Institut de Neuropsiquiatria i Addiccions, Barcelona, Spain, <sup>2</sup>Hospital Universitari Germans Trias i Pujol, Badalona, Spain, <sup>3</sup>Denver Health Rocky Mountain Poison & Drug Center (RMPDC), Denver,

- CO, <sup>4</sup>Associazione per l'Utilizzo delle Conoscenze Neuroscientifiche a fini Sociali, Pietrasanta, Italy, <sup>5</sup>Rocky Mountain Poison & Drug Center, Denver, CO
- 45 *Inability to discontinue chronic hypnotic use*  
Timothy Roehrs, Henry Ford Health System, Detroit, MI
- 46 *How representative are insomnia clinical trials?*  
Thomas Roth, Timothy Roehrs, Henry Ford Health System, Detroit, MI
- 47 *A comparison between the ICD-10 and DSM-5 diagnostic criteria for sedative, hypnotic and anxiolytic use disorders*  
Daniela Curado<sup>1</sup>, Viviam de Barros<sup>2</sup>, Emérita Opaleye<sup>2</sup>, Ana Regina Noto<sup>3</sup>, <sup>1</sup>Federal University of São Paulo, São Paulo, Brazil, <sup>2</sup>Universidade Federal de Sao Paulo, São Paulo, Brazil, <sup>3</sup>Universidade Federal de Sao Paulo, São Paulo

## POSTER IV E ALCOHOL

**Sapphire ABC/EFG**  
**12:00 - 2:00 PM**

- 48 *Ayahuasca blocks the development and expression of ethanol-induced conditioned place preference in mice: Role of DMT and  $\beta$ -carbolines*  
Elisangela Cata-Preta<sup>1</sup>, Yasmin Serra<sup>1</sup>, Eliseu Moreira Junior<sup>1</sup>, Henrique Reis<sup>1</sup>, Natali Kisaki<sup>1</sup>, Matheus Santos<sup>1</sup>, Raiany Silva<sup>1</sup>, Thaisa Santos<sup>1</sup>, Paulo Ribeiro-Barbosa<sup>1</sup>, Jose Costa<sup>2</sup>, Alexandre Oliveira-Lima<sup>1</sup>, Lais Berro<sup>3</sup>, Eduardo Marinho<sup>1</sup>, <sup>1</sup>Universidade Estadual de Santa Cruz, Ilheus, Brazil, <sup>2</sup>University of Campinas, Faculty of Pharmaceutical Sciences, Campinas, Brazil, <sup>3</sup>University of Mississippi Medical Center, Jackson, MS
- 49 *Does glucagon-like peptide 1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence?*  
Mette Klausen<sup>1</sup>, Nina Le Dous<sup>1</sup>, Mathias Jensen<sup>1</sup>, Kamilla Miskowiak<sup>1</sup>, Patrick Fischer<sup>2</sup>, Gerda Thomsen<sup>2</sup>, Henrik Rindom<sup>3</sup>, Thomas Fahmy<sup>3</sup>, Sabine Vollstädt-Klein<sup>4</sup>, Helene Benveniste<sup>5</sup>, Nora Volkow<sup>6</sup>, Ulrick Becker<sup>7</sup>, Claus Ekstrøm<sup>8</sup>, Gitte Knudsen<sup>2</sup>, Tina Vilsboell<sup>9</sup>, Anders Fink-Jensen<sup>1</sup>, <sup>1</sup>University Hospital of Copenhagen, Copenhagen, Denmark, <sup>2</sup>Copenhagen University Hospital and Center for Integrated Molecular Brain Imaging, Copenhagen, Denmark, <sup>3</sup>Novavì Outpatient Clinics, Copenhagen, Denmark, <sup>4</sup>Central Institute of Mental Health, Mannheim, Germany, <sup>5</sup>Yale University, New Haven, CT, <sup>6</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD, <sup>7</sup>National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark, <sup>8</sup>University of Copenhagen, Department of Public Health, Copenhagen, Denmark, <sup>9</sup>University of Copenhagen, Copenhagen, Denmark
- 50 *What drives us to drink? Examination of a novel progressive-ratio intravenous (IV) alcohol self-administration paradigm in humans*  
Bethany Stangl, Nia Byrd, Molly Zametkin, Vijay Ramchandani, National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD
- 51 *Intravenous alcohol self-administration in participants with alcohol use disorder: Piloting a progressive-ratio schedule*  
Christina Nona<sup>1</sup>, Chidera Chukwueke<sup>2</sup>, Matthew McPhee<sup>2</sup>, Laura Heath<sup>2</sup>, Saima Malik<sup>1</sup>, Isabelle Boileau<sup>1</sup>, Bernard LeFoll<sup>1</sup>, Christian Hendershot<sup>3</sup>, <sup>1</sup>Centre for Addiction and Mental Health, Toronto, ON, Canada, <sup>2</sup>University of Toronto, Toronto, ON, Canada, <sup>3</sup>Center of Addiction and Mental Health, Toronto, ON, Canada
- 52 *The effects of the COMT inhibitor tolcapone and gender on alcohol consumption in individuals with alcohol use disorder (AUD)*  
Jennifer Mitchell, University of California San Francisco, San Francisco, CA
- 53 *Neurobiological factors underlying risk for alcohol abuse in women*

- Jessica Weafer, Harriet de Wit, University of Chicago, Chicago, IL
- 54 *Direct correlations between breath and blood alcohol concentrations in six different real-world settings*  
Elizabeth Ryan<sup>1</sup>, Scott Lukas<sup>1</sup>, Justin Shepherd<sup>1</sup>, Jane McNeil<sup>2</sup>, Lucy Bingham<sup>2</sup>, <sup>1</sup>McLean Hospital, Harvard Medical School, Belmont, MA, <sup>2</sup>McLean Hospital, Belmont, MA
- 55 *Identifying predictors of high blood alcohol concentration (BAC) among those in a DUI program*  
Natasia Courchesne<sup>1</sup>, Conner Muth<sup>2</sup>, Melanie Barker<sup>3</sup>, Susan Woodruff<sup>3</sup>, <sup>1</sup>University of California San Diego, San Diego, CA, <sup>2</sup>Virginia Commonwealth University, Richmond, VA, <sup>3</sup>San Diego State University, San Diego, CA
- 56 *Repeated episodic future thinking produces cumulative reductions of delay discounting in current and former alcohol users*  
Alexandra Mellis<sup>1</sup>, Sarah Snider<sup>2</sup>, Warren Bickel<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Addiction Recovery Research Center, Roanoke, VA
- 57 *Willing to work but not to wait: Individuals with alcohol use disorder show increased delay discounting, but not effort discounting, compared to social drinkers*  
Quan Phung<sup>1</sup>, Sarah Snider<sup>2</sup>, Warren Bickel<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Addiction Recovery Research Center, Roanoke, VA
- 58 *Delay discounting and sequential decision making across the alcohol use and recovery spectrum*  
Lara Moody<sup>1</sup>, Allison Tegge<sup>2</sup>, Harhim Park<sup>3</sup>, Woo-Young Ahn<sup>3</sup>, Warren Bickel<sup>2</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Durham, NC, <sup>2</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>3</sup>Seoul National University, Seoul, Korea, Republic of
- 59 *Influence of impulsivity fluctuations on craving and substances use among patients beginning treatment for addiction: An ecological momentary assessment study*  
Louise Jakubiec<sup>1</sup>, Manon Chevalier<sup>1</sup>, Fuschia Serre<sup>2</sup>, Melina Fatseas<sup>3</sup>, Maud Dupuy<sup>1</sup>, Joel Swendsen<sup>1</sup>, Marc Auriacombe<sup>2</sup>, <sup>1</sup>Université de Bordeaux, Bordeaux, France, <sup>2</sup>Université de Bordeaux, Bordeaux, <sup>3</sup>Centre Hospitalier Charles Perrens, Bordeaux, France
- 60 *Pre-loading effects on ad-libitum alcohol intake in binge drinkers*  
Kimberly A Bernosky, D'Youville College, Kenmore, NY
- 61 *Increases in binge drinking concentrated among cigarette smokers in the US, 2002-2014*  
Daniel Paulus<sup>1</sup>, Michael Zvolensky<sup>1</sup>, Steven Bell<sup>2</sup>, Deborah Hasin<sup>3</sup>, Misato Gbedemah<sup>4</sup>, Renee Goodwin<sup>5</sup>, <sup>1</sup>University of Houston, Houston, TX, <sup>2</sup>Strangeways Research Laboratory, Cambridge, United Kingdom, <sup>3</sup>Columbia University, New York, NY, <sup>4</sup>CUNY Graduate School of Public Health and Health Policy, New York, NY, <sup>5</sup>The City University of New York, New York, NY
- 62 *Effects of yoga on substance use and stress from an RCT during reentry*  
Alexandra Wimberly<sup>1</sup>, Malitta Engstrom<sup>2</sup>, Molly Layde<sup>3</sup>, James McKay<sup>2</sup>, <sup>1</sup>Columbia University, Baltimore, MD, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>PeaceCorps, Masasi, Tanzania
- 63 *Influence of comorbid drug use disorder on receipt of specialty addictions treatment for alcohol use disorder among VA patients with Hepatitis C*  
Emily Williams<sup>1</sup>, Madeline Frost<sup>1</sup>, Judith Tsui<sup>2</sup>, <sup>1</sup>Veterans Affairs Puget Sound Health Services Research & Development, Seattle, WA, <sup>2</sup>University of Washington, Seattle, WA
- 64 *Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care*  
Mia Malone<sup>1</sup>, Alexandria Vittitow<sup>1</sup>, Ryan McDonald<sup>1</sup>, Babak Tofighi<sup>1</sup>, Ann Garment<sup>1</sup>, Daniel Schatz<sup>2</sup>, Eugene Laska<sup>1</sup>, Keith Goldfeld<sup>1</sup>, John Rotrosen<sup>1</sup>, Joshua Lee<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>New York University, New York, NY
- 65 *Barriers to integrating the continuum of care for opioid and alcohol use disorders in primary care: A qualitative longitudinal study*  
Erik Storholm<sup>1</sup>, Allison Ober<sup>1</sup>, Sarah Hunter<sup>2</sup>, Katherine Watkins<sup>1</sup>, <sup>1</sup>RAND Corporation, Santa Monica, CA,

- <sup>2</sup>RAND Corporation, Arlington, VA
- 66 *Intensive motivational interviewing for heavy drinking among women*  
Douglas Polcin<sup>1</sup>, Rachael Korcha<sup>2</sup>, Michelle Salinardi<sup>2</sup>, Madhabika Nayak<sup>2</sup>, Gantt Galloway, Shelia Pugh<sup>2</sup>,  
<sup>1</sup>Behavioral Health and Research Studies, Lafayette, CA, <sup>2</sup>Alcohol Research Group, Emeryville, CA
- 67 *Which client statements matter most in motivational interviewing? A meta-analysis of the relation between subtypes of change or sustain talk and addictive behavior outcome*  
Michael Bernstein, Brown University, Providence, RI
- 68 *A prospective study of alexithymia, negative mood and alcohol expectancies among alcohol-dependent treatment seekers*  
Fred Thorberg<sup>1</sup>, Ross Young<sup>2</sup>, Michael Lyvers<sup>3</sup>, Jason Connor<sup>2</sup>, Edythe London<sup>4</sup>, Gerald Feeney<sup>5</sup>, <sup>1</sup>Innlandet Hospital Trust, Brumunddal, Norway, <sup>2</sup>University of Queensland, Brisbane, <sup>3</sup>Bond University, Robina, Australia, <sup>4</sup>University of California Los Angeles, Los Angeles, CA, <sup>5</sup>Princess Alexandra Hospital, Queensland, Australia
- 69 *Opportunistic drinking refusal self-efficacy moderates the relationship between borderline personality traits and alcohol consequences*  
Rachel Zelenak<sup>1</sup>, Jennifer Ellis<sup>2</sup>, Emily Grekin<sup>2</sup>, <sup>1</sup>Wayne State University, Detroit, MI, Canada, <sup>2</sup>Wayne State University, Detroit, MI
- 70 *The role of violence and mental health in alcohol use disorders among Black women at risk for HIV in Baltimore, MD*  
Kiyomi Tsuyuki<sup>1</sup>, Noor Al-Alusi<sup>1</sup>, Jacquelyn Campbell<sup>2</sup>, Andrea Cimino<sup>2</sup>, Kristin Gundersen<sup>1</sup>, Jamila Stockman<sup>1</sup>, <sup>1</sup>University of California San Diego Department of Medicine, La Jolla, CA, <sup>2</sup>Johns Hopkins University, School of Nursing, Baltimore, MD
- 71 *Relationship between substance use and sexual network characteristics among men who have sex with men and transgender women in Tijuana, Mexico*  
Heather Pines<sup>1</sup>, Rudy Patrick<sup>1</sup>, Martina Morris<sup>2</sup>, Shirley Semple<sup>1</sup>, Alicia Vera<sup>1</sup>, James Fowler<sup>1</sup>, Gudelia Rangel<sup>3</sup>, Thomas Patterson<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>University of Washington, Seattle, WA, <sup>3</sup>Comision Binacional Fronteriza, Mexico
- 72 *Trajectories of repeated AUDIT-C scores as a phenotype for GWAS discovery*  
Rachel Vickers Smith<sup>1</sup>, Henry Kranzler<sup>2</sup>, Amy Justice<sup>3</sup>, Janet Tate<sup>3</sup>, <sup>1</sup>University of Louisville, School of Nursing, Louisville, KY, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Yale University, New Haven, CT

**POSTER IV F**  
**PSYCHIATRIC COMORBIDITY**

**Sapphire ABC/EFG**  
**12:00 - 2:00 PM**

- 73 *Social-ecological determinants of health contributing to co-occurring substance use and mental health problems: How do sexual and gender minority young adults' experiences differ from their heterosexual, cisgender counterparts?*  
Jennifer Felner<sup>1</sup>, Jennifer Wisdom<sup>2</sup>, Laura Katuska<sup>3</sup>, Hee Jin Jun<sup>1</sup>, Heather Corliss<sup>1</sup>, <sup>1</sup>San Diego State University, San Diego, CA, <sup>2</sup>The City University of New York, New York, NY, <sup>3</sup>Harvard Medical School, Boston, MA
- 74 *Perceptions of helpfulness of a mindfulness meditation program in women with PTSD and SUD*  
Therese Killeen<sup>1</sup>, Hayley Feigyl<sup>1</sup>, Mary Shaw<sup>1</sup>, Sarah Bowen<sup>2</sup>, <sup>1</sup>Medical University of South Carolina, Charleston, SC, <sup>2</sup>Pacific University, Forest Grove, OR
- 75 *Drug craving and use in response to prolonged exposure for PTSD*  
Jessica Peirce<sup>1</sup>, Rebecca Schacht<sup>2</sup>, Michael Kidorf<sup>3</sup>, Van King<sup>4</sup>, Robert Brooner<sup>1</sup>, <sup>1</sup>Johns Hopkins University

- School of Medicine, Baltimore, MD, University of Maryland, Baltimore, MD, Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>4</sup>University of Texas Health Science Center, San Antonio, TX
- 76 *Current depressive symptoms are associated with drug craving and drug use in methadone-maintained patients*  
Andrew Huhn<sup>1</sup>, Mary Sweeney<sup>1</sup>, Michael Kidorf<sup>2</sup>, D. Andrew Tompkins<sup>3</sup>, Robert Brooner<sup>1</sup>, Kelly Dunn<sup>1</sup>,  
<sup>1</sup>Johns Hopkins University School of Medicine, Baltimore, MD, <sup>2</sup>Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>3</sup>University of California San Francisco School of Medicine, San Francisco, CA
- 77 *The longitudinal association between substance use and depression from pre- to 1-year post substance use treatment*  
Deepika Anand<sup>1</sup>, Anna Bartuska<sup>1</sup>, CJ Seitz-Brown<sup>2</sup>, Stacey Daughters<sup>1</sup>, <sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, <sup>2</sup>University of Maryland, College Park, MD
- 78 *Change talk in group motivational interviewing (GMI) predicts outcome among patients with substance use and co-existing psychiatric disorders*  
Elizabeth Santa Ana<sup>1</sup>, Antonio Morgan-Lopez<sup>2</sup>, Kayla Lamb<sup>3</sup>, Steve Martino<sup>4</sup>, <sup>1</sup>University of South Carolina, Charleston, SC, <sup>2</sup>RTI International, Durham, NC, <sup>3</sup>Charleston VAMC, Charleston, SC, <sup>4</sup>Yale University Department of Psychiatry, New Haven, CT
- 79 *Risk of substance use and mental health outcomes among military spouses and partners*  
Jessica Kulak<sup>1</sup>, Jennifer Fillo<sup>2</sup>, D. Lynn Homish<sup>1</sup>, Linda Kahn<sup>1</sup>, Gregory Homish<sup>1</sup>, <sup>1</sup>State University of New York at Buffalo, Buffalo, NY, <sup>2</sup>Research Institute on Addictions, Buffalo, NY
- 80 *Prevalence of trauma exposure and post-traumatic stress disorder (PTSD) in rehabilitation center ANAS Le Courbat in France during first semester of 2016*  
Damien Maugé<sup>1</sup>, Servane Barrault<sup>1</sup>, Kevin Lebigre<sup>1</sup>, Hussein el Ayoubi<sup>2</sup>, Paul Brunault<sup>3</sup>, Ballon Nicols<sup>1</sup>, Wissam El-Hage<sup>1</sup>, <sup>1</sup>CHRU de Tours, Clinique Psychiatrique Universitaire, Tours, France, <sup>2</sup>Centre Hospitalier Louis Sevestre, Tours, France, <sup>3</sup>University Hospital of Tours, Tours, France
- 81 *Current use of alcohol and marijuana among people with anxiety, depression, both or neither*  
Ayodeji Otufowora<sup>1</sup>, Yiyang Liu<sup>2</sup>, Shivani Khan<sup>2</sup>, Catherine Woodstock Striley<sup>2</sup>, Deepthi Varma<sup>1</sup>, Linda Cottler<sup>2</sup>, <sup>1</sup>University of Florida, College of Public Health and Health Professions, Gainesville, FL, <sup>2</sup>University of Florida, Gainesville, FL
- 82 *Psychotic disorder and cannabis: Examining hospitalizations trends prior to legalization in Canada*  
Bridget Hall, Sarah Wallingford, Matthew Young, Canadian Centre on Substance Abuse, Ottawa, ON, Canada
- 83 *Longitudinal evaluation of PTSD symptoms as a function of cannabis use status*  
Megan Brunstetter<sup>1</sup>, Alexandra Simonian<sup>1</sup>, Meredith Kurtz<sup>1</sup>, Ryan Vandrey<sup>2</sup>, Hal Wortzel<sup>1</sup>, Marcel Bonn-Miller<sup>3</sup>, <sup>1</sup>Rocky Mountain MIRECC, VA Eastern Colorado Health Care System, Denver, CO, <sup>2</sup>Behavioral Pharmacology Research Unit, Johns Hopkins Hospital, Baltimore, MD, <sup>3</sup>University of Pennsylvania, Southmont, NC
- 84 *Cannabis use moderates associations between physical health and anxiety sensitivity and distress tolerance*  
Kate Stewart<sup>1</sup>, Kristina Jackson<sup>2</sup>, Brian Borsari<sup>3</sup>, Jane Metrik<sup>1</sup>, <sup>1</sup>Brown University School of Public Health, Providence, RI, <sup>2</sup>Center for Alcohol and Addiction Studies, Providence, RI, <sup>3</sup>San Francisco Veterans Affairs Health Care System, San Francisco, CA
- 85 *Negative urgency mediates the relationship between depression and marijuana problems*  
Rachel Gunn<sup>1</sup>, Kristina Jackson<sup>2</sup>, Brian Borsari<sup>3</sup>, Jane Metrik<sup>4</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Center for Alcohol and Addiction Studies, Providence, RI, <sup>3</sup>San Francisco Veterans Affairs Health Care System, San Francisco, CA, <sup>4</sup>Brown University School of Public Health, Providence, RI
- 86 *Association between negative affect and symptoms of anxiety and depression in a cannabis cessation clinical trial.*  
Kristen Morella, Brian Sherman, Nathaniel Baker, Gregory Sahlem, Amanda Wagner, Kevin Gray, Aimee

- McRae-Clark, Medical University of South Carolina, Charleston, SC
- 87 *Depression, anger, and drug use trajectory over one year in people who use marijuana, opioids, and stimulants*  
Landhing Moran<sup>1</sup>, Sara Hertzell<sup>1</sup>, Jennifer Schroeder<sup>2</sup>, David Epstein<sup>1</sup>, Kenzie Preston<sup>1</sup>, Karran Phillips<sup>3</sup>,  
<sup>1</sup>NIDA Intramural Research Program, Baltimore, MD, <sup>2</sup>Schroeder Statistical Consulting, LLC, Ellicott City, MD, <sup>3</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 88 *Decreased cigarette demand among treatment-seeking smokers with depressive symptoms*  
Sara Weidberg<sup>1</sup>, Ángel García-Pérez<sup>1</sup>, Aris Grande-Gonsende<sup>1</sup>, Irene Pericot-Valverde<sup>2</sup>, Roberto Secades Villa<sup>1</sup>, <sup>1</sup>University of Oviedo, Oviedo, Spain, <sup>2</sup>University of Vermont, Burlington, VT
- 89 *Factors associated with psychiatric symptomatology among a cohort of people who inject drugs (PWID) in Haiphong, Vietnam and clinical implications*  
Laurent Michel<sup>1</sup>, Mai Le Sao<sup>2</sup>, Huong Duong Thi<sup>3</sup>, Oanh Khuat Thi Hai<sup>4</sup>, Delphine Rapoud<sup>5</sup>, Khuê Pham Minh<sup>3</sup>, Catherine Quillet<sup>6</sup>, Thanh Nham Thi Tuyet<sup>4</sup>, Giang Hoang Thi<sup>3</sup>, Jonathan Feelemyer<sup>7</sup>, Vinh Vu Hai<sup>8</sup>, Jean-Pierre Moles<sup>9</sup>, Didier Laureillard<sup>6</sup>, Don Des Jarlais<sup>7</sup>, Nicolas Nagot<sup>6</sup>, <sup>1</sup>Centre Pierre Nicole, Paris, France, <sup>2</sup>Mental Health Department, Hai Phong, Viet Nam, <sup>3</sup>Hai Phong University of Medicine and Pharmacy, Hai Phong, Viet Nam, <sup>4</sup>SCDI, Hanoi, Viet Nam, <sup>5</sup>Department of Medical Information, Montpellier, <sup>6</sup>University of Montpellier, Montpellier, France, <sup>7</sup>Icahn School of Medicine at Mount Sinai, New York, NY, <sup>8</sup>Infectious Diseases Department, Viet Tiep Hospital, Hai Phong, Viet Nam, <sup>9</sup>University of Montpellier, Montpellier
- 90 *Motivations for the misuse of prescription drugs related to many mental health problems*  
Tess Drazdowski, Oregon Social Learning Center, Eugene, OR
- 91 *The role of impulsivity in the relationship between prescription opioid use and borderline personality disorder features in a substance use disorder treatment sample*  
Noel Vest, Sarah Tragesser, Washington State University, Pullman, WA
- 92 *Problematic cybersexual behaviours: The implication of borderline personality disorder and childhood trauma*  
Servane Barrault<sup>1</sup>, Komlan Hegbé<sup>2</sup>, Robert Courtois<sup>1</sup>, Paul Brunault<sup>3</sup>, Jérôme Bachellier<sup>1</sup>, Damien Maugé<sup>1</sup>, Ballon Nicols<sup>1</sup>, <sup>1</sup>CHRU de Tours, Clinique Psychiatrique Universitaire, Tours, France, <sup>2</sup>Université Francois Rabelais de Tours, Tours, France, <sup>3</sup>University Hospital of Tours, Tours, France
- 93 *Externalizing and internalizing symptoms as common and specific candidate endophenotypes for heroin and amphetamine dependence*  
Jasmin Vassileva<sup>1</sup>, Elizabeth Long<sup>1</sup>, F. Gerard Moeller<sup>1</sup>, Radka Kaneva<sup>2</sup>, Kiril Bozgunov<sup>3</sup>, Elena Pshederska<sup>3</sup>, Dimitar Nedelchev<sup>3</sup>, Georgi Vasilev<sup>3</sup>, <sup>1</sup>Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Medical University - Sofia, Sofia, Bulgaria, <sup>3</sup>Bulgarian Addictions Institute, Sofia
- 94 *Association between methamphetamine psychosis and facial emotion recognition*  
Shalini Arunogiri<sup>1</sup>, Rebecca McKetin<sup>2</sup>, Dan Lubman<sup>3</sup>, Antonio Verdejo-Garcia<sup>1</sup>, <sup>1</sup>Monash University, Melbourne, Australia, <sup>2</sup>National Drug Research Institute, Perth, Australia, <sup>3</sup>Turning Point, Fitzroy, Australia
- 95 *Problem-gambling severity, suicidality and DSM-IV Axis I and II psychiatric disorders*  
Silvia Ronzitti<sup>1</sup>, Shane Kraus<sup>2</sup>, Rani Hoff<sup>3</sup>, Massimo Clerici<sup>4</sup>, Marc Potenza<sup>5</sup>, <sup>1</sup>Yale University, New Haven, CT, <sup>2</sup>VISN 1 New England MIRECC, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, <sup>3</sup>Yale University Department of Psychiatry, West Haven, CT, <sup>4</sup>University of Milan-Bicocca, Monza, Italy, <sup>5</sup>Yale University School of Medicine, New Haven, CT
- 96 *Clinical and personality characteristics of problem and pathological gamblers with and without symptoms of adult ADHD*  
Molly Cairncross<sup>1</sup>, Aleks Milosevic<sup>2</sup>, Cara Struble<sup>3</sup>, Jennifer Ellis<sup>3</sup>, David Ledgerwood<sup>3</sup>, <sup>1</sup>University of Windsor, Windsor, ON, Canada, <sup>2</sup>Centre For Interpersonal Relationships, Ottawa, ON, Canada, <sup>3</sup>Wayne State

**POSTER IV G**  
**NICOTINE: HUMAN STUDIES**

**Sapphire ABC/EFG**  
**12:00 - 2:00 PM**

- 97 *Respiratory physiology of healthy smokers during distress intolerance testing*  
 Annie Umbricht, Nicolas Schlien, Martha Velez, Delcora Huggins, Johns Hopkins University School of Medicine, Baltimore, MD
- 98 *Promoting substitution of e-cigarettes for cigarettes through narratives: The Roles of authority and in-group biases in modulating narrative effectiveness*  
 William DeHart, Aenia Amin, Warren Bickel, Virginia Tech Carilion Research Institute, Roanoke, VA
- 99 *E-cigarette smoking in Thailand*  
 Chitlada Areesantichai<sup>1</sup>, Usaneya Perngparn<sup>1</sup>, Linda Cottler<sup>2</sup>, <sup>1</sup>Chulalongkorn University, Bangkok, Thailand, <sup>2</sup>University of Florida, Gainesville, FL
- 100 *Electronic nicotine delivery systems (ENDS) and social media use among young adult college students*  
 Paul Harrell, Kelli Will, Andrew Plunk, Eastern Virginia Medical School, Norfolk, VA
- 101 *Comparison of combustible and electronic cigarette dependence severity between heterosexual and bisexual adolescents*  
 Madalyn Liautaud, Jessica Barrington-Trimis, Rob McConnell, Raina Pang, University of Southern California, Los Angeles, CA
- 102 *Predicting initiation of vaporized nicotine products, frequency of use and ongoing use among daily smokers in longitudinal data from the International Tobacco Control (ITC) Four Country Survey*  
 Gary Chan<sup>1</sup>, Kylie Morphett<sup>2</sup>, Coral Gartner<sup>2</sup>, Janni Leung<sup>3</sup>, Hua-Hie Yong<sup>4</sup>, Wayne Hall<sup>5</sup>, Ron Borland<sup>4</sup>, <sup>1</sup>Centre for Youth Substance Abuse Research, Herston, Australia, <sup>2</sup>School of Public Health, Brisbane, Australia, <sup>3</sup>NDARC, UNSW, Australia, Brisbane, Australia, <sup>4</sup>Cancer Council Victoria, Melbourne, Australia, <sup>5</sup>University of Queensland, Brisbane, Australia
- 103 *Frequency of tobacco use in emerging adults is associated with self-reported, but not a laboratory measure of, inattention*  
 Timothy Regan, Bethany Harris, Sherece Fields, Texas A&M University, College Station, TX
- 104 *Effects of device voltage level on e-cigarette appeal differs by e-cigarette dependence*  
 Elaine Qian<sup>1</sup>, Hannah Hardy<sup>2</sup>, Nicholas Goldenson<sup>2</sup>, Jessica Barrington-Trimis<sup>2</sup>, Raina Pang<sup>2</sup>, Adam Leventhal<sup>2</sup>, Matthew Kirkpatrick<sup>2</sup>, <sup>1</sup>University of Southern California, Dublin, CA, <sup>2</sup>University of Southern California, Los Angeles, CA
- 105 *Impact of mentholation as a moderator of nicotine dose on relative reinforcing and subjective effects*  
 Danielle Davis<sup>1</sup>, Cecilia Bergeria<sup>1</sup>, Joanna Streck<sup>2</sup>, Mollie Miller<sup>3</sup>, Janice Bunn<sup>1</sup>, Diann Gaalema<sup>1</sup>, Sarah Heil<sup>1</sup>, Stacey Sigmon<sup>1</sup>, Maxine Stitzer<sup>4</sup>, Jennifer Tidey<sup>5</sup>, Stephen Higgins<sup>1</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>Vermont Center on Behavior and Health, Burlington, VT, <sup>3</sup>Brown University Center for Alcohol and Addiction Studies, Providence, RI, <sup>4</sup>Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>5</sup>Brown University, Providence, RI
- 106 *Subjective effects of cigarettes varying in nicotine content among opioid-maintained individuals*  
 Joanna Streck<sup>1</sup>, Stacey Sigmon<sup>2</sup>, Maria Parker<sup>2</sup>, Maxine Stitzer<sup>3</sup>, Jennifer Tidey<sup>4</sup>, Sarah Heil<sup>2</sup>, Diann Gaalema<sup>2</sup>, Cecilia Bergeria<sup>2</sup>, Danielle Davis<sup>2</sup>, Jeff Priest<sup>2</sup>, Anthony Barrows<sup>2</sup>, Matthew Rothman<sup>2</sup>, John Hughes<sup>2</sup>, Stephen Higgins<sup>2</sup>, <sup>1</sup>Vermont Center on Behavior and Health, Burlington, VT, <sup>2</sup>University of Vermont, Burlington, VT, <sup>3</sup>Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>4</sup>Brown University, Providence, RI
- 107 *Learning and memory performance following acute intranasal insulin administration in abstinent smokers*



- Ajna Hamidovic, University of Illinois, Chicago, IL
- 108 *Characterizing tobacco use in a military sample*  
Alexa Lopez<sup>1</sup>, Alexxa Bessey<sup>2</sup>, Julie Merrill<sup>1</sup>, Walter Sowden<sup>3</sup>, <sup>1</sup>US Army Medical Research Directorate-West, Tacoma, WA, <sup>2</sup>Walter Reed Army Institute of Research, Washington, DC, <sup>3</sup>Walter Reed Army Institute of Research, Silver Spring, MD
- 109 *California tobacco tax increase: Impact on a low-income drug treatment sample*  
Denise Williams, Noah Gubner, Thao Le, Deborah Yip, Joseph Guydish, University of California San Francisco, San Francisco, CA
- 110 *An examination of psychological distress, healthcare coverage, and poly-tobacco product use among gay and bisexual men*  
Raymond Moody<sup>1</sup>, Christian Grov<sup>2</sup>, Jeffrey Parsons<sup>3</sup>, <sup>1</sup>Graduate Center and CHEST, New York, NY, <sup>2</sup>CUNY Graduate School of Public Health and Health Policy, New York, NY, <sup>3</sup>Hunter College, CUNY, New York City, NY
- 111 *Anxiety sensitivity in relation to smoking variables and other substance use in African-American smokers*  
Megan Kelly<sup>1</sup>, Casey Guillot<sup>1</sup>, Nathan Kearns<sup>1</sup>, Michael Zvolensky<sup>2</sup>, Norman Schmidt<sup>3</sup>, <sup>1</sup>University of North Texas, Denton, TX, <sup>2</sup>University of Houston, Houston, TX, <sup>3</sup>Florida State University, Tallahassee, FL
- 112 *Anxiety sensitivity as a predictor of the acute subjective effects of smoking in African-Americans during non-abstinence*  
Sage Luna<sup>1</sup>, Casey Guillot<sup>1</sup>, Megan Kelly<sup>1</sup>, Sara Hartigan<sup>1</sup>, Raina Pang<sup>2</sup>, Michael Zvolensky<sup>3</sup>, Adam Leventhal<sup>2</sup>, <sup>1</sup>University of North Texas, Denton, TX, <sup>2</sup>University of Southern California, Los Angeles, CA, <sup>3</sup>University of Houston, Houston, TX
- 113 *Anxiety sensitivity moderates the association of relationship status with cigarette smoking heaviness and dependence*  
Casey Guillot<sup>1</sup>, Eileen Quinn<sup>1</sup>, Megan Kelly<sup>1</sup>, Aurora Brown<sup>1</sup>, Casey Horani<sup>1</sup>, Noah Phillips<sup>1</sup>, Yuqing Liu<sup>1</sup>, Adam Leventhal<sup>2</sup>, <sup>1</sup>University of North Texas, Denton, TX, <sup>2</sup>University of Southern California, Los Angeles, CA
- 114 *Amplitude of demand predicts abstinence among treatment-seeking smokers with elevated depressive symptoms: Further evidence of its internal structure*  
Carla López Núñez<sup>1</sup>, Alba González-Roz<sup>2</sup>, Ángel García-Pérez<sup>3</sup>, Sara Weidberg<sup>3</sup>, Víctor Martínez-Loredo<sup>2</sup>, Roberto Secades Villa<sup>3</sup>, <sup>1</sup>Universidad Loyola Andalucía, Sevilla, Spain, <sup>2</sup>University of Oviedo, Addictive Behaviors Group, Oviedo, Spain, <sup>3</sup>University of Oviedo, Oviedo, Spain
- 115 *Relationship of trait anger among smokers with SUD to nicotine dependence, barriers to quitting smoking, intolerance for discomfort, smoking, craving and compliance with smoking cessation medication*  
Damaris Rohsenow<sup>1</sup>, Rosemarie Martin<sup>1</sup>, Suzanne Colby<sup>2</sup>, Shelley Gresko<sup>1</sup>, Jennifer Tidey<sup>1</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Brown University Center for Alcohol and Addiction Studies, Providence, RI
- 116 *Validation of a brief behavioral economic assessment of demand among cigarette smokers*  
Liqa Athamneh<sup>1</sup>, Jeffrey Stein<sup>1</sup>, Michael Amlung<sup>2</sup>, Warren Bickel<sup>1</sup>, <sup>1</sup>Virginia Tech Carilion Research Institute, Roanoke, VA, <sup>2</sup>Peter Boris Centre for Addictions Research, Hamilton, ON, Canada
- 117 *A novel delayed cigarette purchase task: Associations with craving and smoking urges*  
Mikhail Koffarnus, Brent Kaplan, Virginia Tech Carilion Research Institute, Roanoke, VA
- 118 *Predictors of smoking cessation during pregnancy*  
Lauren Micalizzi<sup>1</sup>, Leslie Brick<sup>1</sup>, Valerie Knopik<sup>2</sup>, <sup>1</sup>Brown University, Providence, RI, <sup>2</sup>Purdue University, West Lafayette, IN
- 119 *Improving equity and consistency In hospital administration of smoking cessation pharmacotherapy*  
Alex Ramsey<sup>1</sup>, Donna Prentice<sup>2</sup>, Ellis Ballard<sup>3</sup>, Melanie Houston<sup>3</sup>, Hannah Kramer<sup>3</sup>, Sophie Cheng<sup>3</sup>, Li-Shiun Chen<sup>1</sup>, Laura Bierut<sup>1</sup>, <sup>1</sup>Washington University School of Medicine, St. Louis, MO, <sup>2</sup>Barnes-Jewish

- Hospital, St. Louis, MO, <sup>3</sup>Washington University, St. Louis, MO
- 120 *Utilization of smoking cessation interventions during VA Medical Center initial visits*  
David Friedrich, James Walker, Shalika Whig, Karen Hartwell, Medical University of South Carolina, Charleston, SC
- 121 *Impact of an employee-focused program for tobacco addiction treatment among employees of a French healthcare institution*  
Marie Thérèse Ceccato<sup>1</sup>, Jacques Dubernet<sup>2</sup>, Jean-Marc Alexandre<sup>2</sup>, Fuschia Serre<sup>2</sup>, Marc Auriacombe<sup>2</sup>,  
<sup>1</sup>University of Bordeaux, Bordeaux, France, <sup>2</sup>Université de Bordeaux, Bordeaux

**POSTER IV H**  
**SEX/GENDER II**

**Sapphire ABC/EFG**  
**12:00 - 2:00 PM**

- 122 *Cannabis dependence: Measurement equivalence by age and sex*  
Christopher Thompson<sup>1</sup>, Karl Alcover<sup>2</sup>, James Anthony<sup>2</sup>, <sup>1</sup>Theo Pediatric Health, Lansing, MI, <sup>2</sup>Michigan State University, Lansing, MI
- 123 *Dimensions of negative consequences in regular marijuana users differ by sex*  
Cara Struble<sup>1</sup>, Jennifer Ellis<sup>1</sup>, Molly Cairncross<sup>2</sup>, Leslie Lundahl<sup>1</sup>, <sup>1</sup>Wayne State University, Detroit, MI, <sup>2</sup>University of Windsor, Windsor, ON, Canada
- 124 *Sex-differences in the associations between social support and frequency of use and severity of cannabis dependence: A secondary data analysis*  
Kechna Cadet<sup>1</sup>, Lesia M. Ruglass<sup>2</sup>, <sup>1</sup>CUNY School of Medicine, New York, NY, <sup>2</sup>The City University of New York, New York, NY
- 125 *Gender differences in emotional reactions to cigarette warning labels in teens*  
Amanda Quisenberry, Elizabeth Klein, Ellen Peters, Ohio State University, Columbus, OH
- 126 *Effects of gender on affect during acute tobacco abstinence differ between African-American and White smokers*  
Raina Pang, Mariel Bello, Madalyn Liautaud, Adam Leventhal, University of Southern California, Los Angeles, CA
- 127 *Gender differences in utilization of quitline services and tobacco cessation among callers at a state quitline*  
Alicia Allen, Nicole Yuan, Betsy Wertheim, Laurie Krupski, Melanie Bell, Uma Nair, University of Arizona, Tucson, AZ
- 128 *Cocaine exposure and caregiving quality: Sex differences and effects on child behavior problems*  
Ariana Roman<sup>1</sup>, Rina Eiden<sup>2</sup>, Shannon Shisler<sup>1</sup>, <sup>1</sup>Research Institute on Addictions, Buffalo, NY, <sup>2</sup>State University of New York at Buffalo, Buffalo, NY
- 129 *Mood, meth, and sex: Latent growth curve modeling results from a randomized trial*  
Eileen Pitpitan, University of California San Diego, La Jolla, CA
- 130 *The impacts of childhood sexual and physical abuse on adulthood sex trade involvement in the US: Evaluating gender differences in associations and mediation*  
MacRegga Severe<sup>1</sup>, Kriupa Samson<sup>2</sup>, Joy Scheidell<sup>1</sup>, Christopher Frueh<sup>3</sup>, Jarrett Williams<sup>1</sup>, Kailyn Pearce<sup>1</sup>, Maria Khan<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>New York University, College of Nursing, New York, NY, <sup>3</sup>University of Hawaii at Hilo, Hilo
- 131 *Gender differences in HIV, anti-HCV and HBsAg prevalence among people who inject drugs – A multi-stage systematic review and meta-analysis of global evidence*  
Janni Leung<sup>1</sup>, Amy Peacock<sup>2</sup>, Samantha Colledge<sup>2</sup>, Jason Grebely<sup>3</sup>, Evan Cunningham<sup>4</sup>, Matthew Hickman<sup>5</sup>, Peter Vickerman<sup>6</sup>, Jack Stone<sup>6</sup>, Adam Trickey<sup>6</sup>, Kostyantyn Dumchev<sup>7</sup>, Michael Lynskey<sup>8</sup>, Lindsey Hines<sup>8</sup>, Paul Griffiths<sup>9</sup>, Richard Mattick<sup>4</sup>, Sarah Larney<sup>2</sup>, Louisa Degenhardt<sup>2</sup>, <sup>1</sup>NDARC, UNSW, Australia, Brisbane,

Australia, <sup>2</sup>National Drug and Alcohol Research Centre, Sydney, Australia, <sup>3</sup>The Kirby Institute, Sydney, Australia, <sup>4</sup>University of New South Wales, Sydney, Australia, <sup>5</sup>NIHR School of Public Health, Bristol, <sup>6</sup>Bristol University, Clifton, United Kingdom, <sup>7</sup>Ukrainian Institute on Public Health Policy, Kyiv, Ukraine, <sup>8</sup>King's College, London, United Kingdom, <sup>9</sup>EMCDDA, Lisbon, Portugal

132 *Gender differences in the provision of injection initiation assistance: A comparison of three North American settings*

Stephanie Meyers<sup>1</sup>, Ayden Scheim<sup>1</sup>, Sonia Jain<sup>1</sup>, Shelly Sun<sup>1</sup>, M-J Milloy<sup>2</sup>, Kora DeBeck<sup>3</sup>, Kanna Hayashi<sup>4</sup>, Richard S Garfein<sup>1</sup>, Steffanie Strathdee<sup>1</sup>, Dan Werb<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>British Columbia Centre for Excellence in HIV/AIDS, Vancouver, <sup>3</sup>BC Centre for Excellence in HIV/AIDS, Vancouver, <sup>4</sup>Simon Fraser University, Vancouver, BC, Canada

133 *A re-evaluation of the KMSK scales, rapid dimensional measures of exposure to specific drugs*  
Carina Chen, Eduardo Butelman, Rebecca Fry, Rachel Kimani, Joel Correa da Rosa, Mary Jeanne Kreek, The Rockefeller University, New York, NY

## POSTER IV I THEORETICAL COMMENTARY

**Sapphire ABC/EFG  
12:00 - 2:00 PM**

134 *FDA and other US agency roles in the drug scheduling process for substances assessed under our international drug control treaties*

James Hunter, U.S. Food and Drug Administration, Silver Spring, MD

135 *How drugs without abuse potential are removed from control under the controlled substances act*

Katherine Bonson, U.S. Food and Drug Administration, Silver Spring, MD

136 *Developing hallucinogenic drugs as therapeutic agents: Regulatory framework*

Silvia Calderon<sup>1</sup>, Joshua Hunt<sup>2</sup>, Michael Klein<sup>3</sup>, <sup>1</sup>U.S. Food and Drug Administration, Silver Spring, MD, <sup>2</sup>FDA/CDER/OCD/CSS, Silver Spring, MD, <sup>3</sup>Controlled Substance Scientific Solutions LLC, Chevy Chase, MD

137 *Category I assessment of opioid vaping: A focus of FDA advisory committee interest*

August Buchhalter<sup>1</sup>, Edward Cone<sup>1</sup>, Christopher Altomare<sup>2</sup>, Anthony Costantino<sup>2</sup>, <sup>1</sup>Pinney Associates, Inc., Bethesda, MD, <sup>2</sup>DRUGSCAN, Horsham, PA

138 *Kratom and its mitragynines in the opioid crisis: A path to or away from opioids?*

Jack Henningfield<sup>1</sup>, Robert Raffa, Albert Garcia-Romeu<sup>2</sup>, Tina Doshi, <sup>1</sup>Pinney Associates, Inc., Bethesda, MD, <sup>2</sup>Johns Hopkins University School of Medicine, Baltimore, MD

139 *Pain treatment with buprenorphine as a strategy to reduce the epidemic of opioid abuse and overdose*

Reginald Fant<sup>1</sup>, Sidney Schnoll<sup>2</sup>, Lisa Zapawa<sup>1</sup>, Karen Gerlach<sup>1</sup>, <sup>1</sup>Pinney Associates, Inc., Bethesda, MD, <sup>2</sup>Pinney Associates, Inc., Stamford, CT

140 *Solutions to financial barriers to pharmacy-based naloxone access*

Jeffrey Bratberg<sup>1</sup>, Traci Green<sup>2</sup>, Alexander Walley<sup>2</sup>, <sup>1</sup>University of Rhode Island, College of Pharmacy, Attleboro, MA, <sup>2</sup>Boston University School of Medicine, Boston, MA

141 *The landscape of bundled payment: Where does addiction fit in?*

Maureen Stewart<sup>1</sup>, Constance Horgan<sup>2</sup>, Jennifer Perloff<sup>2</sup>, Alexandra Kritikos<sup>2</sup>, Amity Quinn<sup>3</sup>, <sup>1</sup>Brandeis University, Waltham, MA, <sup>2</sup>Brandeis University, Heller School for Social Policy and Management, Waltham, MA, <sup>3</sup>University of Calgary, Calgary, AB, Canada

142 *Rewarding value in substance use treatment: What are the unique challenges?*

Constance Horgan<sup>1</sup>, Maureen Stewart<sup>2</sup>, Dominic Hodgkin<sup>1</sup>, Alexandra Kritikos<sup>1</sup>, <sup>1</sup>Brandeis University, Heller

- School for Social Policy and Management, Waltham, MA, Brandeis University, Waltham, MA
- 143 *Statistical considerations on pharmacodynamic assessment*  
Ling Chen, U.S. Food and Drug Administration, Silver Spring, MD
- 144 *How is the abuse potential of opioids affected by drugs used concomitantly with opioids?*  
Greg Hawkins<sup>1</sup>, Shalini Bansil<sup>2</sup>, <sup>1</sup>U.S. Food and Drug Administration, Silver Spring, MD, <sup>2</sup>FDA/CSS, Silver Spring, MD
- 145 *Tobacco product abuse liability: State of the science and major challenges*  
Stacey Sigmon<sup>1</sup>, Dorothy Hatsukami<sup>2</sup>, Chad Reissig<sup>3</sup>, Mark Lesage<sup>4</sup>, Eric Donny<sup>5</sup>, Andrea Villanti, Jack Henningfield<sup>6</sup>, <sup>1</sup>University of Vermont, Burlington, VT, <sup>2</sup>University of Minnesota Medical School, Minneapolis, MN, <sup>3</sup>FDA Center for Tobacco Products, Sandy Spring, MD, <sup>4</sup>Minneapolis Medical Research Foundation, Minneapolis, MN, <sup>5</sup>Wake Forest University School of Medicine, Winston-Salem, NC, <sup>6</sup>Pinney Associates, Inc., Bethesda, MD
- 146 *Adjusting for sampling bias in cross-sectional surveys*  
Olga Vselvolozhskaya<sup>1</sup>, James Anthony<sup>2</sup>, Dmitri Zaykin<sup>3</sup>, <sup>1</sup>College of Public Health, Lexington, KY, <sup>2</sup>Michigan State University, Lansing, MI, <sup>3</sup>NIEHS, Research Triangle Park, NC
- 147 *Childhood trauma matters for addiction, STI/HIV, and criminal justice: Where do we go from here?*  
Maria Khan<sup>1</sup>, Christopher Frueh<sup>2</sup>, Joy Scheidell<sup>1</sup>, <sup>1</sup>New York University School of Medicine, New York, NY, <sup>2</sup>University of Hawaii at Hilo, Hilo
- 148 *Medical licensing application questions and physician reluctance*  
Paige Marnell, Bryon Adinoff, University of Texas Southwestern Medical Center, Dallas, TX
- 149 *Changing career opportunities for trainees and early career professionals in the field of drug abuse science*  
Bethea Kleykamp<sup>1</sup>, Katherine Saulsgiver<sup>2</sup>, Cassandra Gipson-Reichardt<sup>3</sup>, <sup>1</sup>Pinney Associates, Inc., Bethesda, MD, <sup>2</sup>BetterUp Inc., San Francisco, CA, <sup>3</sup>Arizona State University, Tempe, AZ
- 150 *Video enhancements to a virtual self-administration laboratory*  
Adithya Kashyap<sup>1</sup>, Harika Mandela<sup>1</sup>, Vladimir Tsibulsky<sup>1</sup>, Andrew Norman<sup>2</sup>, <sup>1</sup>University of Cincinnati, Cincinnati, OH, <sup>2</sup>University of Cincinnati, College of Medicine, Cincinnati, OH

## ORAL COMMUNICATIONS 22

### GETTING ON THE WAGON: ALCOHOL

**Indigo E**  
**2:00 - 3:00 PM**

Chairs: Rajita Sinha

- 2:00 *Human kappa opioid receptor (KOP-r) partial agonist nalmefene and agonist nalfurafine reduce excessive and "relapse" alcohol drinking in C57BL/6J mice*  
Yan Zhou, Mary Jeanne Kreek, The Rockefeller University, New York, NY
- 2:15 *Paternal alcohol exposure reduces operant alcohol self-administration in adult male and female offspring*  
Steven Nieto<sup>1</sup>, Cana Quave<sup>1</sup>, Sergio Sanchez<sup>1</sup>, Tamara Shan<sup>1</sup>, Richard Meisch<sup>2</sup>, Therese Kosten<sup>1</sup>, <sup>1</sup>University of Houston, Houston, TX, <sup>2</sup>University of Texas Health Science Center, Houston, TX
- 2:30 *Translocator protein expression in alcoholism: a [11C]PBR28 PET study in humans and rats*  
Corinde Wiers<sup>1</sup>, Sunny Kim<sup>1</sup>, Ryan Tyler<sup>1</sup>, Ehsan Shokri Kojori<sup>2</sup>, Luke Park<sup>3</sup>, Jei-San Liow<sup>4</sup>, Nancy Diazgranados<sup>2</sup>, Leandro Vendruscolo<sup>5</sup>, George Koob<sup>2</sup>, Robert Innis<sup>4</sup>, Dardo Tomasi<sup>2</sup>, Gene-Jack Wang<sup>1</sup>, Nora Volkow<sup>5</sup>, <sup>1</sup>NIH, NIAAA, Bethesda, MD, <sup>2</sup>National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, <sup>3</sup>National Institutes of Health Clinical Center, Bethesda, MD, <sup>4</sup>National Institute of Mental Health, Bethesda, MD, <sup>5</sup>National Institute of Drug Abuse, National Institutes of Health, Bethesda, MD
- 2:45 *Ethanol reinforcement elicits a novel response inhibition behavior in a model of ethanol dependence*  
Sucharita Somkuwar<sup>1</sup>, Leon Quach<sup>2</sup>, Jacqueline Quigley<sup>3</sup>, Dvijan Purohit<sup>4</sup>, Chitra Mandyam<sup>4</sup>, <sup>1</sup>Veterans

Medical Research Foundation, San Diego, CA, <sup>2</sup>Veterans Affairs San Diego Healthcare System, San Diego, CA, <sup>3</sup>University of Michigan, Ann Arbor, MI, <sup>4</sup>University of California San Diego, La Jolla, CA

**ORAL COMMUNICATIONS 23**  
**OVERDOSE: TOO MUCH OF A BAD THING**

**Indigo H**  
**2:00 - 4:00 PM**

Chairs: Alexander Walley and Erika Pike

- 2:00 *A novel platform to generate opioid-specific monoclonal antibodies to counteract opioid overdose*  
Carly Baehr<sup>1</sup>, Christine Robinson<sup>2</sup>, Marco Pravetoni<sup>2</sup>, <sup>1</sup>University of Minnesota, Department of Veterinary Medicine, Vadnais Heights, MN, <sup>2</sup>Minneapolis Medical Research Foundation, Minneapolis, MN
- 2:15 *Gender-specific facilitators and barriers to accessing an overdose prevention intervention: A rapid ethnographic study*  
Jade Boyd<sup>1</sup>, Samara Mayer<sup>2</sup>, Alexandra Collins<sup>2</sup>, Ryan McNeil<sup>3</sup>, <sup>1</sup>British Columbia Centre on Substance Use, Vancouver, BC, Canada, <sup>2</sup>BC Centre on Substance Use, Vancouver, BC, Canada, <sup>3</sup>University of British Columbia, BC Centre on Substance Use, Vancouver, BC, Canada
- 2:30 *Injectable naltrexone, oral naltrexone, and buprenorphine/naloxone and overdose among individuals treated for opioid use disorder in a United States commercially insured population*  
Jake Morgan<sup>1</sup>, Bruce Schackman<sup>2</sup>, Zoe Weinstein<sup>1</sup>, Alexander Walley<sup>1</sup>, Benjamin Linas<sup>1</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Weill Cornell Medical College, New York, NY
- 2:45 *Opioid overdoses and suicidality in an emergency setting*  
A Srivastava<sup>1</sup>, Randi Foraker<sup>2</sup>, Evan Schwarz<sup>3</sup>, Anne Glowinski<sup>2</sup>, Mark Gold<sup>2</sup>, Laura Bierut<sup>2</sup>, <sup>1</sup>Department of Psychiatry, Washington University School of Medicine, Saint Louis, Missouri, <sup>2</sup>Washington University School of Medicine, St. Louis, MO, <sup>3</sup>Washington University School of Medicine Division of Emergency Medicine, St. Louis, MO
- 3:00 *Overdose experiences increase risk for injection drug use following incarceration in rural women who use opioids*  
Erika Pike<sup>1</sup>, Amanda Bunting<sup>1</sup>, Michele Staton<sup>2</sup>, <sup>1</sup>University of Kentucky, Lexington, KY, <sup>2</sup>University of Kentucky, College of Medicine, Lexington, KY
- 3:15 *Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the US*  
Barrot Lambdin<sup>1</sup>, Corey Davis<sup>2</sup>, Eliza Wheeler<sup>3</sup>, Jennifer Lorvick<sup>4</sup>, Alex Kral<sup>1</sup>, <sup>1</sup>RTI International, Research Triangle Park, NC, <sup>2</sup>Network for Public Health Law, Edina, MN, <sup>3</sup>Harm Reduction Coalition, Oakland, CA, <sup>4</sup>RTI International, San Francisco, CA
- 3:30 *Touchpoints to identify individuals at high risk for opioid overdose death*  
Marc Laroche<sup>1</sup>, Dana Bernson<sup>2</sup>, Thomas Land<sup>2</sup>, Thomas Stopka<sup>3</sup>, Adam Rose<sup>4</sup>, Jane Liebschutz<sup>5</sup>, Alexander Walley<sup>1</sup>, <sup>1</sup>Boston University School of Medicine, Boston, MA, <sup>2</sup>Massachusetts Department of Public Health, Boston, MA, <sup>3</sup>Tufts University School of Medicine, Boston, MA, <sup>4</sup>RAND Corporation, Boston, MA, <sup>5</sup>University of Pittsburgh, Pittsburgh, PA
- 3:45 *“Generally, you get 86’ed because you’re a liability.” Social consequences of frequent overdoses among drug using networks*  
Jeanette Bowles<sup>1</sup>, Karla Wagner<sup>2</sup>, Silvia Verdugo<sup>1</sup>, Peter Davidson<sup>1</sup>, <sup>1</sup>University of California San Diego, La Jolla, CA, <sup>2</sup>University of Nevada, Reno, NV

**SYMPOSIUM XXI**  
**NEW TARGETS FOR DRUG ABUSE THERAPY**

**Indigo BCFG**  
**2:00 - 4:00 PM**

Chairs: Thomas Prisinzano and Nurulain Zaveri

- 2:00 *Progress towards the development of novel therapeutics for drug dependence*  
N. Cosford, NCI-Designated Cancer Center, LaJolla, CA
- 2:25 *NOP receptor-targeted agonists as non-addictive analgesics and potential anti-opioid treatment in primates*  
M. Ko, University of Michigan, Ann Arbor, MI
- 2:50 *Dissecting the neuropeptide S system and its role in substance abuse*  
S. Runyon, RTI International, Research Triangle Park, NC
- 3:15 *Small molecule TLR modulators targeting neurological diseases*  
H. Yin, University of Colorado, Aurora, CO
- 3:40 *The synthesis, optimization and biological characterization of a novel series of D4 antagonists as a potential new treatment for drug abuse*  
C. Hopkins, University of Nebraska Medical Center, Omaha, NE

## **SYMPOSIUM XXII**

## **Indigo D**

### **SEX AND GENDER IMPLICATIONS FOR EMERGING DRUG POLICY 2:00 - 4:00 PM**

Chairs: Sherry McKee and Cora Lee Wetherington

- 2:00 *Sex-dependent therapeutic and adverse effects of cannabis and cannabinoids*  
Z. Cooper, Columbia University and NYSPI, New York, NY
- 2:25 *Why gender matters in opioid drug policy*  
H. Jones, University of North Carolina at Chapel Hill, Carrboro, NC
- 2:50 *Sex differences in nicotine and non-nicotine determinant of smoking and tobacco product regulation*  
E. Donny, Wake Forest University School of Medicine, Winston-Salem, NC
- 3:15 *The epidemiology of gender differences in drinking and related problems*  
D. Hasin, Columbia University, New York, NY
- 3:40 *Discussant: Sex and gender-based science informs basic, translational, clinical and policy relevant research*  
S. Greenfield, McLean Hospital, Harvard Medical School, Belmont, MA

## **ORAL COMMUNICATIONS 24**

## **Indigo E**

### **DOUBLE JEOPARDY: COMORBIDITY**

**3:15 - 4:15 PM**

Chairs: Mark Ilgen

- 3:15 *Associations between PTSD, alcohol poisoning, and drug overdose among individuals in residential treatment*  
Kipling Bohnert<sup>1</sup>, Rebecca Sripada<sup>2</sup>, Mark Ilgen<sup>2</sup>, Maureen Walton<sup>1</sup>, Frederic Blow<sup>1</sup>, Amy Bohnert<sup>2</sup>,  
<sup>1</sup>University of Michigan, Addiction Center, Ann Arbor, MI, <sup>2</sup>University of Michigan, Ann Arbor, MI
- 3:30 *Receipt of opioid medications and other treatments among soldiers with post-traumatic stress disorder (PTSD)*  
Mary Jo Larson, Rachel Adams, Mayada Saadoun, Sue Lee, Mark Bauer, Brandeis University, Heller School for Social Policy and Management, Waltham, MA
- 3:45 *Embedding tobacco dependence treatment within addictions treatment settings: Substance use co-morbidity and other predictors of cessation*  
Laurie Zawertailo, Peter Selby, Centre for Addiction and Mental Health, Toronto, ON, Canada
- 4:00 *Hospital stay in patients with bipolar disorder, schizophrenia, and other psychotic disorders is negatively associated with synthetic cannabinoid or marijuana use*

Huiqiong (Joan) Deng<sup>1</sup>, Pratikumar Desai<sup>2</sup>, Satyajit Mohite<sup>2</sup>, David Nielsen<sup>3</sup>, Olaoluwa Okusaga<sup>2</sup>, Thomas Kosten<sup>4</sup>, <sup>1</sup>University of Texas Health Science Center, McGovern Medical School, Houston, TX, <sup>2</sup>Department of Psychiatry and Behavioral Sciences, McGovern Medical School at the University of Texas Health Sciences Center, Houston, TX, <sup>3</sup>Baylor College of Medicine, Montgomery, TX, <sup>4</sup>Baylor College of Medicine, Bellaire, TX

## **SWEEPSTAKES DRAWING**

**Indigo A**  
**4:15 - 5:15 PM**

HAVE A SAFE TRIP HOME!  
SEE YOU IN SAN ANTONIO, TEXAS  
JUNE 15 - 20, 2019

## **Friday, June 15, 2018**

### **CPDD/INRC/RSA**

**Aqua DEF**  
**1:00 - 3:00 PM**

Chairs: Sherry McKee

*Translating the molecular underpinnings of alcohol and tobacco interactions towards effective treatment*  
Presenters: John A. Dani, Marissa Ehinger, Sherry McKee, Dieter Meyerhoff and David Lovinger

### **CPDD/INRC/RSA**

**Aqua DEF**  
**3:00 - 5:00 PM**

Chairs: Lara Ray

*Pharmacogenetics of addiction treatment*  
Presenters: Lara Ray, Danielm Roche, Jermaine Jones, Eric Otto Johnson and Jonathan Pollock